<SEC-DOCUMENT>0000719135-21-000072.txt : 20211112
<SEC-HEADER>0000719135-21-000072.hdr.sgml : 20211112
<ACCEPTANCE-DATETIME>20211112080845
ACCESSION NUMBER:		0000719135-21-000072
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		58
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211112
DATE AS OF CHANGE:		20211112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apyx Medical Corp
		CENTRAL INDEX KEY:			0000719135
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				112644611
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31885
		FILM NUMBER:		211399780

	BUSINESS ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760
		BUSINESS PHONE:		7273842323

	MAIL ADDRESS:	
		STREET 1:		5115 ULMERTON ROAD
		CITY:			CLEARWATER
		STATE:			FL
		ZIP:			33760

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL Corp
		DATE OF NAME CHANGE:	20150319

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BOVIE MEDICAL CORP
		DATE OF NAME CHANGE:	19990216

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AN CON GENETICS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>apyx-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4,d:b63e0db1bd5f459082b7c90c0bd2a7a9--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:apyx="http://apyxmedical.com/20210930" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>apyx-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18xLTEtMS0xLTU0ODQ_4ad7dba5-a9bf-46e5-a7cd-aaedc331fbee">0000719135</ix:nonNumeric><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18yLTEtMS0xLTU0ODQ_e7f6d641-2d2f-4b2e-ba75-d6b5fb4821b8">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18zLTEtMS0xLTU0ODQ_e671456f-105a-4c11-852e-7dd59a3499d4">December 31</ix:nonNumeric><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N180LTEtMS0xLTU0ODQ_e31a12ca-003f-45cb-9199-db9a47966d1d">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N181LTEtMS0xLTU0ODQ_492ca689-f972-48b0-bde5-67ce8f8ef55f">2021</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="apyx-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8d87cc0d00dd430e93bc08d22ef413d3_I20211109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i49aee00ecd564aaf8b7b1b4942930967_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa26429c0b0840458a09f15ab78444da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cd62ad6efef478ea9253454d1b323fc_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied69cc4d5a424703ad140e56f728ec4c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaac4971ea2db4dc09b26a866c233c20f_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75344978b6a74bc49f92004b47d2a99a_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i288fa9706cf44b8facc8faf026ba5348_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief9af1557e4f4da285e53418666bd7c3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb31e9500ecb42efb36391b9387777c7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7d4ef659eb7431bbcfe190050698da3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ff89a354600483cb01afeea6bec3ba9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee57ebf3a9b340788524d62a380a9faa_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i984f1d5dd05b4d329a24c070a595974a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43b8251fde224eef8a0347a6e3949722_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f06f183d7144f57a3f2a51f639d94a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ba94fe7a6414cc99d227e2c683db25c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fe0683ef1f64486a18c7e5908f33e7a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i863033745e7146f18475cca8dedbfbe2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3da259ec02054f349636d5e80c3147bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148f935a59024792a748fb1d4f38671f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f70eafe2be446e695a8ccd7a1f65471_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i401e199c245e45e2b3bc3d4d91130100_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38848fe39ff64851a1cbe4f24a730945_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29b421bc868b4e08849cd49dfe789fd2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9315b652eeb413db25d16425efd6de9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae1ce0523054de58fd6ba4b0d5d6563_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c8cceba9d44f1b81b235e990ff326a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ad44ab908404be1b219b693527268fd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie01729704401438f9953c87c6f6cd951_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a176064ef443598ec51cc2bb38bc3f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5479fed4aae147488d8d0627f13aaecc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c89473017f4de187b5214a631371df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8c8bf58148c4c71bb4b113ba65e0d64_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie14d7e777681449e8cbe2e5ae99cf56f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idffa3da465324394823951b3715cae7c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2fc895348acb46d3a770cfb612e019f6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac1cefbb0fa4631b29d06f046c1d8a3_D20180830-20180830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-08-30</xbrli:startDate><xbrli:endDate>2018-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4aa6006334a64ba98deab070fa192566_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i92566696a8e842be9629c3e2d9e89188_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i217ab7fc63be424d813ed59e43cfbac4_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacceeec5e6124e9bbe558a3cf8f40e58_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc6f0ef7bcae45cd8999ef7fb8dcb6e6_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd8e5c679d74d2ea0ab1f9c045914f9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie99d69e989dd4e2d9a91ac92c9cf93ea_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec38858c0924aa1a1b042bab111733f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1441d9eeae7465492a27c8ba288bcfc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia199374e753e4fc58c3d346ef47fee8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie06daf7da08d42bd910e91a19e6f42f8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib577766e74e4437fa096335a9fac4637_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82c871421e3b4f6d90a3c5b264aa99af_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic941034edd2f42ed87948712260e3dfd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c18ff4efe54c20b92677b523d29b9f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff855cdb40594dde993ebab82bcd68fb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i477c509d866a43a2bfe6a5b2524881f1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fe00d501071471994cd751b9c0b71e3_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27f6f313d1dd482988fc432dda095837_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b6022e971f4bba87288e373844658a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida603cbbdd6941a4875a53a9b110041d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb26ef99753941d797c8d6e6df4e31de_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87b7ef7e804c45fb914663a18ee558d1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ff578dfa0b48819e4f52ffe351100c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff92c63086be4b03a94436089380d2dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>apyx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd587233451f4a38903c8c534991b8af_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8feb8845b0564256867ba343b1691830_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ed5cc3391d04992bf148b8012572185_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277888b4c0464b438c89a4092e556552_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3dbf503dc59424c8962bef0a15c5e70_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id99d505a25264d4e876738d2927baa96_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i298c6efeca634aa8b52e461c51a9d455_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f706102a934d86aa02ba701cfc9f97_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728134f0ae5e4afabac37e4c4216d794_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000719135</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_1"></div><div style="min-height:31.5pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:22pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUz_ae8d6dc8-b7ba-481e-bead-a0f44168bba3">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV8wLTItMS0xLTU0ODQ_f9a7c15c-ca14-4c68-ba0c-66366ca8fedb">&#9746;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the quarterly period ended</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV8xLTQtMS0xLTU0ODQ_ef040ce1-93ed-43b2-8180-a651cf8ca4c8">September 30, 2021</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">or</span></td></tr><tr style="height:3pt"><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV81LTItMS0xLTU0ODQ_aecb58f3-667b-4867-8ec0-65f86a57c1d8">&#9744;</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">For the transition period from _____ to _____</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commission File Number: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV83LTQtMS0xLTU0ODQ_2e38d356-0d20-42ce-a077-280fd28c1e36">0-12183</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:114pt"><td colspan="3" style="padding:0 1pt"><div style="text-align:center"><img src="apyx-20210930_g1.jpg" alt="apyx-20210930_g1.jpg" style="height:145px;margin-bottom:5pt;vertical-align:text-bottom;width:223px"/></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZGZhZjYxOWU5ODJjNGE3MGFhM2JhMmNiN2VmZDlmNzUvdGFibGVyYW5nZTpkZmFmNjE5ZTk4MmM0YTcwYWEzYmEyY2I3ZWZkOWY3NV8xLTAtMS0xLTU0ODQ_0f3bbf48-6f7b-4f2d-b147-60ed3a9502fa">APYX MEDICAL CORPORATION</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZDhlYTA3YTJiZWI2NDgzZThjYjBiODQxZDE4NDMwNzIvdGFibGVyYW5nZTpkOGVhMDdhMmJlYjY0ODNlOGNiMGI4NDFkMTg0MzA3Ml8wLTAtMS0xLTU0ODQ_84601134-7111-4615-a63d-5f8ca5e1ee6e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZDhlYTA3YTJiZWI2NDgzZThjYjBiODQxZDE4NDMwNzIvdGFibGVyYW5nZTpkOGVhMDdhMmJlYjY0ODNlOGNiMGI4NDFkMTg0MzA3Ml8wLTItMS0xLTU0ODQ_e8762deb-1506-4c63-89e8-12861e89c4a1">11-2644611</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTQ4_148042c2-84a1-4cb4-a7b9-7dcbf0f0238b">5115 Ulmerton Road,</ix:nonNumeric> <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTQ5_53f328d3-1e96-48ba-a613-ebef22c1c359">Clearwater</ix:nonNumeric>, <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUw_7786192f-0811-4836-be11-1032800b7aff">FL</ix:nonNumeric> <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUx_03594bec-49df-4391-821e-a2cc8bba258b">33760</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices, zip code)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUy_c475b042-8c3b-4801-9d6a-2fa7ff51a580">727</ix:nonNumeric>) <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU0_8a611db8-079c-406b-9374-176c5a7baa2c">384-2323</ix:nonNumeric> </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number)</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Securities Registered Pursuant to Section 12 (b) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:34.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.254%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTAtMS0xLTU0ODQ_8a736fed-6855-40a8-8c01-dfacdd6e5028">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTEtMS0xLTU0ODQ_67838133-c73f-4651-9983-c0fb9bd82284">APYX</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTItMS0xLTU0ODQ_3dea0948-14a3-4c5d-9c1b-e1d59a5cfb84">Nasdaq Stock Market, LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU1_a0d05563-c8db-4b4c-bdb8-605a02096f95">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU2_7ecbd937-d424-49fd-8155-61a7122def27">Yes</ix:nonNumeric>: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.560%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.584%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18xLTAtMS0xLTU0ODQ_17467e5f-9b2e-4b96-85f2-90c2e8ceb900">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18xLTQtMS0xLTU0ODQ_1264f969-4663-48be-8dec-d0736b289f38">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18yLTQtMS0xLTU0ODQ_259f57bf-921f-4814-b692-ab22b7f9bd76">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#9744;</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes: </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU3_cf94d85c-de7c-4b9a-9d10-b178882a9171">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">s of November&#160;9, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i8d87cc0d00dd430e93bc08d22ef413d3_I20211109" decimals="0" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF82NTk3MDY5NzY4MjU0_1e2fff91-768b-4a5a-88de-e55b50c7a175">34,343,750</ix:nonFraction> s</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">hares </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">of the registrant&#8217;s $0.001 par value common stock were outstanding.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.283%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:13.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO QUARTERLY REPORT ON FORM 10-Q</span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended September 30, 2021</span></div><div style="margin-bottom:3pt;text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.775%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part I.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_10">Financial Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_10">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_13">Financial Statements</a> (Unaudited)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_13">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_16">Consolidated Balance Sheets at </a>September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_16">2</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_19">Consolidated Statements of Operations for the three </a>and nine months ended September 30, 2021 and 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed <a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_22">Consolidated Statements of Changes in Equity for the </a>three and nine months ended September 30, 2021 and 2020</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2021 and 2020</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_28">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_67">15</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_76">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_76">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_79">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_79">24</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Part II.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_82">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_82">25</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_85">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_85">25</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_88">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_88">26</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_94">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_94">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_97">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_97">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_100">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_100">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_103">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_103">27</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_106">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_106">28</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_109">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_109">29</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_10"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. &#160;&#160;&#160;&#160;Financial Information</span></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_13"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Condensed Consolidated Financial Statements</span></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:70.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.517%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September&#160;30, 2021</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Unaudited)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMy0xLTEtMS01NDg0_4441cc07-cd81-4cb8-bd2f-c27ab3460c31">30,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMy0zLTEtMS01NDg0_05221523-ed14-414a-a024-8f0e315f5ebe">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Trade accounts receivable, net of allowance of $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0wLTEtMS01NDg0L3RleHRyZWdpb246MzY1YTM2YTI3NmFlNGMwNzgxM2NjNjJlZDk0ZDBiOGFfNTQ_6b7a3bd6-492c-4954-a033-48d0f434c5c7">360</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0wLTEtMS01NDg0L3RleHRyZWdpb246MzY1YTM2YTI3NmFlNGMwNzgxM2NjNjJlZDk0ZDBiOGFfNjE_7bdc6fc2-ffe2-4146-a95d-f75144419ca0">300</ix:nonFraction></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0xLTEtMS01NDg0_a6a06a22-cdaa-4adc-8688-52b9397bde17">11,444</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0zLTEtMS01NDg0_5b079b1d-4393-410b-b446-606dfecba067">8,399</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNS0xLTEtMS01NDg0_20c22ac5-fee8-4255-ab2e-7b3162d896a1">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNS0zLTEtMS01NDg0_5cd97f19-6f8a-41d1-a152-c30b044297ca">7,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNi0xLTEtMS01NDg0_262d5c94-0c68-44bf-ab33-15d926d4f091">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNi0zLTEtMS01NDg0_8c0dbb5c-4444-4e94-85ff-e6bf06f3c40d">1,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net of provision for obsolescence of $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0wLTEtMS01NDg0L3RleHRyZWdpb246NDM0MmI2M2MxZDQ1NDZlNGEyMjE3ZmYxZmYwZjE4NzhfNTQ_147def7d-263f-40e1-9942-5c669375d465">303</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="apyx:ProvisionForObsolescenceInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0wLTEtMS01NDg0L3RleHRyZWdpb246NDM0MmI2M2MxZDQ1NDZlNGEyMjE3ZmYxZmYwZjE4NzhfNjE_621dce97-4ada-4676-a341-cbc2bb375058">388</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0xLTEtMS01NDg0_63e7f6e1-23ed-44f6-8108-f2397889c512">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0zLTEtMS01NDg0_2da1b3fe-7b2d-40d4-961d-090ebb663631">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOC0xLTEtMS01NDg0_c9c09e08-e820-462e-a304-e92b1eef599e">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOC0zLTEtMS01NDg0_15166425-1dc9-4c0d-992d-601395245384">2,795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOS0xLTEtMS01NDg0_bb7b6c4a-3afe-4196-bd63-5f0ab4fa1abe">59,876</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOS0zLTEtMS01NDg0_881781df-78d0-468a-a10f-a1d23b9a8bba">66,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmIxMjYyNmQ5MGJkMDRiZDViMTM2MTYyMDE1ZWI1ZWNkXzgw_ee0f4621-34c1-4892-9df2-0bb66d933cf8">5,145</ix:nonFraction> and </span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;$<ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmIxMjYyNmQ5MGJkMDRiZDViMTM2MTYyMDE1ZWI1ZWNkXzkx_f8dc5949-8064-41d3-9eaf-131d265408cd">4,813</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMS0xLTEtNTQ4NA_b6704565-4646-4d2a-88e0-5e448f400d71">6,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMy0xLTEtNTQ4NA_ccddf578-8363-46c9-a22c-a5d3678031f8">6,541</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTEtMS0xLTEtNTQ4NA_00f3055e-b26e-42eb-9d01-d0add46201e8">152</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTEtMy0xLTEtNTQ4NA_f2f37653-71a6-48c0-80f8-bbb735d3d350">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTItMS0xLTEtNTQ4NA_39a6cd89-8b09-454c-bfc9-6097cfe78325">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTItMy0xLTEtNTQ4NA_d5df506d-c8dd-4d5c-acfe-23e3178d0ef0">437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTQtMS0xLTEtNTQ4NA_553c038a-5045-4648-b1c8-29aaa033f9a6">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTQtMy0xLTEtNTQ4NA_a89f782e-9206-4a04-bba6-508876633850">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTUtMS0xLTEtNTQ4NA_17a95614-acfd-47da-bce6-3e51b98f696c">67,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTUtMy0xLTEtNTQ4NA_80e14491-e3ee-489d-b308-9bcab5747719">74,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjEtMS0xLTEtNTQ4NA_a3dfeb61-f921-40a2-ac42-59d79e70470a">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjEtMy0xLTEtNTQ4NA_f3cf9789-f002-443e-9462-80cb17dc0819">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjItMS0xLTEtNTQ4NA_e5e7fc28-6779-46fa-9403-6d03eed0d86d">8,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjItMy0xLTEtNTQ4NA_820470f2-70ac-4b1c-a735-1826a5b05c2e">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjMtMS0xLTEtNTQ4NA_0cdb3175-c2a3-485f-8256-e73606c7d38d">125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjMtMy0xLTEtNTQ4NA_fc5273a9-ebfc-4643-b48b-04b0e7eedddb">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjQtMS0xLTEtNTQ4NA_f23d0a60-046a-42ae-b9dd-6c10f0f6d66c">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjQtMy0xLTEtNTQ4NA_74620dab-5889-47b9-ade1-066cf64de47f">238</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjYtMS0xLTEtNTQ4NA_d9a7edf7-492c-4853-97c7-3011d0d1c022">11,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjYtMy0xLTEtNTQ4NA_0f487b20-097f-42bc-aad5-8855bd8e8910">9,153</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjctMS0xLTEtNTQ4NA_8041aeb4-5d2d-46d7-8aae-13a85f7a7c36">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjctMy0xLTEtNTQ4NA_0af1b9c1-22ba-4eb4-a993-a593f7168094">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjgtMS0xLTEtNTQ4NA_97de4c5c-e96d-4a80-82d3-39b0d5a42e0a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjgtMy0xLTEtNTQ4NA_763ab9dd-5ce8-49ff-b8e0-0abffe126774">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjktMS0xLTEtNTQ4NA_529ea040-8604-44a9-8379-183b75a58925">1,200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjktMy0xLTEtNTQ4NA_6e8aaa86-61d7-4d7e-ad4d-27b2a7f05d6e">621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzAtMS0xLTEtNTQ4NA_dc6985e9-c146-437c-9977-b26ecf986181">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzAtMy0xLTEtNTQ4NA_66b12424-d030-4140-9677-6ab2ebfd7ab7">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzEtMS0xLTEtNTQ4NA_be4645a5-acbb-43e5-a5e7-397610921321">13,109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzEtMy0xLTEtNTQ4NA_0387fa97-1ff1-41c2-8b60-96c6c2a5652b">10,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzE4_cb608e00-c639-43db-9dd0-4eea781af387"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzE4_dd2fd3ec-c16b-4ef8-bfa0-807605389260">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzMy_7d82cfae-dfe0-48ad-b51c-81a31eb2f374"><ix:nonFraction unitRef="shares" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzMy_8f1ce9b8-a8d3-4fd6-b2fd-5c9b5569f709">75,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzU0_1d4e4c21-6104-45d2-bbc6-f00eb63d78a8"><ix:nonFraction unitRef="shares" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzU0_5bbbc98d-1475-4f1f-8d61-7f41e0c503c8">34,339,533</ix:nonFraction></ix:nonFraction> issued and outstanding as of September&#160;30, 2021, and <ix:nonFraction unitRef="shares" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzEwNQ_6afb917e-4160-438f-b2f2-214a55661bf0"><ix:nonFraction unitRef="shares" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzEwNQ_e3676368-0fd0-4b2d-ba28-14d9e4c3aa3b">34,289,222</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMS0xLTEtNTQ4NA_c21c9e09-b302-40f4-a9bd-c2ff0aceed0c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMy0xLTEtNTQ4NA_88a485a0-604a-48d4-b1ce-3cf727614cb5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzQtMS0xLTEtNTQ4NA_fcfa32c4-53e8-4c20-bb76-3020f07dcdd0">64,862</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzQtMy0xLTEtNTQ4NA_d89a0428-0775-46cd-82ca-54c8a8270c4a">61,066</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Accumulated deficit) retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzUtMS0xLTEtNTQ4NA_2a8c428b-0ec0-44b8-b563-a91448974056">10,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzUtMy0xLTEtNTQ4NA_5520b0d8-4632-42e7-852d-c9d020973f87">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders' equity</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzYtMS0xLTEtNTQ4NA_ad0e7d67-a14f-41e7-b9a4-092a42375bc7">54,348</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzYtMy0xLTEtNTQ4NA_7ea90434-b6ea-4e35-b4d0-133e8d72ecac">63,721</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzctMS0xLTEtNTQ4NA_442d7997-218a-44aa-82bd-16e676d42fd6">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzctMy0xLTEtNTQ4NA_69b8cc23-0785-4ab2-95ed-e6d9e28c6e2c">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzgtMS0xLTEtNTQ4NA_b1c05358-e5a6-4c7b-9737-6b01fb96ee13">54,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzgtMy0xLTEtNTQ4NA_b440ea69-4fd0-412e-acca-85b32b1c4a0e">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzktMS0xLTEtNTQ4NA_494165f2-a172-43e9-95a7-f3943656f7f6">67,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzktMy0xLTEtNTQ4NA_632db8c9-20a6-413c-b8d2-78826d6792bb">74,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands, except per share data) </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi0xLTEtMS01NDg0_d152d5e4-9137-4f9a-a08e-937e2e3c0c8b">11,831</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi0zLTEtMS01NDg0_603d13fe-d85c-4768-96ba-b202f2e235d2">6,954</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi01LTEtMS01NDg0_14321190-4149-4451-89f7-80247ab8c72a">31,693</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi03LTEtMS01NDg0_0c87594f-da55-4667-a9bb-c999c7d9879b">16,247</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy0xLTEtMS01NDg0_c16d3450-2b11-4d85-b9bb-2890b5586089">3,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy0zLTEtMS01NDg0_fa18c27f-693d-4043-a995-4bb277404ee4">2,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy01LTEtMS01NDg0_585a1c51-f5dc-4e3a-a936-bb53360d0f1f">10,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy03LTEtMS01NDg0_cbce067e-61dc-400a-b0d0-94935d2ac829">6,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross profit</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC0xLTEtMS01NDg0_9b9c213a-2d0e-4ec9-8317-f915755ab140">8,056</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC0zLTEtMS01NDg0_4551e6e8-6d17-49b5-bfdb-919598e71604">4,725</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC01LTEtMS01NDg0_dd3168b4-b24a-43e7-b459-7c4d3f41bb22">21,450</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC03LTEtMS01NDg0_46dd6df6-d53d-4177-b8ff-09fcd1f3c599">9,803</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other costs and expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi0xLTEtMS01NDg0_6ad92ee5-cfb4-4d5b-9344-fbcd2f4c6485">1,175</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi0zLTEtMS01NDg0_667334cf-60e0-45bc-a689-f14ede06d9b2">1,047</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi01LTEtMS01NDg0_e2364048-e950-439a-a8bd-92c33892fba7">3,374</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi03LTEtMS01NDg0_d0a378b9-5464-44ed-aff9-d8d9cfeaaa5a">3,002</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy0xLTEtMS01NDg0_7987c03b-b4d4-4fe1-a1c0-cd4b08d14841">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy0zLTEtMS01NDg0_76c6623b-cf3d-4593-9a85-b499e323fd37">1,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy01LTEtMS01NDg0_9eee41e3-8e12-44a1-9224-f49a09c045a3">5,442</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy03LTEtMS01NDg0_cdd36785-6ed6-466d-af5b-5970f92aca69">5,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related costs</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC0xLTEtMS01NDg0_4a09ea34-419a-4333-8c47-89e376a4d229">4,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC0zLTEtMS01NDg0_e8772a91-a4df-4c7c-982b-ff61afe01642">3,508</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC01LTEtMS01NDg0_4aeeae28-a226-4212-a60c-97509b391cf9">12,794</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesAndWages" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC03LTEtMS01NDg0_7fa82f85-49e1-4af6-8ce0-bf54588148c5">10,258</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS0xLTEtMS01NDg0_b3c2f24f-1588-4f8a-8ce0-e8bffdfe8626">4,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS0zLTEtMS01NDg0_e7de52c8-ef37-418c-951d-01bd4bc7bcfa">2,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS01LTEtMS01NDg0_af2c12cc-1f97-421f-bacb-b4410d9a22cb">12,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS03LTEtMS01NDg0_87cf7f17-e737-4435-bfdc-c916032c3fd9">8,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other costs and expenses</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtMS0xLTEtNTQ4NA_5c9a5225-d925-42d6-b399-3b14f9fc377e">12,024</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtMy0xLTEtNTQ4NA_99fdf07e-7d11-4de3-b636-be1ef9c503c9">9,096</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtNS0xLTEtNTQ4NA_2448bc4a-5c10-494a-a2fb-f474e821d07c">34,206</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtNy0xLTEtNTQ4NA_1ba59113-67ce-4858-adb6-a78170029387">27,833</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtMS0xLTEtNTQ4NA_e618f654-82e8-4cfb-8045-80c1319f48dd">3,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtMy0xLTEtNTQ4NA_9cf397a8-cf2e-4699-8e98-0060d3d9f0bc">4,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtNS0xLTEtNTQ4NA_1b983284-087a-4e36-9f21-94b0b7dbfe71">12,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtNy0xLTEtNTQ4NA_2a511857-63c0-4db7-931e-0465bad407c0">18,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItMS0xLTEtNTQ4NA_8863cc46-3e8a-4b19-880d-0034705a63d7">2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItMy0xLTEtNTQ4NA_cf6f0da9-5319-4b97-a971-926b50a12bb4">10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItNS0xLTEtNTQ4NA_b99cb05e-3dd5-46f8-87a2-d7ad15cbcba2">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItNy0xLTEtNTQ4NA_ffcef594-7cda-44a9-a342-8a02a1bd66ba">233</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtMS0xLTEtNTQ4NA_5b6c1e27-7877-47f1-be3b-7f0b8069ef3e">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtMy0xLTEtNTQ4NA_d5d351f6-b1da-4d80-9fec-59ee13c9dcf5">25</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtNS0xLTEtNTQ4NA_5fa78f9a-055d-45ae-abb6-fa8e7ccd54ae">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtNy0xLTEtNTQ4NA_f2be2daa-4bc4-412f-b2ee-accc05e94851">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtMS0xLTEtNTQ4NA_40d003f8-23ce-4097-869a-b32ad203ca21">192</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtMy0xLTEtNTQ4NA_697d6ee4-c09b-4566-9d71-a4462a1fc59e">63</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtNS0xLTEtNTQ4NA_c2a55ce8-f03c-413b-ada0-dfe5439d2db0">188</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtNy0xLTEtNTQ4NA_d125000c-d82b-4c3b-9a15-b919093124c8">349</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtMS0xLTEtNTQ4NA_d11d0a19-684f-497f-8019-2f71e9afdeb4">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtMy0xLTEtNTQ4NA_a21aee35-e660-453e-a4b0-d9a5c1e76e28">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtNS0xLTEtNTQ4NA_90d2bf62-3ce5-46d0-8817-d3415cd9f6ee">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtNy0xLTEtNTQ4NA_496fe173-aacb-4515-b1d4-33e1e11b5f8e">543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtMS0xLTEtNTQ4NA_7998e2ba-71af-4067-9335-7434ee75ea9d">4,161</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtMy0xLTEtNTQ4NA_b6a8366d-3d85-426d-8b0a-341286983718">4,449</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtNS0xLTEtNTQ4NA_18427d13-4718-4959-9a5b-20644b99a97c">12,944</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtNy0xLTEtNTQ4NA_a3e16521-68da-48ee-913b-98e2c5ec3276">17,487</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctMS0xLTEtNTQ4NA_fb9aa610-172c-4307-ac30-a1b226288d2e">73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctMy0xLTEtNTQ4NA_3d4a295e-7cb0-47dd-839c-ee907243b679">715</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctNS0xLTEtNTQ4NA_817f65a0-cad8-4625-a289-a5738919c387">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctNy0xLTEtNTQ4NA_5cf1c471-1487-4408-ab9b-c7b77ff897eb">7,112</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtMS0xLTEtNTQ4NA_7c8275c3-1131-4529-9a58-ac05ec25d122">4,234</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtMy0xLTEtNTQ4NA_52232f09-3c20-4d70-b8f5-89489b19daf1">3,734</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtNS0xLTEtNTQ4NA_7dffd905-1a97-4449-97b7-1209ca092e8a">13,190</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtNy0xLTEtNTQ4NA_7967767d-8211-4057-9760-1980c315bbd4">10,375</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Net loss attributable to non-controlling interest</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktMS0xLTEtNTQ4NA_e3063243-2dea-4fb8-b930-e99ac174c248">12</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktMy0xLTEtNTQ4NA_33032b1b-6187-4fdc-a91b-0114a83eb079">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktNS0xLTEtNTQ4NA_5ca83e40-5d10-4ff5-a1dc-62915aa12304">21</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktNy0xLTEtNTQ4NA_23220fee-5a2b-4ab5-8e0d-6e5aa7ece1b7">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss attributable to stockholders</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtMS0xLTEtNTQ4NA_b1769e79-6559-47bf-b246-5eb40f4b9209">4,222</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtMy0xLTEtNTQ4NA_7e9c0235-7178-41ea-8f58-824c80760671">3,728</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtNS0xLTEtNTQ4NA_a94a9418-ed84-485d-a4da-686d3ccb8f2f">13,169</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtNy0xLTEtNTQ4NA_ea574d74-e841-4562-809f-5c918fa383bd">10,369</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMS0xLTEtNTQ4NA_37c0f6a0-dbce-425f-92dd-ef57a9d222d3"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMS0xLTEtNTQ4NA_4feed867-5d33-4ab6-8529-f2bb2fdd757b">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMy0xLTEtNTQ4NA_4d9a996d-897d-4648-a233-f93cf6763783"><ix:nonFraction unitRef="usdPerShare" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMy0xLTEtNTQ4NA_f32361b3-a08f-47e8-b05f-589b6cafc8d5">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNS0xLTEtNTQ4NA_0643f3cb-b592-4529-8850-5a6bc8d2fc7d"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNS0xLTEtNTQ4NA_ba85f1c2-9b73-4110-a3b6-8ad52ce0578f">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNy0xLTEtNTQ4NA_89587003-04f8-4d44-ab99-588d0649bf61"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNy0xLTEtNTQ4NA_8e8bda4f-6ea2-4569-9b45-a89b6966d920">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:12.719%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_22"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.850%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021 and 2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Equity</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8cd62ad6efef478ea9253454d1b323fc_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0xLTEtMS01NDg0_4cbe32c8-6d07-4396-902b-709a35a94632">34,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cd62ad6efef478ea9253454d1b323fc_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0zLTEtMS01NDg0_a84e3584-0649-4ea1-ae06-34a7c6e48aa9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied69cc4d5a424703ad140e56f728ec4c_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy01LTEtMS01NDg0_838c125d-903e-4990-8c64-54c748943ed9">58,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaac4971ea2db4dc09b26a866c233c20f_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy03LTEtMS01NDg0_c03a62c3-609b-403f-8a86-d0723d37dacb">7,876</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75344978b6a74bc49f92004b47d2a99a_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy05LTEtMS01NDg0_a06f65c3-8d56-45c5-8d95-df58cd1ff457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i288fa9706cf44b8facc8faf026ba5348_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0xMS0xLTEtNTQ4NA_e895de34-b299-4671-a4a9-18c688f43bbd">66,836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNC05LTEtMS01NDg0_e89e6370-14b4-4c09-8e7b-89ea779b95f4">148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNC0xMS0xLTEtNTQ4NA_a0c0298a-9daf-4de3-9525-2912817ce84e">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS0xLTEtMS01NDg0_f3293201-d690-4ad9-9208-f9dcf9f18437">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS01LTEtMS01NDg0_5d3b273c-aadc-45ac-af4a-b90b3f6a9479">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS0xMS0xLTEtNTQ4NA_59f60b7e-269f-42b7-b5a2-8cab0ffb4628">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNi01LTEtMS01NDg0_c945a4da-afe4-4881-860e-85995d689b9f">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNi0xMS0xLTEtNTQ4NA_23bbecc9-b0df-4aa4-80b5-c1f1ce2ca354">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNy0xLTEtMS01NDg0_9ad7fa46-de20-4f70-9585-4742b82918ff">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief9af1557e4f4da285e53418666bd7c3_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS03LTEtMS01NDg0_dd1d7f8a-dd05-4e23-a164-0f4098213f7d">3,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS05LTEtMS01NDg0_3c04e8f4-e004-4264-b0d7-7a37d298e126">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS0xMS0xLTEtNTQ4NA_a2e60395-8cc1-4dfe-a5bd-fd88f8b6c986">3,734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMS0xLTEtNTQ4NA_970ee826-f08e-4f8d-88a2-7205bc504c60">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMy0xLTEtNTQ4NA_85ae1587-8e2b-4083-ab3d-16348b81322e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb31e9500ecb42efb36391b9387777c7_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtNS0xLTEtNTQ4NA_097b11a8-a8a8-402e-bc74-96352d8a167e">60,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtNy0xLTEtNTQ4NA_db286eb3-0463-458e-9c08-0643f89ec87d">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d4ef659eb7431bbcfe190050698da3_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtOS0xLTEtNTQ4NA_6150228e-3754-4719-99f2-23aef169d710">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMTEtMS0xLTU0ODQ_424e4582-da4e-4008-93e0-ee32f9668ca7">64,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee57ebf3a9b340788524d62a380a9faa_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMS0xLTEtNTQ4NA_ad6e5f5c-2b30-4398-84e0-6698d4d1ccc2">34,323</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee57ebf3a9b340788524d62a380a9faa_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMy0xLTEtNTQ4NA_c114c663-482e-4dd6-8c65-18f5632d9ed9">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i984f1d5dd05b4d329a24c070a595974a_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItNS0xLTEtNTQ4NA_9f33a7a3-bfe7-4660-85ae-7283219ec608">63,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43b8251fde224eef8a0347a6e3949722_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItNy0xLTEtNTQ4NA_9c827d68-993b-4fb8-a491-a657b3d1185f">6,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f06f183d7144f57a3f2a51f639d94a3_I20210630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItOS0xLTEtNTQ4NA_2b71dcd2-9fd9-48de-b813-ba5263ac7090">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ba94fe7a6414cc99d227e2c683db25c_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMTEtMS0xLTU0ODQ_839b5645-e522-46b9-9851-522d2accd9bb">57,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtMS0xLTEtNTQ4NA_16063043-8f99-4595-a941-19e1d7e5d48f">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtNS0xLTEtNTQ4NA_ee793690-48b0-4072-bfeb-5ae15f74364d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtMTEtMS0xLTU0ODQ_f3629de6-b8da-4e85-9fbe-546f99c350fc">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTUtNS0xLTEtNTQ4NA_52de5005-a860-4329-a89c-a5bac3451dcf">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTUtMTEtMS0xLTU0ODQ_62d7d1f4-caa4-40da-bc06-0c32113ecde7">1,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTYtMS0xLTEtNTQ4NA_ffb189c3-d5a0-4e39-ab9e-69518930c915">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fe0683ef1f64486a18c7e5908f33e7a_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtNy0xLTEtNTQ4NA_4e3ef9e3-2ef8-4006-8df0-f112102f92ae">4,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863033745e7146f18475cca8dedbfbe2_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtOS0xLTEtNTQ4NA_a9d41424-0d4b-423d-ad3c-cff47b3bb34f">12</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtMTEtMS0xLTU0ODQ_37f21d18-0991-4f1d-a8bc-1eb1baf6c338">4,234</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMS0xLTEtNTQ4NA_1c0f3473-316e-4c8b-a750-78ab343ae06d">34,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMy0xLTEtNTQ4NA_2972b6d9-41b9-485e-953a-740889b407a4">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148f935a59024792a748fb1d4f38671f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktNS0xLTEtNTQ4NA_9243a26d-2ef1-4d6d-9576-16eee149cad2">64,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f70eafe2be446e695a8ccd7a1f65471_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktNy0xLTEtNTQ4NA_6056699e-65f9-4e5d-bde2-f9a87b10d11b">10,548</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401e199c245e45e2b3bc3d4d91130100_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktOS0xLTEtNTQ4NA_3d9f1943-263e-4357-a379-d820637364fe">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMTEtMS0xLTU0ODQ_e0877848-1295-4ec3-8e42-8872a061ccab">54,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021 and 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained Earnings (Accumulated Deficit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-controlling Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i38848fe39ff64851a1cbe4f24a730945_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMS0xLTEtNTQ4NA_d047eaf7-50e6-453d-8d7f-0988cd96a850">34,170</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38848fe39ff64851a1cbe4f24a730945_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMy0xLTEtNTQ4NA_1fa05ca9-dfc9-4abe-9dd4-459b36e6c49b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b421bc868b4e08849cd49dfe789fd2_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtNS0xLTEtNTQ4NA_752dff56-bc46-4309-96e9-1ef0245b35cd">56,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9315b652eeb413db25d16425efd6de9_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtNy0xLTEtNTQ4NA_e4a74675-8f33-44b2-90ff-d9b020e96967">14,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae1ce0523054de58fd6ba4b0d5d6563_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtOS0xLTEtNTQ4NA_4a154e9f-f850-435d-ad39-10617bac973e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMTEtMS0xLTU0ODQ_8b424e02-134e-457f-8dcd-26535da20875">71,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ad44ab908404be1b219b693527268fd_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjUtOS0xLTEtNTQ4NA_a508054d-9b83-4113-8a4a-f80f57beb258">148</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjUtMTEtMS0xLTU0ODQ_23691de8-be23-4ae9-ac56-5ad37a558f86">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie01729704401438f9953c87c6f6cd951_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtMS0xLTEtNTQ4NA_9a3b60f6-48d7-4557-8108-da3e2abb0e25">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtNS0xLTEtNTQ4NA_df3c5361-baa1-4e93-bc7b-5766e3d533c8">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtMTEtMS0xLTU0ODQ_e9acd83e-1132-4da5-ba4d-3ef0bb3ea16d">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjctNS0xLTEtNTQ4NA_267fe93c-6b6c-4cdb-8c50-f1d65bd3c1be">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjctMTEtMS0xLTU0ODQ_737b8aed-3d41-4dd8-afa4-2f2c8a247477">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie01729704401438f9953c87c6f6cd951_D20200101-20200930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjgtMS0xLTEtNTQ4NA_b72bd83f-635e-4722-8ab4-5bb11aed7bf6">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i73a176064ef443598ec51cc2bb38bc3f_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtNy0xLTEtNTQ4NA_741b3361-84bb-4d8b-ab2e-de79a05a1f42">10,369</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ad44ab908404be1b219b693527268fd_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtOS0xLTEtNTQ4NA_cc6e5205-ee21-46c2-8067-4b4a81e56e74">6</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtMTEtMS0xLTU0ODQ_d3270c09-6c69-4cc0-ba5b-2855b51514c6">10,375</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMS0xLTEtNTQ4NA_314cf343-f05b-49c8-8616-86f2a3010a26">34,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMy0xLTEtNTQ4NA_0f7dd9fb-6e87-4b3e-a624-ba686f0b96b1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb31e9500ecb42efb36391b9387777c7_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtNS0xLTEtNTQ4NA_4b028db3-a78c-4583-a7a2-96d776457a2a">60,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtNy0xLTEtNTQ4NA_47a3e8bb-ebb7-41c8-8a69-b3b51559f87d">4,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7d4ef659eb7431bbcfe190050698da3_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtOS0xLTEtNTQ4NA_d25b6556-3260-49ea-a15f-5dcbee363d20">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMTEtMS0xLTU0ODQ_27628af9-dee6-4786-a71a-b745233aef04">64,338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5479fed4aae147488d8d0627f13aaecc_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMS0xLTEtNTQ4NA_1adcfb00-ab20-43a9-afa5-52ab8949ff15">34,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5479fed4aae147488d8d0627f13aaecc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMy0xLTEtNTQ4NA_48754169-6862-4e5f-a2de-5a8822b865b7">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c89473017f4de187b5214a631371df_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtNS0xLTEtNTQ4NA_72907c8f-a116-4afb-b6f7-00652faa20f5">61,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c8bf58148c4c71bb4b113ba65e0d64_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtNy0xLTEtNTQ4NA_494cbe9b-ad79-40bd-8557-0861183c3ece">2,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie14d7e777681449e8cbe2e5ae99cf56f_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtOS0xLTEtNTQ4NA_e3d13fab-0f19-47d2-abf3-0a7ca39f4f68">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMTEtMS0xLTU0ODQ_133c8529-05c7-453b-82d2-d948811cb5c3">63,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzQtOS0xLTEtNTQ4NA_fc7671d9-26a2-4c51-acea-e1ead95f3ac4">195</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzQtMTEtMS0xLTU0ODQ_51ca9c50-ce09-4bf8-8048-5bab978dddca">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on stock options exercises for cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtMS0xLTEtNTQ4NA_707c3c1f-8551-4f6e-bf06-aeef2d92d914">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffa3da465324394823951b3715cae7c_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtNS0xLTEtNTQ4NA_548d369f-f833-41ee-b6f8-3b6e1fb719f2">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtMTEtMS0xLTU0ODQ_21cf0418-148c-40a4-9c2a-ee7d09a135bc">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idffa3da465324394823951b3715cae7c_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzYtNS0xLTEtNTQ4NA_87ac5415-ce0a-4761-99f5-482101205987">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzYtMTEtMS0xLTU0ODQ_361653c8-e932-4255-808b-8beafa534d1d">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares issued on net settlement of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930" decimals="-3" name="apyx:StockSwapToAcquireOptionsShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzctMS0xLTEtNTQ4NA_6aeabb62-7da6-40a8-8cf2-66abe5e99171">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2fc895348acb46d3a770cfb612e019f6_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktNy0xLTEtNTQ4NA_75b2c900-2d3f-4282-841d-28529a4ff409">13,169</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktOS0xLTEtNTQ4NA_64cedcd7-acbe-4ce7-b5be-590ade8d18d8">21</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktMTEtMS0xLTU0ODQ_6f425911-5d83-4c24-bcb7-7698243dc6a2">13,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMS0xLTEtNTQ4NA_1c92e48c-15d1-465e-9f58-101ce137d30c">34,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMy0xLTEtNTQ4NA_ca89bb03-6afd-4ff8-9daf-68a93f24f0a5">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148f935a59024792a748fb1d4f38671f_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtNS0xLTEtNTQ4NA_bf5f43f5-f5ba-4273-952b-7f5f1166d511">64,862</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f70eafe2be446e695a8ccd7a1f65471_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtNy0xLTEtNTQ4NA_8e23dd9d-7e64-4b9e-ab71-3f97495ce4a2">10,548</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i401e199c245e45e2b3bc3d4d91130100_I20210930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtOS0xLTEtNTQ4NA_68c8d186-6916-4e2c-b254-a913f1d3a454">312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMTEtMS0xLTU0ODQ_48480139-b0b2-4184-9d2a-0ca2bfb884b4">54,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMy0xLTEtMS01NDg0_0b25e39b-cb74-40c3-9aeb-0e4fdede0cb8">13,190</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMy0zLTEtMS01NDg0_d83e044f-6cf6-48db-8ff4-17af3eb16fd9">10,375</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNS0xLTEtMS01NDg0_b58074a6-db2d-44f7-9b83-260144c3fb0d">674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNS0zLTEtMS01NDg0_af646188-3dca-4296-bf55-d452d0f4a60c">662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for inventory obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNi0xLTEtMS01NDg0_cce36409-0487-4b49-89c0-49afcead5a69">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="apyx:ProvisionForInventoryObsolescence" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNi0zLTEtMS01NDg0_b8ee5729-e0ca-44a1-b676-f0335de80bf8">427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOC0xLTEtMS01NDg0_fde8f332-01e6-4ba5-84b5-3b114f360207">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOC0zLTEtMS01NDg0_dec9698d-cc6d-47d0-b1ed-e3b2f0a94ea8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOS0xLTEtMS01NDg0_80776ccb-e1d3-4ebb-9655-883fe555ecf5">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOS0zLTEtMS01NDg0_e9519785-e8f1-4727-9a3c-df7aeb14369b">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTAtMS0xLTEtNTQ4NA_5337b637-1435-4c4b-8c48-b28edea21fd8">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTAtMy0xLTEtNTQ4NA_3cb31d19-be58-46d3-b280-7412b46010fc">486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTMtMS0xLTEtNTQ4NA_9ce75c95-47bf-4185-8fe8-20a4213e7428">3,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTMtMy0xLTEtNTQ4NA_1e11949a-8775-45b5-b684-adc20b3b8bd7">1,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTQtMS0xLTEtNTQ4NA_2e138725-b46f-4aa0-aed2-903e731b36b2">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTQtMy0xLTEtNTQ4NA_5596bb2c-0f70-47ab-b3fa-b9571b65bbf2">981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTUtMS0xLTEtNTQ4NA_3d5deb91-c1c6-4fad-bcbf-a34df2c26949">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInIncomeTaxesReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTUtMy0xLTEtNTQ4NA_e43efaa5-b117-458a-810a-9768a2ded7fc">6,812</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTYtMS0xLTEtNTQ4NA_cf93c8ec-cfd4-4548-a8ce-257429db1a86">1,982</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTYtMy0xLTEtNTQ4NA_86a3531d-8947-46e8-a376-1f63827e6a05">717</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTctMS0xLTEtNTQ4NA_730d3463-081a-44ab-853f-cffa2cdff8f2">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTctMy0xLTEtNTQ4NA_1633d8b5-cb01-47b2-b41e-651e7b622850">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTgtMS0xLTEtNTQ4NA_e4ff242c-dc87-4ea0-a5d1-e4745c013596">1,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTgtMy0xLTEtNTQ4NA_fab32f46-3fcc-4db0-883f-7f3229258cb8">2,352</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTktMS0xLTEtNTQ4NA_a360cea3-cb06-4e40-b49d-e75f0874ac73">10,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTktMy0xLTEtNTQ4NA_0e587a6f-945e-4aae-8f45-a45d703c3242">15,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjEtMS0xLTEtNTQ4NA_7e000ef2-3a14-41db-84ad-ba82358329e1">391</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjEtMy0xLTEtNTQ4NA_7e17546b-7b43-4501-9227-783b355e1274">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjQtMS0xLTEtNTQ4NA_1be14777-057a-42db-b395-fb9975944d10">391</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjQtMy0xLTEtNTQ4NA_eb695208-b22d-4946-bd2c-0969cf52ad85">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from stock option exercises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjYtMS0xLTEtNTQ4NA_a473682d-7431-4471-a756-9ec3707d0c1e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjYtMy0xLTEtNTQ4NA_96aa2bc6-99d4-4ab2-8328-40193432d032">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayment of finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjgtMS0xLTEtNTQ4NA_03d86e29-08d7-4fca-9a9b-0c72b814f9d9">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="apyx:RepaymentofFinanceLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjgtMy0xLTEtNTQ4NA_61f24434-a6ee-490d-9677-3221f6917081">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions from non-controlling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjktMS0xLTEtNTQ4NA_5c81dae3-2e00-4d13-961f-21a10cc22f0a">195</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:ProceedsFromMinorityShareholders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjktMy0xLTEtNTQ4NA_82f435d4-f2ae-4e2b-a36a-fdab73d35d4a">148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzAtMS0xLTEtNTQ4NA_06a2091e-df27-422c-b344-432a282d9ba3">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzAtMy0xLTEtNTQ4NA_16abaea3-5657-4ff3-b584-6fd514a93c0c">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effect of exchange rates on cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzEtMS0xLTEtNTQ4NA_5315f991-9611-420d-bd16-04cd0edd3567">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzEtMy0xLTEtNTQ4NA_7e170a82-5e81-4539-85f0-3439c9bb71a1">92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzItMS0xLTEtNTQ4NA_d4ce44e9-8caf-48cd-9666-32292fc3924e">11,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzItMy0xLTEtNTQ4NA_98961b7d-8b37-42f0-a089-a7ec00483154">15,273</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzMtMS0xLTEtNTQ4NA_242f802b-403c-4a69-9886-8827e53885da">41,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzMtMy0xLTEtNTQ4NA_8f2c6ba0-db3b-4123-8933-45530c69dd6c">58,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzQtMS0xLTEtNTQ4NA_afa6d932-32b8-4eff-807e-6869c2717c99">30,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzQtMy0xLTEtNTQ4NA_950b00bc-cc74-4bed-b254-4ec7133f1c74">43,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash paid for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzctMS0xLTEtNTQ4NA_700610f9-dbd1-40b2-ba51-797c1cb0eeae">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzctMy0xLTEtNTQ4NA_b759065a-3c95-44d9-9883-0779bd217b5e">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzgtMS0xLTEtNTQ4NA_c03a8fad-e023-4005-8661-5ef08c7b8940">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzgtMy0xLTEtNTQ4NA_567712df-5c71-4a36-8568-b8e33e6ca075">54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of the condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_31"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zMS9mcmFnOmIxOTM3OTVmZjZhMDQ5YWRhOGYxMDc4NTllOWQ0YmQwL3RleHRyZWdpb246YjE5Mzc5NWZmNmEwNDlhZGE4ZjEwNzg1OWU5ZDRiZDBfMjg5NQ_7d53ae78-9609-4e68-9693-2488d855712e" continuedAt="if0c7d422f9ce48dcaf4bd8a9c81b0d09" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if0c7d422f9ce48dcaf4bd8a9c81b0d09"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic and its impact on the level of economic activity around the world including ongoing supply chain disruptions. The extent of the impact of the pandemic on the Company's business is highly uncertain and difficult to predict, as the responses and information related to it continue to change.  As elective surgery cases using the Company&#8217;s Helium Plasma Technology have started to increase again, it is unknown whether these trends will continue.  The full extent to which the COVID-19 pandemic may materially and adversely impact the Company&#8217;s future financial position, liquidity, or results of operations remains uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zMS9mcmFnOmIxOTM3OTVmZjZhMDQ5YWRhOGYxMDc4NTllOWQ0YmQwL3RleHRyZWdpb246YjE5Mzc5NWZmNmEwNDlhZGE4ZjEwNzg1OWU5ZDRiZDBfMjg5NA_1cc08d4e-8255-4766-aeac-5fd730727611" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_34"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNC9mcmFnOmNkN2VlOTc5ZWFhYTRkNzI4OTllODdhNjcyNDg3M2Y5L3RleHRyZWdpb246Y2Q3ZWU5NzllYWFhNGQ3Mjg5OWU4N2E2NzI0ODczZjlfMTU2OA_99beec51-dd19-4125-bb88-d58305cc6d23" continuedAt="i8eb4b6cd1f714d1aa7334fe6575d8e23" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i8eb4b6cd1f714d1aa7334fe6575d8e23"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNC9mcmFnOmNkN2VlOTc5ZWFhYTRkNzI4OTllODdhNjcyNDg3M2Y5L3RleHRyZWdpb246Y2Q3ZWU5NzllYWFhNGQ3Mjg5OWU4N2E2NzI0ODczZjlfMTU2Mw_62091a07-1cf7-481d-afe9-cce0bcdd6d6e" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_37"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY3MQ_08353bc6-712d-49b3-9f1b-6fd29ceadf06" continuedAt="ib0027351c68144778cd8631b74374d2d" escape="true">DISPOSAL OF BUSINESS</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="ib0027351c68144778cd8631b74374d2d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfNTAy_c7d41889-233c-4567-aaed-0547550d0053">97</ix:nonFraction>&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a <ix:nonNumeric contextRef="i2ac1cefbb0fa4631b29d06f046c1d8a3_D20180830-20180830" format="ixt-sec:durwordsen" name="apyx:AssetPurchaseAgreementTerm" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY3Mg_831c6abc-1e73-4c9e-aac2-2d17cc8b6738">four-year</ix:nonNumeric> term, whereby it will manufacture certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). Core activity for the three months ended September&#160;30, 2021, amounted to $<ix:nonFraction unitRef="usd" contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTAzMA_de63c596-7a62-479a-a52f-252b54fc9c31">1.6</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA2Nw_907dba19-df3d-40ed-b88a-01b923515926">1.3</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTEwMA_37373e13-d4f3-42ad-8961-e2af68872f2e">0.5</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTEyNw_1e62223d-3398-42b2-b283-08eb65f1e749">0.3</ix:nonFraction>&#160;million. Core activity for the three months ended September&#160;30, 2020, amounted to $<ix:nonFraction unitRef="usd" contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTE5OQ_4c77c2d1-8a69-43c2-b217-06a68508f8c2">1.8</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTIzNg_a10d8c9e-7b90-49c4-81f8-675706cbdd69">1.6</ix:nonFraction>&#160;million and related other expenses of $<ix:nonFraction unitRef="usd" contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTI2OQ_54351d07-6e30-4241-8a1f-265723d95602">0.3</ix:nonFraction>&#160;million for net other loss of $<ix:nonFraction unitRef="usd" contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA5OTUxMTYyOTU5MA_85deef5b-6071-4f0f-8f1b-af4de7cad9a5">0.1</ix:nonFraction>&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $<ix:nonFraction unitRef="usd" contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTM3Nw_0917c23c-d118-4393-8aad-1c29b1841860">5.2</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTQxNA_d76efefe-46ca-4080-ab2e-90a0ad36ea77">4.4</ix:nonFraction>&#160;million and other related expenses of $<ix:nonFraction unitRef="usd" contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTQ0Nw_c6284439-9753-47eb-afb5-cb636ac1dbdd">1.1</ix:nonFraction>&#160;million&#160;for net other loss of $<ix:nonFraction unitRef="usd" contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA5OTUxMTYyOTYzMA_177560e7-af29-4fe2-ae7c-82414618db35">0.3</ix:nonFraction>&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $<ix:nonFraction unitRef="usd" contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTU1NQ_5a5b0c68-e834-474c-bfa1-7cf961ca6c7f">6.9</ix:nonFraction>&#160;million with cost of sales equivalents of $<ix:nonFraction unitRef="usd" contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTU5Mg_f564987a-b4e2-4a16-9287-f166df9a6b54">6.1</ix:nonFraction>&#160;million and net other related operating expenses of $<ix:nonFraction unitRef="usd" contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTYzOQ_d6a66b88-0e8e-4d06-b253-8d9f299a2458">0.5</ix:nonFraction>&#160;million for net other income of $<ix:nonFraction unitRef="usd" contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY2Ng_a063826c-5e26-4cfe-969d-b15a6f462970">0.3</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfMzk5_11c927c4-5167-4a65-897e-af625326b982" continuedAt="i15d003a996fe4ec19360f95c4b2fdd85" escape="true">INVENTORIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i15d003a996fe4ec19360f95c4b2fdd85"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfNDA4_d6c80e1d-24a4-4bac-9d88-ebb7c6f6bcb5" escape="true">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfMzk3_3858e143-75b1-403f-b0df-2908579094e5" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMS0xLTEtMS01NDg0_97ebe29d-1de6-4621-b6a5-091c2dfc8352">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMS0zLTEtMS01NDg0_bacd983f-0f60-42ee-b5b5-dd1d5ed97ed7">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMi0xLTEtMS01NDg0_b13fda27-995d-471b-899d-687e3c4bb8e9">1,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMi0zLTEtMS01NDg0_2fa8f41e-fa36-4843-9a6d-68a3b8bb42ea">1,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMy0xLTEtMS01NDg0_9a5254e9-67f3-49c5-ad81-5f7e83ee9403">1,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMy0zLTEtMS01NDg0_ef7a71cb-73e6-453b-a7dd-d07064a76edb">1,087</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNC0xLTEtMS01NDg0_6ad31389-7fab-45da-b022-68bed21bde72">6,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNC0zLTEtMS01NDg0_14cae2a4-e846-4f51-8613-6a1c77b544d4">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNS0xLTEtMS01NDg0_a90e632a-d405-41d0-9e61-e899ca5eb6fb">303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:InventoryValuationReserves" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNS0zLTEtMS01NDg0_ed553118-bd3b-4085-a66f-4191d7e68844">388</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNi0xLTEtMS01NDg0_d8a061ae-eb60-4373-9581-4bc0b3eb07a6">6,040</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNi0zLTEtMS01NDg0_7367b18b-531b-434e-85c8-4732fc89d755">4,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_43"></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RleHRyZWdpb246ZWE2ZmIxNzcyYTVlNGMxZjllMTgyMTM2MWVmZTUwY2JfMTQ3_95da1a5a-5e16-4641-94bc-5ac05273ec4c" continuedAt="i13aec7ecc4f249f58bb21b9ea20281b0" escape="true">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i13aec7ecc4f249f58bb21b9ea20281b0"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RleHRyZWdpb246ZWE2ZmIxNzcyYTVlNGMxZjllMTgyMTM2MWVmZTUwY2JfMTQy_2582ed71-eb8d-441d-b434-397e0899b3c7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMS0xLTEtMS01NDg0_383d32c7-8a53-45f6-b056-3bddd8351db0">894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMS0zLTEtMS01NDg0_36b62841-a847-4b70-99c9-3d0c085ae1f8">808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMi0xLTEtMS01NDg0_f646df35-6ab6-437e-99cd-5c9e64d11962">1,559</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:AccruedBonusesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMi0zLTEtMS01NDg0_cd5226c1-2689-4db3-b071-0bcd07c4bce3">811</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMy0xLTEtMS01NDg0_02aa6f17-d1ee-4fb2-a036-e050132e1fea">897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalesCommissionCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMy0zLTEtMS01NDg0_8de519a1-8900-4285-ad20-77e7449f72d8">1,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNC0xLTEtMS01NDg0_e5140161-ad77-4f21-92da-1169a29e078c">547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:ProductWarrantyAccrualClassifiedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNC0zLTEtMS01NDg0_f8d3854b-4b87-4657-8b30-0e1cc5e09beb">498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNS0xLTEtMS01NDg0_9d1538f2-10ef-482e-a260-9369cc6c6ab8">440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:AccruedInsuranceCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNS0zLTEtMS01NDg0_cab73c3e-40a0-474b-836d-574860e098b3">435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNi0xLTEtMS01NDg0_00e0480e-9de1-40de-8c1b-baad1def6eeb">252</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNi0zLTEtMS01NDg0_be826ecf-900c-410d-a096-12e8b12ad920">222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNy0xLTEtMS01NDg0_53e69095-138d-40ee-bf9d-c0e332ef9d5b">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="apyx:JointAndSeveralPayrollLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNy0zLTEtMS01NDg0_7a2ef9ba-43c1-4226-84a0-2a1c2d0e2a8e">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOC0xLTEtMS01NDg0_0725d688-7ad9-4b4c-926a-b901e56c2b44">1,810</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="apyx:UncertainTaxPositionsLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOC0zLTEtMS01NDg0_fedd349c-49c4-4a12-a65b-729976db9799">1,658</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOS0xLTEtMS01NDg0_7f01c40a-0420-4d34-b99c-e3e795156ee2">243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOS0zLTEtMS01NDg0_38596adc-6255-4ef5-b9a1-095bed236c27">591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTAtMS0xLTEtNTQ4NA_f4894f58-3599-4bfc-924b-534f807e09b1">655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" name="apyx:OtherAccruedExpensesAndLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTAtMy0xLTEtNTQ4NA_4577b095-a138-48e0-aa72-cf2568ab9eb5">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTEtMS0xLTEtNTQ4NA_e5e7fc28-6779-46fa-9403-6d03eed0d86d">8,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTEtMy0xLTEtNTQ4NA_08ef76d5-3478-4a29-8d82-9a548d18e923">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:MinorityInterestDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfNjQ3_dd0809b4-427d-4a22-a05a-af3ce19da021" continuedAt="i956971c038d447209e956221c1ac365a" escape="true">CHINA JOINT VENTURE</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i956971c038d447209e956221c1ac365a" continuedAt="ife063b0f1ddf4dfd82ba6da900376e24"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV") whereby the Company has a <ix:nonFraction unitRef="number" contextRef="i92566696a8e842be9629c3e2d9e89188_I20191231" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMTU2_9faf4b8d-cb05-455f-aa51-52cb2c8729cb">51</ix:nonFraction>% interest in the China JV. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="apyx:NoncontrollingInterestRequiredCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMjk2_9a59da5b-6981-4966-a249-267a38b9d2e3">357,000</ix:nonFraction>, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i217ab7fc63be424d813ed59e43cfbac4_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMzIz_603f58d4-e5bb-411f-aa86-ab6bf134e8a6">203,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMzMw_4b7075f6-e828-41f3-900d-ff2705ee8b2d">154,000</ix:nonFraction>, respectively, were contributed during the three months ended June 30, 2021 and the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="apyx:NoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfNjQ4_7f263798-59b5-4aae-9a1f-bbb3afe87714" continuedAt="i930c598b518f4583bf102a4d147fdbd7" escape="true">Changes in the Company's investment in the China JV were as follows:</ix:nonNumeric></span></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div><ix:continuation id="ife063b0f1ddf4dfd82ba6da900376e24"><ix:continuation id="i930c598b518f4583bf102a4d147fdbd7"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacceeec5e6124e9bbe558a3cf8f40e58_I20210630" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi0xLTEtMS01NDg0_8d782a8c-70ba-4a7f-8f58-27ed190b24b2">338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc6f0ef7bcae45cd8999ef7fb8dcb6e6_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi00LTEtMS02NDkz_7e0e19e4-8627-4241-9197-39aece6f5b70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcd8e5c679d74d2ea0ab1f9c045914f9_I20201231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi01LTEtMS01NDg0_0624072c-7bc0-4882-bf34-3c4a7631aeb3">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie99d69e989dd4e2d9a91ac92c9cf93ea_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi04LTEtMS02NDk3_bbcca46b-33fe-425e-868a-4ec77e27a5b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy0xLTEtMS01NDg0_54af9cbb-3a5f-48f0-b285-716ec1644521">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy00LTEtMS02NDkz_f4129c91-b871-42b2-b9cc-75c16c6b8abe">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec38858c0924aa1a1b042bab111733f_D20210101-20210930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy01LTEtMS01NDg0_fff77c00-d79b-403a-b00c-24ed7ae228f5">203</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy04LTEtMS02NDk3_08230d35-25bd-4afb-9491-127b7840c781">154</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC0xLTEtMS01NDg0_8a460225-b099-492f-95d1-f373c91100c1">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC00LTEtMS02NDkz_2b420a73-6d9b-4c19-9921-fd4d0be1a61d">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idec38858c0924aa1a1b042bab111733f_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC01LTEtMS01NDg0_ec60c56f-a0ed-4076-91d0-a40094fd135c">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC04LTEtMS02NDk3_fd731a5e-4029-4e15-9e58-6149e32f1153">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1441d9eeae7465492a27c8ba288bcfc_I20210930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS0xLTEtMS01NDg0_523ae2fd-c3a1-4918-b495-912e6569af1a">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia199374e753e4fc58c3d346ef47fee8c_I20200930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS00LTEtMS02NDkz_b4d544a5-e4cb-47d4-aff7-e6d9a2742732">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1441d9eeae7465492a27c8ba288bcfc_I20210930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS01LTEtMS01NDg0_e59e04fe-b8ea-4c73-ae16-4b4e3b207263">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia199374e753e4fc58c3d346ef47fee8c_I20200930" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS04LTEtMS02NDk3_3d5c2adf-40f1-42f1-b36d-885df3e76d55">148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_49"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RleHRyZWdpb246OGM0NzkyNTc0ODg3NDU3M2E4YzQzZDVjYjZmZTkwNDNfNTM4_69896d63-412d-4940-bbba-6b3ca7972596" continuedAt="ia232c316d8f54748b79d4e5fa0760e15" escape="true">EARNINGS (LOSS) PER SHARE </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia232c316d8f54748b79d4e5fa0760e15"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RleHRyZWdpb246OGM0NzkyNTc0ODg3NDU3M2E4YzQzZDVjYjZmZTkwNDNfNTM2_821b2575-ce2f-4d96-92f7-7fa594a9cce4" continuedAt="idfaf3ea9bde74f139ab007b477deaadd" escape="true">The following table provides the computation of basic and diluted loss per share.</ix:nonNumeric></span></div><div style="margin-top:5pt"><ix:continuation id="idfaf3ea9bde74f139ab007b477deaadd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:46.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.329%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy0yLTEtMS01NDg0_1de252bc-9195-4a7f-91f4-10e74bfca509"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy0yLTEtMS01NDg0_d356e3d7-1882-41b8-8855-c8384e5540a8">4,222</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy00LTEtMS01NDg0_13cca5cc-8cba-4fce-a8d6-a57c8ae8e769"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy00LTEtMS01NDg0_b07da3cb-d42c-467d-afd8-508a68974327">3,728</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy02LTEtMS01NDg0_6ec16d21-eb5d-4bbf-aa79-9d05e2aafe1f"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy02LTEtMS01NDg0_f3e9ee1a-9090-4594-9035-6f12687f0d01">13,169</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy04LTEtMS01NDg0_50d7ec66-549e-4f48-aa49-b00d967b0346"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy04LTEtMS01NDg0_c49eeb31-e874-4ba8-8bf1-7e39527084e1">10,369</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi0yLTEtMS01NDg0_9e7e9cd1-65f2-4d51-9e4b-bcdb0463a340"><ix:nonFraction unitRef="shares" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi0yLTEtMS01NDg0_e1d14705-9980-4f77-8961-81d1b6352f2a">34,330</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi00LTEtMS01NDg0_325f865c-3a02-4eb4-b5d6-c627229603f5"><ix:nonFraction unitRef="shares" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi00LTEtMS01NDg0_b1ab0a57-6aa0-4b95-a27b-e105088b286d">34,216</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi02LTEtMS01NDg0_09905f29-ae3f-43be-8e14-68667989d08a"><ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi02LTEtMS01NDg0_630b4661-cf6b-48b6-bee3-7909ec3a83c5">34,318</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi04LTEtMS01NDg0_524f3d0b-1eea-4612-88f4-43ffab1f20f5"><ix:nonFraction unitRef="shares" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi04LTEtMS01NDg0_b8ac59c4-ad97-4408-84ee-548e76febafa">34,193</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS0yLTEtMS01NDg0_8239201d-ab32-4fc8-85bf-656fa8ad5f57"><ix:nonFraction unitRef="usdPerShare" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS0yLTEtMS01NDg0_d2c5c77c-7821-41bd-b853-5b4320e38810">0.12</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS00LTEtMS01NDg0_59016d1f-9ea6-4d8a-ae35-8b937888d921"><ix:nonFraction unitRef="usdPerShare" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS00LTEtMS01NDg0_aed3d481-9c5d-4434-9705-68311147a708">0.11</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS02LTEtMS01NDg0_7a869129-8901-4c54-af12-5db48cfb2811"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS02LTEtMS01NDg0_e3d46e99-a47a-4db9-90b8-c359a8e4a2c8">0.38</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS04LTEtMS01NDg0_1317955c-fb1c-4b6f-83fc-7ac61f75a6b0"><ix:nonFraction unitRef="usdPerShare" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS04LTEtMS01NDg0_28c07697-a8aa-400e-835d-d66d62b0b099">0.30</ix:nonFraction></ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie06daf7da08d42bd910e91a19e6f42f8_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItMi0xLTEtNTQ4NA_27677f65-6952-4253-b06c-fced8e460f29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib577766e74e4437fa096335a9fac4637_D20200701-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItNC0xLTEtNTQ4NA_e13dd887-187a-4d64-95ec-3f18dc198360">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82c871421e3b4f6d90a3c5b264aa99af_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItNi0xLTEtNTQ4NA_a44c10f8-752f-4563-8c65-9ea3bb325bdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic941034edd2f42ed87948712260e3dfd_D20200101-20200930" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItOC0xLTEtNTQ4NA_aa827c25-ed81-43b8-92eb-9c1f25086874">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c18ff4efe54c20b92677b523d29b9f_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtMi0xLTEtNTQ4NA_2e883f55-5f00-4ca2-be58-8c6b919febd6">5,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff855cdb40594dde993ebab82bcd68fb_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtNC0xLTEtNTQ4NA_bf5c8bc9-bab6-4627-9c14-9d1a8f7c3a59">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i477c509d866a43a2bfe6a5b2524881f1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtNi0xLTEtNTQ4NA_7678bba7-cf3b-4b22-9ccb-273369b6000e">5,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6fe00d501071471994cd751b9c0b71e3_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtOC0xLTEtNTQ4NA_3899a9eb-b3fe-4a48-86cf-6001b09c6b11">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg0Ng_c859ef9c-63e4-4709-a7f7-3a3cb1e44e6e" continuedAt="i33372986777a4b88badfc339bef312e3" escape="true">STOCK-BASED COMPENSATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i33372986777a4b88badfc339bef312e3"><div style="text-align:justify"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg1MA_cc9b5483-8049-410d-b24a-75fc23049daa" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNjUw_b354bf5e-7927-402c-a783-67d8b11cb0b2">1,184,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNjU3_419c52b4-48eb-4a84-b464-0e6be97ef545">3,747,000</ix:nonFraction>, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2021, as compared with $<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNzgx_115b9d18-6f4d-4702-a99e-83ddfb6c7c66">1,063,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNzg4_5c1e5827-0660-482b-acbb-1535f93696fa">3,209,000</ix:nonFraction>, respectively, for the three and nine months ended September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg0Mg_771480db-480e-437a-9dab-d6b75be4ab91" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNS0xLTEtMS01NDg0_e5a2738c-a983-41e3-8b88-bc4383ed1f92">4,938,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNS0zLTEtMS01NDg0_c3e2d9cc-d929-4daf-9316-2c93661dc3c6">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNi0xLTEtMS01NDg0_e4ddcf35-154a-4270-b662-e5b42c250861">894,980</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNi0zLTEtMS01NDg0_d7cb6043-ea29-4186-a022-eb88d6f17c7e">9.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNy0xLTEtMS01NDg0_220ae90c-d9f8-4340-91e5-d2db12cfc1bb">109,415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNy0zLTEtMS01NDg0_a4f8c140-2767-4439-80b8-7be5bfc686ab">6.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOC0xLTEtMS01NDg0_f273a704-1ab0-4cb6-bf70-941c7bd301ff">190,793</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOC0zLTEtMS01NDg0_121348a2-63b9-4d04-bc11-ddc8021dd6f8">8.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOS0xLTEtMS01NDg0_959eee13-ae25-48d2-9d8c-067ef42ac8ab">5,533,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOS0zLTEtMS01NDg0_b3872445-f117-4c88-aa1e-7fa8e878fcc3">5.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2021 and 2020, respectively, we received <ix:nonFraction unitRef="shares" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTMyMA_7f67ebd8-004c-4ecd-9ec7-ce44f1fe7c8f">37,049</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ3NA_9f3fb7ec-7793-414e-a785-e19d496d6a9b">16,140</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTM2OA_33e49b0d-1bec-44d9-8461-dc92b24b22e0">13,285</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ2Ng_e97b5e92-192e-4492-84c6-b7a949a9164f">10,610</ix:nonFraction> options. For the nine months ended September 30, 2021 and 2020, respectively, we received <ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTQ2Mg_c6b486a3-9afe-40fb-bc1e-08b842701935">59,104</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ1OA_8689fdf4-b090-46da-a360-b3f7dddb4938">29,149</ix:nonFraction> options as payment in the exercise of <ix:nonFraction unitRef="shares" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTUxMA_a11dae88-99ca-48e2-a616-87145e7096be">39,312</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="apyx:StockIssuedDuringPeriodSharesStockSwaps" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ1MA_a7145df0-0014-4411-9606-eb3cf1709cf6">32,637</ix:nonFraction> options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. <ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg1Nw_5dd0b41a-8062-42d1-bf75-8c99074e1ff4" continuedAt="i3ad66d8e50fe40379613fdcbcb891017" escape="true">The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model.</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i3ad66d8e50fe40379613fdcbcb891017"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"></td><td style="width:66.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.150%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.650%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMS0xLTEtMS01NDg0_ab60fc97-39fa-43db-9f74-182e02088d99">9.29</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMS0zLTEtMS01NDg0_702322eb-faf0-4cb6-8135-0d0d40e5223e">11.51</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMi0xLTEtMS01NDg0_8ced24bc-3f8e-4a5a-a82f-bd91589769db">0.6</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMi0zLTEtMS01NDg0_c7a20a56-7b5c-41c3-8d7d-7e238023cceb">0.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="3" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMy0xLTEtMS01NDg0_9816f335-0a73-45af-8f6b-f61012a392c1">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNC0xLTEtMS01NDg0_f973d3fd-a407-4b94-8ec0-194cb90604b5">68.9</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNC0zLTEtMS01NDg0_ba6455d6-1666-4bdd-95c3-c14eb16fe7d7">70.8</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNS0xLTEtMS01NDg0_a603ad45-05e4-400f-b380-c3be9b4b69cf">4.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNS0zLTEtMS01NDg0_afe0e713-8093-4098-89a3-6d4604503500">6</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_55"></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMzAyMA_d52c88ad-1ed7-47b4-a11e-1865dbfc9591" continuedAt="i8fdc25f037f74a64b5e8f23f18f3a35e" escape="true">INCOME TAXES </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8fdc25f037f74a64b5e8f23f18f3a35e" continuedAt="i1ddb8491d778421eb2e6858609a36881">On March 27, 2020, the U.S. government enacted the CARES Act to provide financial relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequently, the Company generated net losses in 2019 and 2020. For the net losses generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with its NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company recognized an income tax benefit of approximately $<ix:nonFraction unitRef="usd" contextRef="i27f6f313d1dd482988fc432dda095837_D20200101-20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODY5_36e6fc84-79fa-46df-9992-6eb9d048eea5">3.7</ix:nonFraction> million associated with the release of the valuation allowance on its Federal NOL carryforward related to 2019. For the three and nine months ended September 30, 2020, the Company also recognized income tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTA5MQ_fc0258ff-9287-422e-be72-f108942c6526">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTA5OA_a41a110c-6e7b-48dc-b3f5-0525d972bbb9">7.1</ix:nonFraction> million, respectively, related to losses before income taxes.</ix:continuation></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1ddb8491d778421eb2e6858609a36881" continuedAt="iaa664a344e7a4f02a4c8f6c1c3f80e31">Income tax expense (benefit) was approximately $<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTIwMw_36482a5a-9605-451b-9a03-12fe81e67225">73,000</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTIxMA_66f97af2-28cf-47d0-9239-784140cf28ef">715,000</ix:nonFraction>) with effective tax rates of (<ix:nonFraction unitRef="number" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTI0MQ_8f612e0d-52d8-4da5-a331-62abf48ffcae">1.8</ix:nonFraction>)% and <ix:nonFraction unitRef="number" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTI0OA_c53da2ca-926e-4e73-82df-ea29e1001725">16.1</ix:nonFraction>% for the three months ended September&#160;30, 2021 and 2020, respectively. Income tax expense (benefit) was approximately $<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTM2Mw_9633e0cb-2f91-4295-8165-761efaf6ef1a">246,000</ix:nonFraction> and $(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTM3MA_b65f32bb-b8fe-451d-b360-ddfe6ac31fd6">7,112,000</ix:nonFraction>) with effective tax rates of (<ix:nonFraction unitRef="number" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTQwMQ_6724d2a8-cd65-405b-930e-1f11d971f50b">1.9</ix:nonFraction>)% and <ix:nonFraction unitRef="number" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTQwOA_b0aa58f2-5154-4f4d-9648-75a8c00b8f57">40.7</ix:nonFraction>% for the nine months ended September 30, 2021 and 2020, respectively. For the three and nine months ended September&#160;30, 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on the NOL carryforward from 2019. </ix:continuation></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa664a344e7a4f02a4c8f6c1c3f80e31">The Company has gross unrecognized tax benefits of approximately $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTk4NA_3026f104-577d-43be-9aa6-a963866a04c3">1,313,000</ix:nonFraction> at September&#160;30, 2021. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODkyMQ_dba86349-6723-4a0e-aded-1736b99e9440">497,000</ix:nonFraction> in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense (benefit) for the three months ended September&#160;30, 2021 and 2020, respectively, are approximately $<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODk0MQ_f7c28adc-d02a-4889-88cd-70a7096c123d">52,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMjQzNA_9bd02200-d4a2-41bd-98fb-7e2f4e05147b">43,000</ix:nonFraction> of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense (benefit) for the nine months ended September 30, 2021 and 2020, respectively, are approximately $<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfNjU5NzA2OTc3MzQzMQ_6421df88-d133-4d48-a073-07c979e29225">152,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODI0NjMzNzIxMzI5NQ_2dfdedcb-b34f-49f2-80bd-4b53d1e7cf11">125,000</ix:nonFraction> of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODk1MA_02113f6f-1986-439a-bb64-0851d3097a0f">1,810,000</ix:nonFraction> of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_58"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81OC9mcmFnOjQ5ZTRmMWFjNTExZDRlNGRhYThlZmQ4YmM0ZDg0NzA1L3RleHRyZWdpb246NDllNGYxYWM1MTFkNGU0ZGFhOGVmZDhiYzRkODQ3MDVfMjM4NA_24a6c87b-6b9a-4287-bfe6-d176a1ad38d5" continuedAt="if6353ba107544ddbbf37c8f53580a6a6" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if6353ba107544ddbbf37c8f53580a6a6"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company had purchase commitments totaling approximately $<ix:nonFraction unitRef="usd" contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PurchaseObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81OC9mcmFnOjQ5ZTRmMWFjNTExZDRlNGRhYThlZmQ4YmM0ZDg0NzA1L3RleHRyZWdpb246NDllNGYxYWM1MTFkNGU0ZGFhOGVmZDhiYzRkODQ3MDVfMjI5Ng_9fcabdbb-7a1e-4a38-be8b-66248421a624">5.2</ix:nonFraction>&#160;million, substantially all of which is expected to be purchased within the next twelve months.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTE0_34fa5f29-dfaa-4bdb-8b1f-08ab16ef57aa" continuedAt="ia83641f4d1ef4ca1bfae567e61b033d4" escape="true">RELATED PARTY TRANSACTIONS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="ia83641f4d1ef4ca1bfae567e61b033d4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2021 and 2020, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="ic3b6022e971f4bba87288e373844658a_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNjQy_e1014519-5e62-434b-a8d1-bcb65511dfcd">456,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ida603cbbdd6941a4875a53a9b110041d_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNjQ5_029e9ff8-1e3a-4280-a1f0-476386ece2c1">410,000</ix:nonFraction>, respectively. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020, the Company made purchases from this supplier of approximately $<ix:nonFraction unitRef="usd" contextRef="ieb26ef99753941d797c8d6e6df4e31de_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNzc5_99d75ec2-caf0-467b-b1cb-087888f1a98c">1,102,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i87b7ef7e804c45fb914663a18ee558d1_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNzg2_b7adc6de-5671-4890-bd72-c00e3f05bbc9">1,250,000</ix:nonFraction>, respectively. At September&#160;30, 2021 and December&#160;31, 2020, respectively, the Company owed this supplier approximately $<ix:nonFraction unitRef="usd" contextRef="i18ff578dfa0b48819e4f52ffe351100c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTAz_51ca889e-6dbf-446f-9cf9-8c372c3c255a">48,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="iff92c63086be4b03a94436089380d2dd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTEw_dcd5b871-e6b0-4d0d-af9b-7aac29c44bb4">38,000</ix:nonFraction>.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_64"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTc0MA_5f9fcfed-8524-4222-99d5-9d56028b1c74" continuedAt="i356e3995c6254f3bb51b1da97c440384" escape="true">GEOGRAPHIC AND SEGMENT INFORMATION </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="i356e3995c6254f3bb51b1da97c440384" continuedAt="i1a5ec71a554545d5b3359b9cb11f1c7f"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as <ix:nonFraction unitRef="segment" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfODYy_36cce254-aced-4095-b24a-2e4c69ecdff4"><ix:nonFraction unitRef="segment" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfODYy_37dce6ed-b97a-422f-8704-771ec3fbedd1">two</ix:nonFraction></ix:nonFraction> operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTcyOA_763077e8-9c23-4780-91b3-9c2ceeabf826" continuedAt="icbc15da193464756a1112a34fe3b0d99" escape="true">Summarized financial information with respect to reportable segments is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i1a5ec71a554545d5b3359b9cb11f1c7f" continuedAt="if97c0fbb85084d03ba2803a50548d24e"><ix:continuation id="icbc15da193464756a1112a34fe3b0d99" continuedAt="i42a08d9ede7348a2a9f4d8b57aa303e8"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi0zLTEtMS01NDg0_35d72a99-7d05-4dc9-b2ca-e7507b5d4d28">10,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi01LTEtMS01NDg0_ba9911ad-211c-47c7-8542-b8d62c589d7a">1,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi03LTEtMS01NDg0_8165f62e-c23d-4ddc-8b1c-db8051b42bed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi05LTEtMS01NDg0_5c07f96d-3038-4dd6-900d-380889d8f462">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtMy0xLTEtNTQ4NA_a1cdbcf3-ced5-4bcc-b8e8-4078cfd43cff">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtNS0xLTEtNTQ4NA_598b5804-7581-447a-8f78-22cfddde5290">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtNy0xLTEtNTQ4NA_8c728d95-b125-441c-9c21-ccebc5212286">4,348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtOS0xLTEtNTQ4NA_c0f95fac-2c77-4a1f-9f70-63d3626f4ddb">3,968</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtMy0xLTEtNTQ4NA_ecb4b5ca-0c80-4ac9-a401-85acf411abca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtNS0xLTEtNTQ4NA_422153b1-8519-43d3-8ffa-a1a280834e75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtNy0xLTEtNTQ4NA_905a3b8b-8461-401a-9761-7559d25bbe82">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtOS0xLTEtNTQ4NA_15564f04-2d0b-49dc-bde0-9766a87824a7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctMy0xLTEtNTQ4NA_09013afe-2c22-4c17-89ca-4b0e059568be">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctNS0xLTEtNTQ4NA_3fe4e83a-c6a3-415d-bfa1-4584c750dbfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctNy0xLTEtNTQ4NA_b087658f-6ec7-4442-8a21-4da4afde8ac1">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctOS0xLTEtNTQ4NA_8d8288d8-74e8-4943-9353-478a5fa201ec">3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtMy0xLTEtNTQ4NA_bb91ecb4-80f8-4129-99f5-a6d3bf703eb2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtNS0xLTEtNTQ4NA_6ba9a97f-a684-4779-bd5f-dc42c7a13034">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtNy0xLTEtNTQ4NA_63d46a01-27f3-4ee9-b818-0ff632eee9ec">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtOS0xLTEtNTQ4NA_87a0bf0c-9a9d-4ddd-b0d4-1d3a1067b283">192</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItMy0xLTEtNTQ4NA_a261f8be-ffc7-40b4-8092-ed05c5916fe1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItNS0xLTEtNTQ4NA_f9c9b680-af31-45e8-893a-b15d967704f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItNy0xLTEtNTQ4NA_649fec62-d1c8-4ce2-9cad-fcf36006077d">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItOS0xLTEtNTQ4NA_3ac90b9b-238f-4294-8394-c000c99a5a84">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi0zLTEtMS01NDg0_764b964b-d37f-4693-a963-369e460f7888">5,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi01LTEtMS01NDg0_57ad3cff-032f-472d-9779-637cca086521">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi03LTEtMS01NDg0_632c46d6-f87e-4214-a814-ace4028d5ac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi05LTEtMS01NDg0_e45e73f0-03a4-4709-90f7-8e65dacbea97">6,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtMy0xLTEtNTQ4NA_8bcabc92-7866-4c00-8759-637f9a17aefa">1,095</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtNS0xLTEtNTQ4NA_0ade32b1-c800-47c4-b854-d8a663b3cd87">556</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtNy0xLTEtNTQ4NA_092c891f-523e-4299-8ce4-41b042b63298">3,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtOS0xLTEtNTQ4NA_40bbd337-56e6-4a0f-b77f-b8ca4e351392">4,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtMy0xLTEtNTQ4NA_0b2ccbfc-406c-4f60-9afa-cae3c7af1bb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtNS0xLTEtNTQ4NA_5a408139-f985-443e-9e66-88444079794b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtNy0xLTEtNTQ4NA_e01db2e8-7303-4784-8de0-a518c7edac85">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtOS0xLTEtNTQ4NA_091707b8-d022-409a-aa24-0886467c3a54">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtMy0xLTEtNTQ4NA_0fb8c4a7-7d40-4937-9ac2-94a4052435b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtNS0xLTEtNTQ4NA_883cb446-9fa8-4487-8391-2bbfcd611709">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtNy0xLTEtNTQ4NA_2dd4a57a-2d8c-43aa-b988-b55e8e84f119">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtOS0xLTEtNTQ4NA_06350199-f39d-4abe-9280-8a42f08f90fd">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktMy0xLTEtNTQ4NA_53cb52a8-e12f-4b31-abcf-c36b5db6bbb0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktNS0xLTEtNTQ4NA_ba04bf99-1af7-4508-9647-545efc005ed5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktNy0xLTEtNTQ4NA_0bbb9a79-b117-4a21-9b73-b184298c56f6">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktOS0xLTEtNTQ4NA_90eb59fc-aae2-4ed3-b5a4-d52551515091">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtMy0xLTEtNTQ4NA_3ac151ac-9bcf-49ba-8598-574520306ea5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtNS0xLTEtNTQ4NA_b47a2108-59b2-4af2-9baa-8bc47415cec2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtNy0xLTEtNTQ4NA_8e093025-5717-4c13-9214-67ac8c6e5725">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtOS0xLTEtNTQ4NA_24e10d2d-9478-47d8-b88b-c462f2ac0182">715</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi0zLTEtMS01NDg0_c55995a9-2d2e-41f8-a904-44d206577071">27,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi01LTEtMS01NDg0_61e9e55e-4dd4-4de8-96c3-9e596b55ea81">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi03LTEtMS01NDg0_dc186cbb-a2e9-48bd-9f92-3304d39bf38a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi05LTEtMS01NDg0_2e21bcab-7735-407b-888d-256ab9ed34ba">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtMy0xLTEtNTQ4NA_5c1e9547-8a8f-4cf5-a950-3fc2dbbcac93">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtNS0xLTEtNTQ4NA_6582c21c-2b3c-4c1b-b471-18a34be55ace">588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtNy0xLTEtNTQ4NA_d4efe301-5bd2-4ee1-96e7-c2f95a9c68bc">13,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtOS0xLTEtNTQ4NA_bcbff355-0c76-47ac-b275-538627ccd05d">12,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtMy0xLTEtNTQ4NA_047fd664-cb7b-4568-a11f-43b1e9f3c8c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtNS0xLTEtNTQ4NA_e7f49f0c-d495-45bb-86fc-c33021609b7e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtNy0xLTEtNTQ4NA_44973f15-4f3a-4a88-9161-4819eef297ee">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtOS0xLTEtNTQ4NA_d612cf82-f032-41ab-afb9-89ab6c994cdc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctMy0xLTEtNTQ4NA_f6c60fa5-de53-466d-9d31-6e8760b5a762">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctNS0xLTEtNTQ4NA_dbb8fa44-359b-4ed6-a77e-7c826c4ddf9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctNy0xLTEtNTQ4NA_c87d21ce-d73b-4106-bc48-4ee7900ea775">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctOS0xLTEtNTQ4NA_7f1990fd-0c1f-49cf-ad83-858ca6b3754d">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtMy0xLTEtNTQ4NA_ddf429a4-a12d-4efa-be30-f1a8dac403d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtNS0xLTEtNTQ4NA_f73ee1ff-a764-4fc9-8e4d-952fba1b270c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtNy0xLTEtNTQ4NA_b8074bed-dfd1-4f98-96d7-790fce3a31ad">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtOS0xLTEtNTQ4NA_fcff5007-217e-4748-a6b0-30e91d6f6fd2">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItMy0xLTEtNTQ4NA_dd95bd99-8dd5-4226-bf7c-9afc2b21094a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItNS0xLTEtNTQ4NA_59f31491-4009-4070-85c7-bc552ea460ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItNy0xLTEtNTQ4NA_e616d928-43d6-4926-a8d1-9c40c02a6217">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItOS0xLTEtNTQ4NA_5b2089e7-ec13-4410-8683-30cfe42544a4">246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="if97c0fbb85084d03ba2803a50548d24e"><div style="text-align:justify"><ix:continuation id="i42a08d9ede7348a2a9f4d8b57aa303e8"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.811%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi0zLTEtMS01NDg0_4db9d0b7-fb39-4cd7-9c31-71dca60acee7">12,332</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi01LTEtMS01NDg0_3d4ee9c7-b1f1-43bb-88a4-9015c097fcec">3,915</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi03LTEtMS01NDg0_0451437b-955f-4cc7-9be1-6c30d3da39d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi05LTEtMS01NDg0_47c78c39-11b6-43fe-9f43-8c74fc8d160b">16,247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtMy0xLTEtNTQ4NA_dbc69704-2d51-4592-936a-ce125277df3c">8,371</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtNS0xLTEtNTQ4NA_cb91e433-ee57-4175-8162-569e82746670">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtNy0xLTEtNTQ4NA_0f479d39-66bf-4f43-9ca5-babd7e0cb05b">11,046</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtOS0xLTEtNTQ4NA_f07d53ea-e582-494c-af21-c0d4e427724a">18,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtMy0xLTEtNTQ4NA_4e65b3b7-e814-4547-901d-df0a4b399c37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtNS0xLTEtNTQ4NA_eceae333-34e0-4380-ae43-cd4cf24b3b7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtNy0xLTEtNTQ4NA_2ed73b37-59d5-47fc-9acd-cc4e62d27cf1">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:InterestIncomeOperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtOS0xLTEtNTQ4NA_8652d5d1-8712-4f8b-ad59-68dec5b15e47">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctMy0xLTEtNTQ4NA_83ef2173-2077-4e09-ac78-d3ced3e6bb0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctNS0xLTEtNTQ4NA_16963ffa-e5c9-490a-b258-b6a27a9ab115">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctNy0xLTEtNTQ4NA_19bac88c-0722-435b-b133-6db544387d58">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctOS0xLTEtNTQ4NA_fbb3cce0-f8d2-4d51-8517-9f94b1a35e40">39</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtMy0xLTEtNTQ4NA_272a7405-367a-42b4-990b-9027fe137d9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtNS0xLTEtNTQ4NA_48849324-2fb9-44ea-bbae-ea94aa6757b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtNy0xLTEtNTQ4NA_732b2d85-848d-421d-b4c5-736040b54bf1">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtOS0xLTEtNTQ4NA_eb39e13e-d6ea-4914-a0df-377fc47a6689">349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItMy0xLTEtNTQ4NA_d62a3549-ebe6-472c-a4b7-cde52ce00cd4">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItNS0xLTEtNTQ4NA_e06e6ae2-748b-4855-b3ce-d709769595de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItNy0xLTEtNTQ4NA_8fd6158e-dd79-4168-8859-046a07730e7b">7,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItOS0xLTEtNTQ4NA_e3b1ed34-332c-4a04-9852-95d05bdcd656">7,112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately <ix:nonFraction unitRef="number" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTQwNg_96463b09-b3e7-481c-84a9-6a857acaab13">33.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTQxMw_1570c32e-7c7c-401d-a581-3341944fd191">34.2</ix:nonFraction>% of total revenues for the three and nine months ended September 30, 2021, respectively, as compared with approximately <ix:nonFraction unitRef="number" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTUyOQ_cec00171-0e45-4ad2-b770-07e94f2f24b2">25.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="3" name="apyx:TotalRevenuePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTUzNg_87aac80b-60b3-423e-9120-1a6464933c95">24.8</ix:nonFraction>% of total revenues for the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" name="us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTczOA_3c89d769-98bb-4ea8-afca-aa71a8446541" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8feb8845b0564256867ba343b1691830_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy0xLTEtMS01NDg0_a737f3af-6318-4c0b-8d8a-2d0a0031a884">7,911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ed5cc3391d04992bf148b8012572185_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy0zLTEtMS01NDg0_6feac2f7-808d-4ecb-a817-cce1fa41cc51">5,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277888b4c0464b438c89a4092e556552_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy01LTEtMS01NDg0_56bfad84-5fe3-4db1-811c-50b7d5ea796d">20,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3dbf503dc59424c8962bef0a15c5e70_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy03LTEtMS01NDg0_863e6c10-26c0-4ee9-b20c-d5be9a76c378">12,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id99d505a25264d4e876738d2927baa96_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC0xLTEtMS01NDg0_38ca38f3-481e-4b5d-9ed8-299094b5d68a">3,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i298c6efeca634aa8b52e461c51a9d455_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC0zLTEtMS01NDg0_b73df41f-d329-4056-901e-be65978a59a4">1,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f706102a934d86aa02ba701cfc9f97_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC01LTEtMS01NDg0_07771b69-70df-46c4-9bdb-81b98123a710">10,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728134f0ae5e4afabac37e4c4216d794_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC03LTEtMS01NDg0_a584bf4a-77f2-4270-b023-a7dea5fb549c">4,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS0xLTEtMS01NDg0_9e213872-e499-4035-a647-70daeb169054">11,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS0zLTEtMS01NDg0_fbdf83b1-4e3d-42c1-8e0b-13f009f23eed">6,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS01LTEtMS01NDg0_d2a83985-807d-4e9c-8966-da1d76b0f663">31,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS03LTEtMS01NDg0_1ab7c283-5de5-45da-a288-61d8b720a40c">16,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_67"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should read the following discussion and analysis in conjunction with our financial statements and related notes contained elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors discussed in this report and those discussed in other documents we file with the SEC. In light of these risks, uncertainties and assumptions, readers are cautioned not to place undue reliance on such forward-looking statements. These forward-looking statements represent beliefs and assumptions as of the date of this report. While we may elect to update forward-looking statements and at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. Past performance does not guarantee future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Level Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for our innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients it serves. Our Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to tissue to achieve their desired res</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ults. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. We also leverage our deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to drive sales in our Advanced Energy business by increasing the adoption and utilization of our handpieces in the U.S. cosmetic surgery market and fulfilling demand from distributors in our international markets. Management estimates that our products have been sold in more than 60 countries. As of September&#160;30, 2021, we had a direct sales force of 31 field-based selling professionals and utilized 2 independent sales agencies. We also had 5 sales managers. This selling organization is focused on the use of Renuvion&#174; in the cosmetic surgery market. In addition, we have invested in both in-person and virtual training programs and marketing-related activities to support accelerated adoption of Renuvion&#174; into physicians' practices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regards to our operating segments, our results are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, we also consider the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to our chief operating decision maker for operating and administrative activities, availability of discrete financial information, and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment and, accordingly, we have not presented a measure of assets by reportable segment.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which are not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, and all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly encourage investors to visit our website: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.apyxmedical.com</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to view the most current news and to review our filings with the Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 ("2020 Form 10-K"), an outbreak of a novel strain of the coronavirus, COVID-19, was identified in China and subsequently recognized as a pandemic by the World Health Organization. While the situation shows signs of improvement in certain countries, the COVID-19 outbreak generally continues to severely restrict the level of economic activity around the world. In response to the COVID-19 outbreak the governments of many countries, states, cities and other geographic regions have taken preventative or protective actions, such as imposing restrictions on travel and business operations and advising or requiring individuals to limit or forego their time outside of their homes. Temporary closures of businesses in some jurisdictions were ordered, and numerous other businesses closed permanently. Many other businesses continue to be operated at reduced capacity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As vaccines have become more available, the number of COVID-19 cases has declined in the United States and various other countries, and economic conditions have improved. However, uncertainty remains regarding the extent, timing, and duration of the pandemic, including the extent to which the availability and acceptance of these vaccines will positively impact public health conditions and whether new, potentially more contagious variants may pose additional public health risks. The pandemic continues to cause uncertainty and potential economic volatility, including with regard to the pandemic&#8217;s various and unpredictable impacts on our  customers and our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any future significant reductions in business-related activities could result in loss of sales and profits and other material adverse effects. The extent of the impact of COVID-19 on our business, financial results, liquidity and cash flows will depend largely on future developments, including new information that may emerge concerning actions taken to contain or prevent further spread of the virus, or its newly forming variants, within the U.S. and the related impact on consumer confidence and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">spending, all of which are highly uncertain and cannot be predicted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our revenues were affected by the continued impacts of the COVID-19 pandemic, starting in the latter half of 2020 we saw strong utilization of our Renuvion&#174; handpieces from existing customers in the U.S., along with shipments to several new customers in our international markets, which helped to offset sluggish global demand for capital equipment.  Throughout this event, we continued our efforts to support our customers during this challenging time. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were pleased to see overall improvements in our Advanced Energy business trends starting in the latter half of 2020, and continued to see improvements through the first three quarters of 2021 in utilization based global demand for our handpieces and adoption of our generator technology. Demand trends, however, for generator adoption continue to remain in varying stages of recovery in the markets we serve. Although the timing of a return to a more normalized economic environment remains uncertain, we remain optimistic with respect to the continued recovery of the cosmetic and plastic surgery market, and the utilization and adoption of our products globally. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We source the components used in our products from a variety of suppliers and we have collaborative arrangements with four key foreign suppliers. At this time our suppliers have experienced no significant production disruptions as a result of COVID-19. However, we have started to experience longer lead times and increased delays in our deliveries from these suppliers as a result of the availability of shipping from third party freight carriers. While we continue to monitor these delays, they have not, to date, had a significant impact on our manufacturing operations, but have resulted in increased inbound shipping costs and the necessity to increase levels of our key raw material component inventories. We have also begun to see increasing costs and tightened availability of various components used in our products as a result of global supply chain disruptions; these costs to date have not had a material impact on our results of operations. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to closely monitor developments related to COVID-19 that may impact our operations and financial performance, and continue our efforts to support our employees and customers in the following areas:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Protecting the Health and Safety of our Employees: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reduce the risk to our employees and their families to potential exposure to COVID-19, we have required that all non-essential employees work remotely until further notice. We also split the shifts of our manufacturing personnel to allow for adequate social distancing, and require all personnel to utilize personal protective equipment while on site at our facilities. We also significantly reduced business travel and outside access to our facilities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Maintaining Engagement of or Sales Team and Our Customers:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition to the initiatives we put in place to protect health and safety for all employees, we focused our direct sales team on remaining in close contact with their existing surgeon customers to do everything they can to provide them with support during this difficult time. With this goal in mind, we implemented additional training for our sales reps in order to sharpen their ability to engage with our customers virtually. In addition to engaging with existing customers via virtual methods, our sales representatives also continued to target and reach out to prospective customers, and outside the U.S., we continued to monitor the activities of our distributor partners and helped them navigate the challenges they faced as a result of the slower demand they have seen in their respective countries.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Operating Expenses:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Given the uncertainty surrounding the impacts that COVID-19 could have on our business, we took preemptive steps to curtail spending, including implementing hiring restrictions,reducing discretionary spending, reducing capital expenditures, and delaying certain R&amp;D projects and clinical research studies. Taking into account the early signs of improving economic environment and conditions related to COVID-19, we have started to ease these measures in certain areas. However, we will continue to monitor any future developments related to the pandemic and may reinstate them if necessary.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Governmental Policy:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On March 27, 2020, the U.S. government enacted the CARES Act to provide relief from COVID-19. We have taken advantage of certain provisions of the CARES Act which are applicable to us, including utilizing net operating loss (NOL) carryback provisions. Utilizing these provisions significantly mitigated the working capital impact COVID-19 has had on our sales and operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Reportable Segment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advanced Energy</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OEM</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#cceeff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632,000)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue increased by </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70.1% and 95.1%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or approximately $4.9&#160;million and $15.4&#160;million, for the three and nine months ended September 30, 2021 when compared with the three and nine months ended September 30, 2020. Advanced Energy segmen</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t sales increased 88.2% and 126.7%, or approximately $4.8&#160;million and $15.6&#160;million, for the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when compared with the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In the nine months ended September 30, 2021, we experienced increased global utilization based demand for our handpieces and adoption of our generator technology despite the continued headwinds of the COVID-19 pandemic in certain geographic regions, while the same period in 2020 was more severely impacted on a global basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 33.1% and 34.2% of total revenues for the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, as compared with 25.0% and 24.8% of total revenues for the same prior year period.  Management estimates our products have been sold in more than 60 countries through local dealers coordinated by sales and marketing personnel through our facilities in Clearwater, Florida and Sofia, Bulgaria.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gross Profit</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the three months ended September&#160;30, 2021, increased 70.5% to $8.1 million, compared to $4.7 million for the same period in the prior year. Gross margin for the three months ended September&#160;30, 2021, was 68.1%, compared to 67.9% for the same period in 2020. </span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, increased 118.8% to $21.5 million, compared to $9.8 million for the same period in the prior year. Gross margin for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, was 67.7%, compared to 60.3% for the same period in 2020. </span></div><div style="margin-top:3pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in gross profit margins for the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the prior year periods is primarily attributable to sales mix between our two segments, with our Advanced Energy segment comprising a higher percentage of total sales, as well as product mix within our Advanced Energy segment. Our continued manufacturing efficiency initiatives and the introduction of newer product models have continued to result in improved margins as we obtain registration, allowing these products to be introduced into the markets we serve. Additionally, the strong sales during the three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, resulted in reduced product costs as our fixed costs were spread across higher production volumes. This manufacturing efficiency was partially offset by higher inbound shipping costs, as we expedited the sourcing of key component raw material inventories. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2020, we reassessed our forecasted product mix due to COVID-19, increased availability of our newer handpiece designs, and earlier than expected completion of product registrations in certain international markets.  As a result, certain products were reduced to a lower carrying value, and some components were also written off as it was determined to cease further production on these models. This resulted in a decrease in gross profit of approximately $0.4 million during the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs and Expenses</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,374&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased 12.2% and 12.4% for the</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> three and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily due to continued spending on our two investigational device exemption (IDE) clinical studies and product development initiatives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Professional services</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,032&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,835&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,442&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense increased 10.7% for the three months ended September&#160;30, 2021, primarily attributable to an increase in physician consulting fees ($0.5 million). This increase was partially offset by a decrease in accounting and auditing fees ($0.3 million). In the prior year period, we incurred significant fees related to our change in independent accountants and the associated reaudit of the 2019 financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional ser</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vices expense decreased 7.5% for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, primarily attributable to decreases in accounting and auditing fees ($0.7 million) related to 2019 financial statement restatements, remediation, and reaudit activities that occurred in 2020 and legal fees ($0.2 million). These decreases were partially offset by increases in in physician consulting fees ($0.3 million) and professional services for continued consulting expense associated with our implementation of SAP ($0.1 million).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Salaries and related costs</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,794&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, salaries and related expenses increased 19.9%, primarily driven by increases in bonus expense in 2021 ($0.4 million), higher headcount ($0.2 million), and stock option expense ($0.1 million) as compared to the same period in the prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, salaries and related expenses increased 24.7%, primarily driven by increases in bonus expense in 2021 ($1.3 million), higher headcount ($0.5 million), stock option expense ($0.2 million), and temporary labor ($0.2 million) as compared to the same period in the prior year.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative expenses</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,611&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,706&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,691&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2021, selling, general and administrative expense increased 70.4%, primarily driven by higher commissions on Advanced Energy sales ($0.9 million), advertising expense, including trade show fees and related costs ($0.7 million), travel and entertainment expense ($0.3 million) and higher credit card processing fees ($0.1 million). </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, selling, general and administrative expense increased 44.9%, primarily driven by higher commissions on Advanced Energy sales ($2.5 million), travel and entertainment expense ($0.4 million),   advertising expense, including trade show fees and related costs ($0.4 million), insurance expense ($0.3 million), higher credit card processing fees ($0.3 million) and accrued OEM product recall costs ($0.2 million). These increases were partially offset by lower bad debt expenses ($0.4 million).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other income (loss)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:30.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (loss) income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(153.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96.1%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended September 30, 2021 compared with the same period in the prior year. This decrease is due to a lower yield, as well as a lower average balance, on our investments in U.S. Treasury securities included in cash and cash equivalents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other loss, net increased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">204.8%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the three months ended September&#160;30, 2021, as compared with the same period in the prior year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This increase is primarily due to accrued severance expense for employees of the Core business segment ($0.1 million) and anticipated Core business segment inventory losses at the conclusion of our supply agreement with Symmetry ($0.1 million). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (loss) income, net decreased </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153.9%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the nine months ended September 30, 2021, as compared with the same period in the prior year</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This decrease is primarily due to the receipt of refunds in the first quarter 2020 on tariffs paid in 2019 ($0.3 million), accrued severance expense for employees of the Core business segment ($0.1 million) and anticipated Core business segment inventory losses at the conclusion of our supply agreement with Symmetry ($0.1 million). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:30.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our income tax expense (benefit) was approximately $73,000 and $(715,000) with effective tax rates of (1.8)% and 16.1% for the three months ended September&#160;30, 2021 and 2020, respectively. Our income tax expense (benefit) was approximately $246,000 and $(7,112,000) with effective tax rates of (1.9)% and 40.7% for the nine months ended September 30, 2021 and 2020, respectively. For the three and nine months ended September 30, 2021, the effective rates differ from statutory rates primarily due to the full valuation allowance recorded on our NOL generated during the periods, combined with interest and penalties on our uncertain tax positions. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on our NOL carryforward from 2019. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital at September&#160;30, 2021 was approximately $48.2 million compared with $56.9 million at December&#160;31, 2020. The decrease in working capital from December&#160;31, 2020 was primarily due to the net loss incurred by the Company during the first three quarters of 2021, excluding non-cash activity, comprised primarily of stock-based compensation expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net cash used in operating activities was approximately $10.7 million, which principally funded our loss from operations of $12.8 million, compared with net cash used in operating activities of approximately $15.0 million in the same period for 2020. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities for the nine months ended September 30, 2021 and 2020, was </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.4 million and $0.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, related to investments in property and equipment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, we had purchase commitments totaling approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$5.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, substantially all of which is expected to be purchased within the next twelve months.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_73"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preparing the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), we have adopted various accounting policies. Our most significant accounting policies are disclosed in Note 2 to the consolidated financial statements included in our 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, filed with the SEC on March 31, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Our estimates and assumptions, including those related to inventories, intangible assets, property, plant and equipment, legal proceedings, research and development, warranty obligations, product liability, sales returns and discounts, stock-based compensation and income taxes are updated as appropriate, which in most cases is at least quarterly. We base our estimates on historical experience, or various assumptions that are believed to be reasonable under the circumstances and the results form the basis for making judgments about the reported values of assets, liabilities, revenues and expenses. Actual results may materially differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimates are considered to be critical if they meet both of the following criteria: (1) the estimate requires assumptions about material matters that are uncertain at the time the accounting estimates are made and (2) other materially different estimates could have been reasonably made or material changes in the estimates are reasonably likely to occur from period to period. Our critical accounting estimates include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our stock option plans, options to purchase common shares of the Company may be granted to employees, officers and directors of the Company by the Board of Directors. We account for stock options in accordance with FASB ASC Topic 718-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with compensation expense recognized over the vesting period. Options are valued using the Black-Scholes model, which includes a number of estimates that affect the amount of our expense. We have determined that the most critical of these estimates are the estimates of expected life and volatility used in the calculations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For employee stock-based compensation awards, we estimate the expected life of awards utilizing the SEC's simplified method. We utilize this method, as we have not historically granted stock-based compensation awards to employees in sufficient volumes to determine a reasonable estimate of the life of awards. For awards granted to non-employees, we calculate expected life using a combination of past exercise behavior, the contractual term and expected remaining exercise behavior.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determine the volatility by utilizing the historical volatility of our stock over the period of the awards expected life. The SEC allows us to include periods in excess of the useful life if we determine that they provide a more reasonable basis for the volatility of our stock. Additionally, ASC 718-10 allows us to exclude periods from the volatility if they pertain to events or circumstances that in our judgment are specific to us and if the event or transaction is not reasonably expected to occur again during the expected term of the awards. We have not included any additional periods, nor disregarded any periods, in calculating our volatility.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable Allowance</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for uncollectible accounts receivable. When evaluating the adequacy of the allowance for doubtful accounts, we analyze specific unremitted customer balances for known collectability issues, review historical bad debt experience, customer credit worthiness and economic trends, and we make estimates in connection with establishing the allowance for doubtful accounts, including the future impacts of current trends. Changes in estimates are reflected in the period they are made. If the financial condition of our customers deteriorates, resulting in an inability to make payments, additional allowances may be required.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION AND RESULTS OF OPERATIONS - Continued</span></div><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventory Obsolescence Allowance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a reserve for excess and obsolete inventory resulting from the potential inability to sell our products at prices in excess of current carrying costs. The markets in which we operate are highly competitive, with new products and surgical procedures introduced on an ongoing basis. Such marketplace changes may cause our products to become obsolete. We make estimates regarding the future recoverability of the costs of these products and record a provision for excess and obsolete inventories based on historical experience and expected future trends. If actual product life cycles, product demand or acceptance of new product introductions are less favorable than projected by management, additional inventory write-downs may be required, which would unfavorably affect future operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation Contingencies</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with authoritative guidance, we record a liability in our consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded; actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes includes federal, foreign, state and local income taxes currently payable and those deferred because of temporary differences between the financial statement and tax bases of assets and liabilities. Deferred tax assets or liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using enacted marginal tax rates. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. Deferred income tax expenses or credits are based on the changes in the asset or liability from period to period.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of historical losses, and our expectation to continue to generate losses in the near future, we recorded a valuation allowance on our net deferred tax assets. Exclusive of the carryback provisions of the CARES Act and the associated income tax benefit recognized in 2020, we do not anticipate recording an income tax benefit related to deferred tax assets. We will reassess the realization of deferred tax assets each reporting period and will be able to reduce the valuation allowance to the extent the financial results of continuing operations improve, and it becomes more likely than not that the deferred tax assets will be realizable. As management expects the Company to continue to generate losses in the foreseeable future after 2020, we will continue to record a valuation allowance on the net deferred tax assets balance as of September&#160;30, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the financial statement impact of an uncertain tax position taken or expected to be taken on an income tax return at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax position will not be recognized in the financial statements unless it is more likely than not of being sustained.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation has not materially impacted the operations of our Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no off-balance sheet arrangements at this time.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_34">See Note 2 of the Notes to Condensed Consolidated Financial Statements</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_76"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures about Market Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Controls and Procedures</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:4.55pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures </span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has established and maintains disclosure controls and procedures that are designed to ensure that the information required to be disclosed by us in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that as of September&#160;30, 2021, the Company's disclosure controls and procedures were effective.</span></div><div style="margin-top:0.05pt"><span><br/></span></div><div style="margin-top:4.59pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:0.45pt"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely extensively on information systems to manage our business and summarize and report our financial condition, results of operations and cash flows. In 2020, we began the implementation of a new global enterprise resource planning (&#8220;ERP&#8221;) system, which replaced much of our existing core financial systems in the first quarter of 2021. The ERP system is designed to accurately maintain our financial records, enhance the flow of financial information, improve data management and provide timely information to our management team. </span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of this implementation, certain internal controls over financial reporting have been automated, modified or implemented to address the new environment associated with this type of system. While we believe that this new system will strengthen our internal controls, there are inherent risks in implementing any new system, and we will continue to evaluate these control changes as part of our assessment of internal control over financial reporting throughout 2021. </span></div><div style="margin-top:4.55pt;padding-right:4.5pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_82"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. &#160;&#160;&#160;&#160;Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_85"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. Legal Proceedings</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_58">See Note 10 of Notes to Condensed Consolidated Financial Statements in Part I, Item 1 of this Form 10-Q.</a></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. Risk factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There have been no material changes to the risk factors described under Item 1A of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020, except for the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Any disruption in our suppliers&#8217; operations, or timely availability of shipments from our third party freight carriers, could disrupt our production schedule and our ability to provide product to our customers in a timely manner</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our operations and ability to maintain production is dependent upon our suppliers delivering sufficient quantities of components and raw materials on time to manufacture our products and meet our production schedules. The COVID-19 pandemic has adversely impacted worldwide supply chains and the ability to obtain sufficient amounts of component parts, while disruptions and delays in the ability of our third party freight carriers to transport these items to our manufacturing facilities also continues to be a challenge.  If the situation worsens, these negative impacts on our supply chain could have a material adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any shortage of components or raw materials could cause us to not be able to meet customer demand, to alter production schedules, to delay product launch schedules, or to suspend production entirely, which could cause a loss of revenues or increased costs, which could materially and adversely affect our results of operations and cash flows.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_94"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_97"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. Defaults Upon Senior Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_100"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. Mine Safety Disclosures</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_103"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. Other Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_106"></div><hr style="page-break-after:always"/><div style="min-height:63pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="-sec-extract:summary;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. Exhibits</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:9.603%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.464%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit31.htm">Articles of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000100944811000015/exhibit32.htm">By laws of the Registrant (Incorporated by reference to the Registrant&#8217;s Annual Report on Form 10-K/A filed on March 31, 2011)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913517000064/a2017q3exhibit35.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant&#8217;s Quarterly Report on Form 10-Q filed on November 3, 2017).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000021/bvx_201805xex31certificate.htm">Certificate of Elimination (Incorporated by reference to the Registrant&#8217;s Current Report on Form 8-K filed on May 3, 2018)</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/719135/000071913518000086/0000719135-18-000086-index.htm">Certificate of Amendment of the Certificate of Incorporation of the Registrant (Incorporated by reference to the Registrant's Current Report of Form 8-K filed on December 28, 2018)</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2021q310-qexhibit311.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2021q310-qexhibit312.htm">Certification pursuant to Section 302 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2021q310-qexhibit321.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="-sec-extract:exhibit;color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="a2021q310-qexhibit322.htm">Certification pursuant to Section 906 of Sarbanes-Oxley Act of 202</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Presentation Document</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Filed herewith.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">** XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of registration&#160;statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended and otherwise is not subject to liability under these sections.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ib63e0db1bd5f459082b7c90c0bd2a7a9_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ib63e0db1bd5f459082b7c90c0bd2a7a9_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APYX MEDICAL CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Apyx Medical Corporation</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: November 12, 2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">/s/ Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasurer and Secretary</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>a2021q310-qexhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2a6b6ed4c1344e7aa9f7ba4afa13cb4c_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles D Goodwin II, the Registrant's Chief Executive Officer, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>a2021q310-qexhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i37995b4b193845b09f96859af076da27_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to Section&#160;302</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Tara Semb, the Registrant's Chief Financial Officer, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">I have reviewed this quarterly report on Form 10-Q of Apyx Medical Corporation&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Based on my knowledge, the financial statements and other financial information included in this report fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:29.07pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:10pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal controls over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:42.75pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>a2021q310-qexhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i2b0d0378b34e4011bdedb268c07d496e_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right;text-indent:42.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CEO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Executive Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.064%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.951%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles D. Goodwin II</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>a2021q310-qexhibit322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ia1ea15da260044648a1d68f2255d50c0_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certificate Pursuant to 18 U.S.C Section 1350, as adopted pursuant to</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section&#160;906 of Sarbanes &#8211; Oxley Act of 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CFO</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report on Form 10-Q of Apyx Medical Corporation (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Company&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for the period ended September&#160;30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#34;Report&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the undersigned Chief Financial Officer certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes - Oxley Act of 2002, that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:46.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.034%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; November 12, 2021</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#47;s&#47; Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tara Semb</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Secretary</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>apyx-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:apyx="http://apyxmedical.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://apyxmedical.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="apyx-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://apyxmedical.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION">
        <link:definition>2101101 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>2202201 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2103102 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESS" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS">
        <link:definition>2104103 - Disclosure - DISPOSAL OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DISPOSALOFBUSINESSDetails" roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails">
        <link:definition>2405401 - Disclosure - DISPOSAL OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIES" roleURI="http://apyxmedical.com/role/INVENTORIES">
        <link:definition>2106104 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESTables" roleURI="http://apyxmedical.com/role/INVENTORIESTables">
        <link:definition>2307301 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INVENTORIESDetails" roleURI="http://apyxmedical.com/role/INVENTORIESDetails">
        <link:definition>2408402 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES">
        <link:definition>2109105 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables">
        <link:definition>2310302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails">
        <link:definition>2411403 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURE" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURE">
        <link:definition>2112106 - Disclosure - CHINA JOINT VENTURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURETables" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURETables">
        <link:definition>2313303 - Disclosure - CHINA JOINT VENTURE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURENarrativeDetails" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails">
        <link:definition>2414404 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CHINAJOINTVENTURERollforwardofJointVentureDetails" roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails">
        <link:definition>2415405 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2116107 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2317304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2418406 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATION" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION">
        <link:definition>2119108 - Disclosure - STOCK-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONTables" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables">
        <link:definition>2320305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2421407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails">
        <link:definition>2422408 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
        <link:definition>2423409 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://apyxmedical.com/role/INCOMETAXES">
        <link:definition>2124109 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDetails" roleURI="http://apyxmedical.com/role/INCOMETAXESDetails">
        <link:definition>2425410 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESNarrativeDetails" roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails">
        <link:definition>2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONS" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS">
        <link:definition>2128111 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RELATEDPARTYTRANSACTIONSDetails" roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails">
        <link:definition>2429412 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATION" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION">
        <link:definition>2130112 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONTables" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables">
        <link:definition>2331306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails">
        <link:definition>2432413 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
        <link:definition>2433414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
        <link:definition>2434415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" abstract="false" name="ProceedsFromStockOptionsExercisedAndWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" abstract="true" name="ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_AdvancedEnergyMember" abstract="true" name="AdvancedEnergyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_OtherAccruedExpensesAndLiabilitiesCurrent" abstract="false" name="OtherAccruedExpensesAndLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_SymmetrySurgicalInc.Member" abstract="true" name="SymmetrySurgicalInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_JointAndSeveralPayrollLiability" abstract="false" name="JointAndSeveralPayrollLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" abstract="false" name="CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_NoncontrollingInterestTableTextBlock" abstract="false" name="NoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="apyx_TotalRevenuePercent" abstract="false" name="TotalRevenuePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="apyx_NoncontrollingInterestRequiredCapitalContribution" abstract="false" name="NoncontrollingInterestRequiredCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ProvisionForObsolescenceInventory" abstract="false" name="ProvisionForObsolescenceInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AssetPurchaseAgreementTerm" abstract="false" name="AssetPurchaseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="apyx_RepaymentofFinanceLeaseLiabilities" abstract="false" name="RepaymentofFinanceLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" abstract="false" name="AccruedLiabilitiesAndOtherLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_OEMMember" abstract="false" name="OEMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwaps" abstract="false" name="StockIssuedDuringPeriodSharesStockSwaps" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_StockSwapToAcquireOptionsShares" abstract="false" name="StockSwapToAcquireOptionsShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="apyx_UncertainTaxPositionsLiability" abstract="false" name="UncertainTaxPositionsLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_ChineseSupplierMember" abstract="true" name="ChineseSupplierMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="apyx_ProvisionForInventoryObsolescence" abstract="false" name="ProvisionForInventoryObsolescence" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" abstract="false" name="StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>apyx-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19cabdc3-5db4-419a-88cd-449e49632abd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_352a0ab8-d704-4fbc-9f79-95aeb15efd6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19cabdc3-5db4-419a-88cd-449e49632abd" xlink:to="loc_us-gaap_CommonStockValue_352a0ab8-d704-4fbc-9f79-95aeb15efd6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_dec52512-2101-4711-a957-1600a69ac6af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19cabdc3-5db4-419a-88cd-449e49632abd" xlink:to="loc_us-gaap_AdditionalPaidInCapital_dec52512-2101-4711-a957-1600a69ac6af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6aed4bb9-7387-445e-9798-c92fa0ff94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_19cabdc3-5db4-419a-88cd-449e49632abd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6aed4bb9-7387-445e-9798-c92fa0ff94c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8784341c-d485-401b-a827-6a024e79cc47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:to="loc_us-gaap_AssetsCurrent_8784341c-d485-401b-a827-6a024e79cc47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ed7a347a-dcb3-402d-821b-e822e587408f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ed7a347a-dcb3-402d-821b-e822e587408f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a662dae-d733-41eb-8038-fdfbd6c3125f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_9a662dae-d733-41eb-8038-fdfbd6c3125f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_99fb6551-6d1e-4bd0-ad0f-1121d08a611f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_99fb6551-6d1e-4bd0-ad0f-1121d08a611f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_35eff414-2f8c-412a-b665-b55291a424da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_654a7e1d-4596-498f-b352-e2201b1df2e1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_35eff414-2f8c-412a-b665-b55291a424da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e4f40430-4c96-4908-bdbe-9b0b4fcc80ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_7e65b6a3-915e-4cc8-aef3-638e4c21fedc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4f40430-4c96-4908-bdbe-9b0b4fcc80ea" xlink:to="loc_us-gaap_AccountsPayableCurrent_7e65b6a3-915e-4cc8-aef3-638e4c21fedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7a0148bc-cdd5-45bd-ad90-3433e7ddd79d" xlink:href="apyx-20210930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4f40430-4c96-4908-bdbe-9b0b4fcc80ea" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_7a0148bc-cdd5-45bd-ad90-3433e7ddd79d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6dbe544a-35da-409b-874f-10adb6d68e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4f40430-4c96-4908-bdbe-9b0b4fcc80ea" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6dbe544a-35da-409b-874f-10adb6d68e6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ded0b7cc-aba7-4484-9f09-a4d64b7677ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e4f40430-4c96-4908-bdbe-9b0b4fcc80ea" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ded0b7cc-aba7-4484-9f09-a4d64b7677ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f08b0d93-f9fe-4b62-96ca-99e6cd4fa5df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d83cc5ad-7368-49c5-8760-b80cf30604c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f08b0d93-f9fe-4b62-96ca-99e6cd4fa5df" xlink:to="loc_us-gaap_Liabilities_d83cc5ad-7368-49c5-8760-b80cf30604c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3152bcc4-f543-4114-98fa-c2cc250cf5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f08b0d93-f9fe-4b62-96ca-99e6cd4fa5df" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3152bcc4-f543-4114-98fa-c2cc250cf5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cabea369-cf8b-44e5-a0d5-342e1d658c81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cabea369-cf8b-44e5-a0d5-342e1d658c81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d80e0bf9-c836-4db5-908b-c7c632affeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d80e0bf9-c836-4db5-908b-c7c632affeca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_6c35c78f-1cd8-4a49-9a5c-afc86f216ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_IncomeTaxesReceivable_6c35c78f-1cd8-4a49-9a5c-afc86f216ddf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_2e1629ba-dfb3-4087-be00-8534072ed25b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_2e1629ba-dfb3-4087-be00-8534072ed25b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_8096298b-487e-4561-a676-e9acaeabc31e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_InventoryNet_8096298b-487e-4561-a676-e9acaeabc31e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a8f289b-3afe-411a-9a1f-9b69d1f1e38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_bf39edb3-502f-4f2c-af43-03d2d95e05bf" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3a8f289b-3afe-411a-9a1f-9b69d1f1e38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8ef6f06e-98af-4583-9bbe-dd8d05b5bd56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:to="loc_us-gaap_LiabilitiesCurrent_8ef6f06e-98af-4583-9bbe-dd8d05b5bd56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f585f2ee-e114-4a94-9d4d-a4c2dd7f2d15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f585f2ee-e114-4a94-9d4d-a4c2dd7f2d15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_49e3799c-71a4-416f-9a44-bd14b3c7e18b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_49e3799c-71a4-416f-9a44-bd14b3c7e18b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f0d67d8f-a5ad-4264-907e-c7a8fa37972a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_f0d67d8f-a5ad-4264-907e-c7a8fa37972a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_818ae91e-55ce-4c91-9b23-a2679ff16461" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d1ea4bf3-be8d-4b5e-87b2-346f15b92562" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_818ae91e-55ce-4c91-9b23-a2679ff16461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_855805bf-e793-4656-9e91-80712d19fee8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_814068a9-502e-4dc4-9735-989c192b8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_855805bf-e793-4656-9e91-80712d19fee8" xlink:to="loc_us-gaap_StockholdersEquity_814068a9-502e-4dc4-9735-989c192b8fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_6bd1c077-9e32-47a1-a0c6-fe412f9cd70e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_855805bf-e793-4656-9e91-80712d19fee8" xlink:to="loc_us-gaap_MinorityInterest_6bd1c077-9e32-47a1-a0c6-fe412f9cd70e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8f1082b0-202e-426a-8470-1886c046ac53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c3bc4cc-24f3-43dd-88d5-43b9e7e94906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_8f1082b0-202e-426a-8470-1886c046ac53" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8c3bc4cc-24f3-43dd-88d5-43b9e7e94906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3447101f-a108-4fbe-aac1-0c6ecd439f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_8f1082b0-202e-426a-8470-1886c046ac53" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3447101f-a108-4fbe-aac1-0c6ecd439f1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_a86c739b-68af-49c0-98c3-0ff8b77e4f20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c62debc9-cb83-4a17-8e82-d4523a070726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a86c739b-68af-49c0-98c3-0ff8b77e4f20" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c62debc9-cb83-4a17-8e82-d4523a070726" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d8c74b99-9052-48f5-ae9d-038767759b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_a86c739b-68af-49c0-98c3-0ff8b77e4f20" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d8c74b99-9052-48f5-ae9d-038767759b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8f48eff3-1f48-411a-88e5-1425419e5cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_04bbd631-4393-4639-b903-48f05bb124e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8f48eff3-1f48-411a-88e5-1425419e5cff" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_04bbd631-4393-4639-b903-48f05bb124e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_caa6c34b-ce8a-4557-bed3-eb51cb088b39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8f48eff3-1f48-411a-88e5-1425419e5cff" xlink:to="loc_us-gaap_ProfessionalFees_caa6c34b-ce8a-4557-bed3-eb51cb088b39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_90b28711-f4ef-4feb-bdc4-a35c57a60f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8f48eff3-1f48-411a-88e5-1425419e5cff" xlink:to="loc_us-gaap_SalariesAndWages_90b28711-f4ef-4feb-bdc4-a35c57a60f4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d6b61e92-f9d5-4fae-8c3a-1adc5d9ae481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8f48eff3-1f48-411a-88e5-1425419e5cff" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d6b61e92-f9d5-4fae-8c3a-1adc5d9ae481" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_234f49bd-5373-495e-a261-14e5d91837c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_bb7917a9-aa94-4000-9804-f2a7171e7728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_234f49bd-5373-495e-a261-14e5d91837c1" xlink:to="loc_us-gaap_InterestIncomeOperating_bb7917a9-aa94-4000-9804-f2a7171e7728" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8c0309e8-a324-44c8-b9f7-eb0d14726eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_234f49bd-5373-495e-a261-14e5d91837c1" xlink:to="loc_us-gaap_InterestExpense_8c0309e8-a324-44c8-b9f7-eb0d14726eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_edd5df99-57e4-4735-8f4e-62342299ad3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_234f49bd-5373-495e-a261-14e5d91837c1" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_edd5df99-57e4-4735-8f4e-62342299ad3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2122ca6e-ff9b-4474-8c94-04f2523ab889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6177c4d7-daca-47b3-8533-74087e67c912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2122ca6e-ff9b-4474-8c94-04f2523ab889" xlink:to="loc_us-gaap_OperatingIncomeLoss_6177c4d7-daca-47b3-8533-74087e67c912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2cabdf50-c3c6-4659-8d6b-71cd909d543c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2122ca6e-ff9b-4474-8c94-04f2523ab889" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2cabdf50-c3c6-4659-8d6b-71cd909d543c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7c8f7e88-221a-4403-a5b6-375bc715a1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_96fda228-b017-4422-a3ff-bb48aac1f426" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c8f7e88-221a-4403-a5b6-375bc715a1a3" xlink:to="loc_us-gaap_ProfitLoss_96fda228-b017-4422-a3ff-bb48aac1f426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dab81c98-45b6-4e75-a5e8-e7b6c6d5c224" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_7c8f7e88-221a-4403-a5b6-375bc715a1a3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_dab81c98-45b6-4e75-a5e8-e7b6c6d5c224" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e7b524e-67f2-43a8-9a1d-e2f009174aea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_826635e4-99ae-4177-9d11-8626cefa3e5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e7b524e-67f2-43a8-9a1d-e2f009174aea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_826635e4-99ae-4177-9d11-8626cefa3e5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8000a933-2074-4bf3-ae59-20cf863392b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e7b524e-67f2-43a8-9a1d-e2f009174aea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8000a933-2074-4bf3-ae59-20cf863392b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82064e10-2d01-4d62-8fca-050a8b98304f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e7b524e-67f2-43a8-9a1d-e2f009174aea" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_82064e10-2d01-4d62-8fca-050a8b98304f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a192fd5-4cfd-45b2-92ff-e23a40f3c024" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_8e7b524e-67f2-43a8-9a1d-e2f009174aea" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8a192fd5-4cfd-45b2-92ff-e23a40f3c024" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54e0d878-073f-44eb-8d07-7fd86688e2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa5c58f2-917a-4961-8fa9-1278c2cee603" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_54e0d878-073f-44eb-8d07-7fd86688e2eb" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aa5c58f2-917a-4961-8fa9-1278c2cee603" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d108c35c-0fe0-4b1b-9c8d-d5c325622229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_ProfitLoss_d108c35c-0fe0-4b1b-9c8d-d5c325622229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e82dc44c-70fa-4a85-9488-f92cd315a34a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e82dc44c-70fa-4a85-9488-f92cd315a34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_6f7a32df-5c83-45de-b08e-724233c8fb8f" xlink:href="apyx-20210930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_6f7a32df-5c83-45de-b08e-724233c8fb8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2237c63d-d9d4-4da3-94d3-b527ce109aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_ShareBasedCompensation_2237c63d-d9d4-4da3-94d3-b527ce109aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_cf3359fa-67fe-4ddf-980f-50db54e4b24f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_cf3359fa-67fe-4ddf-980f-50db54e4b24f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0b422c62-3ef0-4cb8-9978-016c8981a31b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_0b422c62-3ef0-4cb8-9978-016c8981a31b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7934d5d7-71c4-435b-901f-f101d69a5bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7934d5d7-71c4-435b-901f-f101d69a5bbf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_092bef77-f234-43c7-810d-9cab31c41b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_092bef77-f234-43c7-810d-9cab31c41b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8031079d-e112-484d-aba9-a7beb8de0a58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8031079d-e112-484d-aba9-a7beb8de0a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_66448857-bb9d-42cc-a7ad-291c80d52a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_66448857-bb9d-42cc-a7ad-291c80d52a08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26529e10-e9ea-454f-8c54-e4829c999b37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26529e10-e9ea-454f-8c54-e4829c999b37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_771fb1fc-68ff-4088-ad4c-758a598626f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b15956d3-629d-42e3-9cb1-8248b3d7ab1b" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_771fb1fc-68ff-4088-ad4c-758a598626f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f79be4d-5c62-47aa-b0b1-b5560c60fd2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_cd0cec20-3cae-4999-814d-16ccc99a9f8d" xlink:href="apyx-20210930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f79be4d-5c62-47aa-b0b1-b5560c60fd2e" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_cd0cec20-3cae-4999-814d-16ccc99a9f8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_4db792c7-b931-4051-918a-00dc3bb74f87" xlink:href="apyx-20210930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f79be4d-5c62-47aa-b0b1-b5560c60fd2e" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_4db792c7-b931-4051-918a-00dc3bb74f87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_5c3d29fe-d9cc-40a2-8670-3c8753cfb719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f79be4d-5c62-47aa-b0b1-b5560c60fd2e" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_5c3d29fe-d9cc-40a2-8670-3c8753cfb719" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#INVENTORIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_6e889471-d0d0-4eea-81ba-88f206eaa83e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_8dd4d0d3-496e-43ba-b92a-f64fd6669132" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6e889471-d0d0-4eea-81ba-88f206eaa83e" xlink:to="loc_us-gaap_InventoryRawMaterials_8dd4d0d3-496e-43ba-b92a-f64fd6669132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_777ccb95-ccb3-401f-a4dc-df051a70092b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6e889471-d0d0-4eea-81ba-88f206eaa83e" xlink:to="loc_us-gaap_InventoryWorkInProcess_777ccb95-ccb3-401f-a4dc-df051a70092b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_eeeb5ad0-f55f-4fcc-ab24-7b1a2a8f286a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_6e889471-d0d0-4eea-81ba-88f206eaa83e" xlink:to="loc_us-gaap_InventoryFinishedGoods_eeeb5ad0-f55f-4fcc-ab24-7b1a2a8f286a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e88d140a-d726-44c7-b04a-7c11cd05958a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_bd112a2d-8b03-4869-8093-8e15e1ece121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e88d140a-d726-44c7-b04a-7c11cd05958a" xlink:to="loc_us-gaap_InventoryGross_bd112a2d-8b03-4869-8093-8e15e1ece121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_cab79dc1-26a4-493a-b12b-5704bbddf937" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_e88d140a-d726-44c7-b04a-7c11cd05958a" xlink:to="loc_us-gaap_InventoryValuationReserves_cab79dc1-26a4-493a-b12b-5704bbddf937" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:href="apyx-20210930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_de5b314d-f4f5-4974-886d-592bd41f6874" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_de5b314d-f4f5-4974-886d-592bd41f6874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_12c9b18c-dafb-47f9-a8f1-a6737865db6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_AccruedBonusesCurrent_12c9b18c-dafb-47f9-a8f1-a6737865db6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_14d57ead-fd74-44ad-a1c0-325208217ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_14d57ead-fd74-44ad-a1c0-325208217ad6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_aab44bbb-be82-40e8-afa3-e7beeed8c52c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_aab44bbb-be82-40e8-afa3-e7beeed8c52c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_48b02b69-4dc5-46f7-8f75-3db3955c40f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_48b02b69-4dc5-46f7-8f75-3db3955c40f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_06143d23-ed67-4719-a477-8b1426ad7bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_06143d23-ed67-4719-a477-8b1426ad7bd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_71816363-6979-4bf9-9cb6-7b77b320a710" xlink:href="apyx-20210930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_71816363-6979-4bf9-9cb6-7b77b320a710" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_44085d99-5cfa-4ed3-af62-90617f4041bd" xlink:href="apyx-20210930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_apyx_UncertainTaxPositionsLiability_44085d99-5cfa-4ed3-af62-90617f4041bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_48ad2346-55d9-4d8a-8c10-1ea61f0401ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_48ad2346-55d9-4d8a-8c10-1ea61f0401ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_cdd8a09b-fd0a-4214-83e6-c98f829f975d" xlink:href="apyx-20210930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_9ffceaf5-fe62-4b0c-8aff-4c81b0a48b2f" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_cdd8a09b-fd0a-4214-83e6-c98f829f975d" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>apyx-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended" id="i6e95a79600f742049d07eedb39cb5283_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9467ecc4-cd03-4d79-a17f-5f11ada03da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_SharesIssued_9467ecc4-cd03-4d79-a17f-5f11ada03da9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d1df14-552a-43ef-893f-afe53a40f34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d1df14-552a-43ef-893f-afe53a40f34b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_71316f01-e022-4416-9e38-2aa4bdecbc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_71316f01-e022-4416-9e38-2aa4bdecbc50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9a5d0c61-b9a4-4789-8567-3f549f376170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9a5d0c61-b9a4-4789-8567-3f549f376170" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7e27781-cddf-42d1-9b80-9b5e7db67c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7e27781-cddf-42d1-9b80-9b5e7db67c3b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_383a1feb-e0f9-45cc-9cf0-c69e0434c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_383a1feb-e0f9-45cc-9cf0-c69e0434c18c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_db06288d-c674-49a5-80ba-c41ebcd0b045" xlink:href="apyx-20210930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_db06288d-c674-49a5-80ba-c41ebcd0b045" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6180ee98-9b2e-448f-b727-3f22a87b5471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_ProfitLoss_6180ee98-9b2e-448f-b727-3f22a87b5471" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6c631c03-e00d-49eb-bdd6-f725daa71bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65c71b5e-2c66-4558-af30-c2415a570702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:to="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b57f36c1-8273-4c62-97d6-860069d8a9c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:to="loc_us-gaap_EquityComponentDomain_b57f36c1-8273-4c62-97d6-860069d8a9c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:to="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01e22c5c-e616-4fa3-b457-947ea1111d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_CommonStockMember_01e22c5c-e616-4fa3-b457-947ea1111d99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_76da1022-21d5-4d08-ba7f-957fe52430ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_76da1022-21d5-4d08-ba7f-957fe52430ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8c111166-3ad9-4c10-ad39-be57e6f425a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_RetainedEarningsMember_8c111166-3ad9-4c10-ad39-be57e6f425a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f26c6138-ce13-427c-834c-cb45b0e75df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f26c6138-ce13-427c-834c-cb45b0e75df0" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended" id="icb2b35a0fbd64fc2af5cbeff0a01d29d_DISPOSALOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4771f95b-3a4f-4ee6-8538-7774758b8504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4771f95b-3a4f-4ee6-8538-7774758b8504" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_10280b1a-e2c9-41e6-919e-a9a9a7c620fa" xlink:href="apyx-20210930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_10280b1a-e2c9-41e6-919e-a9a9a7c620fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_85937b6f-96ff-45d8-98ba-7e7c2b405dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_85937b6f-96ff-45d8-98ba-7e7c2b405dc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4f44783c-0229-41d6-9971-2b4eb6c8f492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4f44783c-0229-41d6-9971-2b4eb6c8f492" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4ed1d5e7-9549-4924-9fa6-9d2eba355e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4ed1d5e7-9549-4924-9fa6-9d2eba355e70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_8d4a7674-6a94-4195-84c9-2a4a64c94b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_8d4a7674-6a94-4195-84c9-2a4a64c94b8d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_319bdffc-100a-41a6-9d97-5a63d7a5394c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:to="loc_us-gaap_RelatedPartyDomain_319bdffc-100a-41a6-9d97-5a63d7a5394c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:to="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_592b9883-058c-48b7-bf94-10ee9a76b220" xlink:href="apyx-20210930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_592b9883-058c-48b7-bf94-10ee9a76b220" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_236b5a92-4682-4cd3-bfc4-4366a6e06af4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_236b5a92-4682-4cd3-bfc4-4366a6e06af4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_c6cd0399-1441-4958-82a3-7c869821f5c9" xlink:href="apyx-20210930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_c6cd0399-1441-4958-82a3-7c869821f5c9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURENarrativeDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="extended" id="ic49c81faba1d4d8e9f1b5cb7a4cf727d_CHINAJOINTVENTURENarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ec061815-eefa-49a8-aff2-cbabdfccc68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ec061815-eefa-49a8-aff2-cbabdfccc68f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_03dc67f9-5e53-4c26-b540-306123b0a612" xlink:href="apyx-20210930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_03dc67f9-5e53-4c26-b540-306123b0a612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4025047b-fd4e-404c-92b2-06ff30cc97e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4025047b-fd4e-404c-92b2-06ff30cc97e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5e81917a-2058-444e-a78a-d3a247a67813_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:to="loc_us-gaap_RelatedPartyDomain_5e81917a-2058-444e-a78a-d3a247a67813_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:to="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_16e0f024-ba6c-48f2-9902-dae18b099644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:to="loc_us-gaap_CorporateJointVentureMember_16e0f024-ba6c-48f2-9902-dae18b099644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:to="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fa0a6d3d-4c42-47d3-aa41-3281649d77f2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:to="loc_srt_OwnershipDomain_fa0a6d3d-4c42-47d3-aa41-3281649d77f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:to="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_6ddbad14-9296-453f-a7ef-4a314aa1c18a" xlink:href="apyx-20210930.xsd#apyx_ChineseSupplierMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:to="loc_apyx_ChineseSupplierMember_6ddbad14-9296-453f-a7ef-4a314aa1c18a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURERollforwardofJointVentureDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="extended" id="i05de5bc76f6045938901ee7fd43899e7_CHINAJOINTVENTURERollforwardofJointVentureDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_12277cf7-c71e-435e-96fb-7b244140a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_MinorityInterest_12277cf7-c71e-435e-96fb-7b244140a687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ba11a455-3b45-4d7d-b948-1d2af413f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ba11a455-3b45-4d7d-b948-1d2af413f17d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83bd2a33-8e01-4e75-bca0-7f6d504be76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83bd2a33-8e01-4e75-bca0-7f6d504be76d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a1845f31-97cf-4ba4-8ec8-180f53b9a7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:to="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_844000ed-cc43-47aa-83da-35d7ddae1e07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:to="loc_us-gaap_RelatedPartyDomain_844000ed-cc43-47aa-83da-35d7ddae1e07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:to="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_99e7d5db-afa5-4afa-b9de-26be05482b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:to="loc_us-gaap_CorporateJointVentureMember_99e7d5db-afa5-4afa-b9de-26be05482b02" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="if6c04edbdf0349c3b8ada2b9da883bfa_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_644e1416-e4ec-47ec-86fe-6056ce81e79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_644e1416-e4ec-47ec-86fe-6056ce81e79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cff540d-5de8-4bba-87c7-d697ba47fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cff540d-5de8-4bba-87c7-d697ba47fe26" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c18f9db-91ae-4e37-a48e-ded48e2cf716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c18f9db-91ae-4e37-a48e-ded48e2cf716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35a41d1b-f8c6-4a94-b1a0-03f182998281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35a41d1b-f8c6-4a94-b1a0-03f182998281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffaced3e-ee70-4df8-9be3-58e163e0c733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffaced3e-ee70-4df8-9be3-58e163e0c733" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3057ee3c-a062-4fd3-827a-290725505d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3057ee3c-a062-4fd3-827a-290725505d4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8345a21e-468f-4b40-ad43-839d667f0184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8345a21e-468f-4b40-ad43-839d667f0184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4678611d-2c4e-4837-9344-563823e18671_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4678611d-2c4e-4837-9344-563823e18671_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2e29310e-e50c-498f-b8f4-2c3ef6aba6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:to="loc_us-gaap_RestrictedStockMember_2e29310e-e50c-498f-b8f4-2c3ef6aba6c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d3791a90-bee3-4d50-bd95-46d6397ad488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d3791a90-bee3-4d50-bd95-46d6397ad488" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended" id="iad0e9fe80a434c228aecdc95d2028a39_STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0eec8957-180c-4e55-aa70-3cb4c2420194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0eec8957-180c-4e55-aa70-3cb4c2420194" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a710e4f3-98f6-42ef-bab3-3b18fdf1410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a710e4f3-98f6-42ef-bab3-3b18fdf1410f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b069d2c8-2b46-47e9-95d7-4ad40be10f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b069d2c8-2b46-47e9-95d7-4ad40be10f51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b16d43f6-e3e3-4c32-ba1b-378e0013e9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b16d43f6-e3e3-4c32-ba1b-378e0013e9f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbb7e715-e8b0-46ce-b24d-6295e22da32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbb7e715-e8b0-46ce-b24d-6295e22da32a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:to="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_682f063d-54d6-40f8-b6af-57ea84046eac_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:to="loc_srt_RangeMember_682f063d-54d6-40f8-b6af-57ea84046eac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:to="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22eb5447-7b1f-4c10-b92d-c0125c360ea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:to="loc_srt_MinimumMember_22eb5447-7b1f-4c10-b92d-c0125c360ea4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1361068c-eb80-478e-9284-6134d6e14182" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:to="loc_srt_MaximumMember_1361068c-eb80-478e-9284-6134d6e14182" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended" id="i106b77fcefc14acab26b9b775e02759e_RELATEDPARTYTRANSACTIONSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_75133655-4fb6-42de-b73b-798f1432d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_75133655-4fb6-42de-b73b-798f1432d612" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5dff558e-cb31-40bd-a9a7-1a7713509f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5dff558e-cb31-40bd-a9a7-1a7713509f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_e84d604b-8c1f-426b-9d2b-9c391c320a4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_e84d604b-8c1f-426b-9d2b-9c391c320a4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_85143f97-7bbd-4743-83ab-4d02be8d84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:to="loc_us-gaap_CoVenturerMember_85143f97-7bbd-4743-83ab-4d02be8d84f6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended" id="i3438fda6ebc94f688a4da1c9841be78f_GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7d15f1f-1ce0-4577-a250-c9174553f52a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7d15f1f-1ce0-4577-a250-c9174553f52a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6671af2c-1201-4255-aea5-6c842c2f8b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_OperatingIncomeLoss_6671af2c-1201-4255-aea5-6c842c2f8b49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_e78e60fc-4a18-4d54-ba85-293d209d9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_InterestIncomeOperating_e78e60fc-4a18-4d54-ba85-293d209d9d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_67dd1dfe-5335-4542-8af6-e99444426768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_InterestExpense_67dd1dfe-5335-4542-8af6-e99444426768" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1698c4d6-8c44-43a5-b110-daaf6e236018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1698c4d6-8c44-43a5-b110-daaf6e236018" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a9413fb6-83a9-4c8f-9d01-856352d18e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a9413fb6-83a9-4c8f-9d01-856352d18e83" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:to="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_6d2ba715-b663-49b1-8cb2-b54332c54ef8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:to="loc_srt_ConsolidationItemsDomain_6d2ba715-b663-49b1-8cb2-b54332c54ef8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:to="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0ac294b2-0cf4-48a5-8135-f953e6c22839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:to="loc_us-gaap_OperatingSegmentsMember_0ac294b2-0cf4-48a5-8135-f953e6c22839" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_50e70e8c-94dd-40a8-b950-079302aab00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_50e70e8c-94dd-40a8-b950-079302aab00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:to="loc_us-gaap_SegmentDomain_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:to="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_890bf854-0385-4e60-b77e-1c959009c6a7" xlink:href="apyx-20210930.xsd#apyx_AdvancedEnergyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:to="loc_apyx_AdvancedEnergyMember_890bf854-0385-4e60-b77e-1c959009c6a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_cbdf61bd-3db8-4ad9-b60d-81681cdcf079" xlink:href="apyx-20210930.xsd#apyx_OEMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:to="loc_apyx_OEMMember_cbdf61bd-3db8-4ad9-b60d-81681cdcf079" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:definitionLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended" id="i105c6600a2e44a9a961abe4a099300a0_GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3ebf515-789d-4c20-becf-60a5d3fb42ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3ebf515-789d-4c20-becf-60a5d3fb42ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:to="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9e5d9127-6c9d-4136-853f-7e28429711d7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:to="loc_srt_SegmentGeographicalDomain_9e5d9127-6c9d-4136-853f-7e28429711d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:to="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_894b5a40-e04e-4397-a7cf-8f3d55a4fa8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:to="loc_country_US_894b5a40-e04e-4397-a7cf-8f3d55a4fa8c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1652ea98-365d-4349-99c3-cc6a44d9dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:to="loc_us-gaap_NonUsMember_1652ea98-365d-4349-99c3-cc6a44d9dc7b" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>apyx-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_f7e0cc62-731e-4a2d-bf1d-02450add9cb9_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_f439fc20-7351-4941-a448-6dba2df8a8db_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_8d1c51bc-0132-450a-84a3-065be72a29fc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_e293471f-467a-4c22-9ab9-b8006ba1d0f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_0d92d606-64de-493c-983d-8b662ef0fe20_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_302d824f-3811-42b0-8063-48b036c2e804_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_340d1735-adc5-465a-aaff-c38f7f5e5bd3_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="lab_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_3e8c5d1d-1872-4586-bf22-7619755d3714_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8cb51f44-0e5b-43e7-a005-ee0d96109021_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_478ab83f-1002-43e0-a6a8-1d53d163f9ed_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_330a3061-ee4b-48a2-93c6-70387652d447_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accumulated deficit) retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_000b86e9-3c0b-4c13-83e3-1b26f6bc821b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_1ea6d6e0-394e-4a5c-a9ab-467890e8ad36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_f849e4bc-a589-4774-877f-398e51e49b84_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of revenue by geographic area</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CoVenturerMember_5ce3a7e1-2c1a-4513-947d-5d648fad7cf8_terseLabel_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer</link:label>
    <link:label id="lab_us-gaap_CoVenturerMember_label_en-US" xlink:label="lab_us-gaap_CoVenturerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Co-venturer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CoVenturerMember" xlink:to="lab_us-gaap_CoVenturerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_f0474e38-e351-454c-bef5-280acce925b0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_TotalRevenuePercent_ecc9dd16-07a8-4585-ba63-6a489d918e21_terseLabel_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International sales, percent of total revenue</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_label_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:label id="lab_apyx_TotalRevenuePercent_documentation_en-US" xlink:label="lab_apyx_TotalRevenuePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Revenue, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent" xlink:href="apyx-20210930.xsd#apyx_TotalRevenuePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_TotalRevenuePercent" xlink:to="lab_apyx_TotalRevenuePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_ebcca8b7-af10-40b2-a851-aee55e6d58e6_negatedTerseLabel_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of valuation allowance</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_label_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:label id="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_documentation_en-US" xlink:label="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:href="apyx-20210930.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:to="lab_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_e864a743-7007-47bf-8a2f-dba710f82be1_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax payable</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_5879e731-05dd-4b43-84e0-f83585e6dd09_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b8fe8476-2576-4daa-b660-1df12838d79e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f2535c98-d9f3-462e-8433-fee746cc6e36_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_694e8b8c-f5a7-42de-8fe3-f7459e7a3549_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture</link:label>
    <link:label id="lab_us-gaap_CorporateJointVentureMember_label_en-US" xlink:label="lab_us-gaap_CorporateJointVentureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Joint Venture [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateJointVentureMember" xlink:to="lab_us-gaap_CorporateJointVentureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_10ef6f38-f340-406c-b417-2fd4fbc60ea4_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_05b24e92-ad09-4345-b605-fa3a2fdc3cc1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_08c1fd7b-1dfc-41db-a9e1-1616955cdc8e_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:href="apyx-20210930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwaps" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_263a60e4-2aa3-46e3-bde1-9aee6ca533c7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3f10cc64-43e5-4810-b0cb-8c47696f3fe4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_f3e4cc3a-7e26-4535-a2b7-36d5b14bbf8f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a3c7ede-f4d9-44bb-9e77-0c8275506a74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_69e7416c-032c-48cd-ba65-b936954fd746_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_1d23dea8-c1a2-41f6-81b8-36fce2b29d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6b4bcca6-6cca-4c42-ac79-c998e5d7a6a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7e84e1da-ad1c-4f1b-bbd3-ce0067bc99d9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOperating_92f82ca8-cc04-45c2-aa28-bfcda5051b3e_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_f430b1bf-cee5-49e9-bcd8-06a1e211d2a0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_42c1c585-5852-4673-a5d7-bb7b6fdde676_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_91f2fe6b-6515-47eb-a455-7c4212428c7f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_180b08b1-e3c6-46c5-8894-6654459bffbf_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_3991b53c-7ff6-400b-8467-4eada04fb34f_netLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c58d279c-c292-4273-8b11-c9a8ace56865_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_352c53af-d474-4df8-b344-6ff32f010da6_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38d02183-f75c-48d0-8d24-e9a90434762c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4243d286-7785-42f0-b147-5f4c7f0b4af6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_22cd61f3-c96a-4c0a-847a-e38e3825a6e9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0b934015-fdeb-4821-b8e9-a45e1f1dada4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade accounts receivable, net of allowance of $360 and $300</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ed373044-f749-4b6c-b6e1-a8ac2a268520_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_af5f5cfc-bfe3-46b5-a491-a5f90168ab0d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_795f7cba-cc0d-4812-9632-bc8d2bd0f7e2_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_80a75f37-aaa7-4e6c-b132-0f21725d07d1_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DISPOSAL OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_aab5b6cf-6f4b-4de6-83ea-71512ed37405_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_edc28496-ce65-4e47-9202-200529f30f40_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OEMMember_4f6f9f83-6825-43b8-abb6-a80260a04434_terseLabel_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM</link:label>
    <link:label id="lab_apyx_OEMMember_label_en-US" xlink:label="lab_apyx_OEMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OEM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember" xlink:href="apyx-20210930.xsd#apyx_OEMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OEMMember" xlink:to="lab_apyx_OEMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_e7bcc5d5-6dbb-408f-9d44-3d2c4714dd04_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued bonuses</link:label>
    <link:label id="lab_us-gaap_AccruedBonusesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Bonuses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedBonusesCurrent" xlink:to="lab_us-gaap_AccruedBonusesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_a7ca48d4-8ea8-43be-b595-a2344e7ffbd0_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net of provision for obsolescence of $303 and $388</link:label>
    <link:label id="lab_us-gaap_InventoryNet_8931a164-d50c-4d04-9dac-0bdcc7056f1a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f63fb3e5-518c-4235-a7a0-871d9f2d8e33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of reporting information by segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a1114e21-caa6-4a29-a0ed-da47b343069a_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_220d8bf5-1d10-4d6c-8243-a18e9ecde0aa_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_91bdaa6b-b858-43e7-9877-33b416cefa44_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_41e0eca5-ec56-4979-b55a-b619fe1ac0cd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15f802d9-82cb-4fee-b538-5337203ece19_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_03f1233b-2c4e-47e4-8be6-1510485e81df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_1067e8fa-eaec-4fe2-a218-3c7a7b937741_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_13a2d138-d7a0-45d7-8214-bb2635f4f194_terseLabel_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_label_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:label id="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_documentation_en-US" xlink:label="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Stock Options Exercised And Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:href="apyx-20210930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:to="lab_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fe61aa8e-02b8-4909-be29-53105101832f_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a73d29b0-553c-4b56-9dfb-221380e584e8_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_5b85f635-1469-49cd-a0dd-8b2ade89532b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_ca20f710-33d5-43cc-baeb-b1bd1d229f3f_terseLabel_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset purchase agreement, term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_label_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:label id="lab_apyx_AssetPurchaseAgreementTerm_documentation_en-US" xlink:label="lab_apyx_AssetPurchaseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Purchase Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm" xlink:href="apyx-20210930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AssetPurchaseAgreementTerm" xlink:to="lab_apyx_AssetPurchaseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b8f916f3-fa7a-4305-9327-02ed94d97f43_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_57752b3e-ffaa-4295-bee9-c9e5bcc0bb70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_f372ba22-b9c1-45bc-b2e4-56b66204c53e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_f9878eb2-e6bd-4add-a0db-b699e3e4fb50_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_1bbb5b1b-7ae8-436b-9bbf-c9788b94778d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_a14eab59-15dd-4fb2-84cb-083dae498ecc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_7522840b-6170-4b95-8d28-bd627596ef3b_negatedTerseLabel_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of finance lease liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_label_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:label id="lab_apyx_RepaymentofFinanceLeaseLiabilities_documentation_en-US" xlink:label="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of Finance Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:href="apyx-20210930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_RepaymentofFinanceLeaseLiabilities" xlink:to="lab_apyx_RepaymentofFinanceLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_01ed6bb9-d640-469e-91bf-e8433687204c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases from related party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Purchases from Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_858c9b40-b3d4-446f-885b-61fa0f7e9591_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c2b9c712-ce24-46a6-bcdf-5ac321b37dfb_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_408e8fe7-c78d-4982-80ea-4e642378affc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_695beb21-46c4-453a-8661-376adabf3934_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0fa90cc0-aea6-46f8-b445-220d8c773587_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d8d1c32b-a02f-4da1-af7a-f71325120099_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_1fb66016-8fcc-4ec7-83dd-a9614cccbda3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_7c7e3cf0-e5ad-4a35-9b0a-2c3a526c1e0e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c8b26e3d-8ff9-4558-9d38-93b84ff7b285_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_4e88e2a1-4149-4a46-a8eb-fdabf14790a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_098425e7-26ed-471f-a878-70f69bd68026_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_73215595-7caf-4140-8487-4c4bb509a520_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate &amp; Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_1fed07ad-6ba3-4641-aa28-aa9c342e890d_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_6c9ecc1c-a427-4c36-b96f-51970fe62daa_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_f64b2e6a-de54-4f81-b8e0-2ccea5233318_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_45d42d01-d36f-4b60-9599-0e2f71dd5b19_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_90553464-f376-4bd5-bc80-1329d0b6f47a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_703efba3-cbd0-4f7e-9132-dda5cdf546c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings (loss) per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_c188bfbf-7d4f-476d-bbd0-b40a3cc72cc5_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, provision for obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_label_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:label id="lab_apyx_ProvisionForObsolescenceInventory_documentation_en-US" xlink:label="lab_apyx_ProvisionForObsolescenceInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Obsolescence, Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory" xlink:href="apyx-20210930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForObsolescenceInventory" xlink:to="lab_apyx_ProvisionForObsolescenceInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_88ff396c-6eec-4b66-a9c9-82648d19fa7f_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1333e659-2858-49b3-bd8c-82f0d6f1976a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b03a2acb-ddda-43c6-8212-a2171353d7fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_c0904a4a-b98e-4055-96ef-f9994015aa67_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_e0f8112b-6d88-4114-b1ff-e3a89232cf65_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6e4767b2-6a01-45b6-a320-344deb67c5a5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4e449dee-5489-40dd-8bc4-3d8ca7aa7f3d_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_eafb181e-1fd3-41cd-9687-02b16412e909_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1a74c688-7fbe-4746-951b-0fba452407e0_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b7256e3d-d55f-4e77-97bd-8bc1d45a4c83_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_a41f8ba8-1833-48ff-b7a5-f65edfa95479_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8581a1cd-cf99-4a2a-aca4-3ba5e89e88d0_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0b0ddd4b-0406-473f-8978-f1c31e3d1477_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_d6171d6d-6f7c-4b99-b85c-c897beef370c_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to stockholders, basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_eb4285f4-e5b3-4177-b433-c3a0c034f830_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9e1fd1b5-d3dc-483f-b016-c0b9f3e1fd7d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2218e12a-32cc-4073-a753-bdc6e2ecb67d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a2fbbee-2275-4915-b34b-5292b93dbaef_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_fa386fd5-ed84-46cb-9043-b61361bd978d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Apyx</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_a275e332-006c-4b49-90f5-a56b1e243a00_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA JOINT VENTURE</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDisclosureTextBlock" xlink:to="lab_us-gaap_MinorityInterestDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_43b7cabb-65e8-4bce-903b-9d0727178d30_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1bf34cd1-98d9-41be-8b78-54c264affc04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_330bf657-ff6d-4997-ba8f-bd6138c22937_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive instruments excluded from diluted loss per common share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_1ab900fd-60cf-4c91-a04d-f79b4a108eed_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_4e010f80-be65-4cdd-9a5a-0258bfa6760a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_62b9a775-193a-4086-8933-2f68179bfdec_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_d374d814-53ac-499c-bd12-78acd08eca11_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_359978cd-622f-420f-abb7-8e073ca34953_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6d6bafaf-c409-4e20-a9cc-dfc86069d1d8_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8d4347dc-037a-4466-be33-4cecdd54bc2e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f3759e53-75f3-453d-aa97-2d5e3d932470_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a15acf4d-1824-424a-918c-4ed46c43fc7c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_a276b56b-6fff-462f-817e-98e528d6ba5c_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d5e8186e-32ce-452f-a0ad-7f1d13c1b927_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_9045d926-ceb9-4388-ae72-8c5e8171bbc3_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_4014d179-e6d0-4aa1-9c90-fcc2970c0a75_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_78bb621b-508d-4f33-8689-9d5d89e6c135_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product liability claim insurance deductibles</link:label>
    <link:label id="lab_us-gaap_AccruedInsuranceCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedInsuranceCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Insurance, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedInsuranceCurrent" xlink:to="lab_us-gaap_AccruedInsuranceCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_824bc879-b789-4c95-9c0e-626a3e7f2899_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_37ef5a04-4cc0-4963-9bf8-d3d7109a1a48_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_272b3224-b481-4439-a272-96c05ec03929_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_9946de9b-b37e-4c98-a2e0-0ff5f4085e41_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_dbc55132-4bb8-45c4-999f-a413e7adcd7b_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_dfabc0e6-94d4-4e4d-9285-c514997618b1_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties included in income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2c8e75f2-fde1-434a-852e-a4c4497b0783_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_c8a61a79-9a19-4394-be52-2e1b091a6158_terseLabel_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_label_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:label id="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_documentation_en-US" xlink:label="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:href="apyx-20210930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:to="lab_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_962d8bc6-a41d-4195-8f75-60775ab98d0b_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_a47d6f40-ec09-475b-9df8-a7c2db1d5791_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_743c13f4-c73f-4391-8274-635d61643571_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_13c9efeb-52fb-4a36-ae95-ead57c2236dc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_fb9306f9-a10c-4f2e-917a-ec6af5d1b355_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6a3c46e7-08d1-4c58-8c34-7dd72d860ea4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_94e4c4e8-bc9a-4c1d-8971-397afb15c4d6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_50adf99e-9b81-49f0-841a-b282d1a2f778_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_1b14bd4e-896e-4c8c-bd7e-3e390a82672d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_038eb089-4cd4-4b3c-af9a-1a5777fb174b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_1299da18-a6a9-4ee0-b44a-9f295e50207b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d401f9e8-aa67-4ab3-80d6-130317e2ed38_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_e809c50c-6dc2-4bea-9159-b75d601abdd9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_05bc25d6-1031-4f45-ad0c-5ac4a5d7422a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_cc7ba451-ea50-4ec2-850b-86a61e24ad6d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on stock options exercises for cash</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_cfd21495-e205-4498-b819-47a9fdda3898_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_a06da776-67b0-4f65-82be-cf01afc68ee9_terseLabel_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued product warranties</link:label>
    <link:label id="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent_label_en-US" xlink:label="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:to="lab_us-gaap_ProductWarrantyAccrualClassifiedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_9984b2f5-ec52-4c22-9801-bfc9073e7f62_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_9c524186-c419-4ff9-8a01-f64c52ac69bb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesReceivable" xlink:to="lab_us-gaap_IncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_0ff0c6ac-05c7-406a-b5f4-e443871ad59a_terseLabel_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain tax positions</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_label_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:label id="lab_apyx_UncertainTaxPositionsLiability_documentation_en-US" xlink:label="lab_apyx_UncertainTaxPositionsLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Uncertain Tax Positions Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability" xlink:href="apyx-20210930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_UncertainTaxPositionsLiability" xlink:to="lab_apyx_UncertainTaxPositionsLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_702473e8-f9b6-47c4-bc84-9a2a7bdb158c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposition of Core business</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f6a5b939-5772-4b73-bebd-8b4b323ee6ce_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract" xlink:to="lab_us-gaap_NoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_a3bf76b8-6785-4a6c-841d-f0987020bd3a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6e2c6f72-f648-483c-9c94-81e636d82cca_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates on cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_29734dab-c4ab-4865-832b-860e361197dc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_eb6e6de8-f4c6-4982-bc90-ff3ae55c93e9_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c94580f6-22ab-4a57-8e60-73df2ae92831_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled and forfeited (in dollars per shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e6b85b2b-571d-4b0b-9301-77e95b550fe4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_f0709435-1470-4938-a74a-8b17f39bc021_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_03deaa51-aab1-445b-a809-fc15d2a6e276_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_aa60ffa0-c214-4ec0-ad6c-5602f0cfd4a7_terseLabel_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued on net settlement of stock options (in shares)</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_label_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options, Shares</link:label>
    <link:label id="lab_apyx_StockSwapToAcquireOptionsShares_documentation_en-US" xlink:label="lab_apyx_StockSwapToAcquireOptionsShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swap to acquire options shares.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares" xlink:href="apyx-20210930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockSwapToAcquireOptionsShares" xlink:to="lab_apyx_StockSwapToAcquireOptionsShares" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_e5bf08bc-236d-4366-a42a-1e1a0a3caf0c_terseLabel_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses and current liabilities</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:label id="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Expenses And Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:href="apyx-20210930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:to="lab_apyx_OtherAccruedExpensesAndLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_7b79fca3-df03-40a9-afe8-74c6b1d3e50d_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net other income (loss)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_09b88653-fe47-42eb-9218-c1b9c7f132ca_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_78bbd93b-c825-4db5-af40-6830713277e4_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2629b228-5bff-4cff-920b-207eb042b6c7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $5,145 and $4,813</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_45d52e96-8992-4f1d-92d8-ebdd51f5d969_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other costs and expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b0145042-8a5b-47e6-9c31-6ff098a93f23_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_9827b4fb-b12d-4501-84d5-2c485f8edcba_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_aec0f504-0232-4612-b0ab-e1b9c854b8cb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_87afeb6f-5635-4010-a7ba-6fcb0fec351e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_392211e9-f2a2-4810-ba22-e46c5de1e812_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_5960cfe5-d941-45c5-b53d-4a19c12ac173_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_fc8cc7db-f099-4940-bcbd-18c7de91a73a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORIES</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_d779345d-54af-48eb-b178-9a6dca4f1383_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_e1943447-0973-43b1-8c62-d8417477189c_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross inventories</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_dcdacde1-0e57-4687-879a-9164188b9aa9_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_4898469a-9b95-4908-a44c-d22f85c1ed89_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e100d1f3-6b6c-4ab6-9ca6-acf051d04882_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_194a1d8e-e1e1-4a03-8f5b-2273d766a502_terseLabel_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint and several payroll liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_label_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:label id="lab_apyx_JointAndSeveralPayrollLiability_documentation_en-US" xlink:label="lab_apyx_JointAndSeveralPayrollLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Joint And Several Payroll Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability" xlink:href="apyx-20210930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_JointAndSeveralPayrollLiability" xlink:to="lab_apyx_JointAndSeveralPayrollLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b6db1409-f7e8-4ed2-8fd0-20e28414781a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2bec1ee3-1c47-4536-b69f-2aeb7aa58d23_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_8985070f-0f4d-47cb-93b4-c456ffc4eb02_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c642657d-e081-43f6-a84e-ee0deb11f0a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0881a081-4111-41dc-b968-aba23532d4bf_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4b0c13d3-8528-40f1-ae83-3f2f2cd6d149_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,339,533 issued and outstanding as of September&#160;30, 2021, and 34,289,222 issued and outstanding as of December 31, 2020</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1f9d5eb1-1cb7-4e8e-9c55-77cd9a98ba5d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_7d52d442-73d7-4542-a27a-0fe37ea44fbd_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_62065687-e492-4025-b149-6b26b4937ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_baa80f3e-7148-4772-b07c-d3191c1ea1fb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_7fc053a9-14b5-4633-a1e9-cace714c3130_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_f1d31455-adff-444a-abf0-271d5295a776_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14b27842-1fad-485a-8214-df3c1a3dbef9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_31cdce0f-845a-4c83-b467-be836b32dbc8_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_f12adacd-7c66-47f9-af12-86243760ab4b_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8a62d844-a367-440a-930b-fafd677889be_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_6e9e14e5-43e9-4702-8a9b-5f729d122472_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_5ae3de61-9a65-4e66-bab1-2008ebfaff62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of option fair value assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_9f088b9b-97a3-471e-9fdf-d3de294d7af3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions from non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_8f831e7d-b96b-4db4-a876-01584c197e58_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contributions</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_42f23717-bdbb-4f82-9d24-f1b464ab4d60_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_8fff6cfb-c1f8-48c4-a138-01ddb996cb15_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b4f75be2-3ccb-44e7-9405-d25266b6627e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_48fc7c75-c1e2-4f73-ac5b-bf6dbf557db5_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryValuationReserves_dc0e5483-bfcc-42e6-be58-efdd4697164d_negatedLabel_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: provision for obsolescence</link:label>
    <link:label id="lab_us-gaap_InventoryValuationReserves_label_en-US" xlink:label="lab_us-gaap_InventoryValuationReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Valuation Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryValuationReserves" xlink:to="lab_us-gaap_InventoryValuationReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_13318018-4082-47c8-b94d-5b0e94e9f7c6_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of China Joint Venture</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table Text Block]</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:href="apyx-20210930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestTableTextBlock" xlink:to="lab_apyx_NoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_218beedc-7056-4a37-9771-2e4e69641a9d_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_05f31808-2ea6-4a1d-adff-ee2460393a35_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dfbcd78d-73d9-412f-bfea-76449f6ca961_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_fc4777c9-d518-4e6e-b158-4cebcb9ac26f_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_65b6e195-91bd-4042-b45f-08fde9725678_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_b565c53c-7062-4311-801d-a6d26f8d9152_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AdvancedEnergyMember_5e37f3db-36a6-4c48-a7a6-d7154e0124ce_terseLabel_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_label_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:label id="lab_apyx_AdvancedEnergyMember_documentation_en-US" xlink:label="lab_apyx_AdvancedEnergyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced Energy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember" xlink:href="apyx-20210930.xsd#apyx_AdvancedEnergyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AdvancedEnergyMember" xlink:to="lab_apyx_AdvancedEnergyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_8bfcdb70-0fef-4f39-96ad-ec141a100949_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_60220b30-98db-4e0e-b2f6-c196a61e567a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_cb86901a-9c87-4019-94b4-dc924fcdb254_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3c84046d-6742-4b7a-8c28-7d50f8b8d07f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_f97a283d-efed-4f19-ad93-68f06a23aa37_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_e9f6e8bf-2c6a-45f6-8495-45e323b68298_terseLabel_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required capital contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_label_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:label id="lab_apyx_NoncontrollingInterestRequiredCapitalContribution_documentation_en-US" xlink:label="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Required Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:href="apyx-20210930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:to="lab_apyx_NoncontrollingInterestRequiredCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_5b0a8a36-3172-4fd5-8ee8-c94ec9e68137_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7e8d221e-4c9e-4ada-b06b-d116a6adfd09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_52fcd4ca-0b9d-4d2a-b717-d10c14060a41_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bd27493-76ed-4715-81af-187ebd27a80e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0b7a893c-4379-4425-a94d-df3bbeb35fdc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_03841e95-aad5-415f-801b-70d8c0854a59_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_5093ba1d-22a4-464a-a070-cd87627dcc3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4106a9f5-b5f9-4f34-95ef-c060981c822a_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_e9d9f41b-a432-4c8b-a73d-06f00a881e45_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_bce15def-00da-4e47-815e-bbcb50e08916_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_02fbae92-4b7e-4771-9f8f-ba1de1218e65_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of stock options and stock awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3c297221-40c6-4105-92bc-9f5f6ec67d67_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_99fb96b9-7af2-4aca-91c7-e676cf6ac4bb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ccc870d9-ed91-4e33-94bc-87f4af6ab0de_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PurchaseObligation_f1d45171-c46d-4113-95ab-4489ae66c3c2_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase obligation</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation" xlink:to="lab_us-gaap_PurchaseObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_22ab5d46-9645-413c-9bc9-827f9ae97c7c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4f61ccb4-de4e-4a9e-a351-fdbcff7f031e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_55323378-28e1-456d-b39b-51378051fdf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalariesAndWages_1c7ef99a-7bad-494d-b0ec-ed5cd3d43fe6_terseLabel_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salaries and related costs</link:label>
    <link:label id="lab_us-gaap_SalariesAndWages_label_en-US" xlink:label="lab_us-gaap_SalariesAndWages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalariesAndWages" xlink:to="lab_us-gaap_SalariesAndWages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5da881a0-cc93-4a25-95ab-b9275c060ad8_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_559f51d1-cec4-452d-bfd9-11e97f71c011_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GEOGRAPHIC AND SEGMENT INFORMATION</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3f79b0cb-00f4-4c4f-a65c-c0857d9b4233_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_55dbc81f-0b59-4556-ac83-aa66f10c130c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalFees_5836f426-9f84-4571-959a-4e1595f25e01_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_ProfessionalFees_label_en-US" xlink:label="lab_us-gaap_ProfessionalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalFees" xlink:to="lab_us-gaap_ProfessionalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_75ac68fd-e172-4781-96e5-bb4b26ae8c7e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_13fc6675-5c2f-4291-9165-aadf021ab7d6_terseLabel_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock swaps equity instruments received (in shares)</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_label_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:label id="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_documentation_en-US" xlink:label="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:href="apyx-20210930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:to="lab_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_21c34a31-917e-4fa7-b781-67c8ee08822b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc2abde3-b410-423a-90e1-12dc0ffdacee_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_5a5748f1-1c8a-47fa-97fc-5efb52f1d6ba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_ca749fe1-8868-4347-8d16-471d3e5d6ef0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8462cd70-58fb-4adb-937f-c90b814e24ec_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ff38cda2-f688-45c4-a5bd-6632e46c799e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_29324b52-bbd2-437f-9de2-6c48db6c9358_terseLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_cea82e8a-9f56-4717-8857-55353e93c129_totalLabel_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_label_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:label id="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_documentation_en-US" xlink:label="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:href="apyx-20210930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:to="lab_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2f2c6cdc-77dc-432e-b73f-552cce0849d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_dcd070e9-891e-40f8-8177-769ec7fec4d0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ChineseSupplierMember_e5e9864d-0d8d-4af1-ad0b-4933d280b9b4_terseLabel_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_label_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier [Member]</link:label>
    <link:label id="lab_apyx_ChineseSupplierMember_documentation_en-US" xlink:label="lab_apyx_ChineseSupplierMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chinese Supplier</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember" xlink:href="apyx-20210930.xsd#apyx_ChineseSupplierMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ChineseSupplierMember" xlink:to="lab_apyx_ChineseSupplierMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_538438a4-4383-4539-b3a5-5e640bfb1d02_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_8c520149-83c6-40e2-a889-8816572eee49_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_19277f02-6edb-4965-a1f9-2be295785463_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_3b96bfd3-14dc-41e4-bb12-00ea97bf900d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_2d696567-a0b0-4aa3-a498-6629f9f21492_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued commissions</link:label>
    <link:label id="lab_us-gaap_AccruedSalesCommissionCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Sales Commission, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalesCommissionCurrent" xlink:to="lab_us-gaap_AccruedSalesCommissionCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_ed91556e-7347-4b7f-96ba-6424dadbcb44_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8a28006c-021a-4890-9f13-6cb114c70af1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_28aa142b-31f2-4cc5-acf6-069bc1c77d96_totalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (loss) income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ef82be56-0c8d-421f-bcc5-eed95315efe8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2a0a9367-8074-4891-97b4-7714207a970f_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01817717-0e03-4b8e-9407-7630efe5617b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_86a35352-9aa8-4f78-b4de-99f9f9072e49_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_bc7481ae-76b1-461d-9bba-c9bf2f3f2a33_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_047866ac-d921-48f1-83c8-6a627452aaa1_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f8f68e0e-ed45-4c4a-80dd-397d0c5c0d33_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0396eb48-1c3a-4ea0-ac75-d5a44ec9934c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_ef2361ae-a621-4e3b-8ec5-5062195fa799_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_397fde4a-8b5f-4907-873d-83f518989fa4_terseLabel_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc.</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_label_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:label id="lab_apyx_SymmetrySurgicalInc.Member_documentation_en-US" xlink:label="lab_apyx_SymmetrySurgicalInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Symmetry Surgical Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member" xlink:href="apyx-20210930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_SymmetrySurgicalInc.Member" xlink:to="lab_apyx_SymmetrySurgicalInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_487b72ac-355a-40d3-a291-0a4e2acf515d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a0661003-e666-48bc-b9c6-a03318d96397_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_5dde79d5-8a2e-478b-8ce3-f657dabee312_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strike price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ccf4421b-880a-45fd-a665-b307570547e1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_4fc7bb4b-3844-4299-be8c-ce107ba621db_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_178655c7-0f6f-44b5-aaf5-232e8e6e4435_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_4c60249c-d461-4f42-9fc4-5f5ccd7a8ad3_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending interest in China JV</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_d41fa12e-748a-44ef-b720-9e9c67f40aab_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_62f519e9-9fcb-439e-b357-25e27c0351fc_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fe62a244-5ba6-42d5-a240-5eeeb7f7bd11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_43c5c320-d984-4936-a2bb-437914e04804_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_950dadf2-5c0c-4ec3-a6fb-6adfd66a7c20_terseLabel_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for inventory obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_label_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:label id="lab_apyx_ProvisionForInventoryObsolescence_documentation_en-US" xlink:label="lab_apyx_ProvisionForInventoryObsolescence" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision For Inventory Obsolescence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence" xlink:href="apyx-20210930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_apyx_ProvisionForInventoryObsolescence" xlink:to="lab_apyx_ProvisionForInventoryObsolescence" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_33d590d1-e89a-4190-a087-ff5e0c40e275_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0c71265b-9560-4ba8-b1e8-632d9bc80db4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6a9a8cb0-e9ae-4b21-b7ac-bbf1483d1231_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>apyx-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:46ca1b85-f7a9-4543-97cb-6ed086a597ae,g:b143a237-a59b-426c-be6c-51eb546c95c4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://apyxmedical.com/role/Cover" xlink:type="simple" xlink:href="apyx-20210930.xsd#Cover"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9f95432a-0fbe-4f97-9fdb-ebbd2c1e49b9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentType_9f95432a-0fbe-4f97-9fdb-ebbd2c1e49b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_d29583c3-0cbd-4e52-8661-6f648ad6c2a5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentQuarterlyReport_d29583c3-0cbd-4e52-8661-6f648ad6c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_c1ca6638-2725-4cab-be02-6155bee1d7b9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentPeriodEndDate_c1ca6638-2725-4cab-be02-6155bee1d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_6edf152d-e508-4cc8-b655-a8389f37fdbd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentTransitionReport_6edf152d-e508-4cc8-b655-a8389f37fdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_3551f5d3-ef88-4bd8-8fa1-db6a4b572505" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityFileNumber_3551f5d3-ef88-4bd8-8fa1-db6a4b572505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_35b77da9-2a9d-4540-9f24-a8ef8dfc7c4d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityRegistrantName_35b77da9-2a9d-4540-9f24-a8ef8dfc7c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bf770102-b05f-485e-86cf-c768d7652b06" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bf770102-b05f-485e-86cf-c768d7652b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d57283c8-8141-47bb-8c6e-385d7d2c338f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityTaxIdentificationNumber_d57283c8-8141-47bb-8c6e-385d7d2c338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_77b0a887-3e64-4444-8fb9-a66eebd065ee" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityAddressAddressLine1_77b0a887-3e64-4444-8fb9-a66eebd065ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_c11798a1-1272-4fb8-afec-ae63d2ee8d90" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityAddressCityOrTown_c11798a1-1272-4fb8-afec-ae63d2ee8d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_72b10488-de2f-4bce-9875-d8a7a3a9f8cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityAddressStateOrProvince_72b10488-de2f-4bce-9875-d8a7a3a9f8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bc912815-c5f4-4684-8cb7-c2072d97abd4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityAddressPostalZipCode_bc912815-c5f4-4684-8cb7-c2072d97abd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_b04b1c1d-6aa4-40d9-bc9b-b71ffdfa2fbd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_CityAreaCode_b04b1c1d-6aa4-40d9-bc9b-b71ffdfa2fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_bcd72269-01a4-4d4b-80c1-45ca0077d8cf" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_LocalPhoneNumber_bcd72269-01a4-4d4b-80c1-45ca0077d8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6eece3a4-8a13-4671-93ca-4f7cc4e9f172" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_Security12bTitle_6eece3a4-8a13-4671-93ca-4f7cc4e9f172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_4de822bc-3a07-4c90-b4ef-7698c8ad60d6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_TradingSymbol_4de822bc-3a07-4c90-b4ef-7698c8ad60d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_38dda087-37d3-4630-a7eb-e5841d56b555" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_SecurityExchangeName_38dda087-37d3-4630-a7eb-e5841d56b555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_6a7ad667-c88f-49ac-af60-e0325c73ec15" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityCurrentReportingStatus_6a7ad667-c88f-49ac-af60-e0325c73ec15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1d8cb4d5-71f2-4123-9c2c-58950961fec4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityInteractiveDataCurrent_1d8cb4d5-71f2-4123-9c2c-58950961fec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_2a43c72d-0e21-4cb9-8285-cab593b1ccc7" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityFilerCategory_2a43c72d-0e21-4cb9-8285-cab593b1ccc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_af087502-7b72-46e3-84d9-79c66999fcfb" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntitySmallBusiness_af087502-7b72-46e3-84d9-79c66999fcfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_b5062e30-64ff-49a8-9677-8e09e5e4e37d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityEmergingGrowthCompany_b5062e30-64ff-49a8-9677-8e09e5e4e37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_5b823c7e-264e-4f4d-bddc-c80ae0ad6c25" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityShellCompany_5b823c7e-264e-4f4d-bddc-c80ae0ad6c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9f294678-7fe4-4baa-87a9-274fdc2e175f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9f294678-7fe4-4baa-87a9-274fdc2e175f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_bfa36b54-1ed7-4a8a-a912-b2c75892abba" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_EntityCentralIndexKey_bfa36b54-1ed7-4a8a-a912-b2c75892abba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_71ef048b-2475-4527-8678-1169ca278ea3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_AmendmentFlag_71ef048b-2475-4527-8678-1169ca278ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4cc0ab3d-f7ac-44ce-ab4d-1391da52d2bc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_CurrentFiscalYearEndDate_4cc0ab3d-f7ac-44ce-ab4d-1391da52d2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_1bb90d14-20ce-4401-8d5d-0f093893eb08" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentFiscalPeriodFocus_1bb90d14-20ce-4401-8d5d-0f093893eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_91dd334a-c4f1-4d50-b7cc-0cde88f73bf1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9bc138ad-e441-4928-836c-7baa52c21b76" xlink:to="loc_dei_DocumentFiscalYearFocus_91dd334a-c4f1-4d50-b7cc-0cde88f73bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5710183c-047d-4029-9ba2-c1e1b228bcb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5710183c-047d-4029-9ba2-c1e1b228bcb2" xlink:to="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7956e22-081c-4a24-adcd-4021e142ea13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7956e22-081c-4a24-adcd-4021e142ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7190f288-9f66-47f4-a096-fb0b9a633616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7190f288-9f66-47f4-a096-fb0b9a633616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesReceivable_932a2091-9136-45ea-b03a-84b03d3afd41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_IncomeTaxesReceivable_932a2091-9136-45ea-b03a-84b03d3afd41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_192f5993-c9d1-4bb9-b987-fa88998f9883" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_192f5993-c9d1-4bb9-b987-fa88998f9883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_48decac7-5b31-48e6-ae2d-5cd7cfbdec42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_InventoryNet_48decac7-5b31-48e6-ae2d-5cd7cfbdec42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c813a80c-76a8-4352-81f3-43854dec2776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c813a80c-76a8-4352-81f3-43854dec2776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_39d0e2fd-04dc-4adb-8db9-5d9de2e130f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2caba2ec-9897-4b17-8bad-fd971e6187b9" xlink:to="loc_us-gaap_AssetsCurrent_39d0e2fd-04dc-4adb-8db9-5d9de2e130f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2a7d7aea-59df-4188-9020-23da8df190b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2a7d7aea-59df-4188-9020-23da8df190b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_865f2436-4889-4906-bd6d-3aae7ace76bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_865f2436-4889-4906-bd6d-3aae7ace76bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_d1364442-3777-403b-affc-b07f31ef9790" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_d1364442-3777-403b-affc-b07f31ef9790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b0925152-bd31-43cc-832b-c8da5939a387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b0925152-bd31-43cc-832b-c8da5939a387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d93125c4-a09a-4269-93d1-cb5ebf22eddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_99bff317-cc6b-4ea2-a0c5-c230af6817d2" xlink:to="loc_us-gaap_Assets_d93125c4-a09a-4269-93d1-cb5ebf22eddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5710183c-047d-4029-9ba2-c1e1b228bcb2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_ea223700-5d07-4dc5-8f41-c218fbf77041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:to="loc_us-gaap_AccountsPayableCurrent_ea223700-5d07-4dc5-8f41-c218fbf77041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_91fccc0d-e034-4f52-be3e-2e24f9b567eb" xlink:href="apyx-20210930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_91fccc0d-e034-4f52-be3e-2e24f9b567eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_da4d49f3-4691-40fc-8e3d-0507e1333a79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_da4d49f3-4691-40fc-8e3d-0507e1333a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a55eb7e-3a34-4d67-94a2-744847312fae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_1a55eb7e-3a34-4d67-94a2-744847312fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7b4fe2ed-16a5-4861-8e92-76b378e7ddc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_de004f09-c755-4bdd-bd64-2ec51d69ca8d" xlink:to="loc_us-gaap_LiabilitiesCurrent_7b4fe2ed-16a5-4861-8e92-76b378e7ddc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86cde916-b59b-4a43-8356-11c746590fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_86cde916-b59b-4a43-8356-11c746590fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6d780075-caa8-4122-be9f-d8469c2e320f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6d780075-caa8-4122-be9f-d8469c2e320f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_364be88e-a333-4e1a-8d5f-02627c119ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_364be88e-a333-4e1a-8d5f-02627c119ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_de8150e3-b951-4b9a-abf1-985dba55b83d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_de8150e3-b951-4b9a-abf1-985dba55b83d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0babb3f6-d58f-445b-a59f-26bebec4c424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_Liabilities_0babb3f6-d58f-445b-a59f-26bebec4c424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d241094c-838a-469a-9ed9-fbf64aa3e5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_CommonStockValue_d241094c-838a-469a-9ed9-fbf64aa3e5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_e5db411a-d446-46d8-8c79-b33accd12545" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_e5db411a-d446-46d8-8c79-b33accd12545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21e67589-4f54-4284-8bec-9991a3dc143b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_21e67589-4f54-4284-8bec-9991a3dc143b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_501357d8-c657-4430-a721-e82e8ad3952f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_StockholdersEquity_501357d8-c657-4430-a721-e82e8ad3952f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_847908af-5df8-42ed-87aa-1b9bef77030c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_MinorityInterest_847908af-5df8-42ed-87aa-1b9bef77030c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_683aa1e4-ac73-4600-b866-f7cfe5d77fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_675008a3-ba10-43fc-9d63-c84be134c5b5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_683aa1e4-ac73-4600-b866-f7cfe5d77fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_78879ffb-1df5-40c5-a7fd-4307ab604e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0482c3b4-5bbb-4933-b3cb-bf0beb7099c0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_78879ffb-1df5-40c5-a7fd-4307ab604e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c4189608-ac2b-4858-9fc5-d02ea4881f62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_c4189608-ac2b-4858-9fc5-d02ea4881f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForObsolescenceInventory_245720de-1545-44dc-bb05-732f7542a1e4" xlink:href="apyx-20210930.xsd#apyx_ProvisionForObsolescenceInventory"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_apyx_ProvisionForObsolescenceInventory_245720de-1545-44dc-bb05-732f7542a1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ab0eb89-8a2b-4194-a0cc-95bf8b2970fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6ab0eb89-8a2b-4194-a0cc-95bf8b2970fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_6708254b-04c0-48dc-89b7-b9b61eb6434e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_6708254b-04c0-48dc-89b7-b9b61eb6434e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_649d392d-7caf-405c-bdc8-1ad8e476ed7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_649d392d-7caf-405c-bdc8-1ad8e476ed7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_44c7f496-af6f-42ac-8753-e10ec1d3c8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_CommonStockSharesIssued_44c7f496-af6f-42ac-8753-e10ec1d3c8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_55fc652b-4eed-4a7a-95e4-d95cce262bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d652e2e4-a13d-414d-be08-a06798a83932" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_55fc652b-4eed-4a7a-95e4-d95cce262bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86171df-481a-4488-8ed0-9748386591ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c86171df-481a-4488-8ed0-9748386591ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2cec586e-7878-47a4-878b-1a336622b927" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2cec586e-7878-47a4-878b-1a336622b927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_36aecfe7-005b-42b1-911f-ca77254aefd8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_GrossProfit_36aecfe7-005b-42b1-911f-ca77254aefd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6dcb2561-1443-431b-90e9-6ae6e3ca72fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6dcb2561-1443-431b-90e9-6ae6e3ca72fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalFees_63b2fee6-11d0-4a12-a29f-d635806d8cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfessionalFees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:to="loc_us-gaap_ProfessionalFees_63b2fee6-11d0-4a12-a29f-d635806d8cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalariesAndWages_532d1b95-185d-4133-8503-35e2d4718b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalariesAndWages"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:to="loc_us-gaap_SalariesAndWages_532d1b95-185d-4133-8503-35e2d4718b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6ffce281-daea-4a47-8a0a-5f7b1d242e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6ffce281-daea-4a47-8a0a-5f7b1d242e9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_16ce0c1a-94bc-4598-b68a-57dcca907757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_79e84af4-0ca7-476d-81fb-8c8db87e2e47" xlink:to="loc_us-gaap_OperatingExpenses_16ce0c1a-94bc-4598-b68a-57dcca907757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c43c91af-ead5-4668-98d2-e6f122b305b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_OperatingIncomeLoss_c43c91af-ead5-4668-98d2-e6f122b305b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_d334f85a-4ed4-439b-b14f-3c1187dd1b59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_InterestIncomeOperating_d334f85a-4ed4-439b-b14f-3c1187dd1b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2bf140e3-358b-46a1-bd72-efaed58916d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_InterestExpense_2bf140e3-358b-46a1-bd72-efaed58916d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_df82e622-2482-4e0e-a36f-91ec4096da26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_df82e622-2482-4e0e-a36f-91ec4096da26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6876ecaf-4df5-4a75-bd45-9f3c164d2016" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6876ecaf-4df5-4a75-bd45-9f3c164d2016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8eb41f9-0f10-4828-9633-76f7e842a81d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d8eb41f9-0f10-4828-9633-76f7e842a81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7e1707e6-7f13-492c-985a-9bc7da2af270" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7e1707e6-7f13-492c-985a-9bc7da2af270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f6a66374-3ce4-4f58-8cd1-c26803e3e70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_ProfitLoss_f6a66374-3ce4-4f58-8cd1-c26803e3e70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a39f1c1-30fe-45b0-aae6-34f53bd2fe34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a39f1c1-30fe-45b0-aae6-34f53bd2fe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10f361b1-1952-4768-8621-473eb58dd5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_NetIncomeLoss_10f361b1-1952-4768-8621-473eb58dd5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f3f0674e-f93b-42e4-ac01-f0c7423f8e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_027a533f-a1d6-47ac-8ea1-3f7e81326ae7" xlink:to="loc_us-gaap_EarningsPerShareAbstract_f3f0674e-f93b-42e4-ac01-f0c7423f8e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_5b104d92-21d3-41ad-ad32-05b20c07ddaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3f0674e-f93b-42e4-ac01-f0c7423f8e89" xlink:to="loc_us-gaap_EarningsPerShareBasic_5b104d92-21d3-41ad-ad32-05b20c07ddaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a376fe7c-acdc-458c-b837-f2eb31d271ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3f0674e-f93b-42e4-ac01-f0c7423f8e89" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a376fe7c-acdc-458c-b837-f2eb31d271ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_58fa32bd-54ff-483d-b5a0-d2b21794b2dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_58fa32bd-54ff-483d-b5a0-d2b21794b2dc" xlink:to="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b57f36c1-8273-4c62-97d6-860069d8a9c3" xlink:to="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_01e22c5c-e616-4fa3-b457-947ea1111d99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_CommonStockMember_01e22c5c-e616-4fa3-b457-947ea1111d99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_76da1022-21d5-4d08-ba7f-957fe52430ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_76da1022-21d5-4d08-ba7f-957fe52430ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8c111166-3ad9-4c10-ad39-be57e6f425a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_RetainedEarningsMember_8c111166-3ad9-4c10-ad39-be57e6f425a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f26c6138-ce13-427c-834c-cb45b0e75df0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_071416e0-22ac-4cf9-b5d0-1773c829d9fa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f26c6138-ce13-427c-834c-cb45b0e75df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c509b600-395e-44b5-a496-8c3c39f883f4" xlink:to="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_30c6924a-9570-4ffb-9626-4b0226f8cf8b" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_9467ecc4-cd03-4d79-a17f-5f11ada03da9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_SharesIssued_9467ecc4-cd03-4d79-a17f-5f11ada03da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d1df14-552a-43ef-893f-afe53a40f34b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0d1df14-552a-43ef-893f-afe53a40f34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_71316f01-e022-4416-9e38-2aa4bdecbc50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_71316f01-e022-4416-9e38-2aa4bdecbc50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9a5d0c61-b9a4-4789-8567-3f549f376170" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_9a5d0c61-b9a4-4789-8567-3f549f376170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7e27781-cddf-42d1-9b80-9b5e7db67c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c7e27781-cddf-42d1-9b80-9b5e7db67c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_383a1feb-e0f9-45cc-9cf0-c69e0434c18c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_383a1feb-e0f9-45cc-9cf0-c69e0434c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockSwapToAcquireOptionsShares_db06288d-c674-49a5-80ba-c41ebcd0b045" xlink:href="apyx-20210930.xsd#apyx_StockSwapToAcquireOptionsShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_apyx_StockSwapToAcquireOptionsShares_db06288d-c674-49a5-80ba-c41ebcd0b045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6180ee98-9b2e-448f-b727-3f22a87b5471" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_ProfitLoss_6180ee98-9b2e-448f-b727-3f22a87b5471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6c631c03-e00d-49eb-bdd6-f725daa71bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_SharesIssued_6c631c03-e00d-49eb-bdd6-f725daa71bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65c71b5e-2c66-4558-af30-c2415a570702" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_4dc3c176-1034-4f4a-90e5-0339663caaa0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_65c71b5e-2c66-4558-af30-c2415a570702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="apyx-20210930.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cb4d9b8-dece-4ec9-be84-9bf9c286b4de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cb4d9b8-dece-4ec9-be84-9bf9c286b4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_001f81d7-3182-4235-b77b-0d921159a701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cb4d9b8-dece-4ec9-be84-9bf9c286b4de" xlink:to="loc_us-gaap_ProfitLoss_001f81d7-3182-4235-b77b-0d921159a701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cb4d9b8-dece-4ec9-be84-9bf9c286b4de" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_80ff2baf-e33e-4e04-8ad7-448f8c7e08c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_80ff2baf-e33e-4e04-8ad7-448f8c7e08c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProvisionForInventoryObsolescence_5ae74f46-b50a-4b8a-86fc-c4b4ee95f489" xlink:href="apyx-20210930.xsd#apyx_ProvisionForInventoryObsolescence"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_apyx_ProvisionForInventoryObsolescence_5ae74f46-b50a-4b8a-86fc-c4b4ee95f489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9abee34d-cf98-41cd-bf67-989460ae9c13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9abee34d-cf98-41cd-bf67-989460ae9c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_217518c5-4f62-4b8e-8e8b-a074767850b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_us-gaap_ShareBasedCompensation_217518c5-4f62-4b8e-8e8b-a074767850b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_b6f1a87e-7ffd-4085-afcb-ce7af1accce5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_b6f1a87e-7ffd-4085-afcb-ce7af1accce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_fe01a2f8-115e-4644-82be-30fc344d428f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7c8a68c7-6b94-4513-bf47-ff3f9009200b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7c8a68c7-6b94-4513-bf47-ff3f9009200b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_82fda011-4289-4ec9-b7bf-6a7f985c8c32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_82fda011-4289-4ec9-b7bf-6a7f985c8c32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_86f13dbd-9fa7-4d33-bd44-372c961c9b07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInIncomeTaxesReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable_86f13dbd-9fa7-4d33-bd44-372c961c9b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0aefaf45-bb78-4d0c-afed-2354d2366496" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0aefaf45-bb78-4d0c-afed-2354d2366496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_359f8e5d-91c9-4aab-8aa6-636e8aba18fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_359f8e5d-91c9-4aab-8aa6-636e8aba18fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_789bd9be-cb19-4983-8430-7ba44ebcc073" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_fccb1afb-b291-4e19-a47d-6c863a1d2658" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_789bd9be-cb19-4983-8430-7ba44ebcc073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_494e5e2b-9dfd-4fd1-a9b8-b1b96adff539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3cb4d9b8-dece-4ec9-be84-9bf9c286b4de" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_494e5e2b-9dfd-4fd1-a9b8-b1b96adff539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79136d13-4453-402b-8702-648e8c90580e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79136d13-4453-402b-8702-648e8c90580e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9f190a0-5f86-4f4e-9db6-590b2f2e8e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79136d13-4453-402b-8702-648e8c90580e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b9f190a0-5f86-4f4e-9db6-590b2f2e8e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7c90d75-d339-4fa0-9678-9d231846a9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_79136d13-4453-402b-8702-648e8c90580e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7c90d75-d339-4fa0-9678-9d231846a9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_89db2d7a-3edd-4079-86b5-9570385c74b0" xlink:href="apyx-20210930.xsd#apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:to="loc_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised_89db2d7a-3edd-4079-86b5-9570385c74b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_RepaymentofFinanceLeaseLiabilities_55e44c86-1093-4c99-94e6-149c273e1146" xlink:href="apyx-20210930.xsd#apyx_RepaymentofFinanceLeaseLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:to="loc_apyx_RepaymentofFinanceLeaseLiabilities_55e44c86-1093-4c99-94e6-149c273e1146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMinorityShareholders_6c8f9ef0-c411-4e1a-9b25-b17acfc659d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromMinorityShareholders"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:to="loc_us-gaap_ProceedsFromMinorityShareholders_6c8f9ef0-c411-4e1a-9b25-b17acfc659d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921b1217-1f72-46e8-aac5-881d525a3792" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8a523ed8-bad4-4634-997f-4a1729f67155" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_921b1217-1f72-46e8-aac5-881d525a3792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5589d3c1-b796-4d5a-9002-95db5af96cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5589d3c1-b796-4d5a-9002-95db5af96cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6669cbf6-35db-4579-aa1d-6fc6e0401b99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6669cbf6-35db-4579-aa1d-6fc6e0401b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca63e875-c7e5-42e1-a8a6-fa708f39b0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ca63e875-c7e5-42e1-a8a6-fa708f39b0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_080f16cf-cca7-4e99-8cbc-de585bc5bb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_080f16cf-cca7-4e99-8cbc-de585bc5bb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_2076fb3a-70b9-4998-86b8-1f0728478efc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0617a06e-cfc6-4be8-b30c-a79a410c2ad3" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_2076fb3a-70b9-4998-86b8-1f0728478efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_288d98cd-28c7-43ce-948c-7276891e2a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2076fb3a-70b9-4998-86b8-1f0728478efc" xlink:to="loc_us-gaap_InterestPaidNet_288d98cd-28c7-43ce-948c-7276891e2a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_e346d15f-3c40-4e2c-bee0-a48949f38b51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_2076fb3a-70b9-4998-86b8-1f0728478efc" xlink:to="loc_us-gaap_IncomeTaxesPaid_e346d15f-3c40-4e2c-bee0-a48949f38b51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="apyx-20210930.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e24e84a-ee9e-4fc3-8a8b-079a2641c5fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2ec515ec-44df-402c-845e-f559b42bab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6e24e84a-ee9e-4fc3-8a8b-079a2641c5fc" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_2ec515ec-44df-402c-845e-f559b42bab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="apyx-20210930.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b89fab13-54a7-49fc-a6d4-deb0afb7a5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b6eda83f-9e44-418f-aae2-d04612979c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b89fab13-54a7-49fc-a6d4-deb0afb7a5bc" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_b6eda83f-9e44-418f-aae2-d04612979c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a08d24cd-e4f1-40c7-9d51-18b22234eb99" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b89fab13-54a7-49fc-a6d4-deb0afb7a5bc" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a08d24cd-e4f1-40c7-9d51-18b22234eb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6e2943fa-1e85-4e12-af3e-f5bcaf7b848a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b89fab13-54a7-49fc-a6d4-deb0afb7a5bc" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6e2943fa-1e85-4e12-af3e-f5bcaf7b848a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e4d20ba5-7e06-42a7-96b3-0e23391273a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b89fab13-54a7-49fc-a6d4-deb0afb7a5bc" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e4d20ba5-7e06-42a7-96b3-0e23391273a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="apyx-20210930.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_7f6cb47e-dbcf-4c51-852e-59a0bcaaf358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_427ce3a7-d6a7-448c-ae4a-e526544981dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_7f6cb47e-dbcf-4c51-852e-59a0bcaaf358" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_427ce3a7-d6a7-448c-ae4a-e526544981dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="simple" xlink:href="apyx-20210930.xsd#DISPOSALOFBUSINESS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0c60bf5f-7ef1-4482-bdd1-8e03c006c474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_53009943-2987-405a-a9a9-c05d3a32efd7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_0c60bf5f-7ef1-4482-bdd1-8e03c006c474" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_53009943-2987-405a-a9a9-c05d3a32efd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#DISPOSALOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d65111b2-2a50-4aff-ad5e-6af3bf173728" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_d65111b2-2a50-4aff-ad5e-6af3bf173728" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_319bdffc-100a-41a6-9d97-5a63d7a5394c" xlink:to="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_SymmetrySurgicalInc.Member_592b9883-058c-48b7-bf94-10ee9a76b220" xlink:href="apyx-20210930.xsd#apyx_SymmetrySurgicalInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0b21c365-d3a6-4f6e-824c-f4ccabbe63d6" xlink:to="loc_apyx_SymmetrySurgicalInc.Member_592b9883-058c-48b7-bf94-10ee9a76b220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_236b5a92-4682-4cd3-bfc4-4366a6e06af4" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_c6cd0399-1441-4958-82a3-7c869821f5c9" xlink:href="apyx-20210930.xsd#apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_a564c6bc-004b-449a-9a39-0adba9010e26" xlink:to="loc_apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember_c6cd0399-1441-4958-82a3-7c869821f5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_71248e1b-17f2-46dc-9956-eed182958943" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4771f95b-3a4f-4ee6-8538-7774758b8504" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4771f95b-3a4f-4ee6-8538-7774758b8504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AssetPurchaseAgreementTerm_10280b1a-e2c9-41e6-919e-a9a9a7c620fa" xlink:href="apyx-20210930.xsd#apyx_AssetPurchaseAgreementTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_apyx_AssetPurchaseAgreementTerm_10280b1a-e2c9-41e6-919e-a9a9a7c620fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_85937b6f-96ff-45d8-98ba-7e7c2b405dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_85937b6f-96ff-45d8-98ba-7e7c2b405dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4f44783c-0229-41d6-9971-2b4eb6c8f492" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_4f44783c-0229-41d6-9971-2b4eb6c8f492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4ed1d5e7-9549-4924-9fa6-9d2eba355e70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_4ed1d5e7-9549-4924-9fa6-9d2eba355e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_8d4a7674-6a94-4195-84c9-2a4a64c94b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_8e93f4f6-46b6-4ce4-9a22-3f249afeac08" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss_8d4a7674-6a94-4195-84c9-2a4a64c94b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIES" xlink:type="simple" xlink:href="apyx-20210930.xsd#INVENTORIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1629437f-17f7-46c2-b973-7760e291fc81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_c1c5b953-e3ea-4b8f-8842-d7af172fec69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1629437f-17f7-46c2-b973-7760e291fc81" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_c1c5b953-e3ea-4b8f-8842-d7af172fec69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="simple" xlink:href="apyx-20210930.xsd#INVENTORIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c762ab0a-72ac-4dcd-a894-f5a36ae80e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_223e632b-1b88-4141-9bcf-7c209469766c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c762ab0a-72ac-4dcd-a894-f5a36ae80e1d" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_223e632b-1b88-4141-9bcf-7c209469766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#INVENTORIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INVENTORIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_a1aaa37a-34ef-4e45-aa8a-57c9b7b79c21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryRawMaterials_a1aaa37a-34ef-4e45-aa8a-57c9b7b79c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_7f67f2c8-c0f6-48bb-b505-0cb9128909c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryWorkInProcess_7f67f2c8-c0f6-48bb-b505-0cb9128909c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_8e925c66-1c82-4fd8-a560-c442c1c7c4f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryFinishedGoods_8e925c66-1c82-4fd8-a560-c442c1c7c4f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_816e406d-3bd7-4ab6-b518-2afa75897152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryGross_816e406d-3bd7-4ab6-b518-2afa75897152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryValuationReserves_d78ad108-3a35-47ed-b1f8-38e4c4896692" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryValuationReserves"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryValuationReserves_d78ad108-3a35-47ed-b1f8-38e4c4896692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_911f724f-08b9-4b81-a930-3c6e26ae7a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_3580d602-e1a1-429f-b5cc-de67832bf319" xlink:to="loc_us-gaap_InventoryNet_911f724f-08b9-4b81-a930-3c6e26ae7a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="simple" xlink:href="apyx-20210930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4e5c5d1c-bb33-47f8-a2d0-10bb11fadabf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d4854729-e2ab-4bac-ace5-c17b6d7f019d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4e5c5d1c-bb33-47f8-a2d0-10bb11fadabf" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d4854729-e2ab-4bac-ace5-c17b6d7f019d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="simple" xlink:href="apyx-20210930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f7c027c5-444d-421b-80b0-8fbefc6e4990" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ec69e4c4-91f9-4983-b9b0-8392e7b1246e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f7c027c5-444d-421b-80b0-8fbefc6e4990" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_ec69e4c4-91f9-4983-b9b0-8392e7b1246e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_25ea65ae-5c64-4e5b-902d-6207fee97ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_AccruedSalariesCurrent_25ea65ae-5c64-4e5b-902d-6207fee97ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedBonusesCurrent_c363a5a7-3e7f-4c62-be85-e2c2915a3296" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_AccruedBonusesCurrent_c363a5a7-3e7f-4c62-be85-e2c2915a3296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalesCommissionCurrent_28a6c499-46fc-42f7-8d29-4af9909de7e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalesCommissionCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_AccruedSalesCommissionCurrent_28a6c499-46fc-42f7-8d29-4af9909de7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_b04b4170-51a7-45f5-a0a6-e706f3cb1386" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductWarrantyAccrualClassifiedCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_ProductWarrantyAccrualClassifiedCurrent_b04b4170-51a7-45f5-a0a6-e706f3cb1386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedInsuranceCurrent_fc11cb82-c02f-4964-ac32-718ade7b3821" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedInsuranceCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_AccruedInsuranceCurrent_fc11cb82-c02f-4964-ac32-718ade7b3821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_aeb1b09c-d2e4-416d-9510-1a92768ba929" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_aeb1b09c-d2e4-416d-9510-1a92768ba929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_JointAndSeveralPayrollLiability_27457e21-3b0b-47df-a42b-bbd6fc6e131f" xlink:href="apyx-20210930.xsd#apyx_JointAndSeveralPayrollLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_apyx_JointAndSeveralPayrollLiability_27457e21-3b0b-47df-a42b-bbd6fc6e131f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_UncertainTaxPositionsLiability_2a111647-7cdc-42d6-b1e0-39951bf7fe73" xlink:href="apyx-20210930.xsd#apyx_UncertainTaxPositionsLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_apyx_UncertainTaxPositionsLiability_2a111647-7cdc-42d6-b1e0-39951bf7fe73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_8cb11b32-07af-44ff-aa60-3da8e4c60e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_8cb11b32-07af-44ff-aa60-3da8e4c60e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_6ede7e0b-88ee-49d7-b642-08a4af24a504" xlink:href="apyx-20210930.xsd#apyx_OtherAccruedExpensesAndLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_apyx_OtherAccruedExpensesAndLiabilitiesCurrent_6ede7e0b-88ee-49d7-b642-08a4af24a504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_159376c8-cd5a-42e9-a0ac-d83107ac08ef" xlink:href="apyx-20210930.xsd#apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_8b25233f-27ab-4cc2-8c35-5150b0d263c8" xlink:to="loc_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent_159376c8-cd5a-42e9-a0ac-d83107ac08ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURE" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_02b1a007-09e2-4feb-94a3-6f957cc6b0c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDisclosureTextBlock_cf0295e0-9b4d-4dd6-bf97-5e4d4a51fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_02b1a007-09e2-4feb-94a3-6f957cc6b0c9" xlink:to="loc_us-gaap_MinorityInterestDisclosureTextBlock_cf0295e0-9b4d-4dd6-bf97-5e4d4a51fd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURETables" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_76db911b-bc00-4c06-b3d7-4bd0f0b6662c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestTableTextBlock_e3fcb83a-84b0-4a3f-933f-2d62262a271f" xlink:href="apyx-20210930.xsd#apyx_NoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_76db911b-bc00-4c06-b3d7-4bd0f0b6662c" xlink:to="loc_apyx_NoncontrollingInterestTableTextBlock_e3fcb83a-84b0-4a3f-933f-2d62262a271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURENarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_21cfd012-f24d-44de-806f-a6c5344fc385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_21cfd012-f24d-44de-806f-a6c5344fc385" xlink:to="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5e81917a-2058-444e-a78a-d3a247a67813" xlink:to="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_16e0f024-ba6c-48f2-9902-dae18b099644" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_0fdd672c-b3ea-452c-b098-d2cbb2f97cd4" xlink:to="loc_us-gaap_CorporateJointVentureMember_16e0f024-ba6c-48f2-9902-dae18b099644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:to="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_fa0a6d3d-4c42-47d3-aa41-3281649d77f2" xlink:to="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_ChineseSupplierMember_6ddbad14-9296-453f-a7ef-4a314aa1c18a" xlink:href="apyx-20210930.xsd#apyx_ChineseSupplierMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_fe4c0dfa-741e-42ac-a874-26b0e30d5324" xlink:to="loc_apyx_ChineseSupplierMember_6ddbad14-9296-453f-a7ef-4a314aa1c18a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_0fb7d6af-d81b-48a6-acff-934613825102" xlink:to="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ec061815-eefa-49a8-aff2-cbabdfccc68f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_ec061815-eefa-49a8-aff2-cbabdfccc68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_03dc67f9-5e53-4c26-b540-306123b0a612" xlink:href="apyx-20210930.xsd#apyx_NoncontrollingInterestRequiredCapitalContribution"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_apyx_NoncontrollingInterestRequiredCapitalContribution_03dc67f9-5e53-4c26-b540-306123b0a612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4025047b-fd4e-404c-92b2-06ff30cc97e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_268c06bc-ca65-446e-a8cf-04f5eba71a81" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_4025047b-fd4e-404c-92b2-06ff30cc97e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#CHINAJOINTVENTURERollforwardofJointVentureDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestAbstract_30708e9a-a566-448c-9f3d-b06c9ca129f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncontrollingInterestAbstract_30708e9a-a566-448c-9f3d-b06c9ca129f7" xlink:to="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_844000ed-cc43-47aa-83da-35d7ddae1e07" xlink:to="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateJointVentureMember_99e7d5db-afa5-4afa-b9de-26be05482b02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateJointVentureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_508d95b6-3ae9-4b93-96d8-b4da556c33d2" xlink:to="loc_us-gaap_CorporateJointVentureMember_99e7d5db-afa5-4afa-b9de-26be05482b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_24522649-d25f-4697-9683-6eb307d85980" xlink:to="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_1c7cfc18-f2e5-4dd0-b421-b2d2a4df3f34" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_12277cf7-c71e-435e-96fb-7b244140a687" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_MinorityInterest_12277cf7-c71e-435e-96fb-7b244140a687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ba11a455-3b45-4d7d-b948-1d2af413f17d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_ba11a455-3b45-4d7d-b948-1d2af413f17d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83bd2a33-8e01-4e75-bca0-7f6d504be76d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_83bd2a33-8e01-4e75-bca0-7f6d504be76d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_a1845f31-97cf-4ba4-8ec8-180f53b9a7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_5a34f8d9-16ad-42ca-a148-9be6d63f0ec3" xlink:to="loc_us-gaap_MinorityInterest_a1845f31-97cf-4ba4-8ec8-180f53b9a7ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="apyx-20210930.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_309c7120-c735-4d9a-a577-60869e7d2ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_8de9ec45-be8a-4c10-910d-f44a85e4ee1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_309c7120-c735-4d9a-a577-60869e7d2ee6" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_8de9ec45-be8a-4c10-910d-f44a85e4ee1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="apyx-20210930.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1d828486-51c8-4433-9a57-13ade38d5930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1a050f7e-f5bb-4a3b-a19b-e581dfd40a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1d828486-51c8-4433-9a57-13ade38d5930" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1a050f7e-f5bb-4a3b-a19b-e581dfd40a3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_fd3582d6-2468-4122-aa29-90ab0203fa61" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_fd3582d6-2468-4122-aa29-90ab0203fa61" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4678611d-2c4e-4837-9344-563823e18671" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2e29310e-e50c-498f-b8f4-2c3ef6aba6c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:to="loc_us-gaap_RestrictedStockMember_2e29310e-e50c-498f-b8f4-2c3ef6aba6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d3791a90-bee3-4d50-bd95-46d6397ad488" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fa044fd6-9d95-403d-a412-5232e78c567c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d3791a90-bee3-4d50-bd95-46d6397ad488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_72597d49-62b2-41d5-ac93-6874b7db7d42" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_644e1416-e4ec-47ec-86fe-6056ce81e79a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_644e1416-e4ec-47ec-86fe-6056ce81e79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cff540d-5de8-4bba-87c7-d697ba47fe26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_bbf8fed1-879e-4252-84f7-6ae33b1bcc29" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2cff540d-5de8-4bba-87c7-d697ba47fe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c18f9db-91ae-4e37-a48e-ded48e2cf716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9c18f9db-91ae-4e37-a48e-ded48e2cf716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35a41d1b-f8c6-4a94-b1a0-03f182998281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_1c78021b-f431-4df7-b541-61ccfaf4b71a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_35a41d1b-f8c6-4a94-b1a0-03f182998281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ffaced3e-ee70-4df8-9be3-58e163e0c733" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:to="loc_us-gaap_EarningsPerShareBasic_ffaced3e-ee70-4df8-9be3-58e163e0c733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3057ee3c-a062-4fd3-827a-290725505d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_0aadcfa5-e86e-48db-afb1-45f67ccca868" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3057ee3c-a062-4fd3-827a-290725505d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_66d53d80-db88-4405-b332-5fa8125431b7" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8345a21e-468f-4b40-ad43-839d667f0184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_44c2840a-b609-40f8-a244-6f17bc3ee5f8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8345a21e-468f-4b40-ad43-839d667f0184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f603e0-4635-4108-8a92-c8a0bee2cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dff19d30-f544-4683-adde-6789d9b9cbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74f603e0-4635-4108-8a92-c8a0bee2cf8a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_dff19d30-f544-4683-adde-6789d9b9cbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73221795-e048-4597-8206-2905074924aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_674ca09b-e95c-4ca2-89d3-1b3da186e801" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73221795-e048-4597-8206-2905074924aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_674ca09b-e95c-4ca2-89d3-1b3da186e801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae85919b-e5e0-4750-98ea-70a5fb28e9cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_73221795-e048-4597-8206-2905074924aa" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ae85919b-e5e0-4750-98ea-70a5fb28e9cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1489462-0abe-4ae3-92f0-6e45b4403b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_0a642418-8977-4efa-88b6-be523ba23541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1489462-0abe-4ae3-92f0-6e45b4403b2f" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_0a642418-8977-4efa-88b6-be523ba23541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_21644eb3-d54a-4256-a3e0-63d1fc263f59" xlink:href="apyx-20210930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1489462-0abe-4ae3-92f0-6e45b4403b2f" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived_21644eb3-d54a-4256-a3e0-63d1fc263f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_3e869f1e-6b06-4883-ac45-99d59fc0e699" xlink:href="apyx-20210930.xsd#apyx_StockIssuedDuringPeriodSharesStockSwaps"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b1489462-0abe-4ae3-92f0-6e45b4403b2f" xlink:to="loc_apyx_StockIssuedDuringPeriodSharesStockSwaps_3e869f1e-6b06-4883-ac45-99d59fc0e699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_438f8bd5-924b-4f5d-a5e0-465e2de87385" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_438f8bd5-924b-4f5d-a5e0-465e2de87385" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6abfa02e-4de0-450a-b684-2f1f2bc86b87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6abfa02e-4de0-450a-b684-2f1f2bc86b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66093611-e005-446a-bbc8-77c897163f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_66093611-e005-446a-bbc8-77c897163f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a86c66c4-627c-42b2-bf0a-a53c9d233c96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a86c66c4-627c-42b2-bf0a-a53c9d233c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_469102ae-6642-4227-a402-87d879ad5950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_469102ae-6642-4227-a402-87d879ad5950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67b3fdce-7395-4222-8065-ce899a01881b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_da443dd1-a74c-403a-8080-990fc92ae178" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_67b3fdce-7395-4222-8065-ce899a01881b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_438f8bd5-924b-4f5d-a5e0-465e2de87385" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2273320d-1df5-41f7-aeef-6cc2865b22a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2273320d-1df5-41f7-aeef-6cc2865b22a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04eb3869-fea5-4f1e-8c56-97f715b6ffe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_04eb3869-fea5-4f1e-8c56-97f715b6ffe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9ae318d6-27f6-470d-a82d-f576767ebc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_9ae318d6-27f6-470d-a82d-f576767ebc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1318147d-bfbe-4612-a994-6c81b3148d67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_1318147d-bfbe-4612-a994-6c81b3148d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9b7fdef-854b-408a-9d82-2707a6411ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_04c9fc7d-a1e2-4f70-8949-57f5c9e65290" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b9b7fdef-854b-408a-9d82-2707a6411ef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff4f758f-807c-4041-b737-9d2c8d44d816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ff4f758f-807c-4041-b737-9d2c8d44d816" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:to="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_682f063d-54d6-40f8-b6af-57ea84046eac" xlink:to="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_22eb5447-7b1f-4c10-b92d-c0125c360ea4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:to="loc_srt_MinimumMember_22eb5447-7b1f-4c10-b92d-c0125c360ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1361068c-eb80-478e-9284-6134d6e14182" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a8dbc2fb-8e2e-4c35-9e0f-f0ae8fc095de" xlink:to="loc_srt_MaximumMember_1361068c-eb80-478e-9284-6134d6e14182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0f76e130-b0e1-46d0-bc82-8476efcea177" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0eec8957-180c-4e55-aa70-3cb4c2420194" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0eec8957-180c-4e55-aa70-3cb4c2420194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a710e4f3-98f6-42ef-bab3-3b18fdf1410f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a710e4f3-98f6-42ef-bab3-3b18fdf1410f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b069d2c8-2b46-47e9-95d7-4ad40be10f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b069d2c8-2b46-47e9-95d7-4ad40be10f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b16d43f6-e3e3-4c32-ba1b-378e0013e9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b16d43f6-e3e3-4c32-ba1b-378e0013e9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbb7e715-e8b0-46ce-b24d-6295e22da32a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_85bf276e-d23a-4545-8e39-cfbb3ef81ffa" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cbb7e715-e8b0-46ce-b24d-6295e22da32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXES" xlink:type="simple" xlink:href="apyx-20210930.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b32a5-86f4-4291-987d-48ad04c1a2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_dacc728c-dc89-4820-95b1-3bdd08867c65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec9b32a5-86f4-4291-987d-48ad04c1a2c3" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_dacc728c-dc89-4820-95b1-3bdd08867c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#INCOMETAXESDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/INCOMETAXESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_cc297511-9f28-49ab-a757-edfaa521117c" xlink:href="apyx-20210930.xsd#apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards_cc297511-9f28-49ab-a757-edfaa521117c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bae27e5d-a059-42aa-ad26-12eb29427db8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bae27e5d-a059-42aa-ad26-12eb29427db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f55720d5-58de-458f-866e-c73871fcbc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f55720d5-58de-458f-866e-c73871fcbc8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_e19f68ca-319a-4a41-b8a0-d9a3b13345d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_e19f68ca-319a-4a41-b8a0-d9a3b13345d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f24d9ef0-a7c4-4e93-947b-9cd506667c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_f24d9ef0-a7c4-4e93-947b-9cd506667c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_80acb418-80d8-414d-9360-ef8c94d7127f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_80acb418-80d8-414d-9360-ef8c94d7127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_81de0954-9c07-403b-903b-163e4bfaadda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ec304d85-7bab-46d5-86fb-67aa0c3ad85b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_81de0954-9c07-403b-903b-163e4bfaadda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="apyx-20210930.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3110ac5-ae02-4591-a926-493d36a55f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0028a7f0-e418-4296-a97a-a8bd871d3ead" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f3110ac5-ae02-4591-a926-493d36a55f2b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0028a7f0-e418-4296-a97a-a8bd871d3ead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#COMMITMENTSANDCONTINGENCIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44fb58e2-85f5-4ed5-ab3e-677b148e9be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PurchaseObligation_c53ab897-cb92-46dd-bd9f-cd6f5bc8a124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PurchaseObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_44fb58e2-85f5-4ed5-ab3e-677b148e9be0" xlink:to="loc_us-gaap_PurchaseObligation_c53ab897-cb92-46dd-bd9f-cd6f5bc8a124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="simple" xlink:href="apyx-20210930.xsd#RELATEDPARTYTRANSACTIONS"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_ae329f90-cc6b-4446-a450-6f1b70c1f3d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_153d7f90-7f77-4d9b-adff-505f3567235d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_ae329f90-cc6b-4446-a450-6f1b70c1f3d4" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_153d7f90-7f77-4d9b-adff-505f3567235d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#RELATEDPARTYTRANSACTIONSDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0929f22f-2b66-4241-9566-5325fec067d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0929f22f-2b66-4241-9566-5325fec067d5" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_e84d604b-8c1f-426b-9d2b-9c391c320a4e" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CoVenturerMember_85143f97-7bbd-4743-83ab-4d02be8d84f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CoVenturerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_ae259714-e90a-4ec8-ad4c-5fd345ebd16e" xlink:to="loc_us-gaap_CoVenturerMember_85143f97-7bbd-4743-83ab-4d02be8d84f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_e16ebe61-931a-4884-80c4-693e6532deb0" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_75133655-4fb6-42de-b73b-798f1432d612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:to="loc_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_75133655-4fb6-42de-b73b-798f1432d612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5dff558e-cb31-40bd-a9a7-1a7713509f71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_5774be5c-69a9-4397-a78d-a9a1c1f813c6" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_5dff558e-cb31-40bd-a9a7-1a7713509f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATION"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_271014ae-d74b-4c74-939d-f19b232bbb8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_a235a5d1-bea3-40cf-a9a1-c18711806ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_271014ae-d74b-4c74-939d-f19b232bbb8e" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_a235a5d1-bea3-40cf-a9a1-c18711806ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONTables"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_db99bfd8-77a8-4727-92b0-3631b15b715a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9fdf36b0-0dc8-47c8-bf98-350ec227217e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_db99bfd8-77a8-4727-92b0-3631b15b715a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_9fdf36b0-0dc8-47c8-bf98-350ec227217e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8a1a8a53-d8b4-4b9f-8959-7da4aebefaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_db99bfd8-77a8-4727-92b0-3631b15b715a" xlink:to="loc_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock_8a1a8a53-d8b4-4b9f-8959-7da4aebefaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2281fa03-866d-42b7-942f-e70f37956003" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_cd795ccb-87e1-4113-bb05-9de7c2bec697" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2281fa03-866d-42b7-942f-e70f37956003" xlink:to="loc_us-gaap_NumberOfReportableSegments_cd795ccb-87e1-4113-bb05-9de7c2bec697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c54be837-e300-4b88-b0bc-a579ae084cde" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2281fa03-866d-42b7-942f-e70f37956003" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c54be837-e300-4b88-b0bc-a579ae084cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_TotalRevenuePercent_e61f5a0e-20cf-4bd3-8727-daee94ac2cbe" xlink:href="apyx-20210930.xsd#apyx_TotalRevenuePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2281fa03-866d-42b7-942f-e70f37956003" xlink:to="loc_apyx_TotalRevenuePercent_e61f5a0e-20cf-4bd3-8727-daee94ac2cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_66a54328-baca-4abc-be8c-ae175ca4d266" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_66a54328-baca-4abc-be8c-ae175ca4d266" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:to="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_6d2ba715-b663-49b1-8cb2-b54332c54ef8" xlink:to="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_0ac294b2-0cf4-48a5-8135-f953e6c22839" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:to="loc_us-gaap_OperatingSegmentsMember_0ac294b2-0cf4-48a5-8135-f953e6c22839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_50e70e8c-94dd-40a8-b950-079302aab00e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_35e3ff94-77e0-40e9-8b66-ef340728578f" xlink:to="loc_us-gaap_CorporateNonSegmentMember_50e70e8c-94dd-40a8-b950-079302aab00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_5576dfb1-aa59-4e44-a6a6-ee8c50f3a47c" xlink:to="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_AdvancedEnergyMember_890bf854-0385-4e60-b77e-1c959009c6a7" xlink:href="apyx-20210930.xsd#apyx_AdvancedEnergyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:to="loc_apyx_AdvancedEnergyMember_890bf854-0385-4e60-b77e-1c959009c6a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_apyx_OEMMember_cbdf61bd-3db8-4ad9-b60d-81681cdcf079" xlink:href="apyx-20210930.xsd#apyx_OEMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb231247-9841-4b43-b498-a6aa79f57e94" xlink:to="loc_apyx_OEMMember_cbdf61bd-3db8-4ad9-b60d-81681cdcf079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3408b7fd-6a28-40ca-9ef2-c3aede3bae3e" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7d15f1f-1ce0-4577-a250-c9174553f52a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_d7d15f1f-1ce0-4577-a250-c9174553f52a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6671af2c-1201-4255-aea5-6c842c2f8b49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_OperatingIncomeLoss_6671af2c-1201-4255-aea5-6c842c2f8b49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOperating_e78e60fc-4a18-4d54-ba85-293d209d9d12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_InterestIncomeOperating_e78e60fc-4a18-4d54-ba85-293d209d9d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_67dd1dfe-5335-4542-8af6-e99444426768" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_InterestExpense_67dd1dfe-5335-4542-8af6-e99444426768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1698c4d6-8c44-43a5-b110-daaf6e236018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1698c4d6-8c44-43a5-b110-daaf6e236018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a9413fb6-83a9-4c8f-9d01-856352d18e83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_ca8b21c0-2944-46c5-8825-a7eb8fbcf726" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a9413fb6-83a9-4c8f-9d01-856352d18e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="simple" xlink:href="apyx-20210930.xsd#GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"/>
  <link:presentationLink xlink:role="http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_e9f3a982-2461-4e24-804a-b6c7507b7e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_e9f3a982-2461-4e24-804a-b6c7507b7e8a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:to="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9e5d9127-6c9d-4136-853f-7e28429711d7" xlink:to="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_894b5a40-e04e-4397-a7cf-8f3d55a4fa8c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:to="loc_country_US_894b5a40-e04e-4397-a7cf-8f3d55a4fa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_1652ea98-365d-4349-99c3-cc6a44d9dc7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8bf3fb49-b603-4f96-ab62-7bcfaa936711" xlink:to="loc_us-gaap_NonUsMember_1652ea98-365d-4349-99c3-cc6a44d9dc7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_add87c93-0f3f-47aa-b908-187f55df2679" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3ebf515-789d-4c20-becf-60a5d3fb42ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_64a1789a-bfaa-4810-b86d-078e19a69758" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b3ebf515-789d-4c20-becf-60a5d3fb42ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>apyx-20210930_g1.jpg
<TEXT>
begin 644 apyx-20210930_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" *0 _(# 2(  A$! Q$!_\0
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MG[CPEF'UO ^PD_>IZ?+I_E\AE%%%?&'VX5]*?LA^.-LFI^%+F3 ;_3;3<>_
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MVX9RCZ]6^LUE^[A^+[?+=_<?#<49S]0H?5J+_>3_  7?U>R^;->BBBOV<_$
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MK\\/$WA^Y\*^(-1TB['^D64[0L<8#8/##V(P1[&OR+B_ ^RQ$<7%:3T?JO\
M-?D?LG!N/]MAI8.;UAJO1_Y/\S,HHHK\_/T0*]P_91\:_P!A^-I]#GD"VNKQ
MX3)X$Z E?S7>/<[:\/JUI>I7&BZG::A:/Y=U:RK-$_HRD$'\Q7H9?BY8'%4\
M1'[+_#K^!Y^88../PE3#2^TOQZ/[S])J*R/"?B.W\7>&=-UFU_U%[ LP7/W2
M1\RGW!R#]*UZ_HJ$XU(J<7=/4_FJ<)4Y.$U9K1A1115D!1110 4UF6-69B%5
M1DDG  IU>7_M%>-?^$.^&MZD,FR^U,_8H<'D!@?,;\$R,]BPKEQ6(AA*$Z\]
MHJ_]>IUX3#3QF(AAZ>\FE_7H?)OQ7\9MX]\?:MJX8M;/+Y5L/2%/E3CMD#<?
M=C7(T45_.5:M.O4E5GO)MOYG]+T:,,/2C1IJRBDE\@HHHK$V);2UFOKJ&VMX
MS+<3.L<<:]68G  ^I-?H7X!\*Q>"?!VDZ)%C_1(%61E_BD/+M^+%C^-?*'[+
M_@K_ (2;XAKJ4T>ZRT9/M!ST,IR(Q^!RW_ *^SZ_6.#\#R49XR2UEHO1;_>_
MR/R+C3'^TK0P47I'5^KV^Y?F%%%%?HI^:!1110 4444 %%%% !1110 4444
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M^G*+BY Z&9Q\H/\ NH?_ !\^E?3GB;Q!;>%?#^H:O>'%M9PM,PZ%L#A1[DX
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M\[****_FD_J **** /H[]C7_ )"7BG_KC;_^A25]15\N_L:_\A+Q3_UQM_\
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M6C7I.THO^OO.7%86GC*$\/65XR5OZ]#]+E99%5E(96&00<@BG5X+^R[\5/\
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MYJZ:L_F:4ZDJ,XU(.S3NO5'YJ7=K-8W4UM<1F*XA=HY(VZJP."#]"*BKV/\
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M<![#"O%36L]O1?YO]#\8XQS#ZQBHX2#]VGO_ (G_ )*WXA1117WI^?!1110
MUF"*68@*!DD]!7XE?M6_&)OCC\<?$/B**4R:3')]@TL9.!:Q$A&&>F\[I,=C
M(:_27]OCXR_\*F^ FI6EI/Y6N>)2=)M-K89(V7]_(._$>5R.C2(:_'ZOJ\EP
M]E*O+T7ZG@9E6NU27JPHHHKZ@\,**** "OV(_80^,O\ PMWX":7'>3^;KGAX
MC2;W<V6=44>3(<\G='M!)ZLCU^.]?3?_  3Y^,P^%GQVM=*O9_*T3Q0JZ9<;
MCA4GSFW<_P# R4]A*3VKR<SP_M\.[;QU._!5O95E?9Z'Z\4445\$?6!1110
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MC"/#3?O4_P GM]SO^!^+<89?]7Q:Q4%[M3?_ !+?[U9_>7****^Z/@ HHHH
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M/X/HG_H6?05X'7XYQ1FWUNO]4I/W(;^<O^!M]Y^U<*91]3H?6ZR]^:T\H_\
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M*^8/J0KW#]F/XJ?\(KX@_P"$<U&;;I.IR#R6<\0W!P ?8-PI]]OO7A]'2N_
MXRI@,1'$4MU^*ZKYG!CL%3S##SPU79_@^C^1^F%%>4_L^?%/_A8GA,6U],&U
MS30L5QD_-,G\,OX]#[CW%>K5_0>$Q5/&4(UZ3]V7]6^1_.6,PM7 UYX>LK2B
M_P"G\PHHHKK.,**** "BBB@ HHHH **** "BBB@ HHHH IZQJMMH>EW>H7C^
M5:VL332OZ*H)/\J_/+Q=XDN?&'B;4M9NS^_O)FE*YSM'\*CV P!]*^G_ -K+
MQS_8_A6T\.6TNVZU1O,G"GD0(<X/^\V/P5A7R37Y%Q=C_:XB.$@](:OU?^2_
M,_9.#<O]CAI8R:UGHO1?YO\ )!1117Y^?H@5);V\EW<100HTLTC!$11DLQ.
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MK[B/[/H=F?EG_P .LOBO_P!#!X-_\#;O_P"1:/\ AUE\5_\ H8/!O_@;=_\
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M:<8'EN2=H]E;<O\ P&OO.O$?VJO W_"0>"8M;MTW7FCN6; Y:!\!_P CM;V
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MWK#[DW#!6!"0GYG<WN"M>WU7L;&#3;*WL[:,16]O&L44:]%50 !^ %6*_HK
M82.!PT,/'[*_'J_FS^:\PQDL?BJF)G]I_AT7R04445WGGA1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !5>^L8-2LKBSN8Q+;W$;12QMT96
M!!'X@U8HI-)JS&FXNZ/SM\>>%)_!'B_5=$GR3:3%$<_QQGE&_%2#^-8-?3G[
M7G@?S(--\5VZ?-'_ *%=D?W228V/T.X?BM?,=?SWF^!>7XV=#INO1[?Y']'9
M/CUF6!IXCKL_5;_Y_,****\<]D<CM&ZNC%74Y#*<$&OOWX2^-E^('@/2]6+
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M/#1J_"M?=EOUZ=SY>HKZA_X8UL_^AIG_ / )?_BZ/^&-;/\ Z&F?_P  E_\
MBZ\[_5C-?^?7_DT?\ST_]:LH_P"?O_DLO\CY>KZI_93^&,^CV=QXLU& Q37D
M?DV*.,,(<Y:3'^T0,>P)Z$5T_@O]F'PCX5NH[N[$VNW2'*_;<>2I]?+ P?\
M@1(KU_IP.!7UV1<-5,'66*Q;5ULEKKW?Z?>?&Y_Q/3QE!X3!IV>[>FG9?K?T
ML+1117Z*?FH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% &/XN\-6WC#PSJ6BW?\ J+R%HBV,E#U5A[A@"/I7Y^^*O"^H>#=>
MN](U2 P7=NVUA_"P[,I[J1R#7Z-5R_CCX;>'_B)9I;ZW8K.T8(BN$.R:+/\
M=8=O8Y'M7R>?9'_:L(SI.U2/?9KL_P!#[#A[/O[(G*G55Z<M[;I]U^I^>]%?
M4]Y^QOI4D[&U\27D,/9)K=)&'X@K_*H?^&-;/_H:9_\ P"7_ .+K\Y?"^:IV
M]G_Y-'_,_2UQ5E+5_:_^2R_R/EZKFBZM<Z#JUGJ5F_EW5I*L\3>C*01^'%?2
MO_#&MG_T-,__ (!+_P#%T?\ #&MG_P!#3/\ ^ 2__%T1X9S:+4HT[-?WH_YB
MEQ1D\DXRJW3_ +LO\CWGPKXBMO%WAO3=8M#FWO85E ZE21RI]P<@_2M:N,^%
M?P\?X9^''T?^U7U6W$S2Q-)"(S$&QE1@G(SD_B:[.OVG"RJRHP=>-IVU7GUV
M/P_%1HQKS6'E>%]'Y=-S\]?B?_R4KQ;_ -A>[_\ 1SUS-=-\3_\ DI7BW_L+
MW?\ Z.>N9K^=,5_O%3U?YG]*87_=Z?\ A7Y(****YCJ/0OV?O^2Q>&O^NTG_
M **>ONQE# @C(/45\)_L_?\ )8O#7_7:3_T4]?=U?L'!O^XU/\;_ "1^,\;?
M[_3_ ,"_-GCGQ!_9E\,^,'DN],SX?U%N2UL@,#GWCXQ_P$CZ&OG[Q=^SOXV\
M)M(XTPZO:+TN--/FY'^YC>/RQ[U]R45Z>.X;P&-;FH\DN\?\MOR/*R_B?,,"
ME!RYX]I:_<]_S/S2FADMY7CE1HI%.&1P00?<4ROT:UOPKHWB1-FK:59:BN,#
M[5 LA'T)''X5P6K?LT> =4+,FE2Z>['):TN77]&)4?@*^.K\&XJ+_<58R7G=
M?YGVN'XVPLU:O2E%^5FOT/B*BOK&_P#V//#TF?L6N:G;^GGK'+_)5K$N?V,V
MY-OXL!YX633\<?42?TKQY\+YI':G?T:_5H]F'%64SWJV]8R_1,^::*^B)OV-
M]55OW7B2S=?5[=U/Y FF?\,<ZS_T,-C_ -^7K#_5W-/^?+^]?YG1_K)E/_/]
M?<_\CYZHKZ.A_8UO6V>=XH@3^]LLV;'T^<9K4L_V-K&/'VOQ1<3^ODV:Q]_=
MVK2/#.:R_P"75OG'_,REQ1E,?^7U_P#MV7^1\NT5]BZ;^R7X+LR&N)]4OSG)
M66X55/\ WRH/ZUV.C?!'P+H15K;PU9.R\AKI3<'/K^\+5Z5'A#'3_B2C'YM_
MDOU/,K<9Y?#^'&4GZ)+\7^A\,:/X?U3Q!<>1IFG76HR_W+6%I#^@KU/PK^RS
MXRUYHWU!+?0K9N2US('DQ[(F>?9B*^R+:UALX5AMX8X(EX6.-0JCZ 5-7TF%
MX.PU/7$5'/R6B_5_BCYG%<:XJHK8:FH>;]Y_HOP9Y!X*_9C\(^%FCGOXW\07
MJ\[[P 1 ^T0X/T8M7K<4,=O&D<2+'&@VJB#  '0 =JDHK[/"X/#X./)AX**\
MOU>[/A\5CL3CI\^)J.3\_P!%LOD%%%%=IQ!1110 4444 %%%% !1110 4444
M %%%% 'FW[0'C;_A"OAKJ,D4FR^OA]BM\'!!<'<P^B!CGUQ7PQ7MG[57C8>(
M/',6BP2;K71TV-@\&9\%_P AM7V(->)U^'<38[ZYCY1B_=A[J]>OXZ?(_>>%
M\!]2R^,Y+WJGO/TZ?AK\PHHHKY,^O"O2?V??!/\ PFGQ*T])4WV.G_Z=<9'!
M"$;5_%RO'IGTKS:OL3]E7P3_ ,(_X$DUF>/;=ZQ)O7(Y$*9"#\3N;W!%?1\/
MX'Z]CX1DO=C[S^7^;LCYKB+'_P!GY?.47[TO=7J_\E=GME%%%?O1_/@4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHK[H^ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 ?GK\3_^2E>+?^PO=_\ HYZY
MFNF^)_\ R4KQ;_V%[O\ ]'/7,U_->*_WBIZO\S^GL+_N]/\ PK\D%%%%<QU'
MH7[/W_)8O#7_ %VD_P#13U]W5\(_L_?\EB\-?]=I/_13U]W5^P<&_P"XU/\
M&_R1^,\;?[_3_P "_-A1117WI^>A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5\-_M)?\EJ\1?\ ;M_Z315]R5\-_M)?\EJ\1?\
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MBBOK#Y **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[QJ7(N "Q"C)  SV%<O_ ,/3?BO_ -"_X-_\ KO_ .2:^>?VBO\ DX+XG?\
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MO':^]HX'#2I1;@KV1\I4Q593DE+J?8__  ]-^*__ $+_ (-_\ KO_P"2:/\
MAZ;\5_\ H7_!O_@%=_\ R37QQ16WU#"_\^T9?6Z_\[/L?_AZ;\5_^A?\&_\
M@%=__)-3V?\ P50^)L<V;OPSX3GC_NPV]U&?S,[?RKXQHH_L_"_\^T'UNO\
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MB5%,L3'WRC(/^NAKLS/#JM0<K:QU_P SGP-9TJJ71Z'ZVT445\&?5A7YZ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ?A;^T5_R<%\3O\ L9]4_P#2N6O/J]!_:*_Y."^)
MW_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZA0K%&#*2K Y!'45[S\1/@BMK^RK\*OB
MAID&%NC>Z7J^Q?XQ?7)@F/U4&,D_W8QWKP:G3J1JIN/1M?<*<'!I/R?WG[4_
MLA_&@?'+X':)K5S/Y^N6:_V=JN?O&XC !<_[ZE'^KD=J]JK\G?\ @G+\;/\
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MN<8RQ4$U=K.\._\ (OZ7_P!>L7_H K1K\Y>Y]DM@HHHI#/Q._;&_Y.<^(O\
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M_>:GJSZS"_P8>@4445Q'2?B=^V-_R<Y\1?\ L*-_Z"M>.U[%^V-_R<Y\1?\
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M97/B?(_?BQM%L;&WMD8LD,:QJS=2 ,<_E5BBBORT^Z"OSU_X*T_\TJ_[BO\
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M_!AZ+\CXJM_$EZL_6S_@FQ_R;#8_]A2[_P#0A7U/7RQ_P38_Y-AL?^PI=_\
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M*7D89X!VJ0,]R.O2OT>4HTH-O1(^,BG.5ENSSNBOTZ_X=4_#[_H;O$WYV_\
M\:H_X=4_#[_H;O$WYV__ ,:KRO[6PO=_<>A_9]?M^)^8M%?IU_PZI^'W_0W>
M)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU1_:V%[O[@_L^OV_$_,6BOTZ_X=4_#[
M_H;O$WYV_P#\:KX]_;"_9M@_9K^(&G:5IM[=:GHFI6(NK:ZO OF;PQ62,[0
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MJ]!_:*_Y."^)W_8SZI_Z5RUY]7Z;1_AQ]$?$5/CEZG[&_P#!/_\ Y-&\!_\
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M,E9:16W^9]/A,*L/&[^)A1117E'>%?GK_P %:?\ FE7_ '%?_;.OT*K\]?\
M@K3_ ,TJ_P"XK_[9UZN5_P"]P^?Y,X,=_N\OE^:/SVK['_X)9?\ )P7B#_L5
M[C_TKM*^.*^Q_P#@EE_R<%X@_P"Q7N/_ $KM*^NS#_=:GH?/83^/ _4RBBBO
MSP^P"L3QIX/TKX@>%-5\.:Y;"\TG4H&M[B$\94CJ#V8'!![$ ]JVZ*:;3NA-
M75F?B!^T=^SWKO[.OC^?0]31[G2YBTNF:H$(CNX<^O0.N0&7L?4%2?*Z_>+X
MI_"?PQ\9O"-QX<\5Z9'J&GR_,C?=EMY .)(GZHXR>1U!(.02#^87[0'_  3[
M\??">ZNM1\-6TWC7PN"62:QCW7D"^DL Y./[R9'&2%Z5]K@<SA6BH57:7X,^
M9Q6!E2;E35X_D?.W@SQUXA^'>N1:QX9UF\T/4H^!<64QC8C^ZV.&4]U.0>XK
MZ=\*_P#!3KXLZ':+!J=IX?\ $15<?:+NS>*8GU/E.J_^.U\CS0O;RO%*C1R(
MQ5D<8*D<$$=C25ZE7#T:^M2*9PTZU2G\$K'V%K__  5$^*>IVC0Z=I'AO1W8
M8^T16LLLBGU&^4K^:FOFCXC?%CQ?\6]8&I^+_$%[KUVN1']I?]W$#U$<:@(@
M/HH KE*%4NP5068G  ZFE2PU&B[TXI!4K5*FDY7"O0_@1\#]?^/OQ LO#.A1
MF-&/F7NH,A:*R@!^:1\?D%R-S$#CK7J'P%_8-^(GQBN;>]U.RD\&^&6(9]0U
M2(K-*O\ TQ@.&8D=&;:ON>E?J#\&?@CX4^ _A&+0/"U@((N&N;R7#7-W(,_/
M*^!N/)P.@!P !7G8W,J>'3C3=Y?D=N&P4ZS4IJT?S-OX<^ -'^%O@G2/"N@0
M?9]*TN 0Q*QRS')+.Q[LS%F)[EC72445\1*3DVWN?3I**L@K\??^"@7Q3_X6
M1^T5J]G;S>9IGAM!H\ !X\Q"3.<>OFLZY]$6OU*^-GQ&@^$GPH\4>+IBN=+L
MGEA5NCSGY84_X%(R#\:_"F]O)]2O)[NZE:>YGD:665SEG=CDL3ZDDU])DM'F
MG*L^FAXN9U;1C3774BK]!O\ @E5\,RTGC#Q_<1<*$T6R<CUVRS_^T.?<U^?-
M?MW^RS\,1\(_@+X0\/20^1?BT6[O@1AOM,W[R0-ZE2VSZ(*]+-ZWL\/R+>1Q
MY?3YZW,^AZQ1117Q!].%%%% !7R/_P %+/A@?&?P*A\26T>^^\+7BW).,G[-
M*1'*!_P+R6/LAKZXK'\8>%[/QMX3UGP]J"[K'5;.:RG Z[)$*$CWP>*Z,/5=
M"K&HNC,:U/VM.4.Y^ E=_P# #XF2?!_XR>%/%JLRV^GWJ_:@O):V?*3+CU,;
M/CWQ7*>+O#-]X+\4ZOH&I1^5J&EW<ME<)Z21N5;'MD5EU^CRC&I!I[,^,3<)
M76Z/Z#K>>.Z@CFAD66&10Z2(<JRD9!!],5+7SQ^PC\5/^%H_LZZ#]HF\W5-!
MSHUWN.6/E >4QSR<Q-'SW(;TKZ'K\UJTW1J2IOH?:TYJI!374^2/^"G7_)M]
MK_V'K7_T7-7Y1U^KG_!3K_DV^U_[#UK_ .BYJ_*.OLLG_P!V^;/F\Q_C_(W_
M (?^/-9^&/C#3?$_A^X2UUC3G9[>:2)9%4E60Y5@0>&/45[K_P /$_CE_P!#
M+9_^"JV_^(KYKHKU*E"E5=ZD4WYHX85:E-6A)H^E/^'B?QR_Z&6S_P#!5;?_
M !%'_#Q/XY?]#+9_^"JV_P#B*^:Z*S^IX?\ Y]K[D7]8K?SO[SZ4_P"'B?QR
M_P"AEL__  56W_Q%'_#Q/XY?]#+9_P#@JMO_ (BOFNBCZGA_^?:^Y!]8K?SO
M[SZ4_P"'B?QR_P"AEL__  56W_Q%?<?[!?QP\7?';X<^(-6\8W\6H7UGJIM8
M7BMHX0(_)C;&$ !Y8\U^1%?IU_P2I_Y([XN_[#Q_])XJ\K,\/1IX9RA!)Z=#
MOP-:I.LHRDVC[9HHHKXT^D"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R?6OV4_A'XBUB_U74O >DWFHWT\EU<W$B-NEE=BS
MN?FZEB3^-4_^&._@M_T3K1O^_;?_ !5>R45O]8K+3G?WLR]C3_E7W&+X/\&Z
M+X \.VF@^'M.ATG1[3?Y%G;@A(]SL[8SZLS'\:VJ**Q;;=V:))*R"BBBD,**
M** "BBB@#RWQ+^R_\*O&&O7NM:UX'TO4=5O9/-N+J9&+R-ZGFLW_ (8[^"W_
M $3K1O\ OVW_ ,57LE%;JO52LIO[V9>RIO5Q7W'/^"/ /A[X;:"FB^&-*M]&
MTI9&E6UM00@9N6//K70445BVY.[-$DE9!1112&>6^)?V7_A5XPUZ]UK6O ^E
MZCJM[)YMQ=3(Q>1O4\UF_P##'?P6_P"B=:-_W[;_ .*KV2BMU7JI64W][,O9
M4WJXK[CQO_ACOX+?]$ZT;_OVW_Q5'_#'?P6_Z)UHW_?MO_BJ]DHI_6*W\[^]
MB]C3_E7W'C?_  QW\%O^B=:-_P!^V_\ BJ/^&._@M_T3K1O^_;?_ !5>R44?
M6*W\[^]A[&G_ "K[CQO_ (8[^"W_ $3K1O\ OVW_ ,51_P ,=_!;_HG6C?\
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M?C-XLC\-^%=9N+[5I(7G6*2PFA&Q!ECN90.]>T5^2/\ P39_Y.>L?^P7=_\
MH(K];JK,,/#"UO9PVL3A*TJ]/GEO<****\T[0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBOG+]LC]J/5/V9=-\+W.F:)9ZTVL37$<BW<KH(_
M+6,@C;USO/Y5K2I3K35.&[,ZE2-*+G+9'T;17P7\$/\ @HUXC^*WQ8\,>$;O
MPAI=C;:M=BV>YAN)&>,$$Y /!/%?>E:5\/4PTE&HK-D4:T*ZO!A7E?QQ_:3\
M%_L]?V)_PF$]Y#_;'G_9?LEL9L^5Y>_.#Q_K4_6O5*_/7_@K3_S2K_N*_P#M
MG6F"HQQ%>-*>SO\ D1B:DJ-)SCNO\SWWP7^WQ\)_'WBW2/#FDWFJOJ>J7,=I
M;++I[(ID<X7+9X&3UKZ-K\/OV5_^3C_AM_V'K3_T:*_<&NK,<+3PLXQI]488
M+$3Q$&Y] HHHKR#T0HHHH **** "BBB@ HHHH **** "BBB@ HHHH H:]K5I
MX;T/4-6OW,5C86\EU/(JEBL:*68X')X!X%?/'_#Q+X&_]#+>?^"JY_\ B*]D
M^-'_ "1WQW_V ;__ -)WK\'J]W+<#2Q<9.HWIV/*QF*GAW%0MJ?O;\-_B)H?
MQ8\%Z?XJ\-7+W>BZAYGV>:2)HF;9(T;95@"/F1ASZ5TU?//_  3_ /\ DT;P
M'_V__P#I?<U]#5Y->"IU9P6R;7XGH4I.=.,GU2"BBBL#4*XKXN?%SP]\$_!T
MGB?Q/)<1:5'-' S6T)E?<YPORCMQ7:U\L?\ !2?_ )-AOO\ L*6G_H1KIP]-
M5:T*<MFS&M-TZ<IK=(/^'D_P6_Y_M9_\%K?XU]0VETE[:PW$63',BR)D8.",
MBOY\J_H"\._\B_I?_7K%_P"@"O3S+!4L(H>SOK?]#AP6)GB.;GZ&C1117AGJ
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '\]E?JY_P3%_Y-ONO^P]=?\ HN&ORCK]7/\ @F+_ ,FWW7_8>NO_ $7#
M7W&<?[M\T?,9=_'^1];T445\.?3A1110 45B>-KZ?2_!NOWEK(8;FWL+B6*0
M $JZQL0>?0BOQ[_X;B^./_10;S_P%MO_ (W7HX3 U,8FX-*W<X\1BH8=I26Y
M^S]%?FAK_P#P4L\0:/\ "WPUHOA](]6\9&P4ZOXAU*(;(YB22L<0 #,!C+'Y
M<C&UNM?..O\ [5_QB\2737%W\2/$4,C')&GWSV:?@D.Q1^5=E/)Z\[\S2.:>
M8TH[*Y^WM%?C;\/?V[OC'X!U"*63Q3+XDL@P,ECKJBY609_YZ']XO?HP_&OT
MJ_9E_:>\/?M*>%9;RPC.EZ_8A5U+1Y7W-"3G#HV!OC;!PV 1C! XSRXK+ZV%
M7-+5=T;T,93KOE6C/:***0D*"2< =Z\P[A:*^"?VD/\ @I1%X=U2[\/?"RWM
M=3F@8Q3>(;M2\&X<$0)D;\?WV^4XX##!KX[\0_M:?&/Q-<-/>?$?Q!"[')&G
MWC62_@L&P#\!7M4<IKU8\TO=7GN>95S"E3?*M3]NJ*_%?PC^VA\:/!MQ');>
M/=3U!%(W0ZNPO5<#L3*&;\00?>OO+]E/]O;2/C=J%OX6\5VMOX<\82#;;O$Y
M^QW[?W8]QRC^B$G/9B>*C$977P\>?=>15''4JSY=F?6U%%<O\4M6NM!^&?B[
M4K"8V]]9Z1>7-O,H!*2)"[*P!X." >:\F*YFD>@W97.HHK\8/^&XOCC_ -%!
MO/\ P%MO_C=>^?$+_@I7K.E_#_POH?@Y(K[Q-_8UG_;/B34(@P%X8$,PBBP%
M+!RP+,-N00%(P:]J>48B+25G?\#S(YC1DFW=6/TCHK\0-<_:K^,/B&Z:XNOB
M3XDBD8Y(L=0DM$_!(2JC\J[CX8_M\_%WX>:I#)>Z^_B[2PV9M/UH"4NN>=LV
M/,4XSCD@=U/2M99+64;J2;,XYG2;LT['[#T5SGPZ\72^/? ^B>(9M'OM DU*
MV6X;3=14+/!GLP'YCH<$9 .0/B#]J+_@HW>Z!X@U#PK\+5M6:SD:"Y\1W"+.
MID'#"W0_*0#QO8,#@X&,,?*H86KB*CIP6JW\CT*N(IT8<\GN?H%17X>ZQ^U-
M\7]<N#/<_$KQ-$Y).+/4I;9>?]F(J/TKM_AK^WM\8/A_J4,EUXCD\5:<&S+8
M:VHF\P=\2X\Q3SQAL=,@]*]:62UDKJ2;//CF=-NS3/V+HK\JOCY_P4 \9>)O
M%6EZC\.?$E]X:T>;2X3=:6\$+FWNP\@D7<R'<,;"&'!!' .0/7?^">O[0WQ$
M^,'Q,\1Z9XQ\37&N6-KI!N(8988D"2>=&N[*(#T8C\:Y:F65J=%UI-:=.IT0
MQU.=14XGWQ17D7[5EUXOTOX%>)=7\#ZM/I'B#28AJ"201HYDAC.9DPX(_P!7
MN;IG*BOR]_X;B^./_10;S_P%MO\ XW487+ZF+@YPDM"J^+AAY*,DS]GZ*XKX
M+_$*'XK?"GPKXMB*DZI81S3*G1)@-LJ#_=D5U_"NUKS91<9.+W1VQ:DDT%%>
M%?MH?&.]^"?P'U;6=(NOL6OWD\6GZ;-M#%)7)9F (()$:2$9'4"OS8M_VV_C
MM=3QPP^/;Z6:1@B1I:6Y+,3@ #RNN:]+"Y=5Q4/:1:2\SAKXRG0ER23;/V<H
MKF_ASIVM:3X"\/VGB34'U7Q!%91#4+QPH,EQM!D.% &-Q(&!T KI*\QJS:.Y
M.ZN%%%%(9^0'_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5QG
M_!1/_DZOQ+_UZV7_ *31UV?_  2R_P"3@O$'_8KW'_I7:5]O4_Y%O_;J/EX_
M[[\V?J91117Q!]0%%%% !7YA?\%5O^2Q>$O^P"/_ $HEK]/:_,+_ (*K?\EB
M\)?]@$?^E$M>QE/^]+T9YN8?P'\CCO\ @FS_ ,G/6/\ V"[O_P!!%?K=7Y(_
M\$V?^3GK'_L%W?\ Z"*_6ZM,X_WGY+]2<M_@_,***\S^/7[0'A;]GGP>=;\1
MSM)/,3'8Z9;D&XO) .B@]%&1N8\ $=20#XT(2J24(*[9Z4I*"<I/0],HK\A_
MBA_P4.^+7CZ\F72=3C\&:4Q/EV>DH#*!VW3L"Y;W7:#Z5Y?#^TY\7(+PW*_$
MOQ49#_"^KSLG_?!;;^E>[#):TE>4DCRI9G23LDV?N117Y3_![_@I/\1?!=]!
M;^,O)\:Z+D+(9(T@O(U]4D0!6/LX.<?>'6OTI^%OQ3\.?&3P;9^)_"U^+[3+
M@E""-LD$@QNBD7^%QD9'H01D$$^=BL%6PNLUIW1V4,53Q'PO7L=?17DG[5$_
MB[3O@7XFU7P/JL^D>(M)A&H1RP(CF2*,[ID(=6!_=[R,#.5%?EW_ ,-Q?''_
M **#>?\ @+;?_&ZTPN7U,7!SA):$5\7##R49)G[/T5Q7P7^(4/Q6^%/A7Q;$
M5)U2PCFF5.B3 ;94'^[(KK^%=K7G2BXR<7NCMBU))H**\-_;,^,5W\$O@/K&
MM:5=?8]?NI8M/TR7"DK-(<E@"""5C61AP>5%?FK;_MM_':ZGCAA\>WTLTC!$
MC2TMR68G  'E=<UZ6%R^KBH>TBTEYG#7QE/#RY))MG[.45SOP]TW6='\"Z#9
M^(M0;5=?ALHEU"\8*/-N-H\Q@%  &[.,=L5\C?M2?\%$K7X;ZU>>%/AY;6FN
M:U;$Q7>KW)+VEM(."D:J1YCCN<A01CYN0.6CAZF(J>SI*_Y'14K0HPYYZ'VW
M17XG^(OVQ/C/XGN));KXAZQ;;\C9ITHLU4'L!"%Q]>M9&G_M/?%W2Y/,A^)?
MBIVR#BXU:><<>SL1_C7L+):MM9K\3S?[3IWTBS]QZ*_*#X6_\%)OB?X.OK>/
MQ2UKXUTD$+(ES"EO=!?]B6-0,_[ZMGVZU^E/P@^+WAOXX>"+/Q1X8NOM%E,3
M'+#( LUM, "T4JY.UAD>Q!!!((->9B<#6PNLUIW1VT,53Q&D=SMJ^!?^"L7_
M "+_ ,./^OJ^_P#0(:^N/V@_$FI>#_@?XYUO2+IK'5=/TBXN+:Y10QCD5"58
M @@X/J*_&KXG?'CQY\9(+"'QGXBGUV*P9WMEFBB3RRX 8C8JYR%'7TKORG#2
MJ5573TC_ )'+F%:,8.DUJ_\ ,Z;]CG_DYSX=?]A1?_06K]L:_ 'PIXJU7P/X
MBL->T.\;3]6L)/.MKI%5C&^,9 8$'KW%>O\ _#<7QQ_Z*#>?^ MM_P#&Z]?,
M,OJ8NHIP:5EU//P>+AAX.,DS]GZK7>G6FH;/M5K#<[<[?.C#XSUQGZ#\JLU\
M=_\ !13XU>-?@WHW@>;P9KTVA2W]Q=I<M%%&_F!%B*@[U;IN/3UKY+#T98BJ
MJ<79L^@K5%1@YRV1]:PZ#IEO(LD>G6L<BG*ND"@@^H(%7Z_*W]F7]KCXN>./
MCUX)T'7/&EUJ&DW]^L-S:O;P*)$VL<$K&".G8U^J5:XK"SPLE&;O<SP^(CB(
MN4$%%?%W_!1KXX^.?@S_ ,*]_P"$+\03:%_:7]H_:_)BB?S?+^S;,[U.,>8_
M3UKYM^!?[>GCW1_BAI-[\1/&6H:GX/@CNGO;*.T@+SD6TOE(NU%.3+Y>.0,]
M2!FNFCEM:M1]O!JVNG70QJ8VG3J^RDC]8Z*_)/XN?\%%?BCX^U*=/#EXG@G1
M-Q$5OIZJ]RR]C).P)W?[@0>QZUY+:_M/_%VSO#<Q_$OQ2TA.=LNK32)US]QF
M*_I73#)J\HWE))F$LRI)VBFS]QJ*_,W]G_\ X*6>)=%U:UTKXH+'KNBRL(SK
M-M L5W;=MSH@"R*.,X ;J<L>#^D^EZI::YIMIJ.GW,5[87<2SV]S X>.6-@"
MKJPZ@@@@^]>9B<)5PLK5%\^AW4<13Q"O MT45\W_ +6W[8VE?LWV,&EV%K'K
MGC2^B\VWL)&(AMHR2!-,1S@D'" @M@\KUK"E2G6FH4U=LUJ5(THN4W9'TA17
MXL>,OVTOC/XUNI9KCQWJ6F1N3MM]'8621@]@8@&./4DGWJCX8_:[^,GA.\CN
M+3XB:Y=%&SY>IW1O4;V*S;N*]Q9+6M\2O\SR_P"TZ=_A9^VM%?F1XN_X*0>(
M_&'P3^S6,Q\)?$>UOX2UWI\2O;7EKM<.5$@;8P;9E3GU!Z@>>_"W]LSXSZ]\
M3/".FWWCJ[N+&]U>SM[B%K:W >-YD5E)$>>02.*PCE.(<7*5E8U>84DTE=W/
MUYHHHKQ3TPHHHH XWXT?\D=\=_\ 8!O_ /TG>OP>K]X?C1_R1WQW_P!@&_\
M_2=Z_!ZOK<D^"?JCY_-/BB?L;_P3_P#^31O ?_;_ /\ I?<U]#5\\_\ !/\
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MPG5]E9IGVS1117DGH!17Y'_&#]N[XHWWQ0\42>$_&5QIOAI;^6/3K>&W@91
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MW8[_ '>7]=3Y(_8Y_P"3G/AU_P!A1?\ T%J_;&OQ._8Y_P"3G/AU_P!A1?\
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MY;:?BSBI<F)Q#G5>G]61[5I_["OP.L=)-A_P@MO<(R@--<7=PTS>^_S,J?\
M=P*^-?VT/V%[7X-Z$_C?P-+<S^&(Y%2_TVY?S)+'<0JR*_5HRQ"D'YE)!R03
MM^T/^&XO@;_T4"S_ / 6Y_\ C5<O\4/VN/@5XY^&_BGP])XZL;@:IIEQ:",V
MMP,L\;*N#Y?!R00>Q&:\+#U<=2J*4E)KK=,]2M3PM2#2<4^FQ^:7[.OQFO\
MX$?%C1?%-I(_V2.00:E;J>+BT<CS4([G ##T95/:OW$M;J*]MX;B"19H)D$D
M<B'*LI&00?0BOY\J_;?]DOQ!)XG_ &:_AU?2N9)!I$5LS'.3Y.8<G/4_N^O>
MN[.J*M"JM]CFRRH[RI_,\8_X*<?$:[\)_!/3/#MC,T$GB/4/*N&4X+6T2[W3
MUY<Q9]@1T-?G!\&_AE>_&3XG>'O!NGS+;7&K7'E&X9=PAC52\DFW(SM16;&1
MG'45^B/_  5&\$76N?!_P_XBM86F30]3*W)7/[J&=-N\^WF)$OU<>]?G/\*O
MB-J7PC^(>A>+](6.2_TFX\Y(IL[)%(*NC8YPRLR\>M=>6?[D_9?%K]_3]#GQ
MW^\^_MI]Q^L'@O\ 8&^"WA'38;>;PM_PD%VJ[9+[5KF25Y#ZE PC'_ 5%5O%
MW_!/;X*>*+.2.W\.7'A^Z92%NM*OI59??9(SI_X[7%>%?^"H?PQU6SA_MO1]
M?T&](_>HL$=S"IQ_"ZN&8=N4'7I7>:-_P4"^!NL.D;>+Y-/D8#"WNFW*#)&2
M"PC*C'N<>F:\*4<QA+F?-?YGJJ6#DK+E/*/@O_P33TSP+\4+C6O%NKV_BKP]
M8NLNE6'DE#._7=<J<C"'&%!(<\G RI^X0 H  P*P/!OQ \-?$/33?^&=?T[7
M[0'#2Z?<I,$/HVTG:?8X-=!7#B*]:O*]9ZHZJ-*G2C:FM&%%%%<IN%%%% !1
M110 4444 ?SV5^KG_!,7_DV^Z_[#UU_Z+AK\HZ_5S_@F+_R;?=?]AZZ_]%PU
M]QG'^[?-'S&7?Q_D?6]%%%?#GTX4444 <[\1O^2>^)_^P7=?^BFK\#J_?'XC
M?\D]\3_]@NZ_]%-7X'5]9D?PU/E^IX&:?%#YG[7_ +'7_)L7PZ_[!:_^A-7L
ME>-_L=?\FQ?#K_L%K_Z$U>R5\WB/XT_5_F>S1_AQ]$?+'_!2?_DV&^_["EI_
MZ$:_*/P[_P C!IG_ %]1?^ABOU<_X*3_ /)L-]_V%+3_ -"-?E'X=_Y&#3/^
MOJ+_ -#%?6Y1_NK]7^A\_F'\=>B/Z Z_(+_@HM"\?[5/B%F0JLEI9,A(^\/L
MZ#(_$$?A7Z^U^8__  5.\"RZ7\4/#'BR.(BTU;339R2!>/.@<GD^I25,9_N'
MTKQ<HDHXFSZIGIYC%RH771GSA\$?V=_&'[05YJMKX1BLYIM,CCEN%N[D0_*Y
M8*5SUY4_I7K/_#MGXT_\^.C?^#)?\*H?\$__ (QV'PE^.T4.LW*VFC>(+8Z9
M+/(<)#*65H78]AN79GH/,R>!D?K[7IX_'8C"UN6*5GMH<&#PM&O3YI-W/R1_
MX=L_&G_GQT;_ ,&2_P"%'_#MGXT_\^.C?^#)?\*_6ZN3U+XJ>$='\=Z;X+O?
M$%E;>*=2B::UTMY/WLBKU]@3S@$@MAL [3CSUF^*ELE]QVO+Z"W;^\^:/V"_
MV8_&_P"SYJWC&X\7P64,>J06L=O]DNA,24:0MG X^^*^D?C1_P D=\=_]@&_
M_P#2=Z[*N-^-'_)'?'?_ & ;_P#])WKS)UI8BNJD]VT=L:4:-+DCLC\'J_;_
M /97_P"3;_AK_P!@&T_]%BOQ K]O_P!E?_DV_P"&O_8!M/\ T6*^ESO^%#U/
M%RS^)+T/5****^//HCX;_P""K-M(WPT\$W QY<>KR1GGG+0DC_T$U\._LPW4
M=G^T7\-9)6VI_P )!9)GW:95'ZD5^C7_  4I\(2^)?V;)=0AB\Q]"U2VU!RJ
MY81D/ WX9F4G_=SVK\H]&U:ZT'6+'4[*3R;RRGCN8)/[LB,&4_@0*^URS]Y@
MW!>:/F,=[F)YGY,_H(HKSSX'?&OP]\=O 6G^(]#O(7EDB7[;8K(#+93X^:)U
MZC!S@D?,,$<&NH\8>,M%^'_AR]U[Q%J4&DZ39H9)KJX;:H]AW9CT"C))P ":
M^-E3E&7(UJ?2J491YD]#\J/^"D4\<W[4&IJC;FBTVS1QZ'R]V/R8?G7:_P#!
M*G_DL7BW_L G_P!*(J^8_CK\3I/C)\7/%'C)HF@35+LO!"_WD@11'"K>XC1
M<=P:^G/^"5/_ "6+Q;_V 3_Z415]MB(.GE[@]U%?H?+T9*IC.9;-L_3VO*/V
MI/A;_P +A^!/BSPY%%YNH-:F[L /O?:8CYD8'IN*[#[.:]7HKXFG-TY*<=T?
M42BIQ<7LS^>^&:6SN(Y8G:&:)@Z.IPRL#D$>A!K]6?CG^TE%>_L)Q^,[6X5-
M4\5Z=%I2>6P&VZE!CNE7'0H$N,8_NCI7P=^V5\+?^%2_M#>*-,AB$.F7TO\
M:M@ ,#R9R6VCV5_,3_@%>>ZA\2-9U+X;Z-X(GGW:+I6H7.HP)WWS+&I!]EV,
M1[RO[8^\JT(8U4JJV3O\OZL?*4ZLL*ZE-]=/F97A'PS?>-/%.D:!IL?FZAJE
MW%96Z>LDCA5S[9-?O%X'\(V7@'P;HGAO35VV.DV<5G#Q@E40+N/N<9/N37YB
M_P#!,_X6?\)E\;+KQ5=0^9I_A:T,J,1D?:I@T<0Q[()F]BJU^J]>%G-;FJ*D
MOL_FSU,MI<L'4?4****^=/9"BBB@#\@/^"B?_)U?B7_KULO_ $FCKL_^"67_
M "<%X@_[%>X_]*[2N,_X*)_\G5^)?^O6R_\ 2:.NS_X)9?\ )P7B#_L5[C_T
MKM*^WJ?\BW_MU'R\?]]^;/U,HHHKX@^H"BBB@ K\PO\ @JM_R6+PE_V 1_Z4
M2U^GM?F+_P %5H77XN^$)2I$;:'M#8X)%Q(2/U'YU[&4_P"]+T9YN8?P'\CB
M_P#@FS_R<]8_]@N[_P#017ZW5^1G_!-VXBA_:@TM)'5'FTZ\2,$_>;R]V!^"
MD_A7ZYUIG'^\KT7ZD9;_  ?F>)_MH6KW7[+OQ#2-S&PT\2;E]%E1B/Q (_&O
MQ8K]ZOBEX1_X3_X:^*O#0(5]7TNYL49NBM)$RJWX$@_A7X,W=I-8W4UM<1-#
M<0NT<D;C#*P.""/4$5Z>227LYP\_Z_(X\SC[\9>1]+:3_P $Z_C%K6EV>H6U
MEI!MKN%)XMVHJ#L90PR,>A%6_P#AVS\:?^?'1O\ P9+_ (5]W?L1_&2P^+GP
M&T"-;A&UO0;>/2M2M=PWHT:[8Y"/1T56SC&=X_A-?0%<-7-,52J2IR2T\O\
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MGZ5^.=FL+7<"W+,EN742,G4+GDCWQFNG)J,.259K6]C#,JLN94UMN>P_"?\
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MJ<.(_P!]^:_0_9^BBBOBCZ8_&_\ ;^_Y.Y\>?]N'_I!;5[M_P2=_Y&#XC_\
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M^\T_5?F<V)_@S]&?D%7]"=?SV5_0G7NYY_R[^?Z'EY7]OY?J%?C1^W)\*_\
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ML1/$=TO^#^AX$J[J48T>W](_2_\ X)?_  L/AOX6ZUXVNX=EUXBNO(MF8?\
M+K 2N1_O2F0'_KFM?8^M6[W6C:A#$N^62WD1%'<E2 *ROASX)LOAOX#T#POI
MX M-)LHK1&QC?L4 N?=CEC[DUT=?#XFLZ]:57NSZFC3]E24#^>RO?OAK^P[\
M3_BQX(TOQ9X>M]*GT?45=H'EOU1_DD:-@5QP0R,/PKSKX[>!I?AK\8_&/AN6
M+R5T_4YDA7UA9B\+?C&R'\:_0#_@F-\9+'7?AO>?#JZN5CUG0YY;NS@8\RVD
MK;F*COME9L_]=%K[7&XBI2PZK4==ON9\SAJ,*E;V=7^F?-?_  [9^-/_ #XZ
M-_X,E_PH_P"';/QI_P"?'1O_  9+_A7ZW4A(4$DX [U\Y_;&)\ON_P"">S_9
MM'S/R2_X=L_&G_GQT;_P9+_A7Z._LR?#_5_A7\"O"?A77DACU;38)([A8)/,
M0%II'&&'7AA72^"?BIX1^)-QJ\'ACQ!9:U-I-RUI>I:R;C%(/YKZ.,J<'!.#
M765S8K&U\1%4ZJM;78VP^%I47STW>YG>(/#^G>*M#OM&U>SBU#2[Z%K>YM9A
ME)(V&"#_ )XK\]OC#_P2WU2/4KJ^^&VO6L^GNQ=-(UIFCEB!/W$F4$.!VW!3
MCJ2>3^AVK:M9:#I=UJ6I7<-CI]I$TT]S<.$CB11EF9CP !67X%\?>'_B9X;M
MM?\ "^JV^LZ1<9$=S;DXR.JL" 58=U8 CN*QP^)KX:\Z>WX&M:C2K^[/?\3\
MC-6_8)^.FDLV?!#W<8Z26FH6L@;C/ $N[\Q7G_C#]GOXE^ +"2_\0>!]<TRP
MC&Z2\DLG:",>K2*"J_B:_=.FR1K*C(ZAT88*L,@CTKU(YU67Q13^_P#X)Y\L
MLI_9DS\#O ?Q \0_#'Q-:>(/#&JW&D:K;-E)H&QN&>4=>CJ>ZL"#Z5^T7[-G
MQI@^/OPAT;Q8L4=M?R;K;4+6(DK#<H<.!G^$\. 23M=<G-?CI\<K71+/XS>-
MX/#?DC08]9NTLA;',0B$K!0G^R.W;&*_0G_@E;YW_"D_%.[=]G_X2%]F?N[O
MLT&['OC;G\*]#-J<*F'5:UFK?CT.3+YRA6=.^A]IT445\<?2!1110 4444 %
M%%% '\]E>@>!?V@?B+\,M$;1_"WBW4-$TQIFG-M:L AD8 %N1U(4?E7WU_PZ
MI^'W_0W>)OSM_P#XU1_PZI^'W_0W>)OSM_\ XU7W$LSP<U:6J]#Y=8'$Q=XZ
M?,^)_P#AL;XT?]%%UG_OXO\ \31_PV-\:/\ HHNL_P#?Q?\ XFOMC_AU3\/O
M^AN\3?G;_P#QJC_AU3\/O^AN\3?G;_\ QJLOKV7_ ,J_\!-/JN,[_B?$_P#P
MV-\:/^BBZS_W\7_XFOKW_@G+\;_'?Q6\:>+[3Q=XGOM>MK33XI8([M@1&QDP
M2, <XK;_ .'5/P^_Z&[Q-^=O_P#&J]>_9R_8_P##7[->M:QJ6AZUJNJ2ZG;I
M;R)J!BVJJMN!&Q!SFN/%XO!5*,HTE[S\CHP^'Q,*JE-Z>IZS\1O^2>^)_P#L
M%W7_ **:OP.K^@37-)CUW1=0TV9VCBO+>2W=TQN574J2/?!KXU_X=4_#[_H;
MO$WYV_\ \:KGRO&4L*IJJ][&V.P]2NXN"V/=?V.O^38OAU_V"U_]":O9*Y7X
M7_#^S^%?P_T/PEI]S/=V6DVXMXIKK;YCJ"3EMH SSV%=57BUI*=24ELVSTJ<
M7&$8OHCY8_X*3_\ )L-]_P!A2T_]"-?E'X=_Y&#3/^OJ+_T,5^WWQX^"NE_'
M[X?S>$]8OKS3K*2XBN#/8[/,#(20/F!&.?2OG*Q_X):^ +&^M[E/%GB1GAD6
M0*QM\$@Y_P">?M7T&7XZAAZ#A4>MV>1C,+5K55."T/M*O)OVG/@/9_M#?"G4
M/#4DD=KJD;"[TN\D!Q#<J#MW8YVL"R-UX;."0*]9HKYVG.5.2G'='LRBIQ<9
M;,_ ;QIX)USX=^)KWP_XBTV?2M7LWV36UPN"/0@]"I&"&'!!R*]F^%O[=7Q;
M^%.CVVD6>M6^MZ3;*$@M-<@^T>4HZ*L@*R;0, +NP!P *_57XK_ OP-\;--6
MS\8>'[;5#&NV&[YCN8._R2J0RC/.,X/<&OEWQ'_P2J\$WMP[Z)XQUS2HV.1%
M>11707V! C./KG\:^KCF>%Q$%'$QU]+H^?E@:]&5Z,OT/G/Q7_P4F^,GB6SD
MM[2?1?#GF+M,NDV!\P9]#,\F#[CD=L5\WMJ.O>+O%27GVC4-8\1WMRK),KO-
M=SSDC:0>69\XQCGI7Z):/_P2C\*PW"G5?'>L7L.[)2SM(K=B/3<QDY]\5](?
M!O\ 9:^&_P "S]H\,:!&-5*[6U:^;[1=D8P0';[@(ZA H/<4?VC@\-%_5XW?
MI8/J>)K->VEH6OV;H_B'#\(=$3XGF%O%*IARC;I?*X\OSR.#+C.XK[9YS6]\
M:/\ DCOCO_L W_\ Z3O795D^*O#\/BSPOK&AW$DD-OJ=G-92218WJLB%"5R,
M9 :OE^?FJ<[5M;Z'O<MH<JUT/P"K]O\ ]E?_ )-O^&O_ & ;3_T6*^>O^'5/
MP^_Z&[Q-^=O_ /&J^MOAWX)M?AQX%T'PM8SS75GH]G'9137&/,=44*"V !GC
ML*]S,\;1Q5.,:;V9Y>!PU2A-N:.CHHHKYT]@R/%GA?3O&WAG5= U>W%UI>IV
MTEI<PG^*-U*G!['G@]C@BOQ=_:+_ &;_ !/^SOXPGT_5;6:XT*:1O[,UI4_<
MW<?4#(X60#[R'D8R,@@G]N:H:UH>G>)--FT[5]/M=4T^<;9;2]@6:*0>C(P(
M(^HKTL%CI8.3TO%[HXL5A8XE+HT?@3HNOZIX;O1>:1J5WI=VHP+BRG:&0#TW
M*0:NZKXD\2^.KVUAU+5=5\0W981V\=U<2W,A8G 5 Q)R3V%?K_JW["_P+UJZ
M:XN/ %K'(3G;:7MU;)_WS%*J_I7:_#O]GOX;_"BX%UX4\'Z9I-X 5%X(S+<
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M/4_$;G6+C<,$(X A7Z>4J-]7-?2=06=G#I]G!:VT206\"+%%%&,*B@8"@=@
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MO4KGQ#K=S=ZE>:A.YEU&Z+.9I %+#<>I 9.!T!7H,5[=^P#_ ,G<^ _^W_\
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M=P=_D>-_9M5.RDK'Y$7?PC\3Z=\+8?B#>Z=)9>&KG48],M)[@%&NI'CED+1
MCYD41$%NF2 ,X;"?!?\ Y+%X$_[#UC_Z4)7Z&_\ !4[4;6S^"'A/25VQS3>(
M(YX8U  \N*VG5L#T!E3\Z_/WX!Z?)JWQS^'EG'G=-XAT]<@9VC[0F3CV&3^%
M>CA\0\3AY59*VYQUJ*HUE33OL?NQ1117Y^?7!1110!QOQH_Y([X[_P"P#?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<91P]#ZMAW=[>B_S'AL/4K5?;5EYG6T445\D?0A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>apyx-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:apyx="http://apyxmedical.com/20210930"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="apyx-20210930.xsd" xlink:type="simple"/>
    <context id="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8d87cc0d00dd430e93bc08d22ef413d3_I20211109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-11-09</instant>
        </period>
    </context>
    <context id="i49aee00ecd564aaf8b7b1b4942930967_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifa26429c0b0840458a09f15ab78444da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8cd62ad6efef478ea9253454d1b323fc_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ied69cc4d5a424703ad140e56f728ec4c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="iaac4971ea2db4dc09b26a866c233c20f_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i75344978b6a74bc49f92004b47d2a99a_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i288fa9706cf44b8facc8faf026ba5348_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ief9af1557e4f4da285e53418666bd7c3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ifb31e9500ecb42efb36391b9387777c7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic7d4ef659eb7431bbcfe190050698da3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0ff89a354600483cb01afeea6bec3ba9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iee57ebf3a9b340788524d62a380a9faa_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i984f1d5dd05b4d329a24c070a595974a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i43b8251fde224eef8a0347a6e3949722_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0f06f183d7144f57a3f2a51f639d94a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0ba94fe7a6414cc99d227e2c683db25c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fe0683ef1f64486a18c7e5908f33e7a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i863033745e7146f18475cca8dedbfbe2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3da259ec02054f349636d5e80c3147bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i148f935a59024792a748fb1d4f38671f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2f70eafe2be446e695a8ccd7a1f65471_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i401e199c245e45e2b3bc3d4d91130100_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i38848fe39ff64851a1cbe4f24a730945_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i29b421bc868b4e08849cd49dfe789fd2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic9315b652eeb413db25d16425efd6de9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6ae1ce0523054de58fd6ba4b0d5d6563_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33c8cceba9d44f1b81b235e990ff326a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0ad44ab908404be1b219b693527268fd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie01729704401438f9953c87c6f6cd951_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i73a176064ef443598ec51cc2bb38bc3f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5479fed4aae147488d8d0627f13aaecc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69c89473017f4de187b5214a631371df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8c8bf58148c4c71bb4b113ba65e0d64_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie14d7e777681449e8cbe2e5ae99cf56f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idffa3da465324394823951b3715cae7c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2fc895348acb46d3a770cfb612e019f6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i2ac1cefbb0fa4631b29d06f046c1d8a3_D20180830-20180830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-30</startDate>
            <endDate>2018-08-30</endDate>
        </period>
    </context>
    <context id="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4aa6006334a64ba98deab070fa192566_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">apyx:ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">apyx:SymmetrySurgicalInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92566696a8e842be9629c3e2d9e89188_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">apyx:ChineseSupplierMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i217ab7fc63be424d813ed59e43cfbac4_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iacceeec5e6124e9bbe558a3cf8f40e58_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="idc6f0ef7bcae45cd8999ef7fb8dcb6e6_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="idcd8e5c679d74d2ea0ab1f9c045914f9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie99d69e989dd4e2d9a91ac92c9cf93ea_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idec38858c0924aa1a1b042bab111733f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if1441d9eeae7465492a27c8ba288bcfc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia199374e753e4fc58c3d346ef47fee8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:CorporateJointVentureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie06daf7da08d42bd910e91a19e6f42f8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib577766e74e4437fa096335a9fac4637_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i82c871421e3b4f6d90a3c5b264aa99af_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic941034edd2f42ed87948712260e3dfd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i27c18ff4efe54c20b92677b523d29b9f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff855cdb40594dde993ebab82bcd68fb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i477c509d866a43a2bfe6a5b2524881f1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6fe00d501071471994cd751b9c0b71e3_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27f6f313d1dd482988fc432dda095837_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic3b6022e971f4bba87288e373844658a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ida603cbbdd6941a4875a53a9b110041d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieb26ef99753941d797c8d6e6df4e31de_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i87b7ef7e804c45fb914663a18ee558d1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i18ff578dfa0b48819e4f52ffe351100c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iff92c63086be4b03a94436089380d2dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:CoVenturerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd587233451f4a38903c8c534991b8af_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5de7dda029e94c8180212239a6d77859_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:AdvancedEnergyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">apyx:OEMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8feb8845b0564256867ba343b1691830_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3ed5cc3391d04992bf148b8012572185_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i277888b4c0464b438c89a4092e556552_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia3dbf503dc59424c8962bef0a15c5e70_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id99d505a25264d4e876738d2927baa96_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i298c6efeca634aa8b52e461c51a9d455_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib8f706102a934d86aa02ba701cfc9f97_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i728134f0ae5e4afabac37e4c4216d794_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000719135</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>apyx:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18xLTEtMS0xLTU0ODQ_4ad7dba5-a9bf-46e5-a7cd-aaedc331fbee">0000719135</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18yLTEtMS0xLTU0ODQ_e7f6d641-2d2f-4b2e-ba75-d6b5fb4821b8">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N18zLTEtMS0xLTU0ODQ_e671456f-105a-4c11-852e-7dd59a3499d4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N180LTEtMS0xLTU0ODQ_e31a12ca-003f-45cb-9199-db9a47966d1d">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80L2ZyYWc6M2I5MjE3YWJlOTBkNDU5MjhkM2FhNzAzZmExNTAzNzMvdGFibGU6OWE2OTYzYjMzZDVmNDJmOWJlZGYyMTFjZDc2YzdhNDcvdGFibGVyYW5nZTo5YTY5NjNiMzNkNWY0MmY5YmVkZjIxMWNkNzZjN2E0N181LTEtMS0xLTU0ODQ_492ca689-f972-48b0-bde5-67ce8f8ef55f">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentType
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUz_ae8d6dc8-b7ba-481e-bead-a0f44168bba3">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV8wLTItMS0xLTU0ODQ_f9a7c15c-ca14-4c68-ba0c-66366ca8fedb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV8xLTQtMS0xLTU0ODQ_ef040ce1-93ed-43b2-8180-a651cf8ca4c8">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV81LTItMS0xLTU0ODQ_aecb58f3-667b-4867-8ec0-65f86a57c1d8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MjY3YTBkMzBjMjg5NGE3ZGIyNzIyOWEzMWNjMWU1MzUvdGFibGVyYW5nZToyNjdhMGQzMGMyODk0YTdkYjI3MjI5YTMxY2MxZTUzNV83LTQtMS0xLTU0ODQ_2e38d356-0d20-42ce-a077-280fd28c1e36">0-12183</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZGZhZjYxOWU5ODJjNGE3MGFhM2JhMmNiN2VmZDlmNzUvdGFibGVyYW5nZTpkZmFmNjE5ZTk4MmM0YTcwYWEzYmEyY2I3ZWZkOWY3NV8xLTAtMS0xLTU0ODQ_0f3bbf48-6f7b-4f2d-b147-60ed3a9502fa">APYX MEDICAL CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZDhlYTA3YTJiZWI2NDgzZThjYjBiODQxZDE4NDMwNzIvdGFibGVyYW5nZTpkOGVhMDdhMmJlYjY0ODNlOGNiMGI4NDFkMTg0MzA3Ml8wLTAtMS0xLTU0ODQ_84601134-7111-4615-a63d-5f8ca5e1ee6e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6ZDhlYTA3YTJiZWI2NDgzZThjYjBiODQxZDE4NDMwNzIvdGFibGVyYW5nZTpkOGVhMDdhMmJlYjY0ODNlOGNiMGI4NDFkMTg0MzA3Ml8wLTItMS0xLTU0ODQ_e8762deb-1506-4c63-89e8-12861e89c4a1">11-2644611</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTQ4_148042c2-84a1-4cb4-a7b9-7dcbf0f0238b">5115 Ulmerton Road,</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTQ5_53f328d3-1e96-48ba-a613-ebef22c1c359">Clearwater</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUw_7786192f-0811-4836-be11-1032800b7aff">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUx_03594bec-49df-4391-821e-a2cc8bba258b">33760</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTUy_c475b042-8c3b-4801-9d6a-2fa7ff51a580">727</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU0_8a611db8-079c-406b-9374-176c5a7baa2c">384-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTAtMS0xLTU0ODQ_8a736fed-6855-40a8-8c01-dfacdd6e5028">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTEtMS0xLTU0ODQ_67838133-c73f-4651-9983-c0fb9bd82284">APYX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6NjQ1NDY4ZmE5NWM0NDE0NmE5NDMwZWE0YjgwYjg4NTEvdGFibGVyYW5nZTo2NDU0NjhmYTk1YzQ0MTQ2YTk0MzBlYTRiODBiODg1MV8xLTItMS0xLTU0ODQ_3dea0948-14a3-4c5d-9c1b-e1d59a5cfb84">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU1_a0d05563-c8db-4b4c-bdb8-605a02096f95">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU2_7ecbd937-d424-49fd-8155-61a7122def27">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18xLTAtMS0xLTU0ODQ_17467e5f-9b2e-4b96-85f2-90c2e8ceb900">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18xLTQtMS0xLTU0ODQ_1264f969-4663-48be-8dec-d0736b289f38">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGFibGU6MzQ5ZGQwNGRmODVhNGI3Y2JlYjg2NDA5YmIwZWM1ZWMvdGFibGVyYW5nZTozNDlkZDA0ZGY4NWE0YjdjYmViODY0MDliYjBlYzVlY18yLTQtMS0xLTU0ODQ_259f57bf-921f-4814-b692-ab22b7f9bd76">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF8xNTU3_cf94d85c-de7c-4b9a-9d10-b178882a9171">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8d87cc0d00dd430e93bc08d22ef413d3_I20211109"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xL2ZyYWc6ZWVjZjJmNTQ0ZWNjNDgxZmFlZjUyMjAzYTA2NzBjMTAvdGV4dHJlZ2lvbjplZWNmMmY1NDRlY2M0ODFmYWVmNTIyMDNhMDY3MGMxMF82NTk3MDY5NzY4MjU0_1e2fff91-768b-4a5a-88de-e55b50c7a175"
      unitRef="shares">34343750</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMy0xLTEtMS01NDg0_4441cc07-cd81-4cb8-bd2f-c27ab3460c31"
      unitRef="usd">30898000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMy0zLTEtMS01NDg0_05221523-ed14-414a-a024-8f0e315f5ebe"
      unitRef="usd">41915000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0wLTEtMS01NDg0L3RleHRyZWdpb246MzY1YTM2YTI3NmFlNGMwNzgxM2NjNjJlZDk0ZDBiOGFfNTQ_6b7a3bd6-492c-4954-a033-48d0f434c5c7"
      unitRef="usd">360000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0wLTEtMS01NDg0L3RleHRyZWdpb246MzY1YTM2YTI3NmFlNGMwNzgxM2NjNjJlZDk0ZDBiOGFfNjE_7bdc6fc2-ffe2-4146-a95d-f75144419ca0"
      unitRef="usd">300000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0xLTEtMS01NDg0_a6a06a22-cdaa-4adc-8688-52b9397bde17"
      unitRef="usd">11444000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNC0zLTEtMS01NDg0_5b079b1d-4393-410b-b446-606dfecba067"
      unitRef="usd">8399000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNS0xLTEtMS01NDg0_20c22ac5-fee8-4255-ab2e-7b3162d896a1"
      unitRef="usd">7654000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNS0zLTEtMS01NDg0_5cd97f19-6f8a-41d1-a152-c30b044297ca"
      unitRef="usd">7654000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNi0xLTEtMS01NDg0_262d5c94-0c68-44bf-ab33-15d926d4f091"
      unitRef="usd">873000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNi0zLTEtMS01NDg0_8c0dbb5c-4444-4e94-85ff-e6bf06f3c40d"
      unitRef="usd">1275000</us-gaap:OtherReceivablesNetCurrent>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0wLTEtMS01NDg0L3RleHRyZWdpb246NDM0MmI2M2MxZDQ1NDZlNGEyMjE3ZmYxZmYwZjE4NzhfNTQ_147def7d-263f-40e1-9942-5c669375d465"
      unitRef="usd">303000</apyx:ProvisionForObsolescenceInventory>
    <apyx:ProvisionForObsolescenceInventory
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0wLTEtMS01NDg0L3RleHRyZWdpb246NDM0MmI2M2MxZDQ1NDZlNGEyMjE3ZmYxZmYwZjE4NzhfNjE_621dce97-4ada-4676-a341-cbc2bb375058"
      unitRef="usd">388000</apyx:ProvisionForObsolescenceInventory>
    <us-gaap:InventoryNet
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0xLTEtMS01NDg0_63e7f6e1-23ed-44f6-8108-f2397889c512"
      unitRef="usd">6040000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfNy0zLTEtMS01NDg0_2da1b3fe-7b2d-40d4-961d-090ebb663631"
      unitRef="usd">4051000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOC0xLTEtMS01NDg0_c9c09e08-e820-462e-a304-e92b1eef599e"
      unitRef="usd">2967000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOC0zLTEtMS01NDg0_15166425-1dc9-4c0d-992d-601395245384"
      unitRef="usd">2795000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOS0xLTEtMS01NDg0_bb7b6c4a-3afe-4196-bd63-5f0ab4fa1abe"
      unitRef="usd">59876000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfOS0zLTEtMS01NDg0_881781df-78d0-468a-a10f-a1d23b9a8bba"
      unitRef="usd">66089000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmIxMjYyNmQ5MGJkMDRiZDViMTM2MTYyMDE1ZWI1ZWNkXzgw_ee0f4621-34c1-4892-9df2-0bb66d933cf8"
      unitRef="usd">5145000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmIxMjYyNmQ5MGJkMDRiZDViMTM2MTYyMDE1ZWI1ZWNkXzkx_f8dc5949-8064-41d3-9eaf-131d265408cd"
      unitRef="usd">4813000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMS0xLTEtNTQ4NA_b6704565-4646-4d2a-88e0-5e448f400d71"
      unitRef="usd">6412000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTAtMy0xLTEtNTQ4NA_ccddf578-8363-46c9-a22c-a5d3678031f8"
      unitRef="usd">6541000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTEtMS0xLTEtNTQ4NA_00f3055e-b26e-42eb-9d01-d0add46201e8"
      unitRef="usd">152000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTEtMy0xLTEtNTQ4NA_f2f37653-71a6-48c0-80f8-bbb735d3d350"
      unitRef="usd">237000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTItMS0xLTEtNTQ4NA_39a6cd89-8b09-454c-bfc9-6097cfe78325"
      unitRef="usd">274000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTItMy0xLTEtNTQ4NA_d5df506d-c8dd-4d5c-acfe-23e3178d0ef0"
      unitRef="usd">437000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTQtMS0xLTEtNTQ4NA_553c038a-5045-4648-b1c8-29aaa033f9a6"
      unitRef="usd">1055000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTQtMy0xLTEtNTQ4NA_a89f782e-9206-4a04-bba6-508876633850"
      unitRef="usd">807000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTUtMS0xLTEtNTQ4NA_17a95614-acfd-47da-bce6-3e51b98f696c"
      unitRef="usd">67769000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMTUtMy0xLTEtNTQ4NA_80e14491-e3ee-489d-b308-9bcab5747719"
      unitRef="usd">74111000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjEtMS0xLTEtNTQ4NA_a3dfeb61-f921-40a2-ac42-59d79e70470a"
      unitRef="usd">3044000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjEtMy0xLTEtNTQ4NA_f3cf9789-f002-443e-9462-80cb17dc0819"
      unitRef="usd">1511000</us-gaap:AccountsPayableCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjItMS0xLTEtNTQ4NA_e5e7fc28-6779-46fa-9403-6d03eed0d86d"
      unitRef="usd">8324000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjItMy0xLTEtNTQ4NA_820470f2-70ac-4b1c-a735-1826a5b05c2e"
      unitRef="usd">7278000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjMtMS0xLTEtNTQ4NA_0cdb3175-c2a3-485f-8256-e73606c7d38d"
      unitRef="usd">125000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjMtMy0xLTEtNTQ4NA_fc5273a9-ebfc-4643-b48b-04b0e7eedddb"
      unitRef="usd">126000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjQtMS0xLTEtNTQ4NA_f23d0a60-046a-42ae-b9dd-6c10f0f6d66c"
      unitRef="usd">218000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjQtMy0xLTEtNTQ4NA_74620dab-5889-47b9-ade1-066cf64de47f"
      unitRef="usd">238000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjYtMS0xLTEtNTQ4NA_d9a7edf7-492c-4853-97c7-3011d0d1c022"
      unitRef="usd">11711000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjYtMy0xLTEtNTQ4NA_0f487b20-097f-42bc-aad5-8855bd8e8910"
      unitRef="usd">9153000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjctMS0xLTEtNTQ4NA_8041aeb4-5d2d-46d7-8aae-13a85f7a7c36"
      unitRef="usd">30000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjctMy0xLTEtNTQ4NA_0af1b9c1-22ba-4eb4-a993-a593f7168094"
      unitRef="usd">129000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjgtMS0xLTEtNTQ4NA_97de4c5c-e96d-4a80-82d3-39b0d5a42e0a"
      unitRef="usd">22000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjgtMy0xLTEtNTQ4NA_763ab9dd-5ce8-49ff-b8e0-0abffe126774"
      unitRef="usd">183000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjktMS0xLTEtNTQ4NA_529ea040-8604-44a9-8379-183b75a58925"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMjktMy0xLTEtNTQ4NA_6e8aaa86-61d7-4d7e-ad4d-27b2a7f05d6e"
      unitRef="usd">621000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzAtMS0xLTEtNTQ4NA_dc6985e9-c146-437c-9977-b26ecf986181"
      unitRef="usd">146000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzAtMy0xLTEtNTQ4NA_66b12424-d030-4140-9677-6ab2ebfd7ab7"
      unitRef="usd">166000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzEtMS0xLTEtNTQ4NA_be4645a5-acbb-43e5-a5e7-397610921321"
      unitRef="usd">13109000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzEtMy0xLTEtNTQ4NA_0387fa97-1ff1-41c2-8b60-96c6c2a5652b"
      unitRef="usd">10252000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzE4_cb608e00-c639-43db-9dd0-4eea781af387"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzE4_dd2fd3ec-c16b-4ef8-bfa0-807605389260"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzMy_7d82cfae-dfe0-48ad-b51c-81a31eb2f374"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzMy_8f1ce9b8-a8d3-4fd6-b2fd-5c9b5569f709"
      unitRef="shares">75000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzU0_1d4e4c21-6104-45d2-bbc6-f00eb63d78a8"
      unitRef="shares">34339533</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzU0_5bbbc98d-1475-4f1f-8d61-7f41e0c503c8"
      unitRef="shares">34339533</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzEwNQ_6afb917e-4160-438f-b2f2-214a55661bf0"
      unitRef="shares">34289222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMC0xLTEtNTQ4NC90ZXh0cmVnaW9uOmVlNjY0MmYxNWJlMjQ2ODg4NWM2ZTBlZWRkZmFjNzU3XzEwNQ_e3676368-0fd0-4b2d-ba28-14d9e4c3aa3b"
      unitRef="shares">34289222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMS0xLTEtNTQ4NA_c21c9e09-b302-40f4-a9bd-c2ff0aceed0c"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzMtMy0xLTEtNTQ4NA_88a485a0-604a-48d4-b1ce-3cf727614cb5"
      unitRef="usd">34000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzQtMS0xLTEtNTQ4NA_fcfa32c4-53e8-4c20-bb76-3020f07dcdd0"
      unitRef="usd">64862000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzQtMy0xLTEtNTQ4NA_d89a0428-0775-46cd-82ca-54c8a8270c4a"
      unitRef="usd">61066000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzUtMS0xLTEtNTQ4NA_2a8c428b-0ec0-44b8-b563-a91448974056"
      unitRef="usd">-10548000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzUtMy0xLTEtNTQ4NA_5520b0d8-4632-42e7-852d-c9d020973f87"
      unitRef="usd">2621000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzYtMS0xLTEtNTQ4NA_ad0e7d67-a14f-41e7-b9a4-092a42375bc7"
      unitRef="usd">54348000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzYtMy0xLTEtNTQ4NA_7ea90434-b6ea-4e35-b4d0-133e8d72ecac"
      unitRef="usd">63721000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzctMS0xLTEtNTQ4NA_442d7997-218a-44aa-82bd-16e676d42fd6"
      unitRef="usd">312000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzctMy0xLTEtNTQ4NA_69b8cc23-0785-4ab2-95ed-e6d9e28c6e2c"
      unitRef="usd">138000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzgtMS0xLTEtNTQ4NA_b1c05358-e5a6-4c7b-9737-6b01fb96ee13"
      unitRef="usd">54660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzgtMy0xLTEtNTQ4NA_b440ea69-4fd0-412e-acca-85b32b1c4a0e"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzktMS0xLTEtNTQ4NA_494165f2-a172-43e9-95a7-f3943656f7f6"
      unitRef="usd">67769000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xNi9mcmFnOjQyYzNmMjBmNTMzMjQ3MDE5YTA4OTc0NGViOGQ0Zjk1L3RhYmxlOmViZjQ1ZTBjNWZjODRjYzBiZDliOGFkMDkyZjIwMDEyL3RhYmxlcmFuZ2U6ZWJmNDVlMGM1ZmM4NGNjMGJkOWI4YWQwOTJmMjAwMTJfMzktMy0xLTEtNTQ4NA_632db8c9-20a6-413c-b8d2-78826d6792bb"
      unitRef="usd">74111000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi0xLTEtMS01NDg0_d152d5e4-9137-4f9a-a08e-937e2e3c0c8b"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi0zLTEtMS01NDg0_603d13fe-d85c-4768-96ba-b202f2e235d2"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi01LTEtMS01NDg0_14321190-4149-4451-89f7-80247ab8c72a"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMi03LTEtMS01NDg0_0c87594f-da55-4667-a9bb-c999c7d9879b"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy0xLTEtMS01NDg0_c16d3450-2b11-4d85-b9bb-2890b5586089"
      unitRef="usd">3775000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy0zLTEtMS01NDg0_fa18c27f-693d-4043-a995-4bb277404ee4"
      unitRef="usd">2229000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy01LTEtMS01NDg0_585a1c51-f5dc-4e3a-a936-bb53360d0f1f"
      unitRef="usd">10243000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMy03LTEtMS01NDg0_cbce067e-61dc-400a-b0d0-94935d2ac829"
      unitRef="usd">6444000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC0xLTEtMS01NDg0_9b9c213a-2d0e-4ec9-8317-f915755ab140"
      unitRef="usd">8056000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC0zLTEtMS01NDg0_4551e6e8-6d17-49b5-bfdb-919598e71604"
      unitRef="usd">4725000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC01LTEtMS01NDg0_dd3168b4-b24a-43e7-b459-7c4d3f41bb22"
      unitRef="usd">21450000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNC03LTEtMS01NDg0_46dd6df6-d53d-4177-b8ff-09fcd1f3c599"
      unitRef="usd">9803000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi0xLTEtMS01NDg0_6ad92ee5-cfb4-4d5b-9344-fbcd2f4c6485"
      unitRef="usd">1175000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi0zLTEtMS01NDg0_667334cf-60e0-45bc-a689-f14ede06d9b2"
      unitRef="usd">1047000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi01LTEtMS01NDg0_e2364048-e950-439a-a8bd-92c33892fba7"
      unitRef="usd">3374000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNi03LTEtMS01NDg0_d0a378b9-5464-44ed-aff9-d8d9cfeaaa5a"
      unitRef="usd">3002000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ProfessionalFees
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy0xLTEtMS01NDg0_7987c03b-b4d4-4fe1-a1c0-cd4b08d14841"
      unitRef="usd">2032000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy0zLTEtMS01NDg0_76c6623b-cf3d-4593-9a85-b499e323fd37"
      unitRef="usd">1835000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy01LTEtMS01NDg0_9eee41e3-8e12-44a1-9224-f49a09c045a3"
      unitRef="usd">5442000</us-gaap:ProfessionalFees>
    <us-gaap:ProfessionalFees
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfNy03LTEtMS01NDg0_cdd36785-6ed6-466d-af5b-5970f92aca69"
      unitRef="usd">5882000</us-gaap:ProfessionalFees>
    <us-gaap:SalariesAndWages
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC0xLTEtMS01NDg0_4a09ea34-419a-4333-8c47-89e376a4d229"
      unitRef="usd">4206000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC0zLTEtMS01NDg0_e8772a91-a4df-4c7c-982b-ff61afe01642"
      unitRef="usd">3508000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC01LTEtMS01NDg0_4aeeae28-a226-4212-a60c-97509b391cf9"
      unitRef="usd">12794000</us-gaap:SalariesAndWages>
    <us-gaap:SalariesAndWages
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOC03LTEtMS01NDg0_7fa82f85-49e1-4af6-8ce0-bf54588148c5"
      unitRef="usd">10258000</us-gaap:SalariesAndWages>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS0xLTEtMS01NDg0_b3c2f24f-1588-4f8a-8ce0-e8bffdfe8626"
      unitRef="usd">4611000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS0zLTEtMS01NDg0_e7de52c8-ef37-418c-951d-01bd4bc7bcfa"
      unitRef="usd">2706000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS01LTEtMS01NDg0_af2c12cc-1f97-421f-bacb-b4410d9a22cb"
      unitRef="usd">12596000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfOS03LTEtMS01NDg0_87cf7f17-e737-4435-bfdc-c916032c3fd9"
      unitRef="usd">8691000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtMS0xLTEtNTQ4NA_5c9a5225-d925-42d6-b399-3b14f9fc377e"
      unitRef="usd">12024000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtMy0xLTEtNTQ4NA_99fdf07e-7d11-4de3-b636-be1ef9c503c9"
      unitRef="usd">9096000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtNS0xLTEtNTQ4NA_2448bc4a-5c10-494a-a2fb-f474e821d07c"
      unitRef="usd">34206000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTAtNy0xLTEtNTQ4NA_1ba59113-67ce-4858-adb6-a78170029387"
      unitRef="usd">27833000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtMS0xLTEtNTQ4NA_e618f654-82e8-4cfb-8045-80c1319f48dd"
      unitRef="usd">-3968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtMy0xLTEtNTQ4NA_9cf397a8-cf2e-4699-8e98-0060d3d9f0bc"
      unitRef="usd">-4371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtNS0xLTEtNTQ4NA_1b983284-087a-4e36-9f21-94b0b7dbfe71"
      unitRef="usd">-12756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTEtNy0xLTEtNTQ4NA_2a511857-63c0-4db7-931e-0465bad407c0"
      unitRef="usd">-18030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItMS0xLTEtNTQ4NA_8863cc46-3e8a-4b19-880d-0034705a63d7"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItMy0xLTEtNTQ4NA_cf6f0da9-5319-4b97-a971-926b50a12bb4"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItNS0xLTEtNTQ4NA_b99cb05e-3dd5-46f8-87a2-d7ad15cbcba2"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTItNy0xLTEtNTQ4NA_ffcef594-7cda-44a9-a342-8a02a1bd66ba"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtMS0xLTEtNTQ4NA_5b6c1e27-7877-47f1-be3b-7f0b8069ef3e"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtMy0xLTEtNTQ4NA_d5d351f6-b1da-4d80-9fec-59ee13c9dcf5"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtNS0xLTEtNTQ4NA_5fa78f9a-055d-45ae-abb6-fa8e7ccd54ae"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTMtNy0xLTEtNTQ4NA_f2be2daa-4bc4-412f-b2ee-accc05e94851"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtMS0xLTEtNTQ4NA_40d003f8-23ce-4097-869a-b32ad203ca21"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtMy0xLTEtNTQ4NA_697d6ee4-c09b-4566-9d71-a4462a1fc59e"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtNS0xLTEtNTQ4NA_c2a55ce8-f03c-413b-ada0-dfe5439d2db0"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTQtNy0xLTEtNTQ4NA_d125000c-d82b-4c3b-9a15-b919093124c8"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtMS0xLTEtNTQ4NA_d11d0a19-684f-497f-8019-2f71e9afdeb4"
      unitRef="usd">-193000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtMy0xLTEtNTQ4NA_a21aee35-e660-453e-a4b0-d9a5c1e76e28"
      unitRef="usd">-78000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtNS0xLTEtNTQ4NA_90d2bf62-3ce5-46d0-8817-d3415cd9f6ee"
      unitRef="usd">-188000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTUtNy0xLTEtNTQ4NA_496fe173-aacb-4515-b1d4-33e1e11b5f8e"
      unitRef="usd">543000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtMS0xLTEtNTQ4NA_7998e2ba-71af-4067-9335-7434ee75ea9d"
      unitRef="usd">-4161000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtMy0xLTEtNTQ4NA_b6a8366d-3d85-426d-8b0a-341286983718"
      unitRef="usd">-4449000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtNS0xLTEtNTQ4NA_18427d13-4718-4959-9a5b-20644b99a97c"
      unitRef="usd">-12944000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTYtNy0xLTEtNTQ4NA_a3e16521-68da-48ee-913b-98e2c5ec3276"
      unitRef="usd">-17487000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctMS0xLTEtNTQ4NA_fb9aa610-172c-4307-ac30-a1b226288d2e"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctMy0xLTEtNTQ4NA_3d4a295e-7cb0-47dd-839c-ee907243b679"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctNS0xLTEtNTQ4NA_817f65a0-cad8-4625-a289-a5738919c387"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTctNy0xLTEtNTQ4NA_5cf1c471-1487-4408-ab9b-c7b77ff897eb"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtMS0xLTEtNTQ4NA_7c8275c3-1131-4529-9a58-ac05ec25d122"
      unitRef="usd">-4234000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtMy0xLTEtNTQ4NA_52232f09-3c20-4d70-b8f5-89489b19daf1"
      unitRef="usd">-3734000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtNS0xLTEtNTQ4NA_7dffd905-1a97-4449-97b7-1209ca092e8a"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTgtNy0xLTEtNTQ4NA_7967767d-8211-4057-9760-1980c315bbd4"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktMS0xLTEtNTQ4NA_e3063243-2dea-4fb8-b930-e99ac174c248"
      unitRef="usd">-12000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktMy0xLTEtNTQ4NA_33032b1b-6187-4fdc-a91b-0114a83eb079"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktNS0xLTEtNTQ4NA_5ca83e40-5d10-4ff5-a1dc-62915aa12304"
      unitRef="usd">-21000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMTktNy0xLTEtNTQ4NA_23220fee-5a2b-4ab5-8e0d-6e5aa7ece1b7"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtMS0xLTEtNTQ4NA_b1769e79-6559-47bf-b246-5eb40f4b9209"
      unitRef="usd">-4222000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtMy0xLTEtNTQ4NA_7e9c0235-7178-41ea-8f58-824c80760671"
      unitRef="usd">-3728000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtNS0xLTEtNTQ4NA_a94a9418-ed84-485d-a4da-686d3ccb8f2f"
      unitRef="usd">-13169000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjAtNy0xLTEtNTQ4NA_ea574d74-e841-4562-809f-5c918fa383bd"
      unitRef="usd">-10369000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMS0xLTEtNTQ4NA_37c0f6a0-dbce-425f-92dd-ef57a9d222d3"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMS0xLTEtNTQ4NA_4feed867-5d33-4ab6-8529-f2bb2fdd757b"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMy0xLTEtNTQ4NA_4d9a996d-897d-4648-a233-f93cf6763783"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtMy0xLTEtNTQ4NA_f32361b3-a08f-47e8-b05f-589b6cafc8d5"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNS0xLTEtNTQ4NA_0643f3cb-b592-4529-8850-5a6bc8d2fc7d"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNS0xLTEtNTQ4NA_ba85f1c2-9b73-4110-a3b6-8ad52ce0578f"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNy0xLTEtNTQ4NA_89587003-04f8-4d44-ab99-588d0649bf61"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8xOS9mcmFnOjgxY2RjYzUzNGVkZDQyODc4MTEwYTFjYTllOTgyMzEwL3RhYmxlOmYyOGY1YWJlN2Y2NjRlMjg5NWFlMzMzYzRkYTAyZTA5L3RhYmxlcmFuZ2U6ZjI4ZjVhYmU3ZjY2NGUyODk1YWUzMzNjNGRhMDJlMDlfMjQtNy0xLTEtNTQ4NA_8e8bda4f-6ea2-4569-9b45-a89b6966d920"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesIssued
      contextRef="i8cd62ad6efef478ea9253454d1b323fc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0xLTEtMS01NDg0_4cbe32c8-6d07-4396-902b-709a35a94632"
      unitRef="shares">34202000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8cd62ad6efef478ea9253454d1b323fc_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0zLTEtMS01NDg0_a84e3584-0649-4ea1-ae06-34a7c6e48aa9"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ied69cc4d5a424703ad140e56f728ec4c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy01LTEtMS01NDg0_838c125d-903e-4990-8c64-54c748943ed9"
      unitRef="usd">58926000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaac4971ea2db4dc09b26a866c233c20f_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy03LTEtMS01NDg0_c03a62c3-609b-403f-8a86-d0723d37dacb"
      unitRef="usd">7876000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i75344978b6a74bc49f92004b47d2a99a_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy05LTEtMS01NDg0_a06f65c3-8d56-45c5-8d95-df58cd1ff457"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i288fa9706cf44b8facc8faf026ba5348_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMy0xMS0xLTEtNTQ4NA_e895de34-b299-4671-a4a9-18c688f43bbd"
      unitRef="usd">66836000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNC05LTEtMS01NDg0_e89e6370-14b4-4c09-8e7b-89ea779b95f4"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNC0xMS0xLTEtNTQ4NA_a0c0298a-9daf-4de3-9525-2912817ce84e"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS0xLTEtMS01NDg0_f3293201-d690-4ad9-9208-f9dcf9f18437"
      unitRef="shares">10000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS01LTEtMS01NDg0_5d3b273c-aadc-45ac-af4a-b90b3f6a9479"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNS0xMS0xLTEtNTQ4NA_59f60b7e-269f-42b7-b5a2-8cab0ffb4628"
      unitRef="usd">25000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i589e2f984874416ab69f78e638ca5bcf_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNi01LTEtMS01NDg0_c945a4da-afe4-4881-860e-85995d689b9f"
      unitRef="usd">1063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNi0xMS0xLTEtNTQ4NA_23bbecc9-b0df-4aa4-80b5-c1f1ce2ca354"
      unitRef="usd">1063000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ic4964452574f4b029cd1874a22d85d38_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNy0xLTEtMS01NDg0_9ad7fa46-de20-4f70-9585-4742b82918ff"
      unitRef="shares">11000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="ief9af1557e4f4da285e53418666bd7c3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS03LTEtMS01NDg0_dd1d7f8a-dd05-4e23-a164-0f4098213f7d"
      unitRef="usd">-3728000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib7c43856c9be4a119c8b9fe55e600922_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS05LTEtMS01NDg0_3c04e8f4-e004-4264-b0d7-7a37d298e126"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfOS0xMS0xLTEtNTQ4NA_a2e60395-8cc1-4dfe-a5bd-fd88f8b6c986"
      unitRef="usd">-3734000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMS0xLTEtNTQ4NA_970ee826-f08e-4f8d-88a2-7205bc504c60"
      unitRef="shares">34223000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMy0xLTEtNTQ4NA_85ae1587-8e2b-4083-ab3d-16348b81322e"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb31e9500ecb42efb36391b9387777c7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtNS0xLTEtNTQ4NA_097b11a8-a8a8-402e-bc74-96352d8a167e"
      unitRef="usd">60014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtNy0xLTEtNTQ4NA_db286eb3-0463-458e-9c08-0643f89ec87d"
      unitRef="usd">4148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7d4ef659eb7431bbcfe190050698da3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtOS0xLTEtNTQ4NA_6150228e-3754-4719-99f2-23aef169d710"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTAtMTEtMS0xLTU0ODQ_424e4582-da4e-4008-93e0-ee32f9668ca7"
      unitRef="usd">64338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="iee57ebf3a9b340788524d62a380a9faa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMS0xLTEtNTQ4NA_ad6e5f5c-2b30-4398-84e0-6698d4d1ccc2"
      unitRef="shares">34323000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iee57ebf3a9b340788524d62a380a9faa_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMy0xLTEtNTQ4NA_c114c663-482e-4dd6-8c65-18f5632d9ed9"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i984f1d5dd05b4d329a24c070a595974a_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItNS0xLTEtNTQ4NA_9f33a7a3-bfe7-4660-85ae-7283219ec608"
      unitRef="usd">63650000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43b8251fde224eef8a0347a6e3949722_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItNy0xLTEtNTQ4NA_9c827d68-993b-4fb8-a491-a657b3d1185f"
      unitRef="usd">-6326000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0f06f183d7144f57a3f2a51f639d94a3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItOS0xLTEtNTQ4NA_2b71dcd2-9fd9-48de-b813-ba5263ac7090"
      unitRef="usd">324000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ba94fe7a6414cc99d227e2c683db25c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTItMTEtMS0xLTU0ODQ_839b5645-e522-46b9-9851-522d2accd9bb"
      unitRef="usd">57682000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtMS0xLTEtNTQ4NA_16063043-8f99-4595-a941-19e1d7e5d48f"
      unitRef="shares">3000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtNS0xLTEtNTQ4NA_ee793690-48b0-4072-bfeb-5ae15f74364d"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTQtMTEtMS0xLTU0ODQ_f3629de6-b8da-4e85-9fbe-546f99c350fc"
      unitRef="usd">28000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iabc0114c1f9a4dc2ae4d509b4a51ce46_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTUtNS0xLTEtNTQ4NA_52de5005-a860-4329-a89c-a5bac3451dcf"
      unitRef="usd">1184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTUtMTEtMS0xLTU0ODQ_62d7d1f4-caa4-40da-bc06-0c32113ecde7"
      unitRef="usd">1184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ieb85c7a379684a12bd66d34ac78ad780_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTYtMS0xLTEtNTQ4NA_ffb189c3-d5a0-4e39-ab9e-69518930c915"
      unitRef="shares">14000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i2fe0683ef1f64486a18c7e5908f33e7a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtNy0xLTEtNTQ4NA_4e3ef9e3-2ef8-4006-8df0-f112102f92ae"
      unitRef="usd">-4222000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i863033745e7146f18475cca8dedbfbe2_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtOS0xLTEtNTQ4NA_a9d41424-0d4b-423d-ad3c-cff47b3bb34f"
      unitRef="usd">-12000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTgtMTEtMS0xLTU0ODQ_37f21d18-0991-4f1d-a8bc-1eb1baf6c338"
      unitRef="usd">-4234000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMS0xLTEtNTQ4NA_1c0f3473-316e-4c8b-a750-78ab343ae06d"
      unitRef="shares">34340000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMy0xLTEtNTQ4NA_2972b6d9-41b9-485e-953a-740889b407a4"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i148f935a59024792a748fb1d4f38671f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktNS0xLTEtNTQ4NA_9243a26d-2ef1-4d6d-9576-16eee149cad2"
      unitRef="usd">64862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f70eafe2be446e695a8ccd7a1f65471_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktNy0xLTEtNTQ4NA_6056699e-65f9-4e5d-bde2-f9a87b10d11b"
      unitRef="usd">-10548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i401e199c245e45e2b3bc3d4d91130100_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktOS0xLTEtNTQ4NA_3d9f1943-263e-4357-a379-d820637364fe"
      unitRef="usd">312000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMTktMTEtMS0xLTU0ODQ_e0877848-1295-4ec3-8e42-8872a061ccab"
      unitRef="usd">54660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i38848fe39ff64851a1cbe4f24a730945_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMS0xLTEtNTQ4NA_d047eaf7-50e6-453d-8d7f-0988cd96a850"
      unitRef="shares">34170000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i38848fe39ff64851a1cbe4f24a730945_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMy0xLTEtNTQ4NA_1fa05ca9-dfc9-4abe-9dd4-459b36e6c49b"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i29b421bc868b4e08849cd49dfe789fd2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtNS0xLTEtNTQ4NA_752dff56-bc46-4309-96e9-1ef0245b35cd"
      unitRef="usd">56708000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9315b652eeb413db25d16425efd6de9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtNy0xLTEtNTQ4NA_e4a74675-8f33-44b2-90ff-d9b020e96967"
      unitRef="usd">14517000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ae1ce0523054de58fd6ba4b0d5d6563_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtOS0xLTEtNTQ4NA_4a154e9f-f850-435d-ad39-10617bac973e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjQtMTEtMS0xLTU0ODQ_8b424e02-134e-457f-8dcd-26535da20875"
      unitRef="usd">71259000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i0ad44ab908404be1b219b693527268fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjUtOS0xLTEtNTQ4NA_a508054d-9b83-4113-8a4a-f80f57beb258"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjUtMTEtMS0xLTU0ODQ_23691de8-be23-4ae9-ac56-5ad37a558f86"
      unitRef="usd">148000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ie01729704401438f9953c87c6f6cd951_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtMS0xLTEtNTQ4NA_9a3b60f6-48d7-4557-8108-da3e2abb0e25"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtNS0xLTEtNTQ4NA_df3c5361-baa1-4e93-bc7b-5766e3d533c8"
      unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjYtMTEtMS0xLTU0ODQ_e9acd83e-1132-4da5-ba4d-3ef0bb3ea16d"
      unitRef="usd">97000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0d4d8026de3d40aba1c0c49598c99a4e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjctNS0xLTEtNTQ4NA_267fe93c-6b6c-4cdb-8c50-f1d65bd3c1be"
      unitRef="usd">3209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjctMTEtMS0xLTU0ODQ_737b8aed-3d41-4dd8-afa4-2f2c8a247477"
      unitRef="usd">3209000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ie01729704401438f9953c87c6f6cd951_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMjgtMS0xLTEtNTQ4NA_b72bd83f-635e-4722-8ab4-5bb11aed7bf6"
      unitRef="shares">33000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i73a176064ef443598ec51cc2bb38bc3f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtNy0xLTEtNTQ4NA_741b3361-84bb-4d8b-ab2e-de79a05a1f42"
      unitRef="usd">-10369000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i0ad44ab908404be1b219b693527268fd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtOS0xLTEtNTQ4NA_cc6e5205-ee21-46c2-8067-4b4a81e56e74"
      unitRef="usd">-6000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzAtMTEtMS0xLTU0ODQ_d3270c09-6c69-4cc0-ba5b-2855b51514c6"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMS0xLTEtNTQ4NA_314cf343-f05b-49c8-8616-86f2a3010a26"
      unitRef="shares">34223000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i36ea82098391493bbc6bac5c3a7cd8ac_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMy0xLTEtNTQ4NA_0f7dd9fb-6e87-4b3e-a624-ba686f0b96b1"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb31e9500ecb42efb36391b9387777c7_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtNS0xLTEtNTQ4NA_4b028db3-a78c-4583-a7a2-96d776457a2a"
      unitRef="usd">60014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaa87bf5c88a04c54ade87dc49e2accf4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtNy0xLTEtNTQ4NA_47a3e8bb-ebb7-41c8-8a69-b3b51559f87d"
      unitRef="usd">4148000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic7d4ef659eb7431bbcfe190050698da3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtOS0xLTEtNTQ4NA_d25b6556-3260-49ea-a15f-5dcbee363d20"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzEtMTEtMS0xLTU0ODQ_27628af9-dee6-4786-a71a-b745233aef04"
      unitRef="usd">64338000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="i5479fed4aae147488d8d0627f13aaecc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMS0xLTEtNTQ4NA_1adcfb00-ab20-43a9-afa5-52ab8949ff15"
      unitRef="shares">34289000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5479fed4aae147488d8d0627f13aaecc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMy0xLTEtNTQ4NA_48754169-6862-4e5f-a2de-5a8822b865b7"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i69c89473017f4de187b5214a631371df_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtNS0xLTEtNTQ4NA_72907c8f-a116-4afb-b6f7-00652faa20f5"
      unitRef="usd">61066000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id8c8bf58148c4c71bb4b113ba65e0d64_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtNy0xLTEtNTQ4NA_494cbe9b-ad79-40bd-8557-0861183c3ece"
      unitRef="usd">2621000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie14d7e777681449e8cbe2e5ae99cf56f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtOS0xLTEtNTQ4NA_e3d13fab-0f19-47d2-abf3-0a7ca39f4f68"
      unitRef="usd">138000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzMtMTEtMS0xLTU0ODQ_133c8529-05c7-453b-82d2-d948811cb5c3"
      unitRef="usd">63859000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzQtOS0xLTEtNTQ4NA_fc7671d9-26a2-4c51-acea-e1ead95f3ac4"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzQtMTEtMS0xLTU0ODQ_51ca9c50-ce09-4bf8-8048-5bab978dddca"
      unitRef="usd">195000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtMS0xLTEtNTQ4NA_707c3c1f-8551-4f6e-bf06-aeef2d92d914"
      unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idffa3da465324394823951b3715cae7c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtNS0xLTEtNTQ4NA_548d369f-f833-41ee-b6f8-3b6e1fb719f2"
      unitRef="usd">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzUtMTEtMS0xLTU0ODQ_21cf0418-148c-40a4-9c2a-ee7d09a135bc"
      unitRef="usd">49000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idffa3da465324394823951b3715cae7c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzYtNS0xLTEtNTQ4NA_87ac5415-ce0a-4761-99f5-482101205987"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzYtMTEtMS0xLTU0ODQ_361653c8-e932-4255-808b-8beafa534d1d"
      unitRef="usd">3747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <apyx:StockSwapToAcquireOptionsShares
      contextRef="ib4e6e02bb8a148d98771b63f5f7f298a_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzctMS0xLTEtNTQ4NA_6aeabb62-7da6-40a8-8cf2-66abe5e99171"
      unitRef="shares">40000</apyx:StockSwapToAcquireOptionsShares>
    <us-gaap:ProfitLoss
      contextRef="i2fc895348acb46d3a770cfb612e019f6_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktNy0xLTEtNTQ4NA_75b2c900-2d3f-4282-841d-28529a4ff409"
      unitRef="usd">-13169000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="id1e796cdcef144d4bb973c2f4aa1815e_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktOS0xLTEtNTQ4NA_64cedcd7-acbe-4ce7-b5be-590ade8d18d8"
      unitRef="usd">-21000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfMzktMTEtMS0xLTU0ODQ_6f425911-5d83-4c24-bcb7-7698243dc6a2"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:SharesIssued
      contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMS0xLTEtNTQ4NA_1c92e48c-15d1-465e-9f58-101ce137d30c"
      unitRef="shares">34340000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3da259ec02054f349636d5e80c3147bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMy0xLTEtNTQ4NA_ca89bb03-6afd-4ff8-9daf-68a93f24f0a5"
      unitRef="usd">34000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i148f935a59024792a748fb1d4f38671f_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtNS0xLTEtNTQ4NA_bf5f43f5-f5ba-4273-952b-7f5f1166d511"
      unitRef="usd">64862000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2f70eafe2be446e695a8ccd7a1f65471_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtNy0xLTEtNTQ4NA_8e23dd9d-7e64-4b9e-ab71-3f97495ce4a2"
      unitRef="usd">-10548000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i401e199c245e45e2b3bc3d4d91130100_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtOS0xLTEtNTQ4NA_68c8d186-6916-4e2c-b254-a913f1d3a454"
      unitRef="usd">312000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yMi9mcmFnOmQxNmY0ZTI2OGZlMzQ1NDQ4YmNjNmEwOTNlMGQ0NGYzL3RhYmxlOmNmOWMxZTQyNmUxMDQ5NGNiZjcwM2ExOTgwNTM2ZjZiL3RhYmxlcmFuZ2U6Y2Y5YzFlNDI2ZTEwNDk0Y2JmNzAzYTE5ODA1MzZmNmJfNDAtMTEtMS0xLTU0ODQ_48480139-b0b2-4184-9d2a-0ca2bfb884b4"
      unitRef="usd">54660000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMy0xLTEtMS01NDg0_0b25e39b-cb74-40c3-9aeb-0e4fdede0cb8"
      unitRef="usd">-13190000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMy0zLTEtMS01NDg0_d83e044f-6cf6-48db-8ff4-17af3eb16fd9"
      unitRef="usd">-10375000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNS0xLTEtMS01NDg0_b58074a6-db2d-44f7-9b83-260144c3fb0d"
      unitRef="usd">674000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNS0zLTEtMS01NDg0_af646188-3dca-4296-bf55-d452d0f4a60c"
      unitRef="usd">662000</us-gaap:DepreciationDepletionAndAmortization>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNi0xLTEtMS01NDg0_cce36409-0487-4b49-89c0-49afcead5a69"
      unitRef="usd">15000</apyx:ProvisionForInventoryObsolescence>
    <apyx:ProvisionForInventoryObsolescence
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfNi0zLTEtMS01NDg0_b8ee5729-e0ca-44a1-b676-f0335de80bf8"
      unitRef="usd">427000</apyx:ProvisionForInventoryObsolescence>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOC0xLTEtMS01NDg0_fde8f332-01e6-4ba5-84b5-3b114f360207"
      unitRef="usd">-47000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOC0zLTEtMS01NDg0_dec9698d-cc6d-47d0-b1ed-e3b2f0a94ea8"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOS0xLTEtMS01NDg0_80776ccb-e1d3-4ebb-9655-883fe555ecf5"
      unitRef="usd">3747000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfOS0zLTEtMS01NDg0_e9519785-e8f1-4727-9a3c-df7aeb14369b"
      unitRef="usd">3209000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTAtMS0xLTEtNTQ4NA_5337b637-1435-4c4b-8c48-b28edea21fd8"
      unitRef="usd">57000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTAtMy0xLTEtNTQ4NA_3cb31d19-be58-46d3-b280-7412b46010fc"
      unitRef="usd">486000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTMtMS0xLTEtNTQ4NA_9ce75c95-47bf-4185-8fe8-20a4213e7428"
      unitRef="usd">3168000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTMtMy0xLTEtNTQ4NA_1e11949a-8775-45b5-b684-adc20b3b8bd7"
      unitRef="usd">-1389000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTQtMS0xLTEtNTQ4NA_2e138725-b46f-4aa0-aed2-903e731b36b2"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTQtMy0xLTEtNTQ4NA_5596bb2c-0f70-47ab-b3fa-b9571b65bbf2"
      unitRef="usd">981000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTUtMS0xLTEtNTQ4NA_3d5deb91-c1c6-4fad-bcbf-a34df2c26949"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInIncomeTaxesReceivable
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTUtMy0xLTEtNTQ4NA_e43efaa5-b117-458a-810a-9768a2ded7fc"
      unitRef="usd">6812000</us-gaap:IncreaseDecreaseInIncomeTaxesReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTYtMS0xLTEtNTQ4NA_cf93c8ec-cfd4-4548-a8ce-257429db1a86"
      unitRef="usd">1982000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTYtMy0xLTEtNTQ4NA_86a3531d-8947-46e8-a376-1f63827e6a05"
      unitRef="usd">717000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTctMS0xLTEtNTQ4NA_730d3463-081a-44ab-853f-cffa2cdff8f2"
      unitRef="usd">1555000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTctMy0xLTEtNTQ4NA_1633d8b5-cb01-47b2-b41e-651e7b622850"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTgtMS0xLTEtNTQ4NA_e4ff242c-dc87-4ea0-a5d1-e4745c013596"
      unitRef="usd">1605000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTgtMy0xLTEtNTQ4NA_fab32f46-3fcc-4db0-883f-7f3229258cb8"
      unitRef="usd">-2352000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTktMS0xLTEtNTQ4NA_a360cea3-cb06-4e40-b49d-e75f0874ac73"
      unitRef="usd">-10663000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMTktMy0xLTEtNTQ4NA_0e587a6f-945e-4aae-8f45-a45d703c3242"
      unitRef="usd">-15049000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjEtMS0xLTEtNTQ4NA_7e000ef2-3a14-41db-84ad-ba82358329e1"
      unitRef="usd">391000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjEtMy0xLTEtNTQ4NA_7e17546b-7b43-4501-9227-783b355e1274"
      unitRef="usd">193000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjQtMS0xLTEtNTQ4NA_1be14777-057a-42db-b395-fb9975944d10"
      unitRef="usd">-391000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjQtMy0xLTEtNTQ4NA_eb695208-b22d-4946-bd2c-0969cf52ad85"
      unitRef="usd">-193000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjYtMS0xLTEtNTQ4NA_a473682d-7431-4471-a756-9ec3707d0c1e"
      unitRef="usd">49000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjYtMy0xLTEtNTQ4NA_96aa2bc6-99d4-4ab2-8328-40193432d032"
      unitRef="usd">97000</apyx:ProceedsFromStockOptionsExercisedAndWarrantsExercised>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjgtMS0xLTEtNTQ4NA_03d86e29-08d7-4fca-9a9b-0c72b814f9d9"
      unitRef="usd">181000</apyx:RepaymentofFinanceLeaseLiabilities>
    <apyx:RepaymentofFinanceLeaseLiabilities
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjgtMy0xLTEtNTQ4NA_61f24434-a6ee-490d-9677-3221f6917081"
      unitRef="usd">184000</apyx:RepaymentofFinanceLeaseLiabilities>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjktMS0xLTEtNTQ4NA_5c81dae3-2e00-4d13-961f-21a10cc22f0a"
      unitRef="usd">195000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:ProceedsFromMinorityShareholders
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMjktMy0xLTEtNTQ4NA_82f435d4-f2ae-4e2b-a36a-fdab73d35d4a"
      unitRef="usd">148000</us-gaap:ProceedsFromMinorityShareholders>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzAtMS0xLTEtNTQ4NA_06a2091e-df27-422c-b344-432a282d9ba3"
      unitRef="usd">63000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzAtMy0xLTEtNTQ4NA_16abaea3-5657-4ff3-b584-6fd514a93c0c"
      unitRef="usd">61000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzEtMS0xLTEtNTQ4NA_5315f991-9611-420d-bd16-04cd0edd3567"
      unitRef="usd">-26000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzEtMy0xLTEtNTQ4NA_7e170a82-5e81-4539-85f0-3439c9bb71a1"
      unitRef="usd">-92000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzItMS0xLTEtNTQ4NA_d4ce44e9-8caf-48cd-9666-32292fc3924e"
      unitRef="usd">-11017000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzItMy0xLTEtNTQ4NA_98961b7d-8b37-42f0-a089-a7ec00483154"
      unitRef="usd">-15273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzMtMS0xLTEtNTQ4NA_242f802b-403c-4a69-9886-8827e53885da"
      unitRef="usd">41915000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzMtMy0xLTEtNTQ4NA_8f2c6ba0-db3b-4123-8933-45530c69dd6c"
      unitRef="usd">58812000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzQtMS0xLTEtNTQ4NA_afa6d932-32b8-4eff-807e-6869c2717c99"
      unitRef="usd">30898000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0ff89a354600483cb01afeea6bec3ba9_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzQtMy0xLTEtNTQ4NA_950b00bc-cc74-4bed-b254-4ec7133f1c74"
      unitRef="usd">43539000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzctMS0xLTEtNTQ4NA_700610f9-dbd1-40b2-ba51-797c1cb0eeae"
      unitRef="usd">8000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzctMy0xLTEtNTQ4NA_b759065a-3c95-44d9-9883-0779bd217b5e"
      unitRef="usd">39000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzgtMS0xLTEtNTQ4NA_c03a8fad-e023-4005-8661-5ef08c7b8940"
      unitRef="usd">13000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8yNS9mcmFnOjljNDhiZjY4MjU5ZDQ0NzU5NzNkNTRhMDg1YWE5NGJkL3RhYmxlOjBmODM4ZWFjZWE2OTQ0ZjFiNzU0YzUzYzNiNTVkYjEzL3RhYmxlcmFuZ2U6MGY4MzhlYWNlYTY5NDRmMWI3NTRjNTNjM2I1NWRiMTNfMzgtMy0xLTEtNTQ4NA_567712df-5c71-4a36-8568-b8e33e6ca075"
      unitRef="usd">54000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zMS9mcmFnOmIxOTM3OTVmZjZhMDQ5YWRhOGYxMDc4NTllOWQ0YmQwL3RleHRyZWdpb246YjE5Mzc5NWZmNmEwNDlhZGE4ZjEwNzg1OWU5ZDRiZDBfMjg5NQ_7d53ae78-9609-4e68-9693-2488d855712e">BASIS OF PRESENTATION&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pyx Medical Corporation (&#x201c;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an advanced energy technology company with a passion for elevating people&#x2019;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#xae; in the cosmetic surgery market and J-Plasma&#xae; in the hospital surgical market. Renuvion&#xae; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#xae; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic and its impact on the level of economic activity around the world including ongoing supply chain disruptions. The extent of the impact of the pandemic on the Company's business is highly uncertain and difficult to predict, as the responses and information related to it continue to change.  As elective surgery cases using the Company&#x2019;s Helium Plasma Technology have started to increase again, it is unknown whether these trends will continue.  The full extent to which the COVID-19 pandemic may materially and adversely impact the Company&#x2019;s future financial position, liquidity, or results of operations remains uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zMS9mcmFnOmIxOTM3OTVmZjZhMDQ5YWRhOGYxMDc4NTllOWQ0YmQwL3RleHRyZWdpb246YjE5Mzc5NWZmNmEwNDlhZGE4ZjEwNzg1OWU5ZDRiZDBfMjg5NA_1cc08d4e-8255-4766-aeac-5fd730727611">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNC9mcmFnOmNkN2VlOTc5ZWFhYTRkNzI4OTllODdhNjcyNDg3M2Y5L3RleHRyZWdpb246Y2Q3ZWU5NzllYWFhNGQ3Mjg5OWU4N2E2NzI0ODczZjlfMTU2OA_99beec51-dd19-4125-bb88-d58305cc6d23">RECENT ACCOUNTING PRONOUNCEMENTS &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNC9mcmFnOmNkN2VlOTc5ZWFhYTRkNzI4OTllODdhNjcyNDg3M2Y5L3RleHRyZWdpb246Y2Q3ZWU5NzllYWFhNGQ3Mjg5OWU4N2E2NzI0ODczZjlfMTU2Mw_62091a07-1cf7-481d-afe9-cce0bcdd6d6e">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY3MQ_08353bc6-712d-49b3-9f1b-6fd29ceadf06">DISPOSAL OF BUSINESS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#x201c;Symmetry&#x201d;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#xae; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core pro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ducts and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). Core activity for the three months ended September&#160;30, 2021, amounted to $1.6&#160;million with cost of sales equivalents of $1.3&#160;million and other related expenses of $0.5&#160;million for net other loss of $0.3&#160;million. Core activity for the three months ended September&#160;30, 2020, amounted to $1.8&#160;million with cost of sales equivalents of $1.6&#160;million and related other expenses of $0.3&#160;million for net other loss of $0.1&#160;million. Core activity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounted to $5.2&#160;million with cost of sales equivalents of $4.4&#160;million and other related expenses of $1.1&#160;million&#160;for net other loss of $0.3&#160;million. Core activity for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2020&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amounted to $6.9&#160;million with cost of sales equivalents of $6.1&#160;million and net other related operating expenses of $0.5&#160;million for net other income of $0.3&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfNTAy_c7d41889-233c-4567-aaed-0547550d0053"
      unitRef="usd">97000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <apyx:AssetPurchaseAgreementTerm
      contextRef="i2ac1cefbb0fa4631b29d06f046c1d8a3_D20180830-20180830"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY3Mg_831c6abc-1e73-4c9e-aac2-2d17cc8b6738">P4Y</apyx:AssetPurchaseAgreementTerm>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTAzMA_de63c596-7a62-479a-a52f-252b54fc9c31"
      unitRef="usd">1600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA2Nw_907dba19-df3d-40ed-b88a-01b923515926"
      unitRef="usd">1300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTEwMA_37373e13-d4f3-42ad-8961-e2af68872f2e"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i9f9a8b46e6a748d19eb7b3876b6732e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTEyNw_1e62223d-3398-42b2-b283-08eb65f1e749"
      unitRef="usd">-300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTE5OQ_4c77c2d1-8a69-43c2-b217-06a68508f8c2"
      unitRef="usd">1800000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTIzNg_a10d8c9e-7b90-49c4-81f8-675706cbdd69"
      unitRef="usd">1600000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTI2OQ_54351d07-6e30-4241-8a1f-265723d95602"
      unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i4aa6006334a64ba98deab070fa192566_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA5OTUxMTYyOTU5MA_85deef5b-6071-4f0f-8f1b-af4de7cad9a5"
      unitRef="usd">-100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTM3Nw_0917c23c-d118-4393-8aad-1c29b1841860"
      unitRef="usd">5200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTQxNA_d76efefe-46ca-4080-ab2e-90a0ad36ea77"
      unitRef="usd">4400000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTQ0Nw_c6284439-9753-47eb-afb5-cb636ac1dbdd"
      unitRef="usd">1100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="id963e4ae7ea84f7badac0cc78ffae71c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTA5OTUxMTYyOTYzMA_177560e7-af29-4fe2-ae7c-82414618db35"
      unitRef="usd">-300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTU1NQ_5a5b0c68-e834-474c-bfa1-7cf961ca6c7f"
      unitRef="usd">6900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTU5Mg_f564987a-b4e2-4a16-9287-f166df9a6b54"
      unitRef="usd">6100000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTYzOQ_d6a66b88-0e8e-4d06-b253-8d9f299a2458"
      unitRef="usd">500000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss
      contextRef="i156f6f916a654c5884ddd89619f5f1ca_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV8zNy9mcmFnOjQ3MDI4MjYzMThiNjQ5OGRiNzAyM2FmMGI2MDA2OTc5L3RleHRyZWdpb246NDcwMjgyNjMxOGI2NDk4ZGI3MDIzYWYwYjYwMDY5NzlfMTY2Ng_a063826c-5e26-4cfe-969d-b15a6f462970"
      unitRef="usd">300000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfMzk5_11c927c4-5167-4a65-897e-af625326b982">INVENTORIES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfNDA4_d6c80e1d-24a4-4bac-9d88-ebb7c6f6bcb5">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RleHRyZWdpb246NjAxMThiYzIyNzIxNDg4Y2I3ZjIzNTlkMGIxODFlY2RfMzk3_3858e143-75b1-403f-b0df-2908579094e5">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: provision for obsolescence&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(303)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMS0xLTEtMS01NDg0_97ebe29d-1de6-4621-b6a5-091c2dfc8352"
      unitRef="usd">3505000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMS0zLTEtMS01NDg0_bacd983f-0f60-42ee-b5b5-dd1d5ed97ed7"
      unitRef="usd">2243000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMi0xLTEtMS01NDg0_b13fda27-995d-471b-899d-687e3c4bb8e9"
      unitRef="usd">1284000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMi0zLTEtMS01NDg0_2fa8f41e-fa36-4843-9a6d-68a3b8bb42ea"
      unitRef="usd">1109000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMy0xLTEtMS01NDg0_9a5254e9-67f3-49c5-ad81-5f7e83ee9403"
      unitRef="usd">1554000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfMy0zLTEtMS01NDg0_ef7a71cb-73e6-453b-a7dd-d07064a76edb"
      unitRef="usd">1087000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNC0xLTEtMS01NDg0_6ad31389-7fab-45da-b022-68bed21bde72"
      unitRef="usd">6343000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNC0zLTEtMS01NDg0_14cae2a4-e846-4f51-8613-6a1c77b544d4"
      unitRef="usd">4439000</us-gaap:InventoryGross>
    <us-gaap:InventoryValuationReserves
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNS0xLTEtMS01NDg0_a90e632a-d405-41d0-9e61-e899ca5eb6fb"
      unitRef="usd">303000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryValuationReserves
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNS0zLTEtMS01NDg0_ed553118-bd3b-4085-a66f-4191d7e68844"
      unitRef="usd">388000</us-gaap:InventoryValuationReserves>
    <us-gaap:InventoryNet
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNi0xLTEtMS01NDg0_d8a061ae-eb60-4373-9581-4bc0b3eb07a6"
      unitRef="usd">6040000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80MC9mcmFnOjYwMTE4YmMyMjcyMTQ4OGNiN2YyMzU5ZDBiMTgxZWNkL3RhYmxlOjAxMDE2ODc4MzEwODRhMzQ4MDljMDZlYTM5ZDlmMzM5L3RhYmxlcmFuZ2U6MDEwMTY4NzgzMTA4NGEzNDgwOWMwNmVhMzlkOWYzMzlfNi0zLTEtMS01NDg0_7367b18b-531b-434e-85c8-4732fc89d755"
      unitRef="usd">4051000</us-gaap:InventoryNet>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RleHRyZWdpb246ZWE2ZmIxNzcyYTVlNGMxZjllMTgyMTM2MWVmZTUwY2JfMTQ3_95da1a5a-5e16-4641-94bc-5ac05273ec4c">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RleHRyZWdpb246ZWE2ZmIxNzcyYTVlNGMxZjllMTgyMTM2MWVmZTUwY2JfMTQy_2582ed71-eb8d-441d-b434-397e0899b3c7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses and other current liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued payroll&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued bonuses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,559&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued commissions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product warranties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued product liability claim insurance deductibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Joint and several payroll liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Uncertain tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses and current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMS0xLTEtMS01NDg0_383d32c7-8a53-45f6-b056-3bddd8351db0"
      unitRef="usd">894000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMS0zLTEtMS01NDg0_36b62841-a847-4b70-99c9-3d0c085ae1f8"
      unitRef="usd">808000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMi0xLTEtMS01NDg0_f646df35-6ab6-437e-99cd-5c9e64d11962"
      unitRef="usd">1559000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMi0zLTEtMS01NDg0_cd5226c1-2689-4db3-b071-0bcd07c4bce3"
      unitRef="usd">811000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMy0xLTEtMS01NDg0_02aa6f17-d1ee-4fb2-a036-e050132e1fea"
      unitRef="usd">897000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:AccruedSalesCommissionCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMy0zLTEtMS01NDg0_8de519a1-8900-4285-ad20-77e7449f72d8"
      unitRef="usd">1001000</us-gaap:AccruedSalesCommissionCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNC0xLTEtMS01NDg0_e5140161-ad77-4f21-92da-1169a29e078c"
      unitRef="usd">547000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:ProductWarrantyAccrualClassifiedCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNC0zLTEtMS01NDg0_f8d3854b-4b87-4657-8b30-0e1cc5e09beb"
      unitRef="usd">498000</us-gaap:ProductWarrantyAccrualClassifiedCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNS0xLTEtMS01NDg0_9d1538f2-10ef-482e-a260-9369cc6c6ab8"
      unitRef="usd">440000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedInsuranceCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNS0zLTEtMS01NDg0_cab73c3e-40a0-474b-836d-574860e098b3"
      unitRef="usd">435000</us-gaap:AccruedInsuranceCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNi0xLTEtMS01NDg0_00e0480e-9de1-40de-8c1b-baad1def6eeb"
      unitRef="usd">252000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNi0zLTEtMS01NDg0_be826ecf-900c-410d-a096-12e8b12ad920"
      unitRef="usd">222000</us-gaap:AccruedProfessionalFeesCurrent>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNy0xLTEtMS01NDg0_53e69095-138d-40ee-bf9d-c0e332ef9d5b"
      unitRef="usd">1027000</apyx:JointAndSeveralPayrollLiability>
    <apyx:JointAndSeveralPayrollLiability
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfNy0zLTEtMS01NDg0_7a2ef9ba-43c1-4226-84a0-2a1c2d0e2a8e"
      unitRef="usd">1027000</apyx:JointAndSeveralPayrollLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOC0xLTEtMS01NDg0_0725d688-7ad9-4b4c-926a-b901e56c2b44"
      unitRef="usd">1810000</apyx:UncertainTaxPositionsLiability>
    <apyx:UncertainTaxPositionsLiability
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOC0zLTEtMS01NDg0_fedd349c-49c4-4a12-a65b-729976db9799"
      unitRef="usd">1658000</apyx:UncertainTaxPositionsLiability>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOS0xLTEtMS01NDg0_7f01c40a-0420-4d34-b99c-e3e795156ee2"
      unitRef="usd">243000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfOS0zLTEtMS01NDg0_38596adc-6255-4ef5-b9a1-095bed236c27"
      unitRef="usd">591000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTAtMS0xLTEtNTQ4NA_f4894f58-3599-4bfc-924b-534f807e09b1"
      unitRef="usd">655000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:OtherAccruedExpensesAndLiabilitiesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTAtMy0xLTEtNTQ4NA_4577b095-a138-48e0-aa72-cf2568ab9eb5"
      unitRef="usd">227000</apyx:OtherAccruedExpensesAndLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTEtMS0xLTEtNTQ4NA_e5e7fc28-6779-46fa-9403-6d03eed0d86d"
      unitRef="usd">8324000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80My9mcmFnOmVhNmZiMTc3MmE1ZTRjMWY5ZTE4MjEzNjFlZmU1MGNiL3RhYmxlOjU0ZThkODBlZDRmMDRiMDM5ZWVhZTMzMTM1ZjhjNmQzL3RhYmxlcmFuZ2U6NTRlOGQ4MGVkNGYwNGIwMzllZWFlMzMxMzVmOGM2ZDNfMTEtMy0xLTEtNTQ4NA_08ef76d5-3478-4a29-8d82-9a548d18e923"
      unitRef="usd">7278000</apyx:AccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:MinorityInterestDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfNjQ3_dd0809b4-427d-4a22-a05a-af3ce19da021">CHINA JOINT VENTURE&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV") whereby the Company has a 51% interest in the China JV. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the three months ended June 30, 2021 and the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's investment in the China JV were as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:MinorityInterestDisclosureTextBlock>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i92566696a8e842be9629c3e2d9e89188_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMTU2_9faf4b8d-cb05-455f-aa51-52cb2c8729cb"
      unitRef="number">0.51</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <apyx:NoncontrollingInterestRequiredCapitalContribution
      contextRef="i33c8cceba9d44f1b81b235e990ff326a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMjk2_9a59da5b-6981-4966-a249-267a38b9d2e3"
      unitRef="usd">357000</apyx:NoncontrollingInterestRequiredCapitalContribution>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i217ab7fc63be424d813ed59e43cfbac4_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMzIz_603f58d4-e5bb-411f-aa86-ab6bf134e8a6"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfMzMw_4b7075f6-e828-41f3-900d-ff2705ee8b2d"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <apyx:NoncontrollingInterestTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RleHRyZWdpb246ZGM4MGFjYjJiOGFlNGQ0OTkwOTFmZTE1MTQ5M2EwZDlfNjQ4_7f263798-59b5-4aae-9a1f-bbb3afe87714">Changes in the Company's investment in the China JV were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contributions &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Apyx&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending interest in China JV&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</apyx:NoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="iacceeec5e6124e9bbe558a3cf8f40e58_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi0xLTEtMS01NDg0_8d782a8c-70ba-4a7f-8f58-27ed190b24b2"
      unitRef="usd">338000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idc6f0ef7bcae45cd8999ef7fb8dcb6e6_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi00LTEtMS02NDkz_7e0e19e4-8627-4241-9197-39aece6f5b70"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="idcd8e5c679d74d2ea0ab1f9c045914f9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi01LTEtMS01NDg0_0624072c-7bc0-4882-bf34-3c4a7631aeb3"
      unitRef="usd">144000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ie99d69e989dd4e2d9a91ac92c9cf93ea_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMi04LTEtMS02NDk3_bbcca46b-33fe-425e-868a-4ec77e27a5b7"
      unitRef="usd">0</us-gaap:MinorityInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy0xLTEtMS01NDg0_54af9cbb-3a5f-48f0-b285-716ec1644521"
      unitRef="usd">0</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy00LTEtMS02NDkz_f4129c91-b871-42b2-b9cc-75c16c6b8abe"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="idec38858c0924aa1a1b042bab111733f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy01LTEtMS01NDg0_fff77c00-d79b-403a-b00c-24ed7ae228f5"
      unitRef="usd">203000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
      contextRef="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfMy04LTEtMS02NDk3_08230d35-25bd-4afb-9491-127b7840c781"
      unitRef="usd">154000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iad8e55cbc2774441a40799fa5a17849c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC0xLTEtMS01NDg0_8a460225-b099-492f-95d1-f373c91100c1"
      unitRef="usd">-13000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i68a8e1f19bf34065ac41caacbe7dc4f0_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC00LTEtMS02NDkz_2b420a73-6d9b-4c19-9921-fd4d0be1a61d"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="idec38858c0924aa1a1b042bab111733f_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC01LTEtMS01NDg0_ec60c56f-a0ed-4076-91d0-a40094fd135c"
      unitRef="usd">-22000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if7a1eb3e96274ae183266c07ee0658b6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNC04LTEtMS02NDk3_fd731a5e-4029-4e15-9e58-6149e32f1153"
      unitRef="usd">-6000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="if1441d9eeae7465492a27c8ba288bcfc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS0xLTEtMS01NDg0_523ae2fd-c3a1-4918-b495-912e6569af1a"
      unitRef="usd">325000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ia199374e753e4fc58c3d346ef47fee8c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS00LTEtMS02NDkz_b4d544a5-e4cb-47d4-aff7-e6d9a2742732"
      unitRef="usd">148000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="if1441d9eeae7465492a27c8ba288bcfc_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS01LTEtMS01NDg0_e59e04fe-b8ea-4c73-ae16-4b4e3b207263"
      unitRef="usd">325000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="ia199374e753e4fc58c3d346ef47fee8c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80Ni9mcmFnOmRjODBhY2IyYjhhZTRkNDk5MDkxZmUxNTE0OTNhMGQ5L3RhYmxlOmEyNGUwMmUyZGM5ODQyZDA5MjRlNjUzNTY4YTc3ODE2L3RhYmxlcmFuZ2U6YTI0ZTAyZTJkYzk4NDJkMDkyNGU2NTM1NjhhNzc4MTZfNS04LTEtMS02NDk3_3d5c2adf-40f1-42f1-b36d-885df3e76d55"
      unitRef="usd">148000</us-gaap:MinorityInterest>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RleHRyZWdpb246OGM0NzkyNTc0ODg3NDU3M2E4YzQzZDVjYjZmZTkwNDNfNTM4_69896d63-412d-4940-bbba-6b3ca7972596">EARNINGS (LOSS) PER SHARE &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings (loss) per share (&#x201c;basic EPS&#x201d;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#x201c;diluted EPS&#x201d;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RleHRyZWdpb246OGM0NzkyNTc0ODg3NDU3M2E4YzQzZDVjYjZmZTkwNDNfNTM2_821b2575-ce2f-4d96-92f7-7fa594a9cce4">The following table provides the computation of basic and diluted loss per share.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.393%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.728%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in thousands, except per share data)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss attributable to stockholders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,728)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,169)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,369)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding - basic and diluted&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss per share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.12)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.11)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.38)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.30)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive instruments excluded from diluted loss per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy0yLTEtMS01NDg0_1de252bc-9195-4a7f-91f4-10e74bfca509"
      unitRef="usd">-4222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy0yLTEtMS01NDg0_d356e3d7-1882-41b8-8855-c8384e5540a8"
      unitRef="usd">-4222000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy00LTEtMS01NDg0_13cca5cc-8cba-4fce-a8d6-a57c8ae8e769"
      unitRef="usd">-3728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy00LTEtMS01NDg0_b07da3cb-d42c-467d-afd8-508a68974327"
      unitRef="usd">-3728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy02LTEtMS01NDg0_6ec16d21-eb5d-4bbf-aa79-9d05e2aafe1f"
      unitRef="usd">-13169000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy02LTEtMS01NDg0_f3e9ee1a-9090-4594-9035-6f12687f0d01"
      unitRef="usd">-13169000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy04LTEtMS01NDg0_50d7ec66-549e-4f48-aa49-b00d967b0346"
      unitRef="usd">-10369000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMy04LTEtMS01NDg0_c49eeb31-e874-4ba8-8bf1-7e39527084e1"
      unitRef="usd">-10369000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi0yLTEtMS01NDg0_9e7e9cd1-65f2-4d51-9e4b-bcdb0463a340"
      unitRef="shares">34330000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi0yLTEtMS01NDg0_e1d14705-9980-4f77-8961-81d1b6352f2a"
      unitRef="shares">34330000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi00LTEtMS01NDg0_325f865c-3a02-4eb4-b5d6-c627229603f5"
      unitRef="shares">34216000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi00LTEtMS01NDg0_b1ab0a57-6aa0-4b95-a27b-e105088b286d"
      unitRef="shares">34216000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi02LTEtMS01NDg0_09905f29-ae3f-43be-8e14-68667989d08a"
      unitRef="shares">34318000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi02LTEtMS01NDg0_630b4661-cf6b-48b6-bee3-7909ec3a83c5"
      unitRef="shares">34318000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi04LTEtMS01NDg0_524f3d0b-1eea-4612-88f4-43ffab1f20f5"
      unitRef="shares">34193000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfNi04LTEtMS01NDg0_b8ac59c4-ad97-4408-84ee-548e76febafa"
      unitRef="shares">34193000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS0yLTEtMS01NDg0_8239201d-ab32-4fc8-85bf-656fa8ad5f57"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS0yLTEtMS01NDg0_d2c5c77c-7821-41bd-b853-5b4320e38810"
      unitRef="usdPerShare">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS00LTEtMS01NDg0_59016d1f-9ea6-4d8a-ae35-8b937888d921"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS00LTEtMS01NDg0_aed3d481-9c5d-4434-9705-68311147a708"
      unitRef="usdPerShare">-0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS02LTEtMS01NDg0_7a869129-8901-4c54-af12-5db48cfb2811"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS02LTEtMS01NDg0_e3d46e99-a47a-4db9-90b8-c359a8e4a2c8"
      unitRef="usdPerShare">-0.38</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS04LTEtMS01NDg0_1317955c-fb1c-4b6f-83fc-7ac61f75a6b0"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfOS04LTEtMS01NDg0_28c07697-a8aa-400e-835d-d66d62b0b099"
      unitRef="usdPerShare">-0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie06daf7da08d42bd910e91a19e6f42f8_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItMi0xLTEtNTQ4NA_27677f65-6952-4253-b06c-fced8e460f29"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib577766e74e4437fa096335a9fac4637_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItNC0xLTEtNTQ4NA_e13dd887-187a-4d64-95ec-3f18dc198360"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82c871421e3b4f6d90a3c5b264aa99af_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItNi0xLTEtNTQ4NA_a44c10f8-752f-4563-8c65-9ea3bb325bdb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic941034edd2f42ed87948712260e3dfd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTItOC0xLTEtNTQ4NA_aa827c25-ed81-43b8-92eb-9c1f25086874"
      unitRef="shares">45000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i27c18ff4efe54c20b92677b523d29b9f_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtMi0xLTEtNTQ4NA_2e883f55-5f00-4ca2-be58-8c6b919febd6"
      unitRef="shares">5534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iff855cdb40594dde993ebab82bcd68fb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtNC0xLTEtNTQ4NA_bf5c8bc9-bab6-4627-9c14-9d1a8f7c3a59"
      unitRef="shares">5028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i477c509d866a43a2bfe6a5b2524881f1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtNi0xLTEtNTQ4NA_7678bba7-cf3b-4b22-9ccb-273369b6000e"
      unitRef="shares">5534000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6fe00d501071471994cd751b9c0b71e3_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV80OS9mcmFnOjhjNDc5MjU3NDg4NzQ1NzNhOGM0M2Q1Y2I2ZmU5MDQzL3RhYmxlOjdhMjE0ODlhODRlMDQ2YzdiMzQ5MjQ0NGRmMDRlMDlmL3RhYmxlcmFuZ2U6N2EyMTQ4OWE4NGUwNDZjN2IzNDkyNDQ0ZGYwNGUwOWZfMTMtOC0xLTEtNTQ4NA_3899a9eb-b3fe-4a48-86cf-6001b09c6b11"
      unitRef="shares">5028000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg0Ng_c859ef9c-63e4-4709-a7f7-3a3cb1e44e6e">STOCK-BASED COMPENSATION &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized approximately $1,184,000 and $3,747,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2021, as compared with $1,063,000 and $3,209,000, respectively, for the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2021 and 2020, respectively, we received 37,049 and 16,140 options as payment in the exercise of 13,285 and 10,610 options. For the nine months ended September 30, 2021 and 2020, respectively, we received 59,104 and 29,149 options as payment in the exercise of 39,312 and 32,637 options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg1MA_cc9b5483-8049-410d-b24a-75fc23049daa">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.&lt;/span&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNjUw_b354bf5e-7927-402c-a783-67d8b11cb0b2"
      unitRef="usd">1184000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNjU3_419c52b4-48eb-4a84-b464-0e6be97ef545"
      unitRef="usd">3747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNzgx_115b9d18-6f4d-4702-a99e-83ddfb6c7c66"
      unitRef="usd">1063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfNzg4_5c1e5827-0660-482b-acbb-1535f93696fa"
      unitRef="usd">3209000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg0Mg_771480db-480e-437a-9dab-d6b75be4ab91">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock option activity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,938,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;894,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled and forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(190,793)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNS0xLTEtMS01NDg0_e5a2738c-a983-41e3-8b88-bc4383ed1f92"
      unitRef="shares">4938943</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ifa26429c0b0840458a09f15ab78444da_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNS0zLTEtMS01NDg0_c3e2d9cc-d929-4daf-9316-2c93661dc3c6"
      unitRef="usdPerShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNi0xLTEtMS01NDg0_e4ddcf35-154a-4270-b662-e5b42c250861"
      unitRef="shares">894980</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNi0zLTEtMS01NDg0_d7cb6043-ea29-4186-a022-eb88d6f17c7e"
      unitRef="usdPerShare">9.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNy0xLTEtMS01NDg0_220ae90c-d9f8-4340-91e5-d2db12cfc1bb"
      unitRef="shares">109415</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfNy0zLTEtMS01NDg0_a4f8c140-2767-4439-80b8-7be5bfc686ab"
      unitRef="usdPerShare">6.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOC0xLTEtMS01NDg0_f273a704-1ab0-4cb6-bf70-941c7bd301ff"
      unitRef="shares">190793</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOC0zLTEtMS01NDg0_121348a2-63b9-4d04-bc11-ddc8021dd6f8"
      unitRef="usdPerShare">8.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOS0xLTEtMS01NDg0_959eee13-ae25-48d2-9d8c-067ef42ac8ab"
      unitRef="shares">5533715</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOmQ2MWY5YTJkMDQ1YjQyYTc5YWI4M2Q5YWVhYTRmYjQ5L3RhYmxlcmFuZ2U6ZDYxZjlhMmQwNDViNDJhNzlhYjgzZDlhZWFhNGZiNDlfOS0zLTEtMS01NDg0_b3872445-f117-4c88-aa1e-7fa8e878fcc3"
      unitRef="usdPerShare">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTMyMA_7f67ebd8-004c-4ecd-9ec7-ce44f1fe7c8f"
      unitRef="shares">37049</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ3NA_9f3fb7ec-7793-414e-a785-e19d496d6a9b"
      unitRef="shares">16140</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTM2OA_33e49b0d-1bec-44d9-8461-dc92b24b22e0"
      unitRef="shares">13285</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ2Ng_e97b5e92-192e-4492-84c6-b7a949a9164f"
      unitRef="shares">10610</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTQ2Mg_c6b486a3-9afe-40fb-bc1e-08b842701935"
      unitRef="shares">59104</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ1OA_8689fdf4-b090-46da-a360-b3f7dddb4938"
      unitRef="shares">29149</apyx:StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTUxMA_a11dae88-99ca-48e2-a616-87145e7096be"
      unitRef="shares">39312</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <apyx:StockIssuedDuringPeriodSharesStockSwaps
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfODI0NjMzNzIxMDQ1MA_a7145df0-0014-4411-9606-eb3cf1709cf6"
      unitRef="shares">32637</apyx:StockIssuedDuringPeriodSharesStockSwaps>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RleHRyZWdpb246YjFkNGYzMzJmN2U1NGFmN2I4NTU2MGY2YjY1NmU4NTdfMTg1Nw_5dd0b41a-8062-42d1-bf75-8c99074e1ff4">The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.650%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021 Grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Strike price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$9.29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.51&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68.9%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMS0xLTEtMS01NDg0_ab60fc97-39fa-43db-9f74-182e02088d99"
      unitRef="usdPerShare">9.29</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMS0zLTEtMS01NDg0_702322eb-faf0-4cb6-8135-0d0d40e5223e"
      unitRef="usdPerShare">11.51</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMi0xLTEtMS01NDg0_8ced24bc-3f8e-4a5a-a82f-bd91589769db"
      unitRef="number">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMi0zLTEtMS01NDg0_c7a20a56-7b5c-41c3-8d7d-7e238023cceb"
      unitRef="number">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfMy0xLTEtMS01NDg0_9816f335-0a73-45af-8f6b-f61012a392c1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNC0xLTEtMS01NDg0_f973d3fd-a407-4b94-8ec0-194cb90604b5"
      unitRef="number">0.689</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNC0zLTEtMS01NDg0_ba6455d6-1666-4bdd-95c3-c14eb16fe7d7"
      unitRef="number">0.708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iafb3a1fb6773443f8ac9f4b48a3582ef_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNS0xLTEtMS01NDg0_a603ad45-05e4-400f-b380-c3be9b4b69cf">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i8bc371f2a854428d9880b40b394ba02c_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81Mi9mcmFnOmIxZDRmMzMyZjdlNTRhZjdiODU1NjBmNmI2NTZlODU3L3RhYmxlOjEwODhkN2E1ZWJiNzRmNDdiZjQyY2VjYjc3NDQ3NWRjL3RhYmxlcmFuZ2U6MTA4OGQ3YTVlYmI3NGY0N2JmNDJjZWNiNzc0NDc1ZGNfNS0zLTEtMS01NDg0_afe0e713-8093-4098-89a3-6d4604503500">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMzAyMA_d52c88ad-1ed7-47b4-a11e-1865dbfc9591">INCOME TAXES On March 27, 2020, the U.S. government enacted the CARES Act to provide financial relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#x2019;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequently, the Company generated net losses in 2019 and 2020. For the net losses generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with its NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company recognized an income tax benefit of approximately $3.7 million associated with the release of the valuation allowance on its Federal NOL carryforward related to 2019. For the three and nine months ended September 30, 2020, the Company also recognized income tax benefits of approximately $0.7 million and $7.1 million, respectively, related to losses before income taxes.Income tax expense (benefit) was approximately $73,000 and $(715,000) with effective tax rates of (1.8)% and 16.1% for the three months ended September&#160;30, 2021 and 2020, respectively. Income tax expense (benefit) was approximately $246,000 and $(7,112,000) with effective tax rates of (1.9)% and 40.7% for the nine months ended September 30, 2021 and 2020, respectively. For the three and nine months ended September&#160;30, 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on the NOL carryforward from 2019. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September&#160;30, 2021. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2021, the Company had approximately $497,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense (benefit) for the three months ended September&#160;30, 2021 and 2020, respectively, are approximately $52,000 and $43,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense (benefit) for the nine months ended September 30, 2021 and 2020, respectively, are approximately $152,000 and $125,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,810,000 of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.</us-gaap:IncomeTaxDisclosureTextBlock>
    <apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards
      contextRef="i27f6f313d1dd482988fc432dda095837_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODY5_36e6fc84-79fa-46df-9992-6eb9d048eea5"
      unitRef="usd">-3700000</apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTA5MQ_fc0258ff-9287-422e-be72-f108942c6526"
      unitRef="usd">-700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTA5OA_a41a110c-6e7b-48dc-b3f5-0525d972bbb9"
      unitRef="usd">-7100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTIwMw_36482a5a-9605-451b-9a03-12fe81e67225"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTIxMA_66f97af2-28cf-47d0-9239-784140cf28ef"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTI0MQ_8f612e0d-52d8-4da5-a331-62abf48ffcae"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTI0OA_c53da2ca-926e-4e73-82df-ea29e1001725"
      unitRef="number">0.161</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTM2Mw_9633e0cb-2f91-4295-8165-761efaf6ef1a"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTM3MA_b65f32bb-b8fe-451d-b360-ddfe6ac31fd6"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTQwMQ_6724d2a8-cd65-405b-930e-1f11d971f50b"
      unitRef="number">-0.019</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTQwOA_b0aa58f2-5154-4f4d-9648-75a8c00b8f57"
      unitRef="number">0.407</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMTk4NA_3026f104-577d-43be-9aa6-a963866a04c3"
      unitRef="usd">1313000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODkyMQ_dba86349-6723-4a0e-aded-1736b99e9440"
      unitRef="usd">497000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODk0MQ_f7c28adc-d02a-4889-88cd-70a7096c123d"
      unitRef="usd">52000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfMjQzNA_9bd02200-d4a2-41bd-98fb-7e2f4e05147b"
      unitRef="usd">43000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfNjU5NzA2OTc3MzQzMQ_6421df88-d133-4d48-a073-07c979e29225"
      unitRef="usd">152000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODI0NjMzNzIxMzI5NQ_2dfdedcb-b34f-49f2-80bd-4b53d1e7cf11"
      unitRef="usd">125000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81NS9mcmFnOjM2ZTA3Y2U1ZGU3NjRhMDlhMDc1ZDA4MmY4MTFhYjNkL3RleHRyZWdpb246MzZlMDdjZTVkZTc2NGEwOWEwNzVkMDgyZjgxMWFiM2RfODc5NjA5MzAyODk1MA_02113f6f-1986-439a-bb64-0851d3097a0f"
      unitRef="usd">1810000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81OC9mcmFnOjQ5ZTRmMWFjNTExZDRlNGRhYThlZmQ4YmM0ZDg0NzA1L3RleHRyZWdpb246NDllNGYxYWM1MTFkNGU0ZGFhOGVmZDhiYzRkODQ3MDVfMjM4NA_24a6c87b-6b9a-4287-bfe6-d176a1ad38d5">COMMITMENTS AND CONTINGENCIES&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#x2019;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#x2019;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#x2019;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Purchase Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2021, the Company had purchase commitments totaling approximately $5.2&#160;million, substantially all of which is expected to be purchased within the next twelve months.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PurchaseObligation
      contextRef="i49aee00ecd564aaf8b7b1b4942930967_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV81OC9mcmFnOjQ5ZTRmMWFjNTExZDRlNGRhYThlZmQ4YmM0ZDg0NzA1L3RleHRyZWdpb246NDllNGYxYWM1MTFkNGU0ZGFhOGVmZDhiYzRkODQ3MDVfMjI5Ng_9fcabdbb-7a1e-4a38-be8b-66248421a624"
      unitRef="usd">5200000</us-gaap:PurchaseObligation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTE0_34fa5f29-dfaa-4bdb-8b1f-08ab16ef57aa">RELATED PARTY TRANSACTIONS&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Several relatives of Nikolay Shilev, Apyx Bulgaria&#x2019;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#x2019;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#x2019;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#x2019;s son, is a quality manager in the quality assurance department.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2021 and 2020, the Company made purchases from this supplier of approximately $456,000 and $410,000, respectively. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 2020, the Company made purchases from this supplier of approximately $1,102,000 and $1,250,000, respectively. At September&#160;30, 2021 and December&#160;31, 2020, respectively, the Company owed this supplier approximately $48,000 and $38,000.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="ic3b6022e971f4bba87288e373844658a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNjQy_e1014519-5e62-434b-a8d1-bcb65511dfcd"
      unitRef="usd">456000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="ida603cbbdd6941a4875a53a9b110041d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNjQ5_029e9ff8-1e3a-4280-a1f0-476386ece2c1"
      unitRef="usd">410000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="ieb26ef99753941d797c8d6e6df4e31de_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNzc5_99d75ec2-caf0-467b-b1cb-087888f1a98c"
      unitRef="usd">1102000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="i87b7ef7e804c45fb914663a18ee558d1_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfNzg2_b7adc6de-5671-4890-bd72-c00e3f05bbc9"
      unitRef="usd">1250000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i18ff578dfa0b48819e4f52ffe351100c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTAz_51ca889e-6dbf-446f-9cf9-8c372c3c255a"
      unitRef="usd">48000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="iff92c63086be4b03a94436089380d2dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82MS9mcmFnOjIyNGQwMWE5N2MzODQ2ZDhhMmQxYzJhNzY2NmU5Mjk2L3RleHRyZWdpb246MjI0ZDAxYTk3YzM4NDZkOGEyZDFjMmE3NjY2ZTkyOTZfOTEw_dcd5b871-e6b0-4d0d-af9b-7aac29c44bb4"
      unitRef="usd">38000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTc0MA_5f9fcfed-8524-4222-99d5-9d56028b1c74">GEOGRAPHIC AND SEGMENT INFORMATION &lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp;amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized financial information with respect to reportable segments is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International sales represented approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively, as compared with approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfODYy_36cce254-aced-4095-b24a-2e4c69ecdff4"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfODYy_37dce6ed-b97a-422f-8704-771ec3fbedd1"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTcyOA_763077e8-9c23-4780-91b3-9c2ceeabf826">Summarized financial information with respect to reportable segments is as follows:&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,968)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,095)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;556&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(715)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(224)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,120)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,756)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other loss, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.811%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.400%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Advanced Energy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OEM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &amp;amp; Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income (loss) from operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,046)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,030)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi0zLTEtMS01NDg0_35d72a99-7d05-4dc9-b2ca-e7507b5d4d28"
      unitRef="usd">10313000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi01LTEtMS01NDg0_ba9911ad-211c-47c7-8542-b8d62c589d7a"
      unitRef="usd">1518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi03LTEtMS01NDg0_8165f62e-c23d-4ddc-8b1c-db8051b42bed"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMi05LTEtMS01NDg0_5c07f96d-3038-4dd6-900d-380889d8f462"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtMy0xLTEtNTQ4NA_a1cdbcf3-ced5-4bcc-b8e8-4078cfd43cff"
      unitRef="usd">52000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtNS0xLTEtNTQ4NA_598b5804-7581-447a-8f78-22cfddde5290"
      unitRef="usd">328000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtNy0xLTEtNTQ4NA_8c728d95-b125-441c-9c21-ccebc5212286"
      unitRef="usd">-4348000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTQtOS0xLTEtNTQ4NA_c0f95fac-2c77-4a1f-9f70-63d3626f4ddb"
      unitRef="usd">-3968000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtMy0xLTEtNTQ4NA_ecb4b5ca-0c80-4ac9-a401-85acf411abca"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtNS0xLTEtNTQ4NA_422153b1-8519-43d3-8ffa-a1a280834e75"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtNy0xLTEtNTQ4NA_905a3b8b-8461-401a-9761-7559d25bbe82"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTYtOS0xLTEtNTQ4NA_15564f04-2d0b-49dc-bde0-9766a87824a7"
      unitRef="usd">2000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctMy0xLTEtNTQ4NA_09013afe-2c22-4c17-89ca-4b0e059568be"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctNS0xLTEtNTQ4NA_3fe4e83a-c6a3-415d-bfa1-4584c750dbfd"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctNy0xLTEtNTQ4NA_b087658f-6ec7-4442-8a21-4da4afde8ac1"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTctOS0xLTEtNTQ4NA_8d8288d8-74e8-4943-9353-478a5fa201ec"
      unitRef="usd">3000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtMy0xLTEtNTQ4NA_bb91ecb4-80f8-4129-99f5-a6d3bf703eb2"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtNS0xLTEtNTQ4NA_6ba9a97f-a684-4779-bd5f-dc42c7a13034"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtNy0xLTEtNTQ4NA_63d46a01-27f3-4ee9-b818-0ff632eee9ec"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMTgtOS0xLTEtNTQ4NA_87a0bf0c-9a9d-4ddd-b0d4-1d3a1067b283"
      unitRef="usd">-192000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItMy0xLTEtNTQ4NA_a261f8be-ffc7-40b4-8092-ed05c5916fe1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i45ca7ce173484a7a85856050c6af09f4_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItNS0xLTEtNTQ4NA_f9c9b680-af31-45e8-893a-b15d967704f9"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i00458d2cca964701b86152bebe9beb0c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItNy0xLTEtNTQ4NA_649fec62-d1c8-4ce2-9cad-fcf36006077d"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjM2NThhNzJjZThlYTQ5Zjg5OGIxZmJjYWRkYmFiM2RjL3RhYmxlcmFuZ2U6MzY1OGE3MmNlOGVhNDlmODk4YjFmYmNhZGRiYWIzZGNfMjItOS0xLTEtNTQ4NA_3ac90b9b-238f-4294-8394-c000c99a5a84"
      unitRef="usd">73000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi0zLTEtMS01NDg0_764b964b-d37f-4693-a963-369e460f7888"
      unitRef="usd">5479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi01LTEtMS01NDg0_57ad3cff-032f-472d-9779-637cca086521"
      unitRef="usd">1475000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi03LTEtMS01NDg0_632c46d6-f87e-4214-a814-ace4028d5ac9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMi05LTEtMS01NDg0_e45e73f0-03a4-4709-90f7-8e65dacbea97"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtMy0xLTEtNTQ4NA_8bcabc92-7866-4c00-8759-637f9a17aefa"
      unitRef="usd">-1095000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtNS0xLTEtNTQ4NA_0ade32b1-c800-47c4-b854-d8a663b3cd87"
      unitRef="usd">556000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtNy0xLTEtNTQ4NA_092c891f-523e-4299-8ce4-41b042b63298"
      unitRef="usd">-3832000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTQtOS0xLTEtNTQ4NA_40bbd337-56e6-4a0f-b77f-b8ca4e351392"
      unitRef="usd">-4371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtMy0xLTEtNTQ4NA_0b2ccbfc-406c-4f60-9afa-cae3c7af1bb4"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtNS0xLTEtNTQ4NA_5a408139-f985-443e-9e66-88444079794b"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtNy0xLTEtNTQ4NA_e01db2e8-7303-4784-8de0-a518c7edac85"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTYtOS0xLTEtNTQ4NA_091707b8-d022-409a-aa24-0886467c3a54"
      unitRef="usd">10000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtMy0xLTEtNTQ4NA_0fb8c4a7-7d40-4937-9ac2-94a4052435b7"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtNS0xLTEtNTQ4NA_883cb446-9fa8-4487-8391-2bbfcd611709"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtNy0xLTEtNTQ4NA_2dd4a57a-2d8c-43aa-b988-b55e8e84f119"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTgtOS0xLTEtNTQ4NA_06350199-f39d-4abe-9280-8a42f08f90fd"
      unitRef="usd">25000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktMy0xLTEtNTQ4NA_53cb52a8-e12f-4b31-abcf-c36b5db6bbb0"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktNS0xLTEtNTQ4NA_ba04bf99-1af7-4508-9647-545efc005ed5"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktNy0xLTEtNTQ4NA_0bbb9a79-b117-4a21-9b73-b184298c56f6"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMTktOS0xLTEtNTQ4NA_90eb59fc-aae2-4ed3-b5a4-d52551515091"
      unitRef="usd">-63000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icd587233451f4a38903c8c534991b8af_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtMy0xLTEtNTQ4NA_3ac151ac-9bcf-49ba-8598-574520306ea5"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia961ef21e77242f4ae24c0b737167740_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtNS0xLTEtNTQ4NA_b47a2108-59b2-4af2-9baa-8bc47415cec2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2324fa0bc5aa487e9b43189e38399b6e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtNy0xLTEtNTQ4NA_8e093025-5717-4c13-9214-67ac8c6e5725"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU2M2I5MDQyYzQ2YjRmMDc4Y2FiM2I3NzFlYzIxNzdlL3RhYmxlcmFuZ2U6NTYzYjkwNDJjNDZiNGYwNzhjYWIzYjc3MWVjMjE3N2VfMjMtOS0xLTEtNTQ4NA_24e10d2d-9478-47d8-b88b-c462f2ac0182"
      unitRef="usd">-715000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi0zLTEtMS01NDg0_c55995a9-2d2e-41f8-a904-44d206577071"
      unitRef="usd">27951000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi01LTEtMS01NDg0_61e9e55e-4dd4-4de8-96c3-9e596b55ea81"
      unitRef="usd">3742000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi03LTEtMS01NDg0_dc186cbb-a2e9-48bd-9f92-3304d39bf38a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMi05LTEtMS01NDg0_2e21bcab-7735-407b-888d-256ab9ed34ba"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtMy0xLTEtNTQ4NA_5c1e9547-8a8f-4cf5-a950-3fc2dbbcac93"
      unitRef="usd">-224000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtNS0xLTEtNTQ4NA_6582c21c-2b3c-4c1b-b471-18a34be55ace"
      unitRef="usd">588000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtNy0xLTEtNTQ4NA_d4efe301-5bd2-4ee1-96e7-c2f95a9c68bc"
      unitRef="usd">-13120000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTQtOS0xLTEtNTQ4NA_bcbff355-0c76-47ac-b275-538627ccd05d"
      unitRef="usd">-12756000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtMy0xLTEtNTQ4NA_047fd664-cb7b-4568-a11f-43b1e9f3c8c6"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtNS0xLTEtNTQ4NA_e7f49f0c-d495-45bb-86fc-c33021609b7e"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtNy0xLTEtNTQ4NA_44973f15-4f3a-4a88-9161-4819eef297ee"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTYtOS0xLTEtNTQ4NA_d612cf82-f032-41ab-afb9-89ab6c994cdc"
      unitRef="usd">9000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctMy0xLTEtNTQ4NA_f6c60fa5-de53-466d-9d31-6e8760b5a762"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctNS0xLTEtNTQ4NA_dbb8fa44-359b-4ed6-a77e-7c826c4ddf9e"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctNy0xLTEtNTQ4NA_c87d21ce-d73b-4106-bc48-4ee7900ea775"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTctOS0xLTEtNTQ4NA_7f1990fd-0c1f-49cf-ad83-858ca6b3754d"
      unitRef="usd">9000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtMy0xLTEtNTQ4NA_ddf429a4-a12d-4efa-be30-f1a8dac403d4"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtNS0xLTEtNTQ4NA_f73ee1ff-a764-4fc9-8e4d-952fba1b270c"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtNy0xLTEtNTQ4NA_b8074bed-dfd1-4f98-96d7-790fce3a31ad"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMTgtOS0xLTEtNTQ4NA_fcff5007-217e-4748-a6b0-30e91d6f6fd2"
      unitRef="usd">-188000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5de7dda029e94c8180212239a6d77859_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItMy0xLTEtNTQ4NA_dd95bd99-8dd5-4226-bf7c-9afc2b21094a"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia86dfd07a2484a5eaba379a8e453cb10_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItNS0xLTEtNTQ4NA_59f31491-4009-4070-85c7-bc552ea460ea"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibbc8dfcac5ba4f08962e254d8ae21ef0_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItNy0xLTEtNTQ4NA_e616d928-43d6-4926-a8d1-9c40c02a6217"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOmJiYzg0NmZjNmVjNTQyOWI4ZWU0OTM5OWU0ZmZkY2Y3L3RhYmxlcmFuZ2U6YmJjODQ2ZmM2ZWM1NDI5YjhlZTQ5Mzk5ZTRmZmRjZjdfMjItOS0xLTEtNTQ4NA_5b2089e7-ec13-4410-8683-30cfe42544a4"
      unitRef="usd">246000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi0zLTEtMS01NDg0_4db9d0b7-fb39-4cd7-9c31-71dca60acee7"
      unitRef="usd">12332000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi01LTEtMS01NDg0_3d4ee9c7-b1f1-43bb-88a4-9015c097fcec"
      unitRef="usd">3915000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi03LTEtMS01NDg0_0451437b-955f-4cc7-9be1-6c30d3da39d1"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMi05LTEtMS01NDg0_47c78c39-11b6-43fe-9f43-8c74fc8d160b"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtMy0xLTEtNTQ4NA_dbc69704-2d51-4592-936a-ce125277df3c"
      unitRef="usd">-8371000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtNS0xLTEtNTQ4NA_cb91e433-ee57-4175-8162-569e82746670"
      unitRef="usd">1387000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtNy0xLTEtNTQ4NA_0f479d39-66bf-4f43-9ca5-babd7e0cb05b"
      unitRef="usd">-11046000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTQtOS0xLTEtNTQ4NA_f07d53ea-e582-494c-af21-c0d4e427724a"
      unitRef="usd">-18030000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtMy0xLTEtNTQ4NA_4e65b3b7-e814-4547-901d-df0a4b399c37"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtNS0xLTEtNTQ4NA_eceae333-34e0-4380-ae43-cd4cf24b3b7c"
      unitRef="usd">0</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtNy0xLTEtNTQ4NA_2ed73b37-59d5-47fc-9acd-cc4e62d27cf1"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTYtOS0xLTEtNTQ4NA_8652d5d1-8712-4f8b-ad59-68dec5b15e47"
      unitRef="usd">233000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestExpense
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctMy0xLTEtNTQ4NA_83ef2173-2077-4e09-ac78-d3ced3e6bb0f"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctNS0xLTEtNTQ4NA_16963ffa-e5c9-490a-b258-b6a27a9ab115"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctNy0xLTEtNTQ4NA_19bac88c-0722-435b-b133-6db544387d58"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTctOS0xLTEtNTQ4NA_fbb3cce0-f8d2-4d51-8517-9f94b1a35e40"
      unitRef="usd">39000</us-gaap:InterestExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtMy0xLTEtNTQ4NA_272a7405-367a-42b4-990b-9027fe137d9e"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtNS0xLTEtNTQ4NA_48849324-2fb9-44ea-bbae-ea94aa6757b3"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtNy0xLTEtNTQ4NA_732b2d85-848d-421d-b4c5-736040b54bf1"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMTgtOS0xLTEtNTQ4NA_eb39e13e-d6ea-4914-a0df-377fc47a6689"
      unitRef="usd">349000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5429b958ddaf4fdb8bbcab9d2188f05a_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItMy0xLTEtNTQ4NA_d62a3549-ebe6-472c-a4b7-cde52ce00cd4"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i5223cc4480ae4649b5dd67cbc7ad21a0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItNS0xLTEtNTQ4NA_e06e6ae2-748b-4855-b3ce-d709769595de"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i56dccb35b8334ad8ab32d7158898e552_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItNy0xLTEtNTQ4NA_8fd6158e-dd79-4168-8859-046a07730e7b"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjU0NTY2MzA0NjExNTRkMDBhMzg0NjQxNDkzYTk5ZDU1L3RhYmxlcmFuZ2U6NTQ1NjYzMDQ2MTE1NGQwMGEzODQ2NDE0OTNhOTlkNTVfMjItOS0xLTEtNTQ4NA_e3b1ed34-332c-4a04-9852-95d05bdcd656"
      unitRef="usd">-7112000</us-gaap:IncomeTaxExpenseBenefit>
    <apyx:TotalRevenuePercent
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTQwNg_96463b09-b3e7-481c-84a9-6a857acaab13"
      unitRef="number">0.331</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTQxMw_1570c32e-7c7c-401d-a581-3341944fd191"
      unitRef="number">0.342</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTUyOQ_cec00171-0e45-4ad2-b770-07e94f2f24b2"
      unitRef="number">0.250</apyx:TotalRevenuePercent>
    <apyx:TotalRevenuePercent
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTUzNg_87aac80b-60b3-423e-9120-1a6464933c95"
      unitRef="number">0.248</apyx:TotalRevenuePercent>
    <us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RleHRyZWdpb246YTFiZjFmODY5NjQ1NDY2OWE2YmU4NzEzMjdkM2RmNGRfMTczOA_3c89d769-98bb-4ea8-afca-aa71a8446541">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by geographic region, based on the customer's &#x201c;ship to&#x201d; location on the invoice, are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales by Domestic and International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8feb8845b0564256867ba343b1691830_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy0xLTEtMS01NDg0_a737f3af-6318-4c0b-8d8a-2d0a0031a884"
      unitRef="usd">7911000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ed5cc3391d04992bf148b8012572185_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy0zLTEtMS01NDg0_6feac2f7-808d-4ecb-a817-cce1fa41cc51"
      unitRef="usd">5214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i277888b4c0464b438c89a4092e556552_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy01LTEtMS01NDg0_56bfad84-5fe3-4db1-811c-50b7d5ea796d"
      unitRef="usd">20860000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia3dbf503dc59424c8962bef0a15c5e70_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfMy03LTEtMS01NDg0_863e6c10-26c0-4ee9-b20c-d5be9a76c378"
      unitRef="usd">12225000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id99d505a25264d4e876738d2927baa96_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC0xLTEtMS01NDg0_38ca38f3-481e-4b5d-9ed8-299094b5d68a"
      unitRef="usd">3920000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i298c6efeca634aa8b52e461c51a9d455_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC0zLTEtMS01NDg0_b73df41f-d329-4056-901e-be65978a59a4"
      unitRef="usd">1740000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8f706102a934d86aa02ba701cfc9f97_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC01LTEtMS01NDg0_07771b69-70df-46c4-9bdb-81b98123a710"
      unitRef="usd">10833000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i728134f0ae5e4afabac37e4c4216d794_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNC03LTEtMS01NDg0_a584bf4a-77f2-4270-b023-a7dea5fb549c"
      unitRef="usd">4022000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6855f102a9a4a479a202f70a292b514_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS0xLTEtMS01NDg0_9e213872-e499-4035-a647-70daeb169054"
      unitRef="usd">11831000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57c8ac9d206e4cf1acf9df9401a3772b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS0zLTEtMS01NDg0_fbdf83b1-4e3d-42c1-8e0b-13f009f23eed"
      unitRef="usd">6954000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS01LTEtMS01NDg0_d2a83985-807d-4e9c-8966-da1d76b0f663"
      unitRef="usd">31693000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a99829c9fc44c789eb9c787469f7058_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmI2M2UwZGIxYmQ1ZjQ1OTA4MmI3YzkwYzBiZDJhN2E5L3NlYzpiNjNlMGRiMWJkNWY0NTkwODJiN2M5MGMwYmQyYTdhOV82NC9mcmFnOmExYmYxZjg2OTY0NTQ2NjlhNmJlODcxMzI3ZDNkZjRkL3RhYmxlOjQxYTk4Yjc4NTJiMjQ2ZGRhMDViNTNlMzYzNjUxZGIzL3RhYmxlcmFuZ2U6NDFhOThiNzg1MmIyNDZkZGEwNWI1M2UzNjM2NTFkYjNfNS03LTEtMS01NDg0_1ab7c283-5de5-45da-a288-61d8b720a40c"
      unitRef="usd">16247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654168184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Nov. 09, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-12183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">APYX MEDICAL CORPORATION<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">11-2644611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5115 Ulmerton Road,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Clearwater<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">33760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">384-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">APYX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,343,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000719135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654916808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 30,898<span></span>
</td>
<td class="nump">$ 41,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, net of allowance of $360 and $300</a></td>
<td class="nump">11,444<span></span>
</td>
<td class="nump">8,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">7,654<span></span>
</td>
<td class="nump">7,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net of provision for obsolescence of $303 and $388</a></td>
<td class="nump">6,040<span></span>
</td>
<td class="nump">4,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,967<span></span>
</td>
<td class="nump">2,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">59,876<span></span>
</td>
<td class="nump">66,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $5,145 and $4,813</a></td>
<td class="nump">6,412<span></span>
</td>
<td class="nump">6,541<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease right-of-use assets</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,055<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">67,769<span></span>
</td>
<td class="nump">74,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,044<span></span>
</td>
<td class="nump">1,511<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,324<span></span>
</td>
<td class="nump">7,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion of finance lease liabilities</a></td>
<td class="nump">218<span></span>
</td>
<td class="nump">238<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">11,711<span></span>
</td>
<td class="nump">9,153<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term finance lease liabilities</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liabilities</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">146<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">13,109<span></span>
</td>
<td class="nump">10,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 75,000,000 shares authorized; 34,339,533 issued and outstanding as of September&#160;30, 2021, and 34,289,222 issued and outstanding as of December 31, 2020</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">64,862<span></span>
</td>
<td class="nump">61,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">(Accumulated deficit) retained earnings</a></td>
<td class="num">(10,548)<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">54,348<span></span>
</td>
<td class="nump">63,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">312<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">54,660<span></span>
</td>
<td class="nump">63,859<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 67,769<span></span>
</td>
<td class="nump">$ 74,111<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654247416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">$ 360<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForObsolescenceInventory', window );">Inventories, provision for obsolescence</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">388<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization</a></td>
<td class="nump">$ 5,145<span></span>
</td>
<td class="nump">$ 4,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">34,339,533<span></span>
</td>
<td class="nump">34,289,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">34,339,533<span></span>
</td>
<td class="nump">34,289,222<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForObsolescenceInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Obsolescence, Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForObsolescenceInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654700632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">3,775<span></span>
</td>
<td class="nump">2,229<span></span>
</td>
<td class="nump">10,243<span></span>
</td>
<td class="nump">6,444<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">8,056<span></span>
</td>
<td class="nump">4,725<span></span>
</td>
<td class="nump">21,450<span></span>
</td>
<td class="nump">9,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Other costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,175<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">3,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional services</a></td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">1,835<span></span>
</td>
<td class="nump">5,442<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesAndWages', window );">Salaries and related costs</a></td>
<td class="nump">4,206<span></span>
</td>
<td class="nump">3,508<span></span>
</td>
<td class="nump">12,794<span></span>
</td>
<td class="nump">10,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">4,611<span></span>
</td>
<td class="nump">2,706<span></span>
</td>
<td class="nump">12,596<span></span>
</td>
<td class="nump">8,691<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total other costs and expenses</a></td>
<td class="nump">12,024<span></span>
</td>
<td class="nump">9,096<span></span>
</td>
<td class="nump">34,206<span></span>
</td>
<td class="nump">27,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(4,371)<span></span>
</td>
<td class="num">(12,756)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (loss) income, net</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other (loss) income, net</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(4,161)<span></span>
</td>
<td class="num">(4,449)<span></span>
</td>
<td class="num">(12,944)<span></span>
</td>
<td class="num">(17,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">73<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="num">(7,112)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,234)<span></span>
</td>
<td class="num">(3,734)<span></span>
</td>
<td class="num">(13,190)<span></span>
</td>
<td class="num">(10,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(12)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to stockholders</a></td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (3,728)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
<td class="num">$ (10,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.2(a),(b),(c),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433917&amp;loc=SL114874205-224268<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesAndWages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesAndWages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745657043880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings (Accumulated Deficit)</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 71,259<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 56,708<span></span>
</td>
<td class="nump">$ 14,517<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">3,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(10,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,369)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">64,338<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">60,014<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2020</a></td>
<td class="nump">66,836<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">58,926<span></span>
</td>
<td class="nump">7,876<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,063<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(3,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,728)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2020</a></td>
<td class="nump">64,338<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">60,014<span></span>
</td>
<td class="nump">4,148<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">63,859<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">61,066<span></span>
</td>
<td class="nump">2,621<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(13,190)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,169)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">54,660<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">64,862<span></span>
</td>
<td class="num">(10,548)<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">57,682<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">63,650<span></span>
</td>
<td class="num">(6,326)<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Shares issued on stock options exercises for cash (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued on stock options exercises for cash</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockSwapToAcquireOptionsShares', window );">Shares issued on net settlement of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(4,234)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,222)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">$ 54,660<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 64,862<span></span>
</td>
<td class="num">$ (10,548)<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockSwapToAcquireOptionsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock swap to acquire options shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockSwapToAcquireOptionsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654993752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (13,190)<span></span>
</td>
<td class="num">$ (10,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">674<span></span>
</td>
<td class="nump">662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProvisionForInventoryObsolescence', window );">Provision for inventory obsolescence</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">3,747<span></span>
</td>
<td class="nump">3,209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for allowance for doubtful accounts</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables</a></td>
<td class="num">(3,168)<span></span>
</td>
<td class="nump">1,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable', window );">Income tax receivables</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,812)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,982)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,555<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">1,605<span></span>
</td>
<td class="num">(2,352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(10,663)<span></span>
</td>
<td class="num">(15,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(391)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_RepaymentofFinanceLeaseLiabilities', window );">Repayment of finance lease liabilities</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMinorityShareholders', window );">Contributions from non-controlling interests</a></td>
<td class="nump">195<span></span>
</td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rates on cash</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(92)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(11,017)<span></span>
</td>
<td class="num">(15,273)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">41,915<span></span>
</td>
<td class="nump">58,812<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">30,898<span></span>
</td>
<td class="nump">43,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Stock Options Exercised And Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_ProvisionForInventoryObsolescence">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provision For Inventory Obsolescence</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_ProvisionForInventoryObsolescence</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_RepaymentofFinanceLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment of Finance Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_RepaymentofFinanceLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652018360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pyx Medical Corporation (&#8220;Company", "Apyx", "it" and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an advanced energy technology company with a passion for elevating people&#8217;s lives through innovative products in the cosmetic and surgical markets. Known for its innovative Helium Plasma Technology, Apyx is solely focused on bringing transformative solutions to the physicians and patients they serve. It's Helium Plasma Technology is marketed and sold as Renuvion&#174; in the cosmetic surgery market and J-Plasma&#174; in the hospital surgical market. Renuvion&#174; offers plastic surgeons, fascial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve their desired results. The J-Plasma&#174; system allows surgeons to operate with a high level of precision, virtually eliminating unintended tissue trauma. The Company also leverages its deep expertise and decades of experience in unique waveforms through original equipment manufacturing (OEM) agreements with other medical device manufacturers.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic and its impact on the level of economic activity around the world including ongoing supply chain disruptions. The extent of the impact of the pandemic on the Company's business is highly uncertain and difficult to predict, as the responses and information related to it continue to change.  As elective surgery cases using the Company&#8217;s Helium Plasma Technology have started to increase again, it is unknown whether these trends will continue.  The full extent to which the COVID-19 pandemic may materially and adversely impact the Company&#8217;s future financial position, liquidity, or results of operations remains uncertain.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements have been prepared based upon SEC rules that permit reduced disclosure for interim periods. For a more complete discussion of significant accounting policies and certain other information, please refer to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. In the opinion of management these condensed consolidated financial statements reflect all adjustments that are necessary for a fair presentation of results of consolidated operations and financial condition for the interim periods shown, including normal recurring accruals and other items. The results for the interim periods are not necessarily indicative of results for the full year.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650604808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652003736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">DISPOSAL OF BUSINESS</a></td>
<td class="text">DISPOSAL OF BUSINESS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2018, the Company closed on a definitive asset purchase agreement (the "Asset Purchase Agreement") with Specialty Surgical Instrumentation Inc., a Tennessee Corporation and wholly owned subsidiary of Symmetry Surgical Inc. (&#8220;Symmetry&#8221;), pursuant to which the Company divested and sold the Company's electrosurgical "Core" business segment and related intellectual property, including the Bovie&#174; brand and trademarks, to Symmetry for gross proceeds of $97&#160;million in cash.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Asset Purchase Agreement, the Company entered into an Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement with Symmetry for a four-year term, whereby it will manufacture certain Core pro</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ducts and sell them to Symmetry at agreed upon prices. Any activity resulting from this agreement is netted and reported in the Condensed Consolidated Statements of Operations as other income (loss). Core activity for the three months ended September&#160;30, 2021, amounted to $1.6&#160;million with cost of sales equivalents of $1.3&#160;million and other related expenses of $0.5&#160;million for net other loss of $0.3&#160;million. Core activity for the three months ended September&#160;30, 2020, amounted to $1.8&#160;million with cost of sales equivalents of $1.6&#160;million and related other expenses of $0.3&#160;million for net other loss of $0.1&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $5.2&#160;million with cost of sales equivalents of $4.4&#160;million and other related expenses of $1.1&#160;million&#160;for net other loss of $0.3&#160;million. Core activity for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2020</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amounted to $6.9&#160;million with cost of sales equivalents of $6.1&#160;million and net other related operating expenses of $0.5&#160;million for net other income of $0.3&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650716488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">INVENTORIES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652269048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652001256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDisclosureTextBlock', window );">CHINA JOINT VENTURE</a></td>
<td class="text">CHINA JOINT VENTURE<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the Company executed a joint venture agreement with its Chinese supplier ("China JV") whereby the Company has a 51% interest in the China JV. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately&#160;$357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the three months ended June 30, 2021 and the three months ended September 30, 2020. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's investment in the China JV were as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650577768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings (loss) per share (&#8220;basic EPS&#8221;) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (&#8220;diluted EPS&#8221;) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652251400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized approximately $1,184,000 and $3,747,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2021, as compared with $1,063,000 and $3,209,000, respectively, for the three and nine months ended September 30, 2020.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,533,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September&#160;30, 2021 and 2020, respectively, we received 37,049 and 16,140 options as payment in the exercise of 13,285 and 10,610 options. For the nine months ended September 30, 2021 and 2020, respectively, we received 59,104 and 29,149 options as payment in the exercise of 39,312 and 32,637 options.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"/><td style="width:66.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.51</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654044328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES On March 27, 2020, the U.S. government enacted the CARES Act to provide financial relief from COVID-19. The CARES Act includes a provision that allows companies to carryback net operating losses (NOL&#8217;s) generated in the period 2018 through 2020 to prior years. In conjunction with the disposition of the Core business in 2018, the Company generated a significant amount of taxable income in 2018. Subsequently, the Company generated net losses in 2019 and 2020. For the net losses generated in 2019, the Company previously recorded a full valuation allowance on the deferred tax assets associated with its NOL carryforwards due to realization of the NOL not being probable under then existing tax law. The CARES Act makes these assets realizable and, as of the date of the CARES Act, the Company recognized an income tax benefit of approximately $3.7 million associated with the release of the valuation allowance on its Federal NOL carryforward related to 2019. For the three and nine months ended September 30, 2020, the Company also recognized income tax benefits of approximately $0.7 million and $7.1 million, respectively, related to losses before income taxes.Income tax expense (benefit) was approximately $73,000 and $(715,000) with effective tax rates of (1.8)% and 16.1% for the three months ended September&#160;30, 2021 and 2020, respectively. Income tax expense (benefit) was approximately $246,000 and $(7,112,000) with effective tax rates of (1.9)% and 40.7% for the nine months ended September 30, 2021 and 2020, respectively. For the three and nine months ended September&#160;30, 2021, the effective rates differ from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period, combined with interest and penalties on uncertain tax positions. For the nine months ended September 30, 2020, the effective rate differs from the statutory rate primarily due to the release of the valuation allowance on the NOL carryforward from 2019. The Company has gross unrecognized tax benefits of approximately $1,313,000 at September&#160;30, 2021. It recognized accrued interest and penalties related to unrecognized tax benefits in the provision for income taxes in the condensed consolidated financial statements. As of September&#160;30, 2021, the Company had approximately $497,000 in accrued interest and penalties related to unrecognized tax benefits. Included in the income tax expense (benefit) for the three months ended September&#160;30, 2021 and 2020, respectively, are approximately $52,000 and $43,000 of interest and penalties on the Company's uncertain tax positions. Included in the income tax expense (benefit) for the nine months ended September 30, 2021 and 2020, respectively, are approximately $152,000 and $125,000 of interest and penalties on the Company's uncertain tax positions. If the Company were to prevail on all uncertain tax positions, the resulting impact will be material as the Company will recognize approximately $1,810,000 of income tax benefits in the consolidated statement of operations. It is expected that all of the uncertain tax positions should be resolved by October 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650726776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company&#8217;s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company&#8217;s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company&#8217;s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchase Commitments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2021, the Company had purchase commitments totaling approximately $5.2&#160;million, substantially all of which is expected to be purchased within the next twelve months.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652037224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">RELATED PARTY TRANSACTIONS<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several relatives of Nikolay Shilev, Apyx Bulgaria&#8217;s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev&#8217;s spouse, is an employee of the Company working in the accounting department. Antoaneta Dimitrova Shileva-Toromanova, Mr. Shilev&#8217;s sister, is the manager of human resources. Svetoslav Shilev, Mr. Shilev&#8217;s son, is a quality manager in the quality assurance department.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September&#160;30, 2021 and 2020, the Company made purchases from this supplier of approximately $456,000 and $410,000, respectively. For the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 2020, the Company made purchases from this supplier of approximately $1,102,000 and $1,250,000, respectively. At September&#160;30, 2021 and December&#160;31, 2020, respectively, the Company owed this supplier approximately $48,000 and $38,000.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652296616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">GEOGRAPHIC AND SEGMENT INFORMATION</a></td>
<td class="text">GEOGRAPHIC AND SEGMENT INFORMATION <div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. "Corporate &amp; Other" includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information with respect to reportable segments is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International sales represented approximately 33.1% and 34.2% of total revenues for the three and nine months ended September 30, 2021, respectively, as compared with approximately 25.0% and 24.8% of total revenues for the three and nine months ended September 30, 2020, respectively.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745742485432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments&#8212;Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the condensed consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text">Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share based compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Company's stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation - Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745741915992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of inventory</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,087&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross inventories</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,343&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: provision for obsolescence</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(303)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,040&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,051&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652239624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued payroll</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued bonuses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,559&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">811&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued commissions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product warranties</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product liability claim insurance deductibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joint and several payroll liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Uncertain tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,810&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,658&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses and current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,324&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650421368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestAbstract', window );"><strong>Noncontrolling Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestTableTextBlock', window );">Schedule of China Joint Venture</a></td>
<td class="text">Changes in the Company's investment in the China JV were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning interest in China JV</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contributions </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Apyx</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending interest in China JV</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652209912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings (loss) per share</a></td>
<td class="text">The following table provides the computation of basic and diluted loss per share.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:46.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.393%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.728%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.329%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in thousands, except per share data)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to stockholders</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,222)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,728)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,169)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,369)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding - basic and diluted<br/></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.12)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.11)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.30)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive instruments excluded from diluted loss per common share:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652675048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock options and stock awards</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock option activity is summarized as follows:</span></div><div style="margin-bottom:3pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,938,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">894,980&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,415)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled and forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190,793)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at September&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,533,715&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of option fair value assumptions</a></td>
<td class="text">The Company calculated the grant date fair value of options granted in 2021 ("2021 Grants") utilizing a Black Scholes model.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:58.479%"><tr><td style="width:1.0%"/><td style="width:66.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.650%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021 Grants</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Strike price</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$9.29</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.51</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.9%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.8%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745652013768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of reporting information by segment</a></td>
<td class="text">Summarized financial information with respect to reportable segments is as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,313&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,518&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,348)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,968)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,479&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(715)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,951&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,120)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,756)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other loss, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.811%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Advanced Energy</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OEM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate &amp; Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,046)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,030)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock', window );">Schedule of revenue by geographic area</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by geographic region, based on the customer's &#8220;ship to&#8221; location on the invoice, are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales by Domestic and International</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,225&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,920&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,831&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,693&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,247&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654127080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DISPOSAL OF BUSINESS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2018</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from the disposition of Core business</a></td>
<td class="nump">$ 97.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member', window );">Symmetry Surgical Inc. | Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AssetPurchaseAgreementTerm', window );">Asset purchase agreement, term</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss', window );">Net other income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="num">$ (0.1)<span></span>
</td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AssetPurchaseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Purchase Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AssetPurchaseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=apyx_SymmetrySurgicalInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654787192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 3,505<span></span>
</td>
<td class="nump">$ 2,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">1,284<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">1,554<span></span>
</td>
<td class="nump">1,087<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Gross inventories</a></td>
<td class="nump">6,343<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryValuationReserves', window );">Less: provision for obsolescence</a></td>
<td class="num">(303)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">$ 6,040<span></span>
</td>
<td class="nump">$ 4,051<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryValuationReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation reserve for inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryValuationReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745738815624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">$ 808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued bonuses</a></td>
<td class="nump">1,559<span></span>
</td>
<td class="nump">811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalesCommissionCurrent', window );">Accrued commissions</a></td>
<td class="nump">897<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent', window );">Accrued product warranties</a></td>
<td class="nump">547<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedInsuranceCurrent', window );">Accrued product liability claim insurance deductibles</a></td>
<td class="nump">440<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_JointAndSeveralPayrollLiability', window );">Joint and several payroll liability</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">1,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_UncertainTaxPositionsLiability', window );">Uncertain tax positions</a></td>
<td class="nump">1,810<span></span>
</td>
<td class="nump">1,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax payable</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent', window );">Other accrued expenses and current liabilities</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 8,324<span></span>
</td>
<td class="nump">$ 7,278<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities and Other Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_JointAndSeveralPayrollLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Joint And Several Payroll Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_JointAndSeveralPayrollLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_OtherAccruedExpensesAndLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accrued Expenses And Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_OtherAccruedExpensesAndLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_UncertainTaxPositionsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_UncertainTaxPositionsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedInsuranceCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedInsuranceCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalesCommissionCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalesCommissionCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductWarrantyAccrualClassifiedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12524-110249<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123377177&amp;loc=d3e11281-110244<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductWarrantyAccrualClassifiedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745654732248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_NoncontrollingInterestRequiredCapitalContribution', window );">Required capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=apyx_ChineseSupplierMember', window );">Chinese Supplier</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestLineItems', window );"><strong>Noncontrolling Interest [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions from non-controlling interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_NoncontrollingInterestRequiredCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Required Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_NoncontrollingInterestRequiredCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=apyx_ChineseSupplierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=apyx_ChineseSupplierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745655208584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">195<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember', window );">Corporate Joint Venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Beginning interest in China JV</a></td>
<td class="nump">338<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="nump">203<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to Apyx</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Ending interest in China JV</a></td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_CorporateJointVentureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745655298520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Earnings Per Share Reconciliation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to stockholders, basic</a></td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (3,728)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
<td class="num">$ (10,369)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to stockholders, diluted</a></td>
<td class="num">$ (4,222)<span></span>
</td>
<td class="num">$ (3,728)<span></span>
</td>
<td class="num">$ (13,169)<span></span>
</td>
<td class="num">$ (10,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in shares)</a></td>
<td class="nump">34,330<span></span>
</td>
<td class="nump">34,216<span></span>
</td>
<td class="nump">34,318<span></span>
</td>
<td class="nump">34,193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in shares)</a></td>
<td class="nump">34,330<span></span>
</td>
<td class="nump">34,216<span></span>
</td>
<td class="nump">34,318<span></span>
</td>
<td class="nump">34,193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.11)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Anti-dilutive instruments excluded from diluted loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive instruments (in shares)</a></td>
<td class="nump">5,534<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="nump">5,534<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650649432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock based compensation</a></td>
<td class="nump">$ 1,184<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
<td class="nump">$ 3,747<span></span>
</td>
<td class="nump">$ 3,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived', window );">Stock swaps equity instruments received (in shares)</a></td>
<td class="nump">37,049<span></span>
</td>
<td class="nump">16,140<span></span>
</td>
<td class="nump">59,104<span></span>
</td>
<td class="nump">29,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_StockIssuedDuringPeriodSharesStockSwaps', window );">Stock swaps (in shares)</a></td>
<td class="nump">13,285<span></span>
</td>
<td class="nump">10,610<span></span>
</td>
<td class="nump">39,312<span></span>
</td>
<td class="nump">32,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwaps">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwaps</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745655277736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">4,938,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">894,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(109,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Canceled and forfeited (in shares) | shares</a></td>
<td class="num">(190,793)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">5,533,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted average exercise price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">9.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">6.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Canceled and forfeited (in dollars per shares) | $ / shares</a></td>
<td class="nump">8.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745736371192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 9.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 9.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Strike price (in dollars per share)</a></td>
<td class="nump">$ 11.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">70.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745655519384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards', window );">Release of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">$ (715)<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="num">$ (7,112)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">40.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and penalties</a></td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Interest and penalties included in income tax expense</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Uncertain tax positions that would impact effective tax rate</a></td>
<td class="nump">$ 1,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650413176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase obligation</a></td>
<td class="nump">$ 5.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650432152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details) - Co-venturer - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchases from related party</a></td>
<td class="nump">$ 456<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 1,102<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_CoVenturerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745650480040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_apyx_TotalRevenuePercent', window );">International sales, percent of total revenue</a></td>
<td class="nump">33.10%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">34.20%<span></span>
</td>
<td class="nump">24.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_apyx_TotalRevenuePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total Revenue, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">apyx_TotalRevenuePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>apyx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745738768936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(4,371)<span></span>
</td>
<td class="num">(12,756)<span></span>
</td>
<td class="num">(18,030)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">73<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="num">(7,112)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Advanced Energy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">10,313<span></span>
</td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">27,951<span></span>
</td>
<td class="nump">12,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">52<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
<td class="num">(8,371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | OEM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">1,518<span></span>
</td>
<td class="nump">1,475<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="nump">3,915<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">556<span></span>
</td>
<td class="nump">588<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate &amp; Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(4,348)<span></span>
</td>
<td class="num">(3,832)<span></span>
</td>
<td class="num">(13,120)<span></span>
</td>
<td class="num">(11,046)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (loss), net</a></td>
<td class="num">(192)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="num">$ (715)<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="num">$ (7,112)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_AdvancedEnergyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=apyx_OEMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139745655331416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 11,831<span></span>
</td>
<td class="nump">$ 6,954<span></span>
</td>
<td class="nump">$ 31,693<span></span>
</td>
<td class="nump">$ 16,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">Domestic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">7,911<span></span>
</td>
<td class="nump">5,214<span></span>
</td>
<td class="nump">20,860<span></span>
</td>
<td class="nump">12,225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales</a></td>
<td class="nump">$ 3,920<span></span>
</td>
<td class="nump">$ 1,740<span></span>
</td>
<td class="nump">$ 10,833<span></span>
</td>
<td class="nump">$ 4,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MWX&MIR#X3*#N?B>_B7)7563_\->CM]3N8/XJ!)Y5Z#-42%Y6)8U#7N:6^PJ
MJJFS"X6W<6$^R>@X2$R$?H.L#:TG*^":4"8U;?0\H1!Z&Y?EO)0\<CM6NV-X
M7*H,%7 O6-Y@%R)OXY+\F57FL<N<<+!+17?K[)S*"%!V?)<0UY1=AR.K_&E^
M1#C,#L9:1??#^>(3-_J5D%"LP-2Z[L%64X<CNT-#RTUVZK646LLHN_4%]X0R
M'>#]2DI]:I@/Y >G@_\ 4$L#!!0    ( !1!;%.$N<7_0@8  .48   8
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MHS-H=09>G;>*SP7,HE2N01S,R%2 TKM<C%$)W4,N$,]ACO,R%>;F@$6X#NN
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M5S.E]NFS-U.$$=SGI,L,TZUUTZ[&#F<T\G+R\I]O5[?_^XX).O!0/WC.95%
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MYGB: Z DZ>&*@ZZK!O]4X+C*1),U2N2VBJZ;/ (;9>!O Q*X>P5 T3!('-(
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MJ/,GUP;J_VO&Y-N+GJ"]CY__#U!+ P04    "  406Q393$VHTX'  !'$
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MZ2%>=JY]^[6;8.OXWEK8@-=;7!9X+K,3 =POK0W;C3CH'^!G_P)02P,$%
M  @ %$%L4\QHOC4\ P  K@8  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&ULG55-C]LX#/TKA-%#!_#$CNVTF2 ),%_=':#M#F:V[6&Q!\6F$Z&RZ)7D
MI+._?BG9<=.B,X>]V!*E]_A(D_3R0.:KW2$Z^-8H;5?1SKEVD22VW&$C[(1:
MU'Q2DVF$XZW9)K8U**H :E22I>F;I!%21^MEL-V;]9(ZIZ3&>P.V:QIAGJY0
MT6$53:.CX4%N=\X;DO6R%5M\1/>IO3>\2T:62C:HK20-!NM5=#E=7!7^?KCP
M6>+!GJS!1[(A^NHW=]4J2KT@5%@ZSR#XM<=K5,H3L8Q_!LYH=.F!I^LC^[L0
M.\>R$1:O27V1E=NMHGD$%=:B4^Z!#K_C$,_,\Y6D;'C"H;^;9Q&4G774#&!6
MT$C=O\6W(0\G@'GZ#" ; %G0W3L**F^$$^NEH0,8?YO9_"*$&M L3FK_41Z=
MX5/).+>^^_CY]N.??SS<W3XN$\>$WIR4 _BJ!V?/@"_@ VFWLW"K*ZQ^Q"<L
M9%23'=5<92\2/F([@3R-(4NSZ0M\^1A='OCRYZ+3>]2.S!/<2%LJLIU!^.MR
M8YWA<OC[!0_%Z*$('HK_E[\7P;[A%K85):XB[BB+9H_1*2,<]4NT(%BZ=<)A
M!<*!VR%P0Z$!JJ$DZX ,:&YB[DPE_Q4;A; 7JL,)7/M3:;E6'1HN(2;P[0"U
M-/Y Q\.*6]87N+03>">UY)JJ8$M4L6M=A>8ZE_J\-52BM8S[+DWJ4G45<EVR
M!RE4#$IL6(_'T1[-CJ=%$.FI.?'^@_QH#]&U1O)@D.H)A%)4AE =C9Z>F%]W
M->/Y*U9L/M]19S$T905=RT%5TG"W#][YU+##TQR6Q-/$>E[.FD]A3>SI(/5V
M :_O-)N8D57;,^!2=-AL.,&^'F^P'#;3&![$80S5PBO(XUDZXW<69T4.7SA1
M+ Z.B9K&V;S@YS2]^#FOTW@V\T?I_"W\9NBGK+Z)<Z8KXB*_@/?,M/"4>QG&
M(4]CH(TEA;9$72*\SM/\C)_S^=EIQ'&HB5?,E18IOXLXG4WA5W6?G,R0!LTV
M3$J?L4Z[?IR,UG$87_8SZ/OU?I)_$&8KM06%-4/3R=M9!*:?COW&41LFTH8<
MS[>P]*6 QE_@\YK('3?>P?B+6O\'4$L#!!0    ( !1!;%-P A(O)P,  /<&
M   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;+5536_;.!#]*P-A#[N
M$7U8BN7 -F [7M2+-C7L9+= T0,MC6RB$JDEJ3CY]SND9,5%DP![Z(4B.?/>
MO.&0H\E)JN_ZB&C@J2J%GGI'8^H;W]?9$2NFKV2-@BR%5!4SM%0'7]<*6>Y
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M](8IE P4!\.=4'.&U%I<L?/^\O>7SP[B:/K:[K(Y*/J.N0KET\7E0F>(+3K
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M%WHC4V'D.G2Z)[SUKB1 LE4 EF3->2S1$43I.A^P7@K\$$47$'<(,W'7E?4
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M^BI/%W"^<BZV'R2@^__%^3]02P,$%     @ %$%L4T.J*>6L @  <04  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL?53?;]HP$/Y73M$>BA0U(0DM
M18!4^F-#6KL*NO9AVH-)#K#JV)GM0/O?[^Q QJ3"2^SSW7WWG>/OAENEW\P:
MT<)[*:09!6MKJT$4F7R-)3/GJD))GJ72);-DZE5D*HVL\$FEB)(XOHA*QF4P
M'OJS)ST>JMH*+O%)@ZG+DNF/"0JU'07=8'\PXZNU=0?1>%BQ%<[1_JR>-%E1
MBU+P$J7A2H+&Y2BX[@XFF8OW 2\<M^9@#ZZ3A5)OSI@6HR!VA%!@;AT"HV6#
M-RB$ R(:?W:805O2)1[N]^CWOG?J9<$,WBCQR@N['@7]  I<LEK8F=I^PUT_
M/8>7*V'\%[9-;)H$D-?&JG*73 Q*+IN5O>_NX2"A'Q])2'8)B>?=%/(L;YEE
MXZ%66] NFM#<QK?JLXD<E^ZGS*TF+Z<\.YX^OMP]/O^83>_F</;,%@)-9QA9
M0G;^*-^A3!J4Y C*%3PH:=<&[F2!Q?_Y$3%J:25[6I/D). <JW-(XQ"2..F>
MP$O;-E./EQYK4VY06J4_X):;7"A3:X1?UPMC-;V+WR<J9&V%S%?(CC$FN12U
M0%!+X/MJG]WD21BGP8&I6(ZC@$1F4&\P:-ES-) K$H2Q6+A"=HVP5(*4Q>5J
M &=324>J-DP6I@-TB1;+!6I_D[>8[XQN"#.VI5=D47,F#'R!-.S%/5J3,,E2
M>"4A41-0:96C,= -DWY&WVY\!?=<<GIN!:R4*IRKUW.NN'\)7[6B8'Y ]B),
M"2X+L_0*OA/2P$%NN%<T#110"Z/HQ>4H<X2S-$X[].WW.W#0<0B29M,7PHJS
MF-8LC'M=^.R/10<R*%&OO-C=C=72-HIH3]MY<MW(Z%]X,XP>F%YQ:4#@DE+C
M\\M> +H1>&-857E1+90EB?KMFF8B:A= _J52=F^X NV4'?\%4$L#!!0    (
M !1!;%/E]M]L.@,  -<&   9    >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM
M;'U5;6_B.!#^*Z/H/NQ*J'DA*:$")*"LEE.WBX#>KG2Z#R89P%HGSMI.:?_]
MC4T(G [ZQ;$]\\SSC,>># Y2_=)[1 -OA2CUT-L;4SWXOL[V6#!])RLLR;*5
MJF"&EFKGZTHARQVH$'X4!/=^P7CIC09N;Z%& UD;P4M<*-!U43#U/D$A#T,O
M]$X;2[[;&[OACP85V^$*S4NU4+3RVR@Y+[#47):@<#OTQN'#)+;^SN$OC@=]
M,0>;R4;*7W8QSX=>8 6AP,S8"(P^KSA%(6P@DO&[B>FUE!9X.3]%_^)RIUPV
M3.-4BA\\-_NAEWJ0XY;5PBSEX2LV^20V7B:%=B,<CK[)O0=9K8TL&C I*'AY
M_+*WYAPN &EP Q U@,CI/A(YE8_,L-% R0,HZTW1[,2EZM DCI>V*"NCR,H)
M9T;CZ73Y,GN$V<_%['DU6\'X^1&^K[_.EC!]62YGSVMXFH\G\Z?Y>D[63VNV
M$:@_#WQ#Y#:$GS5$DR-1=(.H#]]D:?8:9F6.^7_Q/HENE4<GY9/HPX KK.Z@
M&W0@"J+P@WC=]B2Z+E[W1KP%>W>Y 2MS&&>9JIG0\/=XHXVBN_//!Q1Q2Q$[
MBOB69'I2>2T0Y-8RR+HT&AK>,RWF\,39A@MN..IK)_TABWW&#[IB&0X]>J<:
MU2MZHU-D?*/GK)LLI=FCHENF%)8&Q)D4,DG/3AL"D%3R@JT4]'YYN7N 3[RD
M+5EK"J$_ ]7!8+&A0+88CY@UB[#3IE.Q=T5X^ /2?FS'(&UM&UG65D_829(^
MI&'86C)9%%S;UZ\)UR./(#A;*R7S.C-P8$JQTHE.XA[$_?1_+J?$WB$3C!?
M2UT3)D-ZOM:!N[+'<0!Q-[E$;]'1,P%;)(\HB2"*(OA3<CHN>X :7U&1^93@
MF8G$1KUF?"$J99@]-O8&E=3<N*3"3AH&--XG*:R8U>#LS7V(XBXD_1"^NR*Q
M:_6[5KG[)"&1/5A+0\*NPFZ7G4K3Z4:V1+U.U$OAVIWW+YI-@6KG6JJ],72;
MCWVGW6V[]OC8K,[NQY;_C:D=%0,$;@D:W/42#]2QC1X71E:N=6VDH4;HIGOZ
M\Z"R#F3?2FE."TO0_LM&_P)02P,$%     @ %$%L4]]L8L>Z @  TP4  !D
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;'U5VV[C-A#]E8&:+1+
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MQLD,#ZJWQ5P+J/4]8_)YHKNGJEL>_0502P,$%     @ %$%L4^Q>+J$V P
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M X#O2R'T_L4X*/ZS,/@/4$L#!!0    ( !1!;%-2^N-^_ (  *P(   9
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MF4F\2G0SPL\)X J SY>,R4U'"=0?*,/?4$L#!!0    ( !1!;%-:A<7)+0,
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M754H>-'C%!/)LKROF#.INI1\&*N^$+C>H-XO&)/;B790=9J#/U!+ P04
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M+W=O<FMS:&5E=',O<VAE970S-RYX;6RE56UOVC 0_BM6U ^MM)(W0CL4D("
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MP"P<5-5DI9L%891V%@12:$+!]O1X:*O_5*__;Y$/JNHST-."4$I3"W2EU#P
M:F];BW8:^8,:!8.%I';7[8$KG2T  [2V )3:VX)=*<VM<>?0*V;9ICQMS-$R
M?4QX=:K1W&U.-,_*<SSI_CD^OL# ?0\?^]5Y9>N^.CZ]#+)-F.0H8FL1ROK@
MB 7*JA/)ZH*GN_+([2'E/(W+GUL6K%A6 ,3S=9KRUXLB0',N//\74$L#!!0
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  406Q3JM.FR+T#   %&P  #P
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M&HT!  !/&   &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=E-CH)
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !1!;%/#(;]%* 4  $05   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  406Q3A+G%_T(&  #E&   &               @(%K#0  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ %$%L4T.>^"0U P  _P@
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M965T-RYX;6Q02P$"% ,4    "  406Q3PC5B/LP$  "U"@  &
M    @($A,@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M%$%L4QF:5#R1!   C L  !@              ("!(S<  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !1!;%/,:+XU/ ,  *X&   9
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M970Q-"YX;6Q02P$"% ,4    "  406Q3K$;RANT%  "X$   &0
M    @(%U4   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M !1!;%.0DWLC_04  ,P-   9              " @9E6  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ %$%L4U^-9W)Z P  * @  !D
M             ("!S5P  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  406Q3>(0;*ZX&  #D$0  &0              @(%^8   >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( !1!;%,?Q!R!" <
M ,L0   9              " @6-G  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ %$%L4T.J*>6L @  <04  !D              ("!
MHFX  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  406Q3
MY?;?;#H#  #7!@  &0              @(&%<0  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !1!;%/?;&+'N@(  -,%   9
M      " @?9T  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ %$%L4^$B8+0P P  P08  !D              ("!YW<  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  406Q3HX3.KH<#  !E!P
M&0              @(%.>P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( !1!;%-@F%')AP0  )(,   9              " @0Q_  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ %$%L4S"<6Y^A
M P  L0L  !D              ("!RH,  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  406Q3+]4ITK<"  !V!P  &0
M@(&BAP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( !1!
M;%,[PI=RA0,  #D+   9              " @9"*  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ %$%L4^Q>+J$V P  (@L  !D
M         ("!3(X  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  406Q3QYZ:F+0#   C#@  &0              @(&YD0  >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !1!;%,*_]^$, 0  &40
M   9              " @:25  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ %$%L4U+ZXW[\ @  K @  !D              ("!"YH
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  406Q36H7%
MR2T#  !U"@  &0              @($^G0  >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( !1!;%,A[-1L.@,  )8+   9
M  " @:*@  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M%$%L4^;W+Y"B P  ) P  !D              ("!$Z0  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  406Q3;/%#\A("  #U P  &0
M            @('LIP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( !1!;%-)ONW?N0(  . '   9              " @36J  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ %$%L4P"S9L:] @
M_0<  !D              ("!):T  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  406Q3DZ)OFL8%   C'@  &0              @($9
ML   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( !1!;%/_
MPL8:!P,  -X)   9              " @1:V  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ %$%L4P!T0H8F P  #!,   T
M     ( !5+D  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  406Q3EXJ[',
M   3 @  "P              @ &EO   7W)E;',O+G)E;'-02P$"% ,4
M"  406Q3JM.FR+T#   %&P  #P              @ &.O0  >&PO=V]R:V)O
M;VLN>&UL4$L! A0#%     @ %$%L4SQA]1J- 0  3Q@  !H
M ( !>,$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @
M%$%L4YC$(26B 0  IA@  !,              ( !/<,  %M#;VYT96YT7U1Y
><&5S72YX;6Q02P4&     #  ,  '#0  $,4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>106</ContextCount>
  <ElementCount>260</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>19</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2104103 - Disclosure - DISPOSAL OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESS</Role>
      <ShortName>DISPOSAL OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIES</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2109105 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - CHINA JOINT VENTURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURE</Role>
      <ShortName>CHINA JOINT VENTURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2116107 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2119108 - Disclosure - STOCK-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</Role>
      <ShortName>STOCK-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2124109 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2128111 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2130112 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIES</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - CHINA JOINT VENTURE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURETables</Role>
      <ShortName>CHINA JOINT VENTURE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/CHINAJOINTVENTURE</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2317304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2320305 - Disclosure - STOCK-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables</Role>
      <ShortName>STOCK-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/STOCKBASEDCOMPENSATION</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2331306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - DISPOSAL OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails</Role>
      <ShortName>DISPOSAL OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/DISPOSALOFBUSINESS</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INVENTORIESDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INVENTORIESTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2414404 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails</Role>
      <ShortName>CHINA JOINT VENTURE - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2415405 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails</Role>
      <ShortName>CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2421407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2422408 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Summary of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2423409 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails</Role>
      <ShortName>STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2425410 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2429412 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2432413 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2433414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="apyx-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2434415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails</Role>
      <ShortName>GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="apyx-20210930.htm">apyx-20210930.htm</File>
    <File>a2021q310-qexhibit311.htm</File>
    <File>a2021q310-qexhibit312.htm</File>
    <File>a2021q310-qexhibit321.htm</File>
    <File>a2021q310-qexhibit322.htm</File>
    <File>apyx-20210930.xsd</File>
    <File>apyx-20210930_cal.xml</File>
    <File>apyx-20210930_def.xml</File>
    <File>apyx-20210930_lab.xml</File>
    <File>apyx-20210930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>apyx-20210930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "apyx-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 9,
   "contextCount": 106,
   "dts": {
    "calculationLink": {
     "local": [
      "apyx-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "apyx-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "apyx-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "apyx-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "apyx-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "apyx-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 281,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 16,
   "keyStandard": 244,
   "memberCustom": 5,
   "memberStandard": 14,
   "nsprefix": "apyx",
   "nsuri": "http://apyxmedical.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://apyxmedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - INVENTORIES",
     "role": "http://apyxmedical.com/role/INVENTORIES",
     "shortName": "INVENTORIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109105 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - CHINA JOINT VENTURE",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURE",
     "shortName": "CHINA JOINT VENTURE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116107 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2119108 - Disclosure - STOCK-BASED COMPENSATION",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION",
     "shortName": "STOCK-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124109 - Disclosure - INCOME TAXES",
     "role": "http://apyxmedical.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128111 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2130112 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PriorPeriodReclassificationAdjustmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - INVENTORIES (Tables)",
     "role": "http://apyxmedical.com/role/INVENTORIESTables",
     "shortName": "INVENTORIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - CHINA JOINT VENTURE (Tables)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURETables",
     "shortName": "CHINA JOINT VENTURE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317304 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2320305 - Disclosure - STOCK-BASED COMPENSATION (Tables)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables",
     "shortName": "STOCK-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2331306 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405401 - Disclosure - DISPOSAL OF BUSINESS (Details)",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
     "shortName": "DISPOSAL OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i1c7f91281a0c4e6ba607d54d9bd7bdf2_D20180830-20180830",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromDivestitureOfBusinesses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - INVENTORIES (Details)",
     "role": "http://apyxmedical.com/role/INVENTORIESDetails",
     "shortName": "INVENTORIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i33c8cceba9d44f1b81b235e990ff326a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414404 - Disclosure - CHINA JOINT VENTURE - Narrative (Details)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
     "shortName": "CHINA JOINT VENTURE - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i33c8cceba9d44f1b81b235e990ff326a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "apyx:NoncontrollingInterestRequiredCapitalContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ifa26429c0b0840458a09f15ab78444da_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415405 - Disclosure - CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)",
     "role": "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
     "shortName": "CHINA JOINT VENTURE - Rollforward of Joint Venture (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "idc6f0ef7bcae45cd8999ef7fb8dcb6e6_I20200630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted",
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ifa26429c0b0840458a09f15ab78444da_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422408 - Disclosure - STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Summary of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ifa26429c0b0840458a09f15ab78444da_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423409 - Disclosure - STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "role": "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
     "shortName": "STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i27f6f313d1dd482988fc432dda095837_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425410 - Disclosure - INCOME TAXES (Details)",
     "role": "http://apyxmedical.com/role/INCOMETAXESDetails",
     "shortName": "INCOME TAXES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i27f6f313d1dd482988fc432dda095837_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "apyx:CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427411 - Disclosure - COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "role": "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i49aee00ecd564aaf8b7b1b4942930967_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PurchaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ic3b6022e971f4bba87288e373844658a_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429412 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "role": "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ic3b6022e971f4bba87288e373844658a_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432413 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433414 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ic37ec87aca6f42f3829854cd2827d968_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "ie6855f102a9a4a479a202f70a292b514_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434415 - Disclosure - GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "role": "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
     "shortName": "GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i8feb8845b0564256867ba343b1691830_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i38848fe39ff64851a1cbe4f24a730945_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i38848fe39ff64851a1cbe4f24a730945_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://apyxmedical.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104103 - Disclosure - DISPOSAL OF BUSINESS",
     "role": "http://apyxmedical.com/role/DISPOSALOFBUSINESS",
     "shortName": "DISPOSAL OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "apyx-20210930.htm",
      "contextRef": "i5fd13001c9fc4fa49722a5001749d979_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 19,
   "tag": {
    "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities and Other Liabilities, Current",
        "label": "Accrued Liabilities and Other Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_AdvancedEnergyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Energy [Member]",
        "label": "Advanced Energy [Member]",
        "terseLabel": "Advanced Energy"
       }
      }
     },
     "localname": "AdvancedEnergyMember",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_AssetPurchaseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement, Term",
        "label": "Asset Purchase Agreement, Term",
        "terseLabel": "Asset purchase agreement, term"
       }
      }
     },
     "localname": "AssetPurchaseAgreementTerm",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "apyx_CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "label": "CARES Act, Income Tax Expense (Benefit), Release Of Valuation Allowance, Federal Net Operating Loss Carryforwards",
        "negatedTerseLabel": "Release of valuation allowance"
       }
      }
     },
     "localname": "CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ChineseSupplierMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chinese Supplier",
        "label": "Chinese Supplier [Member]",
        "terseLabel": "Chinese Supplier"
       }
      }
     },
     "localname": "ChineseSupplierMember",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "label": "Electro Surgical Disposables And Accessories, Cauteries And Other Products Supply Agreement [Member]",
        "terseLabel": "Electro Surgical Disposables and Accessories, Cauteries and Other Products Supply Agreement"
       }
      }
     },
     "localname": "ElectroSurgicalDisposablesAndAccessoriesCauteriesAndOtherProductsSupplyAgreementMember",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_JointAndSeveralPayrollLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 7.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Joint And Several Payroll Liability",
        "label": "Joint And Several Payroll Liability",
        "terseLabel": "Joint and several payroll liability"
       }
      }
     },
     "localname": "JointAndSeveralPayrollLiability",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestRequiredCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Required Capital Contribution",
        "label": "Noncontrolling Interest, Required Capital Contribution",
        "terseLabel": "Required capital contribution"
       }
      }
     },
     "localname": "NoncontrollingInterestRequiredCapitalContribution",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_NoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Table Text Block]",
        "terseLabel": "Schedule of China Joint Venture"
       }
      }
     },
     "localname": "NoncontrollingInterestTableTextBlock",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "apyx_OEMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OEM [Member]",
        "terseLabel": "OEM"
       }
      }
     },
     "localname": "OEMMember",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_OtherAccruedExpensesAndLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 10.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Accrued Expenses And Liabilities, Current",
        "label": "Other Accrued Expenses And Liabilities, Current",
        "terseLabel": "Other accrued expenses and current liabilities"
       }
      }
     },
     "localname": "OtherAccruedExpensesAndLiabilitiesCurrent",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProceedsFromStockOptionsExercisedAndWarrantsExercised": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "label": "Proceeds From Stock Options Exercised And Warrants Exercised",
        "terseLabel": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercisedAndWarrantsExercised",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForInventoryObsolescence": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Inventory Obsolescence",
        "label": "Provision For Inventory Obsolescence",
        "terseLabel": "Provision for inventory obsolescence"
       }
      }
     },
     "localname": "ProvisionForInventoryObsolescence",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_ProvisionForObsolescenceInventory": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provision For Obsolescence, Inventory",
        "label": "Provision For Obsolescence, Inventory",
        "terseLabel": "Inventories, provision for obsolescence"
       }
      }
     },
     "localname": "ProvisionForObsolescenceInventory",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_RepaymentofFinanceLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of Finance Lease Liabilities",
        "label": "Repayment of Finance Lease Liabilities",
        "negatedTerseLabel": "Repayment of finance lease liabilities"
       }
      }
     },
     "localname": "RepaymentofFinanceLeaseLiabilities",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwaps": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps",
        "label": "Stock Issued During Period, Shares, Stock Swaps",
        "terseLabel": "Stock swaps (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwaps",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "label": "Stock Issued During Period, Shares, Stock Swaps Equity Instruments Received",
        "terseLabel": "Stock swaps equity instruments received (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_StockSwapToAcquireOptionsShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock swap to acquire options shares.",
        "label": "Stock swap to acquire options, Shares",
        "terseLabel": "Shares issued on net settlement of stock options (in shares)"
       }
      }
     },
     "localname": "StockSwapToAcquireOptionsShares",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "apyx_SymmetrySurgicalInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Symmetry Surgical Inc. [Member]",
        "label": "Symmetry Surgical Inc. [Member]",
        "terseLabel": "Symmetry Surgical Inc."
       }
      }
     },
     "localname": "SymmetrySurgicalInc.Member",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "apyx_TotalRevenuePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total Revenue, Percent",
        "label": "Total Revenue, Percent",
        "terseLabel": "International sales, percent of total revenue"
       }
      }
     },
     "localname": "TotalRevenuePercent",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "apyx_UncertainTaxPositionsLiability": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 8.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Uncertain Tax Positions Liability",
        "label": "Uncertain Tax Positions Liability",
        "terseLabel": "Uncertain tax positions"
       }
      }
     },
     "localname": "UncertainTaxPositionsLiability",
     "nsuri": "http://apyxmedical.com/20210930",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://apyxmedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r98",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r169",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r98",
      "r145",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r165",
      "r169",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r221",
      "r223",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r226",
      "r227",
      "r243",
      "r244",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r393",
      "r395",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r226",
      "r227",
      "r243",
      "r244",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r393",
      "r395",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r226",
      "r227",
      "r241",
      "r243",
      "r244",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r393",
      "r395",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r226",
      "r227",
      "r241",
      "r243",
      "r244",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r393",
      "r395",
      "r417",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r173",
      "r174",
      "r234",
      "r236",
      "r394",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r173",
      "r174",
      "r234",
      "r236",
      "r394",
      "r406",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r21",
      "r31",
      "r178",
      "r179"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, net of allowance of $360 and $300"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 2.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Bonuses, Current",
        "terseLabel": "Accrued bonuses"
       }
      }
     },
     "localname": "AccruedBonusesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedInsuranceCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 5.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Insurance, Current",
        "terseLabel": "Accrued product liability claim insurance deductibles"
       }
      }
     },
     "localname": "AccruedInsuranceCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 6.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 1.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "verboseLabel": "Accrued payroll"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalesCommissionCurrent": {
     "auth_ref": [
      "r24",
      "r25",
      "r48"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 3.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales commissions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sales Commission, Current",
        "terseLabel": "Accrued commissions"
       }
      }
     },
     "localname": "AccruedSalesCommissionCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r43",
      "r197"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r268",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r264",
      "r265",
      "r266",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r245",
      "r246",
      "r271",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r246",
      "r262",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r180",
      "r188",
      "r189",
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive instruments (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r94",
      "r153",
      "r160",
      "r167",
      "r184",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r300",
      "r307",
      "r317",
      "r341",
      "r343",
      "r370",
      "r381"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r22",
      "r23",
      "r59",
      "r94",
      "r184",
      "r211",
      "r212",
      "r213",
      "r215",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r300",
      "r307",
      "r317",
      "r341",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r19",
      "r42",
      "r90"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r83",
      "r90",
      "r92"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "periodStartLabel": "Cash and cash equivalents, beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r83",
      "r321"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CoVenturerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.",
        "label": "Co-venturer [Member]",
        "terseLabel": "Co-venturer"
       }
      }
     },
     "localname": "CoVenturerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 75,000,000 shares authorized; 34,339,533 issued and outstanding as of September\u00a030, 2021, and 34,289,222 issued and outstanding as of December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r231",
      "r232",
      "r235"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateJointVentureMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project.",
        "label": "Corporate Joint Venture [Member]",
        "terseLabel": "Corporate Joint Venture"
       }
      }
     },
     "localname": "CorporateJointVentureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169",
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate &amp; Other"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r75",
      "r353"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Other costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r88",
      "r148"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]",
        "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "auth_ref": [
      "r12",
      "r16"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": {
     "auth_ref": [
      "r12"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)",
        "terseLabel": "Net other income (loss)"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "auth_ref": [
      "r12",
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r17",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "DISPOSAL OF BUSINESS"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r97",
      "r214",
      "r216",
      "r217",
      "r223",
      "r224",
      "r225",
      "r336",
      "r374",
      "r386"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r119",
      "r122",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r315",
      "r316",
      "r377",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Loss per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r108",
      "r109",
      "r110",
      "r111",
      "r112",
      "r122",
      "r129",
      "r130",
      "r131",
      "r135",
      "r136",
      "r315",
      "r316",
      "r377",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Anti-dilutive instruments excluded from diluted loss per common share:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r321"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rates on cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r99",
      "r100",
      "r101",
      "r105",
      "r113",
      "r115",
      "r139",
      "r185",
      "r228",
      "r229",
      "r264",
      "r265",
      "r266",
      "r284",
      "r285",
      "r314",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r396",
      "r397",
      "r398",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion of finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Finance lease right-of-use assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r73",
      "r94",
      "r153",
      "r159",
      "r163",
      "r166",
      "r169",
      "r184",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r317"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r66",
      "r153",
      "r159",
      "r163",
      "r166",
      "r169",
      "r369",
      "r375",
      "r379",
      "r390"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r4",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r13",
      "r14",
      "r15",
      "r16",
      "r200",
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r95",
      "r278",
      "r282",
      "r283",
      "r289",
      "r291",
      "r293",
      "r294",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r114",
      "r115",
      "r151",
      "r276",
      "r290",
      "r292",
      "r391"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "netLabel": "Income tax (benefit) expense",
        "terseLabel": "Income tax expense (benefit)",
        "verboseLabel": "Income tax expense (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails",
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r85",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r52",
      "r373",
      "r387"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIncomeTaxesReceivable": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in income taxes receivable, which represents the amount due from tax authorities for refunds of overpayments or recoveries of income taxes paid.",
        "label": "Increase (Decrease) in Income Taxes Receivable",
        "negatedTerseLabel": "Income tax receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInIncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r65",
      "r147",
      "r328",
      "r329",
      "r378"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOperating": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.",
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r81",
      "r84",
      "r91"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORIES"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Gross inventories"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r20",
      "r57",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Inventories, net",
        "verboseLabel": "Inventories, net of provision for obsolescence of $303 and $388"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r26",
      "r58",
      "r93",
      "r138",
      "r192",
      "r193",
      "r195",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryValuationReserves": {
     "auth_ref": [
      "r57",
      "r194"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation reserve for inventory.",
        "label": "Inventory Valuation Reserves",
        "negatedLabel": "Less: provision for obsolescence"
       }
      }
     },
     "localname": "InventoryValuationReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://apyxmedical.com/role/INVENTORIESDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r47",
      "r94",
      "r161",
      "r184",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r301",
      "r307",
      "r308",
      "r317",
      "r341",
      "r342"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r36",
      "r94",
      "r184",
      "r317",
      "r343",
      "r372",
      "r384"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r49",
      "r94",
      "r184",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r301",
      "r307",
      "r308",
      "r317",
      "r341",
      "r342",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r53",
      "r94",
      "r184",
      "r211",
      "r216",
      "r217",
      "r218",
      "r224",
      "r225",
      "r317",
      "r371",
      "r383"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending interest in China JV",
        "periodStartLabel": "Beginning interest in China JV",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDisclosureTextBlock": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest Disclosure [Text Block]",
        "terseLabel": "CHINA JOINT VENTURE"
       }
      }
     },
     "localname": "MinorityInterestDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r53",
      "r74",
      "r297",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r83",
      "r86",
      "r89"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r64",
      "r67",
      "r89",
      "r94",
      "r104",
      "r108",
      "r109",
      "r110",
      "r111",
      "r114",
      "r115",
      "r127",
      "r153",
      "r159",
      "r163",
      "r166",
      "r169",
      "r184",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r316",
      "r317",
      "r376",
      "r388"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss attributable to stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r61",
      "r64",
      "r114",
      "r115",
      "r303",
      "r310"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest",
        "verboseLabel": "Net loss attributable to Apyx"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r111",
      "r119",
      "r120",
      "r128",
      "r131",
      "r153",
      "r159",
      "r163",
      "r166",
      "r169"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to stockholders, basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r121",
      "r123",
      "r124",
      "r125",
      "r126",
      "r128",
      "r131"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to stockholders, diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "Accounting Standards Update and Change in Accounting Principle [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r2",
      "r102",
      "r103",
      "r106",
      "r107",
      "r116",
      "r117",
      "r118",
      "r182",
      "r183",
      "r186",
      "r187",
      "r237",
      "r238",
      "r239",
      "r240",
      "r267",
      "r286",
      "r287",
      "r288",
      "r313",
      "r318",
      "r319",
      "r320",
      "r332",
      "r354",
      "r355",
      "r356",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest [Abstract]"
       }
      }
     },
     "localname": "NoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "auth_ref": [
      "r230",
      "r299",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "terseLabel": "Contributions from non-controlling interest",
        "verboseLabel": "Contributions"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r229",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total other costs and expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r153",
      "r159",
      "r163",
      "r166",
      "r169"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Loss from operations",
        "verboseLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r331"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r330"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r18",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other (loss) income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "terseLabel": "Other (loss) income, net",
        "verboseLabel": "Other income (loss), net"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r22",
      "r40",
      "r41"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from the disposition of Core business"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMinorityShareholders": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.",
        "label": "Proceeds from Noncontrolling Interests",
        "terseLabel": "Contributions from non-controlling interests"
       }
      }
     },
     "localname": "ProceedsFromMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductWarrantyAccrualClassifiedCurrent": {
     "auth_ref": [
      "r48",
      "r209",
      "r210"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 4.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers. For classified balance sheets, represents the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Product Warranty Accrual, Current",
        "terseLabel": "Accrued product warranties"
       }
      }
     },
     "localname": "ProductWarrantyAccrualClassifiedCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfessionalFees": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.",
        "label": "Professional Fees",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "ProfessionalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r16",
      "r60",
      "r61",
      "r64",
      "r82",
      "r94",
      "r104",
      "r114",
      "r115",
      "r153",
      "r159",
      "r163",
      "r166",
      "r169",
      "r184",
      "r211",
      "r212",
      "r213",
      "r216",
      "r217",
      "r218",
      "r220",
      "r222",
      "r224",
      "r225",
      "r298",
      "r302",
      "r304",
      "r310",
      "r311",
      "r316",
      "r317",
      "r379"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r27",
      "r28",
      "r198",
      "r343",
      "r380",
      "r385"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $5,145 and $4,813"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r70",
      "r190"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for allowance for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PurchaseObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.",
        "label": "Purchase Obligation",
        "terseLabel": "Purchase obligation"
       }
      }
     },
     "localname": "PurchaseObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/COMMITMENTSANDCONTINGENCIESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r242",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r242",
      "r335",
      "r336",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails",
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Purchases from Related Party",
        "terseLabel": "Purchases from related party"
       }
      }
     },
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r242",
      "r335",
      "r338",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CHINAJOINTVENTURENarrativeDetails",
      "http://apyxmedical.com/role/CHINAJOINTVENTURERollforwardofJointVentureDetails",
      "http://apyxmedical.com/role/DISPOSALOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r334",
      "r336",
      "r339",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r274",
      "r352",
      "r419"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r229",
      "r268",
      "r343",
      "r382",
      "r399",
      "r403"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "(Accumulated deficit) retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r99",
      "r100",
      "r101",
      "r105",
      "r113",
      "r115",
      "r185",
      "r264",
      "r265",
      "r266",
      "r284",
      "r285",
      "r314",
      "r396",
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings (Accumulated Deficit)"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r144",
      "r145",
      "r158",
      "r164",
      "r165",
      "r172",
      "r173",
      "r176",
      "r233",
      "r234",
      "r353"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalariesAndWages": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.",
        "label": "Salary and Wage, NonOfficer, Excluding Cost of Good and Service Sold",
        "terseLabel": "Salaries and related costs"
       }
      }
     },
     "localname": "SalariesAndWages",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r25",
      "r45"
     ],
     "calculation": {
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": {
       "order": 9.0,
       "parentTag": "apyx_AccruedLiabilitiesAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax payable"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and diluted earnings (loss) per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r26",
      "r37",
      "r38",
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INVENTORIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/RELATEDPARTYTRANSACTIONSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": {
     "auth_ref": [
      "r72",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]",
        "terseLabel": "Schedule of revenue by geographic area"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r153",
      "r156",
      "r162",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r153",
      "r156",
      "r162",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of reporting information by segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r247",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r249",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of stock options and stock awards"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of option fair value assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r140",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r176",
      "r203",
      "r204",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r142",
      "r143",
      "r153",
      "r157",
      "r163",
      "r167",
      "r168",
      "r169",
      "r170",
      "r172",
      "r175",
      "r176",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "GEOGRAPHIC AND SEGMENT INFORMATION"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONGeographicDetails",
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period",
        "negatedTerseLabel": "Canceled and forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Canceled and forfeited (in dollars per shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r251",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)",
        "verboseLabel": "Strike price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails",
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r247",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r257",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r5",
      "r140",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r158",
      "r159",
      "r160",
      "r161",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r169",
      "r176",
      "r196",
      "r199",
      "r203",
      "r204",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/GEOGRAPHICANDSEGMENTINFORMATIONReportableSegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r62",
      "r63",
      "r64",
      "r99",
      "r100",
      "r101",
      "r105",
      "r113",
      "r115",
      "r139",
      "r185",
      "r228",
      "r229",
      "r264",
      "r265",
      "r266",
      "r284",
      "r285",
      "r314",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r396",
      "r397",
      "r398",
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r139",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r29",
      "r30",
      "r228",
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares issued on stock options exercises for cash (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r228",
      "r229",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/STOCKBASEDCOMPENSATIONSummaryofStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r228",
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Shares issued on stock options exercises for cash"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r34",
      "r35",
      "r94",
      "r181",
      "r184",
      "r317",
      "r343"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r63",
      "r94",
      "r99",
      "r100",
      "r101",
      "r105",
      "r113",
      "r184",
      "r185",
      "r229",
      "r264",
      "r265",
      "r266",
      "r284",
      "r285",
      "r296",
      "r297",
      "r309",
      "r314",
      "r317",
      "r322",
      "r323",
      "r327",
      "r397",
      "r398",
      "r426"
     ],
     "calculation": {
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r275",
      "r280"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Interest and penalties included in income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r281"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Uncertain tax positions that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/INCOMETAXESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r121",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r119",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://apyxmedical.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8475-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123377177&loc=d3e11281-110244"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12524-110249"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(k)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=124433917&loc=SL114874205-224268"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r421": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r422": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r423": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r424": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000719135-21-000072-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000719135-21-000072-xbrl.zip
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M$QWDBP_FB'$#'C8( QDKH/ R0*3&2MH)F9-9AD1*9$K/0MI$:5MB/:)8HU7
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M1.T?-TM*AV)P!)(U7K@&*K/;(]@EE="Y-4=1'GU[<T6"4NV[A<G]2)3' =C
MJP4BVQ\@EO3JIW@=*KCO+^2@*]F(QR>0*NH!%8:91D L)=\-M<;*6'B/1[%0
ME\%#H^*(B;Q;=7F+5)AI(+H'=D7(L"GC[K "SS&2;![1>Q_/A)JY1D&*=&L
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MU)/Q@K4&!J$QZ>#W-^/7XPE$H1L./2/?NG7#N2L6IQA )A_(Y!&3FL]XBBB
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MW3SU*=9@/0%.XAQ.@'>,.&K /TZ82T^"MFP*_?98:]B)C;R)Q0?HMHN]O,V
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MWCQM+J(=YYHNBB1JM>"<YE6[&@,%<,QP9S&=A_3HNP1FSQ=58%0EF1AA@83
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M=TS9"_/")?HKBI]*(^[H@\7#H7'%;XLN_PDRW=)%>1S>U&_2!> $PAN.L)=
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MD+2.1I>" EF!F<I9,M-Q+B&9D]S*,4467FJ"U:1S*DM4&@F5;M4-<Y%++JQ
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MB<'XE,#&,4, 0Y?6"%U6IIQ GS7#FZQ_7!K>TPQOV#]6R6J:P#_F)A+$;9)
M-"-&+@DNM"9<>]&OK")F9L0K)\U'<9!C WX\7*X<QE;,6Q%G1]F&9KU5[_8Z
MQ7;!Y13ZC+C0?5&][0L*\&U]2$QECM C\&[WAF/MF*>)\H0(H!OB2=L^WD7M
M4@HI:DEE=JPE&76SDC*D/T>&/6$?O33L9S#L&YZ["E%0KU%,>1LBHL%Y$"0@
M3%S@SBOGD\T9,VK4B%EIV'-EV),- I2&_0R&/1P:L(EZ0KU')!F50P,)@6[G
MS#A.< !&1KTK0@/"E):]P)8]X2A#:=G/8-G#L0>M?%*)*!15'K(Y*XHT>>0-
M&"VCGJ5@<D4U:6:?BY=U( >;N[=[ME%IWU,GHJP,.3OAANV3F,&L=7@%9F4D
M=:2JMGOK&<F*Z$)M[R.OK7\5WEA!J4#!P%^<!HD<,P8Q1WB"80L\RU@P%4S'
MM<]@6<=J^E8[V5A":;5/MMJ+(:LU)H6$540J%+N^1(:<S+7E(XG)>(&9+^I9
MX9'=B])H9]AH)QHG*(WVJ49;&QYJ*>?:>6Z1\ 0C;N"3I<FAQ!6/FI* E5]:
M8X](D"NM=H:M=K(Q@-)JGVRUPT,M<5880AB2RD?$M=#(!B>159J -TD-TVII
MC:IES<K:D0^.8LQT..!]WA4B==K-2KMO3>W6DY;L/V'[X-E#OC\F&QOHP@O#
MI\=AX%;+MYLQB[-$P9%0</-FF"!*HI,4'&D:-0*/T2&-N8"_/&'$)*Y#R#G&
M1M[.N/ISU(CG-';8?=9)CA<+ &,(,Y0 ,"4 N!%Q\(D9937RB0(-DL8@'8U&
M&$L<6# ).Y]SD)BZ/>]1 L#+!8"GARQ* )@. -R(7A!G-*.:(ZR5S=M92F02
M)<APAYT*+D5%^JL=[MA+JD2 %XL 8PA_E @P)008I@  W(1HH9!D'B,>G$*&
MD8@PE\+9P+'R&!! +V-V>\N;N4" LEC!;5O? EONQ&ZO4B\,J:Q0\/28QC!2
M#3JX#U0_<*M$JY'0:NMFQ$)K@"G/)6)1 U]Q!!P6C0,X+(S#N&,E"SEN.ROK
MP\J%F>,+&93V]2SV-<P&?)()!VN08&!:W!F%K%&YV)AT EM"G>-Y$69I8+-F
M8$]WR4L#>PX#N^%P.V.\PR(B%H) 7":-P/.F*"@;B/#..TN7UDQI7S-F7V-P
M>$O[>A;[&A[ 4O(Q"<.1\L'F0ID&6<8ITA:X/7%!2I<7WXTZJS^GWNFBE1#X
MX;9>9?&_L'H!$YZEOQNPR@5'CP&JZJT4?2<]B50A&$04XBH1Y")S2"7L-)8F
M)@96?ANF1@ZYS6EH?<'-\]D<XM(\'VF>PSPBB, $21(YDGE$T!B9%#T2)D;"
M0' ^"> 1MPOFE_:Y&/;Y7/YT:9^/L\\;?K1(5NED+,)"Y#TM;$36.0F*HZ/R
M/@ANXUU^=&F>"V&>S^:.E^;Y2/.\X893%VFP>8K&Y]+1-"%'(]BH]QZ+:+@6
M!-CM3-MG.6]\VT:WB]7T?S3:W>[_S]Z;-[619'O#7Z6"N<_S=D>0[MR7[@DB
M:(-[F*<1ML'3U_['D:N16TB,%MOXT[\G2Q)& FP$ DHHY_;%6JI*F7GR_,Z:
MY_P\B1UO5MWX1#O)/U96_%S22U[SN<R7"4RUXK @U4)(]6K>#N<X8,R21I3E
MDT#8**0EZ!6.40O6&?.6Y@PX<SFF?!U4%6_\2IC/A=L>A-MF]0)I5) Q<N2Q
M<:"V2XE,4+G(/9?4DN3!OM[8DC=W>Q5F6PE;N##;0S#;G(WL@4K"1XT2B#%0
MPIE#-EB,0HJ",P#/X.K4SIL?[BK<MGJ!YL)CR^6Q.3\QH8"$V*.0F[-P#SQF
M+!'(&6* -H1RKW/YA\9D=#0BWMP0&_?'=>-N9>DNGOV^!B=&[MD^;O6ZO2LQ
MK@#<0@#W9MX^#H0$;(E!4O.$0/=+2&-X"[0CT=@48IT1:I80J7ZDTAF/<T)L
M#5C^GHWTPO)+8_E9G<928F-D D4I,1CI+()][L!N,%9X$I6,%'0:=9\U(0K'
MKR;'WZ^GH'#\LCA^SE-@<* N28J8CSDK/6"D-5$H,$Z$#R;)&!?S%!267V&6
M?W1W16'TI3'ZK&CG1J9(%$,V-Z[@(GLJ2."(L4@B(4XD#8PN^*)%[QK&[:4&
M_L6B=RZF7C].G!C5T'ZY6_7[542T%:AO]ZVDQ8M^[^0YC*C='<$R'YQ7*_R]
MIN/XNJ-,Q=TOP[X%,K6[MG^V-XPG P#./)=^K^X9,DUJ*JBY$&J^G?>!*)!Q
MD3J+%+$)<2QSC0RPCQ1G/$8EHC4AE\DB<H$R68]0"6,9I7V?.O<_4G&[POT-
MXOY9G<E)JYF4 ;&0NQ-3>*4=M@AL(ZJET4P1G;F?7Q'D*=R_8MS_.)7M"O<W
MA_OG*^1I3A5L"L2!S1$WPB!CA0/R2\Z=,=;D^OZ$;AI^N95.8?_58O]'*FM7
MV+]![#\7"V&12$$)DCJ? ]0Q(I,3J;)!X$7TC"H)[*\VN5:-9O]&Y'TT[YC#
MU6Z3O7-7R;320/63B]V8VL-+-'WBI[(>M^3 !.\FWM_?QR0HF+80IOEY=T9R
MQEI),"**>L095LAZAI$ECE))M0X4&%\MRP>\HD&=%>359B1G%*Y=$M?.:B(L
M< !2$9'R#H,U$@+2S'@4H\&*<N:D,L"UI)0D6"&.?=R*!(5/E\&G<PX#3522
MPF+D;="(2RJ0I=H@*Q33AA@_;BW&%^T&6)CUL9EU93P)A:?OS--G<_VT$_%<
M$43 S$><8XVL,PYYY91*21L5'<C>34)N?DSXB5<T:+1]WXK#*I_LN$L:Q!JX
M0Q\I$^)EOP>859I[+(Q;'RXE+GA-E? ,$<((XH+6P0L KUR$Q5,1"*4Y=$G9
M$F(7S0]?K '+/E+Z0F'9V[/LG*I!*:,)&\0\S?UX%$9.)X&TX=HX8H)-N7+2
MIBHL^U18]G%R#@K+WIIEYRQ^%5(*!@L$1E^V#CA(63 ,$*'8>(L-C=IN;!&V
M2<P"+;0*SS:89Q_)O"\\>WN>/9M+Z95*2160I@0T8RP4\*S$B!B-/2/"N5 W
MNMED:@&'^A,\[;!B)1VN9NVQ9_7BWZD'H++#8;_M1D/K.K$:]BI8&G0ACZ9J
M3Q)IKG45W&VI5AL&[Z^H ]#G6U;4]@4:'?5*HM,2 /'O>5=!9%@RRAFB(5K$
MD]/( ;E0-,9Z4$4]Y3KG.?X8#$LDH;$6?>&Q!^:QN1 ^PXPZXI D.8R0@D?6
MP%M,"+>:18=S"'\)C;:;&!-<9SEY?W41"@_?-P_/-Q[PF5,Y1B(0##R<!+($
M&%E20X2UA#(,A@.]P4' (B<;:Y(7'GM@'IOK2<\HQ2E&)&PNJFB=0#KB@&0$
M#E/11^)4P^5D";7/A=HO&=J#8<__?=SKA-B_%(>_^SFDQKD@_N=N<WPZ./U(
M204S(%X >A& _K@][RQP1$D3E4%2"(.X<KF]"Y=(1,=QXLY0;.J\ KI /E2#
MSD06_'FZ^/-(&1(%?^Z$/W/1FV@\IKD""U$:<1(MTDEHI'.Y;:PDEFJ<)$$7
MJ%A7\*?@SXKY@@K^/!#^S#F!K.'P']$H!LT1UR(@RX-%4LO O'<ZT33.^)"K
M61.F -#3!:!'RETI '0G )I5@*(5B@?%4=0\)W9+BC0V"0EOB$Z6:>;".'VE
MX0"T%#_9])(I2X@:RQXA@'5A!1DL4^B-LK-K/@-HW7]A-4:Y0K]0G,T7R]V>
M1@"$8]N/O]X@XK; *I=+[W6?W>WAY<I&9H4VK^#3U?KS[W;0]I7MABJT.Z-A
M#'>))*ZX/72C*:ZP.?0R]@^S>%AN7(I>FSZP:_M=6+?!]'=WQCOLW 3"Q02Z
M@0ETJ7$W4QXGF=N9NMRXFXJ$# T!Q224-8%2&MCW"ZP\]D:H0:=L@[MM YYB
M#%HJ) )C.5=$(IW/.2?J'$TA**'<QA9^=D7F<I/S1Q8VGHJ >NH"ZHZ!RR*@
M[AV9YGKM!&.-R=7BC0J(2ZZ1I8!1R3"?I)),Z=L)J ?;"$5 +6$;)$:9)(XA
MBW5"7$6-' 9E16CCI+?)ZR!J 74Y9;@(J"*@5DE W2VR7034?2/37!0;2\X2
M\PXY8>BX.I#6 B-AI0-4HLFK<#L!]5 ;H0BH)6P#9S68NYXBXQ184(1@9%DV
MHVP0U$<LE$Y90+'+N51%0!4!M4("ZHZ9#P67[AF79A5G;816&#.$>=*(!\YS
MT4T#BK,.(+J,2Y+<2CP]V#8H>LIR-D+4+EB>D(PVZRG2@*CB MEL01DI@Z&X
M%E"7JRLU64"5:.K:7%F(M4)7%F*MT)6%6"MT92'6"EU9B+5"5Q9BK="5A5@K
M=&4AU@I=68BU0E<68JW0E858*W1E(=8*75F(M4)7%F*MT)6%6"MT92'6"EU9
MB+5"5Q9BK="5A5@K=&4AU@I=68BU0E<68JW0E858*W1E(=8*75F(M4)7%F*M
MT)4UL7ZIFU' ;75/BLG5DZIL\)R./1W$7Z<O?IL^IMVM3Z/4-_UV8OL?VETT
MSO?^-9<YFLL$KS/%QU__]KD=AL>_$OI,$?-_-LXWR^2')]\^RZ=;SJ<S\YW1
MSPR^_FO\C/R?N<TXO> FE1&O/!?5R.=,Z?9+:'_:^F?])]^\]4_7_V7K/,%_
M^N7T>1=R]GW,G7HV'OSD$LW$.SJ.E?6^=P*_?99;C'9[0WBZ[</'W;K?Z(>^
M[52GMC^L>JD:PN6^UPVQ.XAYG;IU74X[A#>IW;5=WX:+!T/XX 1F-7AV[?PG
M@^!YDY[V!NU\'N+7?NS88?M3G.[-\?:Z<-=D9^-OMU@'(Q@-K[^E*0O-9I?B
MXM\\VOHHCI,LXN"("R)Q8;"F3GF#/7:!6F7->THWIC<=][]MS0\1N7ZT?R.;
M8(*_VLYG>S;8^&5F'4X &"8#$AQ&/+]>UZY*2O>V*N.3*R'Z7M_6U!S!SNKG
MJV!,MC%CJ8[[^:C6/WY,'P4,5<,WL,KS?,H+>."?O]@FP<"E6I7U[MQ^^?9_
MJ_W=G;WGVW]6SP]>OSQXO7VT=]"Z=N"SHH;-GCU]U*D\/VCM[+8.=W=@'JW#
M@S_W=K:/X,WA$?RSO]LZ.JP.7E3/_[7=^F/WL-IK5;NOWNP=O;V*.QM(IY_>
M=.THM %O?V[0GKH:\7[:ZX*\Z(W@&6%P_7 G.RD7GA77;*,'5HDP?H;'N+BH
M3L3H,ZG(C72B11ZK;OW4[W_'-%_Z6/4S0FZF%39AK-*(>QBK8+=;@>^-E<"7
M['9+\"B#->0^=NQ]#%8_TV(A.^8Z&^'RL=U4_^][K80;5[7Z")2=6.W#=<>#
M:A=TH% =QE/0YUWL5PQO5KE(2EV<-A]'OU4;V;E5N575\LDS)L)@ N_7- IH
M] ^49ZS9,ZYQ/O![:1-A?OR,&S?:N*R:/0QPF1OAUO/>R4FO6QWF1J[WVMP:
MGM'O?1Z_OD&CZR>RO-LPUFP6VT[UTK8# MW^N3UM#VVG+/;2%_MU'%KX,%33
M&B[53]O>CTY&G=K3MA-3V[>']]O#?3U7OM7KH@L]U*MI$_6RU$M?ZJ,>@$>U
M^]]1>W@VL[Q7"TC*&M!'J9GK?4/-OJX"=:F[^7)7HJSSQM9+VZ_^8SNC>-^@
ML=+/>%JV]'6-7#JVZV-EA]6_1]TX-9^OMYJ_A_ZS!NEMNF VKV[BM?7RZI99
M@[E2>=H'26V0,<7$E8[64,&XX($X1EGR[_?J"GGR<HO(!3I#CE%R;S 87:B5
MQQZW5M[9?GM2*^_DU9?6R5O\[FB/'OSQKK/_]15I[;SB;T_@:2>[GP^.\C-?
MX=8?;[]^JY77.CGX:__+NZ-79ZV3-U_V=UZ)UA^M]KN/_O,^W?UR</3A<^MH
MG[[[^*X]7ROO+7TKWGY]T6GM[-%W1[N?6SM_X[?TWR>MK]M?WQ[MBH.=;;+_
M]1W\PK_3M-+X_B&&,7W [[EWD5&OD0Q8(<Z,1 93AQ0VE@EKN&1T8XOQ3:#:
MI=)X__<?1.+?;EP?;R'FN._2KC_P(-PCAS<. 6]>]'6QR:\HK%WN?WM[3)N#
MK>SW..YU8/$&8YUZK^L[H[QB+WO]/(KMX;#?=J,Z+';4 T/G@ITS-7,*X"T&
M>%]G ,]J'IG0'.6"L(A'2Y"-6"+&K?(R<FVMR8!7P*Z W5J"70S2>,^#L)QR
MA9D-A.,H9%)41\^7I, 5)'P$)"0S2*B9]H2*  H?BX@;@Y'VDB/!O>+:<!8#
M(*'0FX;*@H8%#=<2#:WUW"@2+0V.!X^-H])J*3UES%.<"AJN+!JR&33T(.DD
M]0Q)H#'BF"6D@= (S&+* E/!>K>QI3:U*F!8P' ]P5"!U0MHJ)VTBCL QF0
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M*IJV06E<UQHATUHCI#25?WQQ]6H^=@SB!K0.SI!.!K1M800"584@8B()*HK
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MO<L6_O%*E'7>V'II^U5=I_"^T6*EG[$.M18NG(#8B7YB.Y-L.Q-SE_H+ZWP
M0FNN4V0F)<FU()9X%WFBW"J&#1<Y3$ ,H8R4 Q"/X.S_>*D?7\!<19L4$CA*
MQ 4+2 >5$#9:^V"DU0+7!R"(NK.O?U%!TN36V.L9_%QL\BL*;%<<@+@UJI7X
M9A,@;S:UC22+A;<&A>0-XM9%9$+@N1FI8S)*SXU;Q@&( G<%[IHSZT7R?8WC
ME#BOI78\8@ _XP,W(46E30IT.4I<P<+'P,*Y Q!*T)"2D,AY#NH?2#-D9#2(
MQ(0I%XX)'S:VA-Q4^,Y-V H>%CQLSJP7P$-O&!%."AJCXX0%1T4@DE,14Y A
MFH*'*XR'L[IA!)6>2R50+JN&.'<4&9P2"L9ABJ.11N;6&WQ3$%7PL.#A6N*A
MM)'XB 5E6/ 0A088=)8['$200K*;X6%J?XD!?8W]7H'"1D#AW)D(;HG@T224
MM,AM]T1=#PU40RR) EXPBL4+]=0+%A8L7$,L9,QK[Z/+U0-Y(DX31YF()FL-
MC$I;=,/5!<3Y<Q':<<HCIH@P'A$7*B$=?$!4"D!'2[%68F-+D4TJS$H XM-*
ME+Z:EY]G1LBLD7N!5:G?.ZFZ<^E#[1^E#Y6&'BO1JZ:0J9"ID*F0::W(]-0:
M="V@>V,+.K=U!FN.N8N@>1/CI&&"*BIU"G5A:(S)N# T_G$QAJOU9M"U^]$.
MX@O0'0Y';M .;=L_F^CA@\$HYY 5W7HAW?K-I>+K NOL3$+&:88X(0QIRRU*
M&B>A7'14Z.QWO1R$*IW<[K46GC5&4^--\IQ[I4UT!OY17)JDL-"%Q9K+8O/F
M*V72D! U<I$"C]EHD/5"(F$#4U8(G;2\FL<:V_/O2:0A7VHJ/M-"O(I?8M^W
M!W!%ZO4K;P?':]8;;L&NXI@H:A3F'!/.=#)&,*^5ETGZ8 19&+%JY]LXV7AG
MU,\N-YA&+XRI5O_]'9 K/.^=G,;NP.8A%JA:"*HN-1LWECF)DT1<!X6X$ II
M@C4*ED5JG<.1BHTMNJR$Y ;%%IXX*Y?&="M!ID5LL,"#QE2&R +'UEGBL>=&
M&.V-L3PN"V[K$UOU=P=CN;@[$8OE!,BB8#N7 A@2\X))@IRU!/%H&')>.224
ME$!4D2-<&UMF6>DNA8L+V)8.@G?N1;_>6_LQ/1A%0-V[-3!?C]!8'S2+B!!&
M$0]6@*SB ;&8L',L6I*;-#5*0JU#9+W>[)7+QB_,\9OU6\+HJQU1*F0J9%H%
MR;X$TW.!'+SM\'$T&)[$[G!PU/M69RN7V=KK3HILU=Y -^\-?!W_.VH/VL-X
M&/N?VCZ.]877T?<^=.NGU*I#T1(6TA+\O!E+I4I@NWHDG?2(^^"0]B+W5P]2
MN, \<;F$^R;%=\[-*Z!0L+LD;2S+DEWOK?VPEFR1=ZLK[^:M8L64TS:"&1QX
M[ET7-++)<D03]=I2KKA2S1-X:QG0[\9A-8C#82=F?JIZ:3;$7^+Y#Q'/MZ=G
M7\;.N\//]A0PS0-,]>/$6W<X^>T"2@N TH?YP+U3U 7-$I),1,05I4A;QY%P
MCA# *N62!$QB#?+4%8?[6L:2"ID*F0J92F2V1&:?V-;^@8$1VH/3CCW+RD?\
M_DXN5Z[FE>L0>FV!0=GI#6YG.:ZNL^S)^8$+F0J9"ID*F;Y'II\6"!$H9HF2
M6/*8.&?"Z.@%\9XZQ[3S+-W 63: "<.KA6(%+_N]U![^"0*I.- 6<:!]W9ZO
M/Z@X<2PG8VON'.)!.V0=C;#PRE@L+$F<;FP1O,GD9:_^I593J\C$3RTTN@C[
M+N% ^SG[%@Y=$H?.G53W7D9!L4 Q4H*X]!1I+!7BCEM-HI!1\8TM^6/F+*)O
MJ;RSA.AX$7T/RECS >W J,(>&R2]-(A[CY&SPB&JA7""",*]',L^)9HA^]8A
MF'VA2=:E#M/7-Y8N7;*^VR5+1JLI-IH9P@USSDM8)N&953YHZW/1R#LG\)0N
M6;?&IMWYN#8#[$F,,Y0P !(W7B,MB80_B5H&0L5267?)HG19L>U2"K=A0%A*
MX?ZH%.ZM4:U4NVT"Y,UZ(G!2(9CDD(PZ6S<L(BLI!Y5, NIA9Z0CI4M6@;NU
MA;OD&(E&8!R]XS3"6PG YPS3"O[GU7*4N(*%CX&%<V>+N,-4!\>05=HC+G1^
M92DR,B@EN8#7=F-+XDU,"AX6/%Q//+16*Y>$U]IB[@6W 12'X+F)U'J?>,'#
M%<;#6=V0*\NB=@Y%YT W)-D<MM(@Q[*?3I@$A-_8XIM+J"59X+# 87-FO4C3
M0!5X3%*8Z!1G!*SA%(G!6&!I=+"L6,.-1KRYJ%^@N0&DD(A1B1'(-(LL$0F)
MX%V,H/D'BG/M7%KPKN#=6N(=3DD;RP27&'/-O,/$IABM=-$S9TU1_U87#"]5
M$E>2:IL,D"E*Q)668 \3BT#2"<J8C0GG' B^R=AJ*("30.YT%%,>$#7</4*&
MTX79,IA2Z(U@.\].=QD)5&6(98CK.,0UR]O8B7Z2MD'NGK;QY),S!%<FQ<"M
MC80KKG70 4NJ$F'PD9^$,>_:T;,D9]Q6'=F?3\X@-OCD,,Z9TKE1L36Y$(I
M@EJG#3<I$3%.SM#+:LNY0D;8&IA:3].@NCT.%9NI"2 UYS+72G B#9):4L2C
M2,C2$)&P6E/JM!1.+3&=H@!4 :C[!BAI/(A7Q3!1B8=(M'*"$FXE(TR1D):C
M*!7T>@STFDN 4-1@Y35@%B$2<9L<<C(IA+$4-%E+<0(52Y)-+"^??"D(5A"L
MF0@6M-<N"4VX]MPKXAQWA#!GI8@X2%X0;(41;$[_,MR[:!RR01G$L0M(Y[YR
M6$M"-/,L^KBQ13<E)07 "H"M"("!91A45$I)P#!NHH8]3J.PT1B?A/R."E8P
MJ@$8-9=D$%D@+%F'<"* 42I09%UB"%OE+3.))YF;8"\MIE80JB#4O6?)6RHY
M-1Z[NJB!T!:;1(1U2G/.@RTJUNK"UWQ: ,FM(@4U" N?V_8RAS0%$ N&:TV(
M=\(SL!+9IA9-<L2O0\&XYWF[9P:H6XJG?N^D@L5'%[B@:D_8H-246^T".H5,
MA4R%3(5,:T6FIU8U;!$G)HG*2!]\3 0T:NZ<4<S3Q*TEFHAQ&SPR+7Q$?GSB
MX&KM&#3J?K2#^ )TA\.1&[1#V_;/)MKV8##*R49%@UY(@WXU[P!(7DE%@D%4
M6HJX%P19'RV*)-I@1&+6\XTM8BZ7/RK%Q>XU%2,%PC F=7&Q9+E1E%H!'RAN
M@E&FL%AS66S>2!7$6Y,;0_J(#>(N::0QUT@X"\"I0PC>7LUCI6G6@S;-FFF1
M5<5)-_5!]@M5W@Z.2Q+K=Y)8'8\R8NJ<MH3K8+12Q$F61%*)&FT71JQKNMZ/
MJ5;__7V^#V"!JH6@ZLU\7JO"RC-/4@Y4$L23C,@E+)$%7*'!P'\D:P-/,%[Y
MQ%GYT7ND%#(MVP9+R;)@N12,<F:XILP(XI@BPMNH_++@MNZ<6G\W:5NX.Q&+
MY1#!HF [E^$F0$HR:1)*FC'$28PYPTTCYF0DR2EB$MW8XDV*6Q0N7DNP+;W6
MRM9^? ]&$5#W;@W,'[HG/F%.-,K9JHACRY'QU*(85<#&$B:<;YB$6H?(>KW9
M*Y>-7YCC-^NWA-%7.Z)4R%3(M J2?0FFYP*9=MOAXV@P/(G=X>"HMPWKFH=G
M.R]M.^QUG]O3]M!V:F^@F_<&OH[_';4'[6$\C/U/;1_'^L+KZ'L?NO53:M6A
M: D+:0EOY\U8K:P7G(@<W;"(*TF0,4D@V!:P R@61N=CIIN*JP;%-PHHK"5V
M/[6DC;M8LNN]M1_6DBWR;G7EW;Q5S"0!S<=K% VCB%,AD,;:(>UB+@+#>""A
M>0)O+0/ZW3BL!G$X[,3,3U4OS8;X2SS_(>+Y]O3LR]AY=_C9G@*F>8"I?IQX
MZPXGOUU :0%0\O.!>VFC=4Y2I(*5V5.GD?:)(BFMBR(:0Q39V.*X09ZZXG!?
MRUA2(5,A4R%3B<R6R.P3V]H_,#!">W#:L6=9^8C?W\GERM6\<AU"KRTP*#N]
MP>TLQ]5UECTY/W A4R%3(5,AT_?(]-,"(0*:O#:"<6V]XS(PJQ3VR4E"(R8F
MR1LXRP8P87BU4*S@9;^7VL,_02 5!]I"#K2_YXOU*>&H-Q@C&EA"G&J*-"<!
MT5Q=QO*4.#:Y$-8FD9?3W7Y^"DS\U$*CB[#O$@ZTG[-OX= E<>C<277)?0P^
M* 00&Q&\4<@)>"4,SGU? ]%!;VQ=44OS$G<6V;=4YEE">+S(O@?EK/F(MDR<
M"D,($D$S8"W*D?-.(26-IIP%+RT="S]S.8+T*,)O':+9%]HI'<;3X:2?$J[[
M*9&[A*XGO:O&D[O4ONH.+32;AV.+A;Q9L, 'T6.*!4^,&\ED$%%CSPA7SM65
M(^^:WU/Z,-T2N5H[VY?Z,'E#8SZ;0D0@B$L1D4E"(Y U/A*F L.^[L/$EA;Z
M7@;S-+SR[;WA0^,@]K8M=N^V-"L*F9<UO]OC92FFVP0PG76!>*N-<Y@A:5-
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M,0%5B"6'P\:65,LZ,5;TWP;R[1+4W\*W]\VWLRJO39)+HC5BP><C2$8BEX1
M@0L:< *.SJ?FY=+.'SUQI7=5%!.P&#^U!YF=P<P$U?83:,*]_EG5RQDW<>!C
MU\<UJVOZ&/I)W0[CG!8O>OV]*24.+A"B(-PB"->>TTQ@1S+)L4&8:X6XXP9I
MXS'BQB8?;1!69J/^LD%?:G(^&89=FF)2&/8^&'96)7$Z1J&H01%GE81;@IQ4
M$B7,F A18Y?TQA:G3>JH]0@J2?.*OC="+UMMAU'VX>=F97DI>@/;R;FFI_WL
M=QR>U0ZDW-;O-/LMB_?H(>*HL^;H'[;=S10ZZ!X"O!^DEQ/*O.S8[G!W2IF"
M_@N@_\'S.74M <(GQBC")$I0UZQ FCN!F".$)R9!/"M _SN#?_$C-9>#EZ"N
M78R>IO:7&-#7V.\5AGX(AIX+JD9OI-&P@[T,B*N D2- C\@<3=@:'JV^T.RI
MX5Q=O$R+]&"M&ZS6O8DK?Z$Y<?$L-:.]=%U^]O?YUM$%[A:!N_E F,9*2>\=
MBB0PQ*-SR,C<%EJS%(40T2?1O([0Q>/4;!6F,/(#,/*LWA*-($9I@< >(:"W
M4(6,91Z%I&QTA#-I7&9DBB\W@6D:(Q<?S*UC8[;3Z7VN:^_G=[D0PC"-.O6Q
M^E%] +BX81XHB>>BVWUG0H?M"1D*U"V2]WITJ7B^8$PYR10"7!.(>^Z0]EPC
M1W4,T5*2<D,=4;PN3YAAEYZ]4QAVF0P[6\:2><=(( :Y*#3*;08SKV*D.*&.
M2Z!2\AM;7,O&<VP)DA6WTF*8]OS8=C_ XV8S\@>#.!S4,;).V[IVIV3G/ZJB
M3^@SVO2-=-2W(>;#'[']*=<563=M_H%/IR[@T-CK^GZT@[@3Q__N=:>*P^MS
M:A458B$58G]>YS<^*N$-J/O*I5Q94""=H@;R64X)BXI3G1T<1"ZA$';1^)^F
MQG^;XZJ%N>^#N6?M Q(),=Q8I)4"#A=.("<U1S9XBAUSV@6UL44VF;ZS]W*U
M+82%E.-54&I>]N.I;8<J?LF!@#A6B7O#X]B?Z,AK%GU]8"7G1U W(<].3+'?
MCV%W3*7M;CC()-JN*53 ;R'P>S6OV=!(F%84((]+T&RLQ<C&0)'!H-4PXIAT
M=&.+LF;T+RZQUP:6X2AL_!AL/*O#"&&D<]0C#%0#*\4ZY%BRR!FAB)/"N01L
M;#1I,A\7C\PB7 Z,UCN)U=!^66.WS.-Y9:[/E+V,@&-2'=DOL9AMMX6\-_.:
M"PLB@+ BR!,O$5 T(.==0I;QD*BG$FRZU4F6+:Z91]5A[N22*>R]%/:>U6@B
M9S%9"X8)(0IQH2W2!%MDE-26AAA4CMK*37U%VZP&N5R+0V8QG69\1/A[!76+
MS?;8\:4+5"HHMQ#*O9U78GPRS.OHD4^! \IQC:SV$5&A.#7!$:ME]CV#?&NR
MY58\,(WVP!2&O0/#SO5$EI8)1@+2AH-:(B,P+%,2D229IBI*B\7&EB*7TS\;
MQ*[%T;((,T\CKM6I/<N:?7&Q-%4QF5+JY9A0!>L6PCH_KYPHA@/CDB&L25U=
MQB$M6 )=)5GJ0THZ.Y7)IA!WK@A5_"O-Y>H'4% *X]Z1<><R6B1C03N!O,/Y
M/)ZCR'$2D10D*B<IU0(OHXY;\9XTBJ>!B_JC&"YDL5Q([UXS?\IJ:2V9;']^
MHU7!OX7P[\.\XA)Y2I13CX+/=2QC3FH1@:#(%1<>$R9,[561N)2R7#7&7H$>
M,X7%[X/%9U6<9!VCB4O$DO>(!X?KLB%()4:IH4+7+:3H)A.-=IPVPA/3$*7F
MFB:M-^DL<Q>7S+6-#9\Z.CY2$ST@:&ZH69]X#C'\?O8&"+O7/9B2=?N<J@4C
M%\+(O^?5(,LD]M&R; 9*4(,X!C/0!!252!BDH/6*U3VZI+Q+?N]"?+1"7IVU
M!89'4IL*,-P?,,PJ3S@*K:Q,R' 1<])_1#IQ@2P706'F&1A/V3^TB?GE(T\K
M 0R-<!PU6J^:;VJ=&YL,EMC4NE0$>.*EOT9]?VSSH;E2=[T!I^=>VK.Z1>=1
M;]O#^O?C3'WF[6XH)9IO)3P_[EZ*BD;81C%1Q"SAB)/<^9;GY'.K*1.:41/)
MQA8S=SEJ4\*A#>;=Y1?_*KQ[;[Q[-L>[1 DN'5*.,\0%D,A0JI#2S#$A(J&*
M@^)KEF .KZANV[R*7641FJ*PKJ"5<\E[O)"9<X,(VK7&[1KXB>ZO>] UKJ"]
M*?&**^B6$O%2_0?B(N%**82%RDUM0SXX;@1*SA@E#.>!X+MJLXNRR@H%T->9
M_9?I)B[L_U#L/W?*TDDC*,[5JW,O>L,E<B&7D3#2^"2H#5K<52%^7/9OA%.O
MT3K2O"<XM;NVZY?@";ZI2Z%YSVB$8KTRGN!^#\8?)KMG4#>RZIW6TB-^B7W?
M'I3LTP=LD%[3X@60HFXI=E 38K [(438[H:_;+]ON\-OGQ4ANI 0O72(UW+%
MI ;YJ3@CB'-%D%5"(A,]4U@%[ E@PQ6AU))K^F38>.EMTPL;WS\;S^K"1EI+
MG0>^-?DLOG44:48UXACT7\YHP"S74&M^+[KB&VV*WK\J*MSK>#J.0>5@_EC_
MCU4GYZ[?^0C1>L0$EZO%G9.CEUZ,B?%GID4Y/G!;K+]T0@BSH&6D!F$=%.+)
M6V2L<0A[19TF/ '5-K;(G>IEEB!^@QEVN?I:8=CE,^RL<B9)HIPSCJR,$7&#
M S)2*<0H)4D:HK FF6%YDQFVN)46:5T%5_3;;E0;/F/?$JP&RES<[W4ZV3_9
M!H;NQ\':U>E_Y-:BYZ;I?KO;Z[>'9W5/Y>->)\1^ ;K%@.[2H1WA-0DV,D0C
MQH@#]0#H2$*46(*]IS1AFR,RY>3R$^;:^^@O6KAVJ5P[5Q:.)LY$X"A1"^I)
MI Y9)BU*P3K%0OXJ<RV_W!ZL:5S;"+])0Q23'^24G4[R$RIWMEC0=-T.'SZF
MOG)-+LF+*;U*+LGM,/#KI<;H6%J*#8DH)*H0I]0CQSA'G%%+-0W&6;:Q=<51
MX]M5G2KGC9\(RR]=V2DL?W\L/U]HSCJ;*PP(*;(;-3'DA.9(IB (MX9YG(OT
M7_:BK@[+-\)GTVA]:#>EZ.O(4?SBZW[C5=\.\\'0;JTGE?3ZIJ77CREVD'8G
M]'H-Y#KH9LS,_Y]/FWT"5*R;S Z&_;8?QI"_V.Z&V0\N7%F0="$DO72J5# B
MDC$D.WL(*$\X(!>(1)C[@&, "U*JC2TJ5S8/MZ3A-S>256"BN3!Q^0 KMIHB
M$37 A& &:9$P8IS!#G!.$4LVMLP2:MZM<[K^JH3(:D_46.-JCW6MN@!'_2)^
M8[KBAUJ=ZGAW0M>7L"R]<+G\J.^,,JDNXO@8VPL<+P3'>_-:6^ ^<AX!A+U-
MB&N?LQ*D1'4-TN29H1RPB9!-?*>&,,7C]<3 Y9$J[!5P:3:XS.6C:[ %G0I(
M.Y;]Z:#F6:P-LBIZC+D&BY'75?JH6M'RG<6W=J.SF5?I=)N5BQ_:W6Z...8"
M;#5SEC2HZP W62HY "YV6'.<N\EBDXBP3FG.>;#O]S+.$LK('5H[%,OXX=!R
M?UX5HP"0&E.'.&8><2L-,EI+I'-7/L&T%L%N;'&R:>[>]Z:D3C67TQGS&B;J
MK F<)^(T<92): Q.B5%9<SHQA=-7B=/G<JT2]=)9C()CP.Y 2J0-R^7<!,->
MFA"DW]@2^LK6X$WC]$;XNU95!8JYT=5URL^M%=X;V9^-\P7^S_W-_\G(!FYL
MC!A''X3DUB;ME"..&] ,&392U5K@71M\%=GP<++A4CDSFZP,AE'$J-.( W8C
MC55$4DOCJ2+*&[.QQ?"F-G=.Q5V4CQ[9,5?PL.#A'!Z"2JR-98++VI^4NX7:
M%*.5+GH&&O38*BYXN$IX..=#%-AA[#SR7G'$70S(40&OHE>$L41\+GC,V:9@
M=RY/\[AXN!1%>GK)E*%HC:"/T+7BPB(R6*;0&[E.O+2*C]U;8VFC+%;0C:R@
M4PNL!-#[:RG'5\Y-7R?_]R:'HN_BXWAJ*MY54WPR6MS2CTQ-=]!+@)M6+''<
MQ70P?ZEA#,:2X&10<($@CAU%S@J"E%&>@,X-"C=@5?-/ABZL2A3$>:*(L_03
M6P5Q[H@XLU:?4\)@*2QBW@C$>:ACH0QAI8P+E"@G8B[JWWC(:81=L#J*G^^=
MQ&IHOZQ=J;['U9;RLA_E5<_P5;!K(>RZ5)G/8V9UL@%%3!EH2U@@+25!(B:L
MO7+:<+RQ199UBKQ!#OK"H_>H7Q0>O1./SNH70BI%:$A(> 46C642:2$U<CHR
M%J6W6(F-+7&Y%E_3>+142BZ+4!:A+$)9A+((91'*(I1%*(M0%J$L0EF$L@AE
M$<HB/,(B_#*TKA/AW]#^M/5/^#.]XX*_P\<<+YOX\;;^Z?J_;)W[5&YZVP.Z
M_VAV_QT=Q\IZWSN!WS[+IU:[O5PCSO;AXVY=R?]#WW:J4]NO2\D-X7+?ZX;8
MS8W;X56=1VB'\&92:A<N'@SA@]QV8_#LVOE/!L%S].:T-VAG/]2O_=BQP_:G
M^-OG=A@>3QV4%^X:.X]^Q=]NL0Y&,!I>?TM3%EK,+L7%OWFTM;_3219Q<,0%
MD;@P6%.GO,$>NT"MLN8]U1O3FX[/LR)/[8>(7#_:OY%-,,%?;>>S/1ML_#*S
M#B?M[G1 BL*(Y]?KVE5)Z=Y69>PL#-'W^K:FY@AV5C]?!6.RC1E+==S/_N]_
M_)@^"A@JXT1FE=PH8USFQS8)!B[E,=:[<_OEV_^M]G=W]IYO_UD]/WC]\N#U
M]M'>0:OQ V\='.T>5D<',.C6SF[K<'<GOSH\^'-O9_L(WKS8:VVWGN_!K Z/
MX(/]W=;18>,G]=.;KAV%-J#JSU>AQCFW7B=C;@8FC&Q\?PT^C@;#=CI[1,I6
MY%DU#DY<_CL)7+5&)_!\OX1H\FQLZJ#_P7;;7VLL>'XNY^#-=C>\[,<![(_Z
M[<&DM10(OL-SN;?3'OA.;S#JQR,8T^^=GO_[<4-:7_>G(:V3O2\'1_OLX.@_
M)^\^OCO>WWDEWO[U^OC@C[=?]G<\;QUU.@=_O<)P[^<_V>M._-?KLW=_A5-'
MN7S[<5?L?_6B]=>[D];)[N?63N?XW1^[_-U'>/WU SGX*X?(7L,X?\^]HD3K
MU7L5!+-1:60D-HA'F5\9ABC7.F@A%*%Q'&5L=T<Q;.>S*PE[%3BER?C(=? V
M<1>T-5X3AP,V&U4<>'N:]VI_!)+B]^W#O</JX$7U\O7N(?#W!+AFML>-$'AV
MOU_%7/#,R5AKVH])^L/Q/C9_7:V0;$^G=O''KPWV/=2H3L^^5/LQY( A2-#^
MZ40:5S_]WW]H2O%OS\>:ZL9FM;$-U^9_V\.-^B#RH WCL?T*</MD\'/UV0Y
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MBJ#KM\US,Y;=%5L]AJW&13? (*72$T2E-H@'Q\ "401AYP-6GCL?&8AN,F6
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M'BM9]1S@\Y76]_>\=%Q+RY"QN1<&3BX?#4:$M=,Y:X(8)A:6A5DD^'HGG >
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MU@)J'M5^:[9KY]%V>]?J8,YH_O,+SS>&#S](=QLQ7&%,_D,XZ>8UO1&8W=W
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MX2/&UR8O"&Q?F<P[W*S\;@=KFIK%5MIC&.E9$U3F"$OXRV#L"><I54DF1E@
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M1),AB%,CD"92("5)3#;)"%R_L S/GI%Z\5BG7*5>S&KW&:@73HK$J'/(Z5Q
M7I" 7"X-'D**TGI&4I"@7BP20I]>P7A\&F6E8#R"(+Z>@H(!U@0/U&KD X
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MV9[)V3Y+M4:GGU<)5,7VY6TY16Z_ Y\NQ]<Y;K8'U ZD8LOZ2Y.G-\"+L%+
M1 6SYP1^,'%[)4A,KE!>[J'^F=]2E)$_ 1WTO%:<.A6/MOO[>3[]N%@F]&?3
MJISNT)J"AP>84V]XT#U,5+XZB\J'5<W^,#<0'M ;5X9+_K>]@UK*Q2&6:O^>
MV!KX #A2;'.P1S#UK#AGQ!H?XM7BMII'@V/;F[;Q&+1S7YBE,,U4*U7W 5U<
M[G'>SF*Q+I^Z.++N5\37+/1X4-![S9RZ50S2=WHWE$HHN>02VK(:?V!_QI&E
MO%S)@>':N<&@>/BRO@_D*T^E<N61*^AOEA1YYU'IT+F:*TL,8.PTEZ2P1>IJ
MWN<2F^"J_*QF*&#ELHC%4!(/2H!X6(C"3K.]3ALN. <MLE^X%<*EG^/RQWCY
M8Q%L</6BRZ</AV!K1?6UDJ?;G>';1G"V^+V\U,5^/PO>X;.!/'.*-G X7-@M
MT>,(<.4(@'ZD<LGH0X8A-L68KU9B9%I#XE\$]:!?P,JUT2\.B/'6%1F$R@P_
MEJ^!!Y3#R&)K\-Y0&CI7WG)X7UE&YA>L,GH:OMZN'0%_%G@/R#A:N^7P).P7
MW%W,[S\GS6YY?CFR?)>[6VPVP S@=>=R7>!:=Q64M)BIZ*0HF5.R9Q9R$^%/
MO:M)OPT.O5FS_W+2!<6V5[#IT(1]"[.]&8]6;@T:N1YM<3Q<&7^U,J724"BZ
MS^V+%%/Y(H?;NN%: WMD;@HH/+_[85TT]O=,\M:!)8Z4);G1&]/(1>V0E)3G
M5%(+_UU8%DOTFE>Q))3+*@I@NV6%L-\L%+*!9_#TH DZW)C?L$"<(1&%43'0
M!EJH]4\C& &#@\()@+EOJ<.JS,(ORRR0V\LLW-_S*<FEY[.JS5#59JAJ,U2U
M&=Y1;89?';>0%SMNV2PC&+_8;O]\&PR1WL HG+NS%EJ_/%1=/V]\_GI:_[XF
MX+H+4$XH*"H']:.O9SL7\/R+'=HX^B;JAS_HM4/5PW50A%;.=K9_P)CJO+&Z
M^V/C\]KY[NJGP_K1&FL<[M#=[1_G&]N["38&[S%85I&H02%9F[N$.*0=20AK
MZXB,22AKKQ7*T$QRDG@@,7%OB4LV"JFB) XS%OCD2<OFVM\%LW]9V=S>J6UO
MKC2V5CYF^'K.8Y8[!_W2['.S8K*5?6AEP=9"^2K<0XWFCTX+S-"M@V8K_ERL
MK1R?G]7^/&GMVV[37GK(ZMG1E>V/53"!?;_3+4/&1IP>P^C>8V".)IBNM>W8
M"2!@!P^VB[5Z=VGPX?*QO>/.22\N%JZ)]N5IP(2;KG;:Z?XHHC<&'DCOL\&=
MOPDQORZ;2$NUE7:_8]NQ;V&,8#=U.S\OWXVV.]V\?)W;AM'L]0OO8F]PK)"]
M>H5O_. $/A0GZZ!0YUEM_8S]3J]E?UXNV$W/R_IZX6[Y#UC[V>$T?.1@"L.O
M;6_H91R9R1.EX+QXA>/LE,N3;%^MPU7\ST<P4FSML--L]VO9N7O2+1U6N=PD
MJ(<GQ\>M9BX(VQF];S(9;<H \/%#LG!E-5WF8L$(+E_]J)0?SYS$E,:<B\F=
MLUI1K2-33',NA;:SC0^_14X-C?/>)YC=Z#7S$@OT[&*K<?CU?"^"R.>"&"2B
MI(@S[I#5@2#GG12"D)!\6%CFXE>Y]%.00LA]7+QS(4C#B>5:"2N8-8Z A<9)
MF&T<>$4*]R<%L8>IB28EC4AD1:P(1I8DC+C*V6'1QZ(5++\E#.RV3-DA9K^$
MS+]/5/A-XWMQ:?$R.!T=!475&"48,&=01GD=9)0A\<A(B+.-9*^8\[[,>>'%
MGC%!B>@I\C:SI%0..>(=F!=*:YV(-=KG*$V"9Q2RKI53,:FH,?=<)&<(EY)9
MHF,4 B3$;$/6*V*X-S'LTSVG;/ R1 1V%T%<&XQ<4$ ;&$>6L'#.FTP,5-P/
MJV\_H2G(9A6P?^0GLGAC%LTH4'5.BVB$461Z."P1G<!ZUF!78\>U)B;R)&A*
MD8FL-?B9Q)&OGL3MS@B%@17WL8S86FF'1J<]"-]ZMW0'8[_8$\1;K4U$,KB$
M0'E/R/ADD/9,4<\\%<*"AJ!G@T I&>HEPUJZR!T&+9%S)K$V3.- 0RCV_7J/
MB&K?9^S;.MT+/@BG 6JB="!\ @[()I-/]:RGQG,PZOC",KMYWY_TF.V>QTG\
M%032TQ?S[&[%(LYC,QYWNMFS-'\>W<;P^/IH#9Z_<[9[N$\WMO,]7VGCL'70
M./JKM;'J<^86VUUM_-@]W+R6)K.S_:FY>_CI*#<N 7N'-%9WZ,;W-;IS](TW
M+M8NZH?A1YUN'C4^YWH9'M=7]D2"14TQ("THSPT@* (]3"#XG\14@P*F^*1/
MEPD9F3'"2RIX8LX)XDBPH$MSCIF^YM/]O+;Q>7/ER[_7/Q;!\UMKG_/936V]
M\6ECLUZ<33U1@[ ;G;MWCWZBY98%I53!OX+#_P%*,":,,Q[L^02KD^8WYOYF
MP^NRT4^M5S+%('QV&%19U'?(D9^958H3T,OK.FW0:YJ%\_:\%L\.FJ[9K_6:
M,$C;K458MLY1YMW+@':8OR\#L'+SU6(+X,EWW7!#0YJA'[HW")7--9#R#)+U
M13QYLPWB,;>/;E[&CM\P_@]EE(0MG(]@1E[V^\HP_K.9!>/BB(.X" SK 0G[
MXH90>,9;YT/_=/%HF$X1:'B0.Z1=-3++DK@HYY)[5Q71\",_9B7!ACQ4>'CA
MJ!\;P"!.N QDA%'F^+<N3&XDNJW9+L7_L/W*Z.=C4%GS"6 8^E+_[.2B4/"@
MH6N_-[CG9^SE3[E<3"_VQQX"6FV.ZLM-Q.)I&4A=!-O]>IIPU6"IRS>4#[F,
M>Q[Y?;%8Q")F>E*OSB'-^;:K>=C:4;2]P9X-&H!=/>H%8NA>G(6WQUSK-W&J
M+0AV&#@)2WK<;0+M' ^"O??ML/]9&!![<=&MFNO@N;,M"P#X?[TO,>BRIT 8
ML/63(KQ1)#1LI,W+Z0Z$^MS4O'IV&0[7G.\QZ7T$48:L!S'.L1$(GF,1C=Q+
M$WU(B5\VE)[OK;T43=7.%CNK@H\2-M49E;W5-"&M,$=*D>A9<C$$LK#</^U<
M,TANR&"^)O4_U%;"SWPV&6IK[=C=/R_08&.MOE1;^-CI'G>*XH3_QQX=_U';
MR,'C"U==/H>IRB?M7([0%UJ#O[SG!@%7)DB4T8Q%BG^&^.Q:*2*QBX#'?ID>
M5@JNLD_C)*Z5B4@PQ$LYT^R-ED_,.3>=XTL!!,AVDC6$LBADD7R4DRQ&L\5"
M%T:7<^I:K<L3[D$)EA)$K[IG]HI)9!G4 Y(L-85NV=FJW;D<T'!.(PL^]KQF
M:6Z'V8FM.9--3VW(^8,83EIQ(TV:=.M7^LN?YX,?W[%Q=[ZQLJ<DPTI%C8S/
M)=^4QL@0Q_)''Z-U25,Y:>YXYXD(EAC&)5="6D((M8RGR!P.QDP:=ULG1YG]
M+L;2+T9UR2(5:N!'K=UB6.1(@-Y K^]]^+4Q^$OOROL+1J95S[<Y&$L55SR_
M Z_BBI\SKOCF]FIW^= FZW,8Y7%R3@NL><#,6:HQ U5!<!THC[<5@KY;>(V_
MAU.+=3 Q1,6XMM2:Q(-V.9"581;UW9@_$&1#.0*J8C<K7BU[W(L?AG_\D3/%
M6_;\0[-=[%YQTQ\@-O<!<0?")TNLGZ!69W5X\)+B?>7/ RPV9HD3D>&XWX7_
MA>&+!TB]5"#UO_KA^F]<+&E";OT9+XW]!@//.UMV;RBO&TX!Y')\T)7W'BHA
M2]+P^PYUBM\$$P^Z\X[!<GS[SW,WV%>ULM+(>SWV7P4W=&\CR./L?6[O?\ U
M<MQ_8BJ_O)*2:^^GQV=Y!']<PY%)QB]Y_OFE"2Z=BSG4MEZ&E*W=$5(VS?+?
M,/U63-=0[ZDG7SSQ0S/GV_I?JWS%<ORVGD.9.R?PU-#[?6S>3TU"5U<.!$N_
M<_P!5K!69+S7AJOQNLAKPNETCP6]U^3OP=MO:!$WUNK5PCUDX6YT;%9+^2 Y
MD4L63",'KKLFO8\1[/4Y$Q"_% =;V??['%+@KD6[-R7AVFM8U_^>7-/9S7]T
MWMW\RKF:^%1)1BIZK:RW,G&:F*9&"^X#U50%(_6LDXQ^1C"4<UCRQ\'1R?=F
M_^#C20\6*W;7SO)9$"QRCAZ _\^EB2^/Z]CK]+<?[!R=M7*=XL;VP4'CXJ_#
MW>V#UL[V5P'WBPT8Z^[17X<[WS=_[!P5M88/A_? NTYVZ3=9O]@A&Y_76/VH
MT=KX_,]!8[5UM+'Z@^\<?CK:.6H<[,+X=[ZO7^Q^;J1Z$U_\O;W6KV]ATEC=
MQWM,!$6M,4B%W%$\>(-<;C4;E<#*B<!AHQ>6"<Z]BVXI)O)D3)1_G9*9?B4%
M[Y($DY*T L,*#"?+'0EOE8\D.^ZX558++206V$N;L$DS[LA3@>&3@R$9 T,'
M0$B(#8@2XA%77B&0=10Y'23U0IN@;,[_$.1Z4_4*"RLL?%=8B#$7.E#OK9$<
M$,]I201UT44#_V _)1:FYED,Z")V.Q4,/CL,LC$8S$W?DZ01><H"Z(3!YY(K
M'@6GL2".PR:'A>6B, 7]HP+""@C?-Q ^;YO&"@V?' W%&!H*CU4R,B"&F<YH
M*)'!&#YJK$$CU(E+FNLS+FI&7@L8WN$T?8K3I.K*AUY9;=8KNK+:K%=TY6"S
M)N)XB2@TOOLJC(-0]Q>)]YCMN*IGO/0S*O1X15=6F_6*KJPVZQ5=66W6*[JR
MVJQ7=&6U6:_HRFJS7M&5[R$.<;UL1_Y;[D+V>UDF]:H1X+-&J=/I%O;&PY97
M?>@P@["\\7.%RS(8Y2;_#5M<G1M,<VZP_;5?/\=G^>P QI6;A%OB@_.)(1^#
M0-QYCYR.&G&LM$^!,Y_2PK*XK4G7M*<&<W1*6O'I#"/&*CZ=-9\VML;X5!CM
MA,XU;H0FB'-ED4Y*(TJ!2T.(@AJ\L,SHK(*^*D9]+D;][7GCF7*75_AKJO/\
MBI]GP,_C<E=[177()<D(!;G+B<_%9P@".G9>4$*IE@O+?!$@^1I'7TNVK)CY
M-3+S#&)R*F9^&6;>&!?.'B<CDO6(>J40MR0A QN)) M,4C!^0G @G!?!YID/
M9JX.E:MGS-4SWH=GJA^[L9<+"F?@K7Q1K\P7=;],@.$NE]+U4MA6(G8J$;LS
MZ:>*WG$GO$78:PPBUAMD.6R6%M8G3HAUWLXZWK]2F^>0D6><WE@Q\E,S\H0C
MBU-*!'.9<XE!'#1DI%.RR))<RDXS'I6H&/D=,/(,?%D5PSX)PXY+7H.%94X[
MI+DD"&2N14;!7TH($ZAP+FJZL%P=$+UA5IV!IZIBU:=@U0D_%!%"\H0YH@$[
MQ$WPR(6(,[]*JY6FH##-%ZM.;?=/.!%>E=T_Z'?P0H;_VX:H9[?OU\K-K"!K
M*LCRDW8]-I@PFR*BGE+$/5%(&S#SN<,1"R.D=O&!YL#3J1)3: QOF^N>W1BO
MN.YA7#=AA+,4>=3,(M@HAC@1 ;ED0;L7FGLE<'#IH=4S*JY[%6$@%7O-E+W&
MA9K#6DFA$Y+1*\0YITA;"NP5P'Q*(6KKR<+R]5J%MYT%5SSU*J(Q*IZ:)4]-
MV+8Z:*KA'Z1X#D\VG"'#1-&\RXH$FT6B?VZ>>@^GUD4A\%K.IEBLM6._.K5^
MDU9ML<L3D6$#X&K$?H5=4V'7_J21ZYPA^0 ;:9P NP@UR)@DD)6!.9 Q+#I:
MG7F] WY^-GNYXN>9\O.$^2P=*(E&)6!@S4$#40;EMH8H>$Z]LH1AQBM^?JW\
M_%()&14'/R4'CTMDR0*7-N^*2F!#Q @<K(E&."7):(3/V9H@YOI9695\\288
M=Y;)%Q7C/B'C3KH!E,4N88]  !=UGP-R.'!$ K,$2^6H9G/$N%5YC%=T9;59
MK^C*:K->T96OJQ'J?>K+].U9%<_S%CR?Y7YNV[.!CO9G;,?4K/2TJ?2TP_5K
M=66H)$F[B%+*1Z"X<'X:BF+ P@M#9(JDBC"85^Y[QKB>BOMFP7T3#LIDO'%2
M8_3_L_>ES6T;V:)_!:5)9I(J@L'2V.P\52F2G*NYD>18RN0Z7U*-1D.$31(<
M )0L__IW3C< @A1IDS(E 6373&Q9:#1Z.?M*8QNC>KBO^X%-]=!T@'AZGD'B
MH,O8MU9<\.ZAY1/$_2CTVPKZ+5@721!SYEIZ9#)?)XQ;>L!HI,<LMEW#< W/
MBPX.O6]N5KH\&/Y)+8SK%@+8>UQ]@G@BA:O;P-4%@Z)-66"$0:A;MA_KQ I
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M8[A6G5@FT:F/?S!.#,N/',H>&U^N"*$BA+M&"!V/^8 1D66XG+#8I"P.HCC
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MD4]=UPYM%OG>P:'CN*HA2,<0=1.NNX68)\5U7PB?%SM36\P/S%AW+!MCG()
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MY(>.1ZEMV-R']P0WF1%ZT: ;+F9()SE_5?WPNN)&R5@<KWCI]8AF-T 22^Z
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M<8U_FL"GN$#N&<K<#-,0R/RT2(;)9Y$CH(7B0<1'>#F(!>DTTP;PCTG"&>P
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M-QY-69$#GM]R+>1 LO-T*)!*X%(!^*^Y!JQH.BZ BN1XV^GT9J -4P9+B#B
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M)S/&@%*M,>,B+TD>YL5=_-=0B)# 4Q8* P(D YB6L@26_)O@HUT&U:.5<@%
M&M<&%%@@"%(#9.) ($9)>5A%B@F0"-!SZ-].P'3: H?Y- 1E8%PD@D3#'TA
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M?T[C7(L_(F"^#(J1%^+Y&E)#-!"#!M04S 0HZS$78PW02H=/EHD6AH.D 89
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MK!-.=<<3>$_?IURGVI:"0> .J.QGXU2):"!"C!&$.A]%N5R*9:?MO229/B^
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MOMA^O?UF9^_PWWM[1X<H1G_;Q=E'^/G9?'S\<0++SSYTD']^5FY,BKZI$[2
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M5;O _\+YMGT=+S.5;\K4FU%=RO%7E/#1)+3]U/>CB_DH\0DK?EW/,,%T1O(
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MD_/SP<55*GJ^#$==VC(Y1YB4C$B<:'%I]X*8:+6SG&45W4HF3!U\CVO^;,B
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M=\R)=22_Y?QSB?PEE0+QV>-BC*_H;"0HP6&@2EH>*A7'/?7\\UHZ6R/_O([
MMQ(^W]TYW-_;_W#T\>#HZ//NX=$_=PYW-PB4WW6YS4/B*X-="'YG':F$%%*F
M0KHH@O7)<Q2\M^@-9=^[Z\(;'@XQ'*.;/YB4[2Q'$"=HKO2AW?U:]OU"*I&
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ME +'Y%P4)$;MI4PN15/GW.YK()ZS5C>5Z;KQEOG'Y:4T>/W'W_X_4$L#!!0
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M?Y,#'.QK#AT^>OCP4?[C/,?Y_Q\?K$8 +]?!CQS;' <D  =Y#W#P'F"U L
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MLH ='V/>L#O/ I2HL@!4_@0B"+[2(E=?D, "-+  V4IX[?/Z3L1B!I8A?3@
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M)\'7*X2:3<5H757"D6%GTP6\VA_A7"!Y)5.B#,'$AGMLPR@#5/8?0T=G[<R
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M26?31WO,9/.7TU''(B0NZYD([[\K^BUGX!KX*XR;[IH.Q<LG%3T.R;A%KTL
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M0V>@_I =F#KW,1M;C//LU65!CUIE 7YCJ+?WNY9'D6QB =P4V'+[U%]WJ%6
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M-^WR:3JUMZ**!="CPMJ6- 0^6!K7_UA?U]N&QM*P"FS<V9C>=BM,P+=%B!.
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MUG%.T&?JX@H+P-T/_&D1O.^S]=M4X<)EHC6PZ[^G=_Y/0[H5X20GPCX7BI/
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M0HY71RU CS\HA8'"%#>JF%(WZ<Y;4@-+TLOFS\ZXGU?X%'W:3R'ZG5X?9*X
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MRXGHN1H(K04,H:!Z!Z$[?@@\E .SWZ(R;!N&%PEM85LP\\?ATI79#]1SO\J
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M_?I!Z4<(S6R!D;X=HOI<]3;U0CUU9@<MPTB"'R@KJB &5^_#B<&3G<_,>K
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MO!C3FM#O77WJ8GO,RNJ/K\V!Z;DO ?2@@$[:6;+TZM7XG*GPT(WXIA6O3!8
M%OSXX9K $S;33:+&8&SQ,KQ?&S5NQY<!)\OIKIS4RBC0LF!+4/B.([IEG6Q%
MY/AX%\C_TBT$_PL&U[]&]Y*(_T;WP/\O=&\-_0;AL$Z1L1%F 0I[$ O9Z.H\
MTI'#+(![#E.%(D9,O<("(/ZCF 2,O?XO%'_]&6T&3TFNRKL06(!6R^!7$J]D
MEX<HOA^?7=\W(8PQS!8<BZK-&Y'&8X8-F :04,SJ" N@GXY^/W7;2TRN4;=0
MV"PVQDHR*WEY 8;@L2,'= I=5?TR+B6[-E 1MKCDEX(JM_X:\9Z0W\4(A )
M()E^?<S3(2&$)YY/%POI,^#M_,Z_:<U/R9MZVL\"=$[0XT$S\-1*Z 7HQCP+
M()% 05VS@0\FT5\R8K5['VC6S,> 9\R^R7J0/A#7BO/?YMSXK#O*7U1A"@J\
M,@=\A99)K\R=]XVS<\0E=(QL%(WHG>N\4-WX!N['])9=2BI;*_/9\0N:V<&!
M=SY7OJM&-:?TW[J /GGON;>K\:B^CCC_[PT>I"5H,_4X[+R"OMA>4Z,8?54
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M]Q98!F O SDUML$\%M3H3;LYV24H[2S\,K6%=(U0ERS9F>=2["";=\;!%I?
M5<!W0-#D!=8'\*9>N[OU4AS7 2!1"J%;V?V.L61/A6*%;DWR%\4$&*3CQ^=U
MPBU"*W^ KP+P]P<"0!^_BGV!-UN@F3(HJK=+]>@.+Q9"<G)G@>H)73U0<<)E
M\#J9L32W4PR>@KFN&]"52L=<&!Q0-%6^[*\,V=^_(4!: VQ9A^QHW,K_=QY:
MG.>P\%E:3BE]ZQPJ>BA0L7K?WB^I!9GF&4[^V@K/9O(Q[,C]3[D--1[:(\01
M_:-K[F@NY)+$Z X[(9)0\/>&>1_D&+X3H55ORA2M--L1H7$AFE@@=J8L_' Q
M^5087)J1FZ/"J)-V9Z1X'C,$)&<;"T5E^,_2@7DV)LXXA-R^CV.!)C<[?A>=
MU*F0OT27MU,X_WS# 1#=J\&"]8Z_/]KB$\,\G$;ROE_\J'NBKXB_9/QQ$>[*
M@YTH"3@3'10 TW#+>2(FLY!&&_B!-T3:!#1.898Y=JN:D3$UE3=6K7_E01M4
M^4N-1;L&;]G^*%%K<CC7U!RY]'I+5 (;N[ASXLRE,^&A]'06Z%40LZT/S$9W
MM9W 'B5*H]]4W&H7[N*I\XIW>K601C6L&<KN#]X'V@/3CG]BA)6UM4"@RB8F
M+^E$4]Y3EN#Q+J[22750WK6*DW4UD]'7)']63UT2>:>V"@.4N,!@^= HN(JK
M7A4CB0OU,+4X;?SEL9+[Z08EW]!C2*)6=8,4N637)+UZ3M>,J4$7Z>5%B 9Y
ML$ GB+HVYV+60@SO%%S>:K["N3/G5"B'S^H1RLWQ9('DT/O,NK+BM5)V!O\\
M@LR49QO T0<<6* $$Q;(%<8HQ/[*HF\"/UO$ K5)LD#?L<P!0O;N47'XV6VY
MP-/,5=GX&52'XS\!(M>QP'>/Q<'6GEN? 3I@/<D"Z2Q++19R;IDG!W?80%#[
M-J\ KJZ#,Y^=S$FD38[2Y;9J!AD/VX ;7X<RJFK2&\:$[E3/&'$:"KP:"C_!
M#:ZT'H7%CI*,<6^-?&(F8X.#NFX^I2M@/MNOOY,1WPMU>=HXQ8D?J13"'2O@
M>]M@(6U6'YXUU^EFL00/"@APS1P9LK;>7:;E*J)W=?VR=U1_=&NKKVBTMGB>
MHZ34 HXJCEMB@>S(@1-!?95Y@]*$8/@ED:3E:<N,MNZ8J;1C"]?DHIC-@7CH
M<%^VD(J"D87(=&9WK-E7+:]GS%: K^@/NTS$)=I-P$Y;6_K \*5['I<6!+$-
MYDU>/UME\_9]8,W9$.;<?@&:4RT@#4@-[# QYY(/IP'NP0]S9\/DY=&A[? _
M("LOI(;LL:^Q'QY*-:^86D5MWLM_GREUWGO&I_0MQ!;V:D2TR%X&(3Q_;4%S
MW_Q"7Z3*UJUFIRDP48YY.--W/.#:(HP*\_;,L[CY1;M(L"O7@_M1#,>+_1^8
MXX+YUR_Z0-(W[G4V/I3068!:):=E!J69F#6,!*_WSW46BF1J&;_*N:2VD?'&
MKC3V? A1D2M0*J7&2'&_<$,5 5" ]\P.KY%#9*OX.N=C \X;'<?O_%IXWO#]
M]FK^_=N7N]ONUK% 1>'(T"IQ[ ]\7Z18=*8PIKDO?:ZMUHIS@+,_D?(*B4(>
MLHDW_J0[D<05UWAO=B8^O%X1O-&IUD&[39WDV3B- *A(C3)3'(=G@8A2NMV/
M$Y]\G+B?J).DK02O5:CNWUSG/D.)RMY<J!*_C,]1\4HK[ 4;!.8L&NFM%.UR
M\<+=L@N@*:8D=8<P[H)'GO#YMNZDGM[?XB%BB[I<O2VR4QAKN-)+U<AQ))A3
M<OTS1^\03I465K:N*T"C^@LO[T0[;:"9[%%D ]HIP-P'T]D<KLD4_T"76I]+
MUB@2?6HJ''%A/Y)P$O:QE^*K(JPCDST"BU9UNI+99JCFP2Z5\HN^)X<:7*MZ
MGBP=6Q!_FT0JH<'[(3_6I]8FEX=?TK.3L;[:2AF_UG(Z!E;[,0!$DT8-C.(5
M"MMF'?TLD0.GZDIFUFWVF'S8*7HBKKC24-F'NPQ,H'@(-RX?(>HT<J \D9>X
MB24N=88T$A_L__9UTSXL&CG_#ML=2J>!M?H?GN<I[(5WY-6:4(H>[BP!!MIW
M]L&?Y^IJT;D7F7I5!":^#[<CXTA/P_9V4"\0Z(D!6$9P+G+#LG=;"^82PP+]
M@ ^L;:/(3*UR!!ZWY@GCQ"TNN##$XG!VB^1 RFG OV91 U@@F#%R_FHQ#6*M
MZ4GWV4'D;+AUC.L2-M1V*]4G?_^OR/M0+6@:R*8:.,"U"M#W "!6YM21_0MI
MC]V^+ALR2I%;0.] I7TW$8E:5-<-K;I[U.D%;BGN!\TZ^8K[/7E6(5RJAW*Q
M2]FD[(DW'P_RSHW,^U75,R\'N#WXP+C'UP09#O?&'L3HISM^F>PLWF)__MP!
M(KZ%+H9\ S>\)+>,>87D6G;,+L8Y,9*R9E<%WU8?Z* M&#+SM!PI6?0D8*ZX
MT9^R0$'NY'=4B[ME:T40GBSBB]EIW7KQGR[. _;4!2L5J<W0*HY+>(;UC]"!
M!51V31^E)\9_]]@K7\BR!CE$]2"=F\P68JJA=Z>1HG)9F]^I;,_]GVQY(X]$
M.H\^[P[,/']HI;U,^Z:,P2.$*[+FINI5<"A,:,7#Z4)= CA(W2'?61'Z_:<"
MY^;(?N3MEZNP2]U?$G0_IB<X")@]>K@J$FWVX5.T@9N>!^0HG>TK79\\$S2N
M=\$=F6V5D?-4T_2209L(\EMV&>I; N-<[/7Q>0GI5%38IVGSM'A3]_?0-&;G
MR/%N)ICN3(:]*?K:ZN<5XU;R_""MWNBJ9<%*([]XF2CADVE^]*=[\4;G3_%?
MKPI>M*.?M&7JO6EDUL8C=XYC,Q>G452Q1GKB410C2(8%VC@+ RCSA]&M!( A
M'I$EV>R6V',]+3[AO1P!.!5%\BEF+?#'YUR?9?]3OS4AXH.91U1.3<%- ,;8
MB\Y%D_10V]<$P31V@,?,W:S"8.,@8XG@M:?7(!3N'P"D"@HP@.T#'O;-7.C(
M :SQ0>&7@.IR=?T_\QS_^]#F7X6@I.M_]G.G]7_V\RSL.K)&35D$'(I[/'I2
M=SKX>]?YDI[//]O[S$R$:(@5;:FYG759HF.]/'B ,/'(H!IV;+3M9\>%?=\9
M]Z":PI:Q*><[TP0Z9S+.3W7@$Y95#U%?5DB18ZJ)Y9\"PBP*/U;VW$D,GK@"
M$9A8T%7"%/QX-:'L^Z[\YX_R1T*AC'.&,V$H]XGN:0?TKP!N0U@\VN/_# B@
M:S!RY4O(;,O2Y'/S:%^4>7*W\D90Q3O('F$(.Z,<6[,:X7W4DQS3&',UV4D;
M.UH6HSBDA_\T4Q4C"JM(7%.V[*1%6=L)[I:C)]T9/2(61E.\EE&Z5=Z =7>#
M[5.Z*WHF8$\(BGZ(,'T T8JHO99I1Q.G[KUZ45W=4[QM@>!>P-#&:BG&YL][
M(V=<I[,V$Y=0_JFA4A.H+W_240+E+56!K1'[FM@8^/B'W@TG/'?<5L>ICQ1?
MD2C+:T/A4P>-.S3ER4CZ#6]3@'*B[ !YQ0/PLWA'7L/[;@,!WQC]*:=*2]I2
M6K)K)N$'1%59"E"82@+ EB/ ED74J"<R12T_71Y"!F14?8:MD-/8K% &6VIH
M>Y5DWGF,R4A]5XK^*\>$XMK=XXB?IX:N88F!$Q^HBB39>H1H)$S*4-?8"?/N
M^:AC_)8KUV)1R?K2F[SCGJ(IIP>N1+^V1*NOX2CMU$P6B,.)\H:LFK%_Q.LC
MIHD1\\ ]=LWFO.Z%#8<CD9!1+%>Z:('H)[3?/)./RKLZ85=G<(QJ^C,6#:T*
M[6[=IVI>"%KCFMNU#(3YN^'VQH;S/  ENJ"3,[C0T07KWZ)X%E4Q(N2MQ(W?
M:GA/]LO(/(K6F!%]?)F8O\G.\UAX%19/;(CQ_+Q *'^\(>WB_UAIT(##4YLK
M]!LZY2 .Z1$@1E#K>EK4PF<ZTMR\O^05SUQ4:I )^ \0MHF3*F&'/TG:HH3V
MRA\ZN[8Q>J*N/.>\GV_N6KO<XHR4(@N4]ZK*^V)]^??0J'@B86<;H540B<_R
M>$ 8^$7J>*-ZXP?5CLR!KY(L:+%T4.BT>EO3^"&K^AOXB64FQ9$QUBD?9L!E
M3T3D8EIE+LKF3I:7?O13?I82&]QSW&E[!]N'IHJ#ZV6I!JH@?,I0"\Z(5(F_
M?]UV7="KI7KT#J\:"V2Y>&<!)7^]S^HJ$Y>7_KA8\<E\%:;WGJ$&_.6N8[S+
MU@0F&6.WK]%@-$YSP"R59:]%XJ"0,0QLS9F"HP@7LT"=[M#ITP%5!LSE=;N6
M&4CCMO \[1@+U-0+5V6!L)FXC01S!AK;P-GOS=3/'M]B!.BQ0.E=A"6&+S^!
M/#F_4]C9 @F2A77N[@91]1O_KTCJC+LL\^Q.>+(2LR%@][S1::PJ5NVW@,2.
M,WB\L1/,93P9G[G32+M 5^I&7$14EW.^+@;LQ<U>9T^^(Q^:0IBCSXW^4#&L
MS=\RA,59RY!*4L:0W LCX-Z42X[F5CUQ\5P[-RX;H^ZZOO-_=10!6/(:" LT
MU5G!Q@*YL$ [,'>8+-!V5_6P#&I"3V3B2:)+R:A) SIKR?I K>S*(]55 <!F
ME>@NPI1>U?DK/S:_0M1C;*F$ZPD_E;\1YA$_!)=][*N:Z'M@. ?KXNERKH6[
MLZ1/R_A=->7,"Z>M?11G*HZM438P69AL5/&$:0^/T)2@<@UC6B0:'QBTLFU9
M.9$6JKJ 6?^8_E3U!#4"26*!#,L&,J@1<-H9P/O/$3XO*?^L8>MIY%NU*LL#
M#]Z=M6B$Q1O'[[$8,)GVO\U0P[884"\$-Z"H>JH7S*B"!FA$_/CKMG8\?N3G
MG@<!7F+U%.DSV$Y(!(S[(O,(79I\*ESVYL]RYP*?!T^J$[QJZ\'TP\V!D2]B
MB+@C\KE/MNK,VRC9F98J(RD!2D-#EK<1#J)>%UL#FD0)L3$VVUDWU@;L*Y'8
MU@TYR:$"P%4G(5XB:V28AS\^*\:&"KS?]TBM*%?<AWEN3[+AAN!=+L8\FR-5
MMQ9QJ@?N,A$@A=^Y=7#6N&?%MJ@DK'?X57@R/MG@P6'LL&P0\MC&ZFL6Z-@&
MYV$'G0/)L8[Y+@U'L'W:G#_*GJ@N.76VD87;X[]9M*Q=_[:CVH4I\I=MI?LQ
M"G!3LZKG6*!^0]P&#_8T]N%O+3!..I^?[,^Q7+JV7^%FX>^.=:WQ[RACS!6W
M*J]BMOD!-H;?W80\<<.@;G50D*GO/B'+"!)D@=3,R42*[-];&+)_O8J:-5H7
MGZT2/VZW[$]6&B.\GB2-!GDF^I\64TSV?*/+]T1I:#IRUL@)"Y"%$+H;"Y02
MUP$X3M-1N@:<H'$KOTAT*&/_X)J04V_HMYC2S T,7=E@,IYQI 1)E2QA@28D
M_NESLID ^9@ETMXQ"RRV1T<"+K! G">ITRR0NC3 3G)QU%#(^ 12"#?WN' W
MN%W* G'!Y#NU>@!U6U\.^*GZYU/(/XCR=?$)&A%U&(]O-8)E#5?JU>2]"O\Q
M#57DM!Y?1M%]D!IZX0A=_U\8@B[@'37!J714Z']J$&Y^1T?\RFBL08(US@5'
M&G N'&KV.^Z<OA_J;.G2@-H6J0*^,O\H"\2,J70PF$1EGJ2:454 A#8_BT?_
M$@N4ZTB9[[I=/^7O,_ Q4ON\FFCO3CMIE1ZV V/XU0.0D+T3VV(].RS]"J>"
M',N%K.O@5@!76^*YPP-+QI%,T=L9L"W :@W>V+R"V_H.!SKP?!(W/+U&[]Q>
MA@%=J;D(F*\*P*8_K&QDQA*AC3P4"/U$"U.?HPY,D1I"SEME!'C9,!>-?VTO
MB9/'_DRN;(]3]L!> N!PZK,/&N@Z;$<^>ZL=MV]7>DU_D"$ S,5M.$&[IY \
M!O$+/KY??FTS@R&P8EQ!A1-X"4^:DPP"#X0^/Z@H4X=NQW%G R[A!H E'U(]
M6: '@&_XE5!>B!UK)&Q<:H&$R*H/[!88G)RK_?O22MP-R%@6F)O9F>4#'9_.
MP;24J.? )),Y2N;&V(8DWD\RBK&=4B&3Q:^TOT0]?",OLZ98F_4R6GNC'L%+
M]Z/&RS9PA@M+DMWCUCP%^YP>/V.W^'*"1W5"_H^ =>L5 RTBE(*R9]K%?NB=
MROA9:L<&<T36R").L4"UZF1="W)QS]EEN(H#Q?^)#0LD:SSMS9FN*P'9_ 6M
M]Z2!:8?I@'$.LJ%=I_K:O:[/7$PL3LS'LUUY.;UOZ.'Y,)0EH3*ACW+?FZ<"
M )ERS=7&E-B8N6+5U]A(Y!@&<H0%&K] E<)0\T:D"<G\E0<U&\\1W0IPS%O'
MP9_E*?(/?-9K*,CCRB?SJ([T)QVFWQ*:C<-CCP5Y<[I^0CV7FGS>&Q!DW[/4
MD9YK0.Q^KX1^Z;FI0#\9/_&1Q-DX=U7W8T6E7#WO,J:\H#8L:'O,=O5=)VIG
M$29'#52O(%559MH37R/TF$GNTAEUR.%H!0D\Z4SW5:N'JWAB_9ML3&O?%D6N
MT=WERJ8V5Z 49PJ(,&>2F;6185"NJIJDI9.*MMTYE%KF$L14*J(FD5;Q55(%
MQ)*=RG HPOS3]M-FA0:#K))IU06G3&Q;QBG>B2TMXI?TO%>A$IG\_\W<=YD[
MHN%W3V^=1HX?CT238\;1;Y7/?EV^7RSU,*H5*G8XN(T[C4%@#R!';DZ/D@Q8
MH.VK+GN R0Y8D_@APJ_>;8J8_O7,9J5,2.O.P@6=U\9+.)%M&OE@8,"XE;]A
M9[&N5U%/$2U$^MD#1,'/<)/WC$-7D\$$V0K9O'EBPT<E\X4; 77>7MW8^].:
M1\)57^^#V2%K]*L.R[Z!NV?0-;J=*?>=)I?*(^NWC=;D!?EV?*-0[6+BN7 M
MF&]PKI >CZ$G\^-:;.8->2$E,(PY.%J<A&F4/>C#IOXKPZ0PNEW%]OX;Y0FE
M+H'+S_R9JUN84;_DWK4#/$[:77F;R^8M>ODO5URPXKK^/B+\@#-GSV++%.5L
MR(O@L\E<4W^DIQ.=J^KP+ #P"/MKJ!+RJWR.HR?D!;V<5+@%3U_^ ,=ZGD-L
M-I9K5B,''_A#YSV?0_8B>,SAW%2#\5$V8FQ4$0VY\;$'F??=S=I,Y;E5(O_<
M)25H .Q 1%W DPI,-R9E\X.Y:FTTRAKSK_'R@!4P]=(&+&HM%A<B:XHH^3V"
M?Q] 2T^13?D ;>XW6@60(,^F"OS87QF:PO]<AF8>O<1)DAU?1>'L?JA8U"&.
M='I6ZA4+?FT;WDS0/6MB4_0H\E55. OT!DH%5.L6 0^A2J/H4BV_1PJ.AN<:
M70\-T5[901N^P;!I'JU_Z@NC7\'5 (HH5L4/Z.93Y+C6WQNL,S7<_/UP[4R*
MA[\DLKEJLADP8;%,3@#FRY,ZF!R GV&'_+UA4T>"LHE,8BRIQ$*F8<]_VNCZ
M&$GTB-JGF-Q[ &+;B];@>?GUSTGT'Q#(OQ2#J9Y$CCCZ%2Y>PM4$[YX85><1
M]!P&SDO&CQG4^7^H_7B6-))Q[LW<[>)WX4R3$0(*02 VS\$*9>N<XIU3]<1T
M+6>%6F^=0;CML3"T['U8T9FD9:^]#0XI,C1'\'2UEP%,5Y]=:,1:W:5HELT_
MJ%%H:QGV1>&Q^P0<-1HFJ%%04%JB>?%=0T&V@A&H$1)[/S647D3[C.V 4:4,
MZ%U86B@+M)R$"(+^X^H*2RQC!0QI^L2WNN4+QUU%^$-WEP_IR@(6Y3BR'^O*
M F5XQ9+K=Y>\[/^VNWZ,S,8(W0+O0!U@5A^0Y3T;JOZ'Z3[@S-V:%CX!+Z!C
M\?52T )JXL2B _O'LWVR(@\K#Y^\?IV>O56"8\?92U^?APBKGAMX5ZT^(:T&
M]3;".<0XT#4Y)V&ZT1"$4Y.PF .IYM-11!>S'OIDBV)!]1>1,"J1%6:CG;S]
M>3<@0"V&Y0,?:)!KYFDPH%5#7KVB;7=^NNBCR"N9C,?@K99<;SO=+2X$,DWQ
M&X'65X'[N;,;(@E7???WU.\V@;*Q2^G9&RD>!-M7AL*8B;U7+1YPMH6HK2>>
M]@EYQ+]DYD0F5@'V\]4G^&[9M\+)8TEC-+/2?NH3PE86YLRP/L_H]<6W=>K]
M<3SDMH 1J%;_>+=_"VQ-%7H:2C1U>%JDA'T).SI%_4'VKTT^H6'+FP$/>=[T
M*:-\>L9F(\*2R4/+=-GOE:]UY'+.W8:4$U?Y3.Y> @E_P#:@^[<F,4$0.^Q;
M@?A0N';ZP@V ,2<JB>;?[WAOU?-SUE_F6"_[Y8&$JEH !&?O,MP4K;K16!P+
M=!H+N9KRMLY$YY-%Z T2CWUGH'MLHNI :I78;W>F,85S231F$/@DPI0%HGM5
MP);HT#6Y[IUISEE5)Z#7D?#+P@<8GV?[G%/6-EB@D\0OJ3\0<Y\0*X]WHK-F
MF>6$%OE-W'(4S8(*IGP@>8789=@+]'W,<U"(N'I*H84SSL:C+G.M[$QT@3"Z
M!B8*)3ZH3$WAZS5U4I\I4$[NTT\LMYO'T$_,3L139O%)_M7Q1C.S-\MHCQ,*
MW2D.31>S5'AWTR($&Y@+86)UR8Q\!R[.2*'+!2B/Z'_,U&;$P+5KMXV/9S4.
M/.(JH!C#BDS6?'/!C]^Z6>C"UE7H59BBU)AA^]V*FHWI\"B (>Q"0A< #>9O
M8IEA"3B)Q4UW)CN $,5&@<[:+,(8I^01AH3!*19H9?0:O,J6CHQ:0>>OTI.@
M^-6=G4062#L#.[!#?\ (1DXM5(&1A)[1'3UI1 <A*@DIK(K.5A$JI!IM,HX#
M,W]]-N\_LIOL?_="\#([86O/82=Q2W:]D(T\\_6%#3!1"L#:$]Z,\!T,,[;%
M.@#VI9,I%,!%YE%5]$,7X/Z)5U_OH)\$_M83K$926"!@PF_);\@C?,-VM]DQ
MQ;?1L+\BQ+Y;C>C7%)B@*K=/8*V"C:EN/X=Y.YZAT4SOU*9>XM\TPE<B!!V)
M5B/!6=8.Y4$_B+"!5LH6[]J1JVXB/(]%>HYKC<-^F< /T&P0-<P+U$2R&Y*7
MNG>D>G A_V)"^"F%<T=+==?B#2/5OQHAB4?\";GO)R8UC3"& RH(._0'F^%;
MF ->J/8$FLAN/AK*/&D0"D4H]IPQNXH](B-=4?-NZ]O>XRBKD++*$'7+6;J2
MW:0!G3HW2KT"(V$[<0/HL1[(7M5C]M8\A\&4:'&BIV*:XHGAIL"S'<^O_X$L
M#[..LT5AEH0N:%_;Z"YH#*SM(&;>BXA6V:US'Z'Z[K^2X/T'6#;$XG?/^T^6
MI+(),M>->]%F0<!X HPG3R3]'];"_%>2V"HYP, DTW6"\;B#&QUL]9(,7!VT
M133*+LIYS[$ZU,[\U"3AZ+PU"T3&4X)(+M7@8[J9/O%&X=;<8MVW7^*MADNO
M'TJZ.9O]26+%CYWN39TFIUE1M\C':/5^Y/O3[P\YYTR(-CH\2U\*D>M_%.U?
M>'GR.M9;JJ8]U\1<=Q@6IISC=>[2EWE,]G6!S8X!D5K920.B[CCE4^:,J%\.
MM.O(HZ>EK<OHAR*-D]9:, #ZUT@CCK>I8B=D0Q1^/>P;D4MWR)E<O3UH;0=>
M^:K1$;"B!.VQ=9*\[MM$H7=P'-7KR>5#I^U6N_$(>/>/_A9W,WN=P&3O9H&N
M9C,G<#0[ZSPH<XL3/=5^Q)M6405+@*AD+R&IY^/IGTZ]A2Q!OP,@_X<.=:*J
M$9"7&8#]?0*9]?XHAE01-J\5,NSH!U9YS53F[&F62,4IJU9+D=,HRZ1LJ@$E
MC9SP=.!@BJAYN'2XRXFZ\%DFTS>0A!WPH^YCLG\DO?%?Y#Q*OUT0Z#> I>BG
M-RO>'PBKGNV7NYV^4\Y.<4O(2A;K6)82?F:CUQY!T#-H+V=< #[ E*[VAE:-
MN$BZ]XVS>)[0DEF=XVO_1$-SWX#U1;2O!L()ZDU2G^0M)$E-J'Z<6#[Y-,;B
MY.GZG.##GOML6T,JK]P0KKNP#(-&X!E/7F?F[@@?%"@MR/I"@7A)Y+&-C39T
ML,,]2>$"6T'%![Z'!YVZYG9<1EI41$S1N$"X\MB5PSRCT-EOX2GB_%)7 ^"/
MTK&G )#E#N9"B/IXCVL%/:-K3$3HGY;5+;&V5E^_W2^J);#I?7U<2^S]PZFE
MN#1G#:MD+L +<%"+P7CD"X5RD\K.0'/RU6P,,<<YF&NOL/?._CV'-V.=UIR8
M)Z2AS%?>:.IQ '!8Q]/T$;\2T,O\9+$ Q(S"MR[IF"6B]:<V=&'U,;?^L1_@
MCZA?=NQ235*K:W39WJ]?6[RS575/P09[W2)_;H('UK7[$*)T9Y)!,"^3<G]5
M_C9\\V09HU;AX^5%XE5W*G2%9S<'*8,XVN*;YX0[L3I>GY%P+?;+"ACQ9,^7
M=\CR1*@*O>%T]H97E8M"%@86#;%;5_E4GA@A8]<C)5)?)59 @@45(X\[&OF:
M(^(=I)?Q6UP-08G"5!XL[ RRYHXJ,&RU@B1]0FU)X=,>96.O<YYL;$OYL='&
M:.]+>4IO'-=(&U9^!5_*DS:S_"6?!:!:88+4<EKCR*6^"JW,:XL,TS6+IK*?
M1Y8L["G\U92]!?;86XQDYDEM,GZ2+1@N=#YNA+CSQ.G'VS^&><HO^/+9O?#*
MW*?R<[$+I_4^3>=HY0G5*Q?:32T*V^>PW5BJIP'@2@4K]+8!WT/.@HSW0CAQ
M<\_("K, +VW(;F;VU6XA7>>0=H1E*OI#$72>0+^!&=]B'!T1HR^S0-1>,&D!
M'3RZH>"3N [PM,E[2"<;?]QW2.$BA6[0:BZUL<@\;0Q FC>K)Q%> *1QK%)A
MY..>]$.>X-X*>,5^&0'FBUC&0YG</.S>[40\3[1<$>CV68-]::%S*1_NUAD,
M=/M]Z*TU21/VS>4\N#]SOQ#8D5'+^,"\P!D.VP>_,.%P?MUEIIAW:U:9D24[
MW&SP9<8(/Q"$ $-' 42JPP*%(O13)G#!\>XV=B9]3[DB#VX."HWY12M'LZ5>
MSKLS@BI*:2\-Z8SOG<INIMC-97 ;PHX'*/YWF.+?"U/ U*$=D'\6A9B194Q@
MJ.B9 ,2?''EW3U>SQ_\L(A R6J) _S1;!Z.Q*S!?%4\6+\'^UK!C_1>W)IO\
M'^#6W^@7&5B$.%R ] DA2,HK=+%-;Y1KSV^R/=+H_ZE@:$$/@*0D,B02MG%E
M@ 4:RP*Z_1:;,/<UCO=UXOO/B0CU"+\"4R.O3=7WOP? P?_DP8Q-90B=!G,#
M]TDAE6@=&;_%O[7^%EB7FBF7V$D&,P.P96S_WC.P///?(^1T.F'CP/CH]JD-
MW,XF@![_X%G_6"_@\5[EDU$E95NXW<K(4ZAL.B!"0"*UZBD%]1]()C2.@Y=C
MR2)CZ, T4N,;F:*YHJ\ST9X6B>=CMQ1;X'4TJ ,+Q"E&!;PKA*C Y(#2G::S
M),^_QK>5Z1PNG;KGRO,P)WTI0/?O-\62Q9<'R/BZOEQGA8B9@J WA[J=SY0@
MZ-MO7S:.#6?72*3G^_C\R'):87N;LY5(:_&K*OSJ$VB(OMLKF^<IM3WH40J-
MN?KM9X#9AVB#OBR3" 7=BCZ7U,+N9?&JB@_+D2/$:]%:JB__$&7R;,*J<51Q
M Q13Q,H"1JU5($&"PPYZ_K <;:X*X20)#\3L]R0.2RX0,H(C%I3.7>A*LK.7
M2I:CJ<+WD#F7.29; O9I1*04HDXLW/@4>L?T^6R<^ _AFUA3U1<G(/9,82J'
M%A4VEBM22SR*&RC*O;)GOU3#S$I[G>>3AV8HM[I>SB#88?AE$JSV&E.(].53
M><!K.WBD_OPST>J#VK!LQ>K9S]4@$"BON4KJ=&3<%5-S#6>F7??XI6Q.05Q(
M$+>AM>'(_YG%#75D3. &]JTP=R]<,<^"HTW<Z&7NREGEQ[<7.)^P[1>NVT<L
MF?N2J#^G9V6&?@LN\E[:RF.V5T'0ZCV=*QYE8;I?'%\>BEP1VMDX5K8GOF#S
M@/9:.6."BB&A\6#^"A'7\0Z>^:@% 3CNBL)PW,@?UZ/%%R*O^)Y6.S-U@G/F
MU/*>/U>S;M7Z9^=JX4V[?0BU8W':.;;#OGMW=$%3D[2FJ(;;UK&4[T+M/*DI
M)D18H*H=S\M8L6D]:TC4>FF@LN<$.-AORKSQC6=B&Z<1ZJ7KX\L1;YF+MF^,
MA_755J3F1]EW%]Q779SS"CN(<0",!1>/94#J2MO$![3Q] TL4PDFTL8QV$S6
MB1!Z6V\F]"!3Z+B6K;9UAJ6*P$Y/J-W1&[T7Z"<**+P IS]PBXK))%Z]X14U
M7GFZWW:9R[SE8FB YK8.T]%I!O5VE%<91G:Y+X .HZOY8ZWR;B$=D,-UG(9"
MCGO/J(:"\HR"C)9XU)Z(@XY]B;TH+R"S,?'N7J[1EYC8VDK.,:UJ!G)RM8Y#
M]LB<X8=.U$?_KU=X0YM!" <P^)UE1.L?D[E^P=6P?H4)\0:I1/]A_6:#@]3'
M;^UZY&^'[FI&-]\Q_I#3_"78LGG85\A!Q"&J\1CD]<-?RM(/SH2]*:N(/^KN
M?::C0VKLF?*G8R^$0 =\^X>:DT]?[_:.G_(:SS?.Z?F2"VX=I+J/'06/N[SR
M0+'/'0] ZW2-':_+<6MUTU427FHU"UFY3]#6X"&?B(EQ7@FXH2/Y4XJ\Q60_
ML'N4D=8R3_; 8-N,0[*@6EKUGLG6FW=FA:N<;LQV\N*,JJ[!-0/'Q6M1W#[E
M#\NZEI+OFY0KSTX'0<:,KG VX-A=7,1[L.(_RF,Q9<F:<6:6TTG]4P6JZ3$P
M[>C.F4_9J@G",G:FG1'R!"-)QD%@.IC Y:3%PY61KJ?83VI\<U/Q:H$P?\T.
M$6;;$,/,%L@1K5K(BZKCI(UWVZ<F.I^MON1S*6JC->WSBY4NG'M5>7&DM!"_
M)CWE.KVQO>BN&IRSNP&)[:\-2' 4,,P7J0_@=B1)\ D+K2I:+2',3?\*HNT"
M5S,;G:/)=NE-U?<<))^/=4?#R,D^N,I7F<73INU.%ZH7O]V2N+U5,U%^:=.*
MO>!KN9Q #R-74;V,>MB*!:KF#(F&@ZE-XP:\V5<&Y[>R*9\KXDK@Z2TH8T%5
M%;(E)JQ"+F ,Q[VP<S #'/O5P=MMP%(\/:K,M+%$XS%A;BW<40U3J'I9X;#5
M,]3<C1&?E<^1]H_,;*+4T]^ZY:0_.AYPV8C0 <Y'U1M0S2&%>8&4D(IA8[7V
M"._OTZCW;.\;E3_5=:X/O=G IBRNFQ<-"T1_V0$[Z3NF<Q.,IU"_P:%L]&_K
M0:I:Q%D@K^W"F77P)#T"\(U,Y3X$'Q6O1X8$KYP@W.].2AYQ.&?&HVVJ'OM
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MG>=Y6JSK[BB8N(F$OGP)+1Q24!_&5=P<= ;_;%].V%C')YT 9E5:(]A;'\2
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M4H,LN/!;]>?O3I: HHA(IZZ>.F^,F2%ED9S0BL0.[3W"8[<5*1.^[>LT 2<
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MA<=YN4D6:Q9+EY,UC7=8G*0MC.Y/"T;EK*^ )\MF4ZEV&^E?)?&V<M,#N9I
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M];BF=AF5;2/]-48I8JWTUE,#/LXS^0M]_U16#&6<*O2<(E&N'>T6:P;.3L9
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MUH/_5=N9OR6!H'$<UD;3-'0--8^LI-3Q-MW!"S-3QVF4Q@LUTUUR=12)TCP
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M?P)YP46AS/$CZAXLEOL74:CG+;Y\%,H*_)@1FLVSY>LGI>*J*-3@,XG"5++
M4XP4^1"ER(<$(0QC3A4[24PPIS:,=';$J7'1QWSQ!:J!GD'>B@[F6G8P;X3/
M1&E'4>=1-R,GIU@.3$MK64$E[!58BWL%-@*[XR-C;)PRT?E11^4@8Q#VV<?\
MQGZ\<[?XIAZ2%Z]Z3W^W^%SD3)3E#'.?13YE"MDP@-KD@1B1$'IQ1$42D$!1
MD0W9'!]F:@RCA0/9 KS4XMEQR0DDS0CD<GP&9HVU@%>@1:D1\@K\7.0=8%D3
M1C<63EGBQ%"C4D.WNOM\<.;JOB2@5I<HE[??7\2B%#,1I"%*? E1G!"(6!#
ME- 44NQY,24^]V0X.]CN&[SD.\,8O=UF+@RW;WHM)1"UF+8LL NEZ?*W1V:L
M==^@<7L&C1[+_*C.CM?W[A@C+^RC"AZNZ..7]5O*G\3R;L'R9_%1<?+,XVG
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M$-+]@%*(J&[[$0L?ZC.K@ 0QC@*K<,_.T:;&/[6,8"/D974=C@)LZ@9W!-O
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M"7A_]_CY_O'Z([C_ -[]^GCWZ?;1LH[]Q5-DQNYC C\PA;>J@%J7[2#%;77
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M3JFQ?1YV\AJ7"5)U/+OBACLE\T*'(WY6\UA^5K3!7F>I3[FRLRBD.-).0)'
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M,J^B?M6NH_XH](V'LYLG0]H?'OVAJ7TKPNTP6.T*;":FT:2)7P.#Y+]<B.=
M,6MVLKQ1<%HOP$Y'H?5[7(_6 E6"<JE(^D->W--2Z5XRH72_6WS3];*+UQGS
M,::22IAPI#;_2<PAU>1)D4="QI* L<B$,LV&FQHSMH)E.I7AI96^ZEF<;\EO
M40?_/.+=Y.<>QX$Y;BVK[B@,MJ75/LU&7J< 6O01< KD2&T$+@/4KHN ,3Z=
M303./V6\'@+&&NVT$#"_JV_1E\>O8C[7]C59O,XPEC),8P9C(9CVN,:0I"R%
M.(@1YGXJ22+M2KUL/WYJ)-O4*ZE$!(V,MC5==N#K9M#+01F8,:WPZ%&RY9C:
M%Q1JV7G<R.59CJER6)3EZ%7V"_6CPG;^^6N^$$V5:S\,0Q%'*0QPA"%*:0@I
MQTPM4^GQ6/II$AMY&8\]?&J+M)(/5 *>*T%]'KCS"_02. 9>GA9(6"W.4RKW
M6IH'#QMM89Y28WM9GKQFP&HFZV!)ZH4D((Q"SCF!*&2Q6K!^ $G@)WX8A3R1
M5G&H5J-/;5F;E]SH&;-J-S=FCI_!$!^8.5R"/4QUDT$C8>TDF%YMDW,QL_T>
M<JD'?#]2]VXA\^*YVH.^>VU^6:<3,R_U$$$$TA0+B+PH@KHS))1IFB+/CPB)
MDW[>;V,9ID9_VP[8P]CS+36NJA.V-F7ELMQP\QFS]8,/,@\C^L#=3<$%SF]K
M$ =R?)O+\49.;VN@3CN\[1_5,\1W)9[RK;!A1<U-03W%V%NIOL*3V/<#"F..
MU<[.]Q&DOI10A 2G01@P&1MYO2W'G1H]*K'!,M_IQVB=76T*N1G7#0#DP/S6
M8+B=?."DRVM/1-Q&YAJ./6XXKAT@!S&XEK?W=?A6A8=T*L,W\9XL25M;-A8H
MB1,:P)@HO%%$8TC"P(,A0ES0.&$1,6*><P--C6H:I^>6L$!+>[8(K1VZII[A
MRS$;QT=L#5</=W$W%A<XCD\\>&07<K=ZA\[D,]?WLTN:KAI(()1R(6"$<*IV
M:)Q#3!F"(<>,)(0D,N0V-27M^VF,4?[Q28_1JUF)5?.1R343<=T;9,!>'V_1
MNZ.[%\=%O36V/33YXG&9L[]7<37E]6KY-2^R_Q)\)HBD/O8%]"4/E<G/.$QC
MG$ OH'Z,_$"DGE%[#8.QIO;MK44%I9;UJ@G^!F0M;O^0\"Z\S5V]#E <P;&K
M 'RL :P%!1M)W3IQS\#AW&5[:KS1';1G%#_FCCUW2S\:J0^M[F63C+?XTG@H
MRIE/$L1BC&$BJ8 H03%,(Y]"3U*"H@!YB;"J@71RI*E12"VH]N'EK:B@;&2U
MXXS3X)HQAA/(!N:+#5IK*5O/ID/[X"P23JGB]&BC$L59I?=IXOP-_4CB: SO
MC"9!5%6-YU$D(1)) M.$5F:^SU%$$,-6W7J.CC(U<JC#V+45P?/YG!3E)I_
MTJ X#JH9,5P,U=!;^E,) .X8H1,"IVQP?*11F:!3V7T6Z+ZX;W)]75K\,\GX
M)[&<$>1+3 F&/@[5#@-+"6E"(BCC2'!)T@@E5CN,O>=/;=6?+?5O!)K9VKX
MBH%7=2L9T*)=-?6J]??^AKQD2S*O-ECM15=;]L"U=C%U5[/MD11_%";'^>^[
M8XR<ZGY4P<.L]N.7V:WSLEBV==)^%OF7@KQ\S1B9O\^?2;:8X0C[1'L1F$QU
M"?^ 0,((@B$ED<"IP)@;;04Z1YG:FM^6$/Q6RV@8)]&-9C<-.,-H8#*P@\=X
M>1NIW[7(U0.V%KCZU_[B[AYAE"5NI&2[T,TN[KG[%\M-'Y+K;R2;5^EX^9:_
MX6L^5\\KFW2]F4<]SCFBT$->#%$22HC3!$/IL]!7FP$?)5:!5]823(TFE )
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M(A",QF9\L?_@J5%#*QO0PIF'B.]@U;WT+T%@X%5NIKQ5P/<Q37L%>.\\:+2
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MZ(5^(@+!0VQWJ.@.Y'$.%VN8F_(.-=KN83:C:G?0#4S6-69K2=O*##\TPBH
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M0!+*J1]AJ\I,!F-.C5Y;D8&>3K#\*@"O2F%G[4[K)E?;*=K(;^T+/#L%QGY
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M1[J#0"(P1(('BF:YIP 6 48^2K!O=0I_>JBID6PMJ:Y:4:QE57Q;"VNWO^S
MUVS[Z :U@:EU ]A&3/!X#C#K;=]Y+)SNZCJ&&W73=E[M_3V9P1V](R#UQNUS
MD4M1EE47J ]B4_LWH(+Y0H309[HN7Q3&D,:IA $1-"$DPMPNF[U[N*G11NN7
M>MD2%TAAZY(Z@[$9;;A#;F#J:$';EA1H41V63K8#Q75$8=>08P<.&JA_)#[0
MY*X+#\H_Z/[J7P7_.<]Y.<,ICKS$D]"3B$.4,-WBE"+(4!1+R9"@9CN\[F&F
MQA^M<."+EJ[GJ?DND&9D<3D\ Y/$UBGZ&J1*QN%.U8]",<SI^NY0;W/*?E3=
MDZ?MQZ_N1P&7MGV^7RW+)5GH@J>=K>M9C((X2C@4'O8A"F4,"48""N%Q07U?
M>L2;O51MW!Z7I%B:,<M(TMNLQ7T=AEN66\)? 2J^9 N=X:RW ;4,54LEKG:K
MI-C*T;<LY#[6^^%AM9^M7@W?UW]P!FD:8T@H"<(H##BBLGD_;A?\#_YVM!J,
M]&Z(!?^#OA5F'] )SO/ 7^3M#.UMG7?2M.DK.)K)K377'02:MF$[KTJK/V@
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M=OOYP]WO-]'#]?]JJ7+WA]3-?0T%5& _51%Q&SVCO:+1GT&N+5T@&;C%=(O
MD9M,7S;]M,VTPV>ZN8R/57?.W]:KYZ<=^;J58US6W+@O>?=DXC9[YE[]L/Q6
M;65G,(DQHQH!CC2UI;T04*0T$#&.:9Z(W'@:'X_20Y>I.9R=?KO#+S^WTV=8
MW+S22& '=EJU%5%A1D'N6<51AY9$.U.NHOW(5-8,Y]4&@'10I]='GU%]X@#
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M7R8C%/JLN&;SRQO14&EY%$$2%0**Q@E!@HB!A$P#!$.=BW7VH54I[-='KGX
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M3;[$):-.EBH*ZTLRSA,'R9$<LI;>"U OMHS8QIVZ3TG?=[N[T? C3VD+<3<
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M32=Y6"ZO>(@9#*%4X4[/0^DRSS*)WAB,@#WD2H[\'2+ZS8/5P,JF$F[@M+S
MO !\V<;YMJ&9<6"ESY)0I!SEH5-IW1R(Q2 C6%-<T'I&YBF*^LU3U3(Q6\N^
M 0-S@JI  LJ$G?>X,8\FBSSNDJN!3C%PI1EA4I;.WRP01\$1E(P&@0SR7"?W
M^2)9_?I$W6C^D5/4E1H:P%2QINBZ+0K%/P#,!EH$I!#*G7)TVJ1GG'A>+OYJ
MH2S5R<9<)['YD))^79TJR-E*V V Y=2/_/2JI.@/_QGI5X(G%IPBS*J2)!&"
M6$4%$0IXDH;94.EFZT-*^O5UJH!E*V&W !98E#?^"F.8^E$YE4SGP_&P2&8^
M_ 8W]C+G"-PRDDI?>>FE(=933U0V@24N.3A?!T(KT=>O-U0'6-TKI@&XW31/
MN9;5@.D(-#)/G R12.4L"=HB R;%Z!TU1E7JK/V0E'X/YJJ :#MQ-Q"0W3!P
M%7%\Q,AR$*6(COE,P"=%I-:6.)LX 9T9YT%@I%FYP]\M,?UBID88MJW$&S R
MU[7Z5QS<,#0H8]ZS56@F(4ET^ET@@<E,1&3,FH3;MJH#G&<(ZO?<M@9XNI!\
M$^/5KAFYWF9YR$R67B3H\0=< 2B/D RN@.PA*>N8KC0<_0$A_1[)UH3,)I)>
M'RKN"BIC^%SJGLZZ[2OTP'0N.2H3F5*V'#3GA$O+<1'0TB])9^(81$F=3I[7
M.=Y_F:Y^K]A4V;VZTT,#&]F"FZ/)>/(D0P-MC89%)=7B=I W"I>*5,1EM*M:
M)DXK3;5^F:Z54.7>'*JZT4,#/O6M8W=]8CP<7R!3RV4S&<_>09Y,X<X\YH/O
M*$34W'#LIY>'*-G9,[<CDX4@67:$YG)!TW+T%+40Q.@B9LF]975231696BTY
M3M\2H%N!0#.K 5E<KN9W,(9R<FF &6I $Y.9(-+Q,M\3/5@7HL%MPF=NZO1I
M?H:@U5#XINI6NA!] [OTU5'W(E#.VFLMC,3 !A:C%$K;GC*TBFM+!0@PM,ZM
MG%L:5L/)FRH^V5# #1@7]#EO3>UJ[06\<)E%% S-0*0*E'B/2P'C9R5"XAE$
MG<Z1:Y.Z&M#>5.5*774U8*KN,3A@- O- B/,*5XRR[B8-()#&@%!V914$O6Q
MMAJ.WE0IR^9B;L!F73<,N[X/=B.1+#+51@+)3I1:KD4/%%1NIM%(+K(%6R=]
M^AQ%JR'G367?.Q%^ X;F(1_O_&P8!RHP*I/CA+.$CAWSB?@D.*$J<!JI2<G7
M.45^DIQ^BYZZT?0K\%E?[ UBY_UP=#&'-/ "0T@P$<61RM&EC21884CF$ 1+
MW+!*(YB>(:C?TJ>=X&<3T;_5VU#[?]\[^O7@]/#HX'__?GCV'_?9Z>A*U,-W
M[.1>U(N,==^*Z(5>6<IF+WA(1,E<;IZ(1(+RE"0>.#-.!EYI1/9*Y&W?.W#Y
MDK.K?C:*NE#:PPFG,#2001%?;JO:*"(&#=:*7">2NT]',\V%.L+%X[9^&TN]
M@;WNAOHKB>Q/SK].QOCE;._[<#8(RF#H@-&EY08W[J@Y<09]2HL,:I>L=[%.
M@/8B68T@:@-]/P>=K87? )(>\/!^<NZ'XP$U3#(-E/!R/5[&['!E)4J8,2):
M[I++E3SNI\AI!#G;J_NAV[2U[!L T)WK\+_!>8#I@#+@/*I(0#,,9'/INRI5
MF;AI,)[%_R17)^!_1$K/H=KVZGV^]< &LFX +,_,+5@R8W3RC/)%P*F(3-22
MX$TF#M<8*"X%A3JGP"^2U7.\UCF(NM-! X!Z.*Y@R86-!?M:$^&30_DP6E(7
M*"10!G26'-W$*DAZFIY^+[!T#Z$.I-X =IX^FUGRDKF.F@E+(I3#9&[*7!X9
M20SEM :,2KD.@EZBJM_[*MWCJ#,--("F&S?Q(ZZ,1:'+0-"H'9>E!9"AN#GG
M0)SFN$T'-+ ZVYAMG6/]Q[0TTNVUP^!K,S$W )3#<9R6P;SOX>K?P_'C%,<)
MKH@/D^F??IH&,J%8F-&$T3*[/A=&*2A"A7!:B^A]I;UL34(;B=(VQ,7C&J-J
M2FH @_<:XCFI#<0H24P4#6TRCGB&+I_*C/GDJ4B^3KRV=C/"FF5J]=3]T()M
M*ON-<?,5IL-)PA4RG;<T[2;2Q%)FDBC%/9$",K&NG']CH"&\I%G(6MOCSJ;=
MU"R8VQUB=Z_O9K#^-"_7TB]ET*<7839,0S^]7,H&5W896S P3#"=$7Y0XFF)
M7C)Q@/XL]UZ&!#&@'[3#$&(5FGOO*K4S3.](KRWL]46&5]O-^XMI6;-72V2Q
M#5V7>T J<1V,9PME#YS'$ ZC+Q*<1\F:TD=>:4-$5M)E832K5,6^ ;&]M[3:
MK1VNJ,EVP;KH-+_XV?'7Q3V3@^\PC4-D=A -<&,L0P^JM*7DB1$7+,4/"DP*
MVL1* V+7)K7W2_]] [4C+38 T[WT?RYF\Q)NSLXFSR34%PLR/%R0)X"2G@WG
ML&R&>269$XB3S^/%4ZZ&@0LK/,L0<(_)CDA5)G?$3 E&M$"ED)'9.B4OM3GK
MO7G!SA9!4QCIM3O"8B;35</T/_U7%$9$_J:P- )7V]<@!:JYM0G)-RAJW+>(
MI<&3*!D$C(X#?3@W_IG)5Z^\J/=6"-4!V+FX&S"X=^YR:68I@+.X-_"2/;:9
M!,.+1\.YMR8H:5@5T[CF9;F:#1!V9L0VE'L#B+F79M-1"Q:I0%-)$Z(=C69(
MJ4S?Y2IY;UBH-5AYW11GS08'_:0XUY']EFF?@W%J*<&I543N%! >M<8-6EGB
ML\ -FDNFO#+4T%HS5'>6X*S:P."M93C747BG4-_UG8>]T[]_^'C\1YT!,+=/
MW\T]AZ>9Z?Z&P[Z???DPFOQYVZ.1:F8\U4!BCN5<$BP)@D;BC?.2T<A]I9NT
M+U'5P67A\LS%#%:4W[O+WS&\.1S?=%?:B_/AMZOAY==R$#'(A/$^21#1M8!8
M:H:L1$\CN\BMQI_6N:*U/JV-G')OBZ8GKA[75%H#_N =3Y92EBU+Z+JRTLZ+
M"X6>K F$)L<94\X;VD0$40U&M;7]?!"QCNB;Z.AX+XM34C#C.!S!O9OZ9Y-U
MA9F!,L^S)<@R"E-+22P/4+I!1"%EDMS6:<-?@YM^S\%W#.7>X=" )5UE,/7
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M4UNK&!SD[",D 03 T+)H%Y7H@B@+3 N@T8@ZES6?)*>MD'@+=:\"I+5DWR"
MK@,C094!$)%XJLO4JR2(Y:7'NJ.&*T55DF$G$&HR=JT'HDWDWRZ,;D0D9>16
M4D^"IHY(BJO"<RF)SLR$* !4WLUN^("P?B\7-;D?;J.Z!I"XI4SWSB<794"Q
MD,KS<B]:VW('2U+BD\0U*%S2VF3*;)TRAD[(;VO'W0I0W9[F;:#=1BO*3\^.
M]__7N[W3@_?[Q[]].C@ZW3L[/#[:I)C\F2=U44>^"I$=E9#?3M8\S@4",)XM
MZ%TV#]J?S.:S!02"GY5>0I?E4N=MF&MDUA2],T1$N77%J"76.TZB]31 R8,\
M;&O?6?9T&[JWSR>O^/9W=]]^>S4CY<Q<$I1DA0M8EMXY/B4@VEB77' QA#HE
MB%L2WG?B;V=8?9R/WIW"WY3EW/PFX8O/JV=%*]XFW!:?@G-F'(9#5*(SJIS!
MT(7J$KHH:J3CTO^(MO2VYNEV =VEXDYQW6POH@,SG%\^N.FFC8R>EJMM3D6"
MGW."RTH0%D3R#(-+2^MDJ[>G_6U;U#40^_Q%GYVHO8$(ZRF.ER+=*]TP[G+\
M#S^ZN$+!;'9Q?O6]!]Q[L,I=W><L>YI1E#@+GACJ50[<@HMUAGUTRT??)SA-
M+8 =P>%->1A=3*]>\<GUO(Z=S+'>$LR!2>NDYH3BHXGT((CCF1(-4@4IJ0B\
MCD'IU__8&RU^9WFP^F@?.OA>/H4!]5IRR3!F<,8060;T6!LT":"X")X+)2M=
MGUR)OC?M1ZR#O$>9K>[5U_=HI87E+QW[(+V_F ['GS]==8-<'/PO?GCZI_\Z
M6W;V&Z,0+Q;R/($(:&+2@+-2/1H$24KZ4@NHB2^!KQ:)Y<BUR,J]9C([H>1-
M;^Z;H'+W^GLC8!T(L-IE!D0'=)"D+1F0TEC)N:1<CA2TZQ23_59L- Z]M;3Q
MIKS%TXOS<S^]G.2[[G/GGN.+;ZGG1:[.7!L>I10VVY 05EP&(K-*Q"^B$ZV
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MKZ.^^K<UES\H'X*?P;_]R_\%4$L! A0#%     @ %$%L4V_V/R95"   E2H
M !D              ( !     &$R,#(Q<3,Q,"UQ97AH:6)I=#,Q,2YH=&U0
M2P$"% ,4    "  406Q3J+V')U4(  "%*@  &0              @ &,"
M83(P,C%Q,S$P+7%E>&AI8FET,S$R+FAT;5!+ 0(4 Q0    ( !1!;%-G1@M*
M  4  /T6   9              "  1@1  !A,C R,7$S,3 M<65X:&EB:70S
M,C$N:'1M4$L! A0#%     @ %$%L4U[RV?CS!   B!8  !D
M ( !3Q8  &$R,#(Q<3,Q,"UQ97AH:6)I=#,R,BYH=&U02P$"% ,4    "  4
M06Q33I2_EAU4 0!:EQ$ $0              @ %Y&P  87!Y>"TR,#(Q,#DS
M,"YH=&U02P$"% ,4    "  406Q3X!^7.*H*  !"80  $0
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3!@     +  L Z (  +*) P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
